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1. Introduction: Antiepileptic Drugs 
 
Epilepsy is a relatively common neurological disorder affecting 0.4-1.0% of world’s 
population [1]. In 1912, the first antiepileptic drug (AED) phenobarbital (1) [2] was used in 
clinics, and then phenytoin (2) [3] was found in 1938 for overcoming the serious side effects of 
the barbitals-like. Since 1960s some AEDs such as diazepam (3) (1965) [4], carbamazepine (4) 
(1974) [5] and valproic acid (5) [5] (1978), etc. have been widely prescribed but patients still 
suffer from a range of side effects. A significant part of patients (20-30%) is still resistant to 
the currently available therapeutics [6]. 
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                  Phenobartibal (1)              Phenytoin (2)                    Diazepam (3) 
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                            Carbamazepine (4)               Valproic acid (5) 
 
In the past decade several new drugs have been launched on market, e.g. gabapentin (6) [7], 
tiagabine (7) [8], vigabatrin (8) [9] and progabide (9) [10]. Many of the new AEDs exhibit 
improved efficacies and relatively less side effects, but are still ineffective to some patients 
with intractable epilepsy. The diverse pathological profiles result in this neural disorder to be 
hard tackled. [11] Thus, there is a urgent need to establish new screening models for epilepsy 
and develop novel drugs with less severe side effects.  
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AEDs comprise a huge number of structurally diverse compounds acting on a variety of 
different targets in the brain. In accordance with the present understanding of the different 
mechanisms, the ways by which AEDs exert their therapeutic effects, may be summarized as 
follows [12]: (a) by inhibiting the function of excitatory system (predominantly by the 
glutamate system); (b) by enhancing the inhibitory system function (predominantly by the 
GABA system); (c) by inhibiting excessive neuronal firing (modulation of membrane cation 
conductance of sodium, calcium or potassium channels). In addition, some drugs work 
through other or unknown mechanisms such as SB-204269 (10) [11]. 
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                                                    SB-204269 (10) 
 
(a):  Glutamate system 
Compounds which modulate glutamic acid receptors are frequently first evaluated for 
anticonvulsant activity. Glutamate receptors may be subdivided into two main classes: the 
iontropic channels (NMDA, kainic acid/AMPA receptors) and the metabotropic receptors 
(mGluRs) [13]. Their therapeutic potentials have been reviewed recently [14, 15, 16, 17]. Owing to 
their adverse effects, so far none of them has succeeded in clinics, but considerable research 
continues in this field. 
  
(b): γ-Aminobutyric acid (GABA) system 
 γ-Aminobutyric acid (GABA) plays a significant role for the inhibitory function in the 
mammalian central nervous system (CNS), as approximate 40% of synapses in the CNS are 
GABA‘ergic. The dysfunctions of the central GABA system have been inferred to involve in 
the development and outbreak of several diseases such as anxiety, pain and epilepsy. 
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Decreased GABA’ergic activity results in the excessive excitement of CNS (namely neuronal 
firing) [18]. Each step of GABA’ergic transmission including metabolism, release, and 
transport as well as activation of specific receptors will affect seizures of epilepsy and may 
become a target for new drugs.  
 
Several drugs, which influence the procedure of GABA transmission, have succeeded in 
clinics, e.g. valproic acid (5) (succinic semialdehyde dehydrogenase), S(+)-vigabatrin (8) 
(GABA transaminase inhibitor) [19], progabide (9) (a novel GABA agonist with a resemblance 
to benzodiazepine) [10]. But directly agonizing or increasing the delivery of the 
neurotransmittors always incurs the exhaustion of GABA in the synapse and exhibits 
unacceptable systematic side effects. 
 
GABA uptake inhibitors  
The discovery of highly selective inhibitors of GABA-transport-system (Iversen et, al, 1968) 
[20, 21] and the isolation of the transport proteins (Kanner, 1978) [22] provided new pathways for 
drug design. GABA-mediated inhibitory synaptic transmission is terminated by the rapid 
removal of GABA from synaptic cleft after its release [23]. Although diffusion can’t be 
neglected, the majority of transmitter molecules are immediately recycled by a cellular uptake 
system of high affinity sodium and chloride-dependent transporter proteins [24, 25], which are 
located in the plasma membrane of glial cells and synaptic nervous terminals. 
 
Despite of the limited understanding to termination of the synaptic and glial GABA, it is 
impossible to figure out their mechanism related to its pharmacological intervention. It has 
been known, however, that neuronal and glial GABA uptakes have dissimilar substrate 
specificities, which are also distinctly different from those of postsynaptic GABA receptors. 
[26, 27] Therefore, this makes it possible to develop selective inhibitors for GABA uptake for 
enhancing the inhibitory effects of synaptic released GABA so as to avoid adverse systematic 
side effects. As a result, GABA uptake inhibitors would be very promising in therapeutic use 
and so far much interest has been focused on the development to GABA uptake inhibitor. 
Conformationally restrained GABA analogs such as (R)-nicopetic acid (11), guvacine (12), 
and (RS)-cis-4-hydroxynicopetic acid (13) are known to be potent GABA uptake inhibitors 
with no affinity for GABA receptors (Johnston et al, 1975) [28]. But these amino acids do not 
readily enter the CNS following peripheral administration due to their hydrophilic nature. 
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                             Fig. 1.1.  Structures and sites of actions at a GABA’ergic synapse [29] 
                             (SSA: Succinate semialdehyde; GAD: Glutamic acid decarboxylatase) 
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           (R)-Nicopetic acid (11)        Guvacine (12)         (RS)-cis-4-hydroxynicopetic acid (13) 
                 IC50: 9 ± 1 µM                 8 ± 1 µM                          8 ± 1 µM 
 
Some novel compounds such as (R)-SK&F 89976-A (14) and SK&F 100330-A (15) and 
(RS)-cis-SK&F 100591-A (16), which can cross the blood brain barrier following peripheral 
administration due to the introduction of appropriate bulky lipophilic groups to nitrogen 
atoms, showed approximately 20-fold more potent inhibition for GABA uptake than their 
precursors (Ali et al, 1985) [30]. These reports on the inhibition resulted in intensive 
investigation in this field.  
Since the discovery of the first potent uptake inhibitor, many similar potent derivatives have 
been synthesized and intensively investigated for their pharmacology, such as CI-966 (17) (M. 
R. Pavia, 1992) [31] and Tiagabine (7) (K. E. Andersen, 1993) [18]. 
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N
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                       (R)-SK&F 89976-A (14)                SK&F 100330-A (15)              
                              IC50:    0.11 µM                                  0.30 µM 
                        (S)-SK&F 89976-A 
                              IC50:   1.91 µM 
N
COOH
OH
CF3 CF3
N
COOH
O
 
                    (RS)-cis-SK&F 100591 (16)                     (R)-CI-996 (17)  
                      IC50:    0.26 µM                                            C 0.34 µM 
 
Heterogenity of GABA transporter: 
Three different GABA transporters have been cloned from animals of different species. They 
were termed GAT-1 [32], GAT-2 and GAT-3 [33] (nomenclature for transporters obtained from 
rat brain). BGT-1, which transports both the osmolyte betaine and GABA, was first cloned 
from dog kidney [34]. All these different transporters provide precise targets for study of the 
pharmacological profiles of GABA transmission and new drugs design. 
 
GAT-1 
After GAT-1 had been cloned [35], it has turned out that potent inhibitors developed so far (e.g. 
14-17) are selective combined for GAT-1. According to the data of many highly selective 
inhibitors for GAT-1, their common structural features may be depicted as follows:  
1.  The nitrogen atom should be situated in the mean plane of the pharmacophore. 
2. The acidic group should be located at a distance of 4.2 Å from the center of the amine     
function. 
3. The two aromatic rings are beneficial to strong affinity. 
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GAT-2 
Up to now, a little is known about the characteristics and the pharmacological role of GAT-2, 
due in part to the lack of selective probes. 
 
GAT-3 
The first relatively selective GAT-3 inhibitor (S)-SNAP-5114 (18) was reported by Dhar et 
al. [35] in 1994. It displays an IC50 of 5 µM at GAT-3, 21 µM at GAT-2, > 200 µM at GAT-1 
and 140 µM at BGT-1 (GAT-B); its (3R) enantiomer shows an IC50 of only 86 µM at GAT-3. 
Later a selective GAT-3 inhibitor NNC-05-2045 (19) was found, which proved to be a 
blocking agent for audiogenic seizure in genetically epilepsy-prone (GEP) rats and to be 
anticonvulsant in the maximal electroshock seizure (MES) test in amygdala kindled rats [12]. 
Compounds 18 and 19 should be useful tools for investigating the role of GAT-3 in the CNS. 
Dhar et al. suggested that the following structural features for the GAT-3 inhibitors of type 18 
appear to affect inhibition and selectivity: (a) a chain of two-carbon length between. 
N
COOH
O
MeO
OMe
OMe N
N
OH
OMe
 
                                (S)-SNAP-5114 (18)                                   NNC-05-2045 (19) 
 
nitrogen and oxygen atom; (b) an oxygen atom linking the carbon chain to a tertiary carbon 
atom with three phenyl groups, and (c) lipophilic groups at the para position of three phenyl 
groups, with p-methoxy groups being preferred with respect to the nitrogen residue at the 
amino acid skeleton. 
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2. DESIGN OF GABA UPTAKE INHIBITORS: 
2-Carboxylic acid and 2-acetic  acid derivatives of 4-hydroxy-pyrrolidines 
and 4-hydroxy-4-(4-methoxy-phenyl)pyrrolidines 
 
As described above, neuronal and glial GABA uptake proteins are different from postsynaptic 
GABA receptors with respect to their substrate specificities. Therefore, it is possible to 
develop compounds that are selective for GABA brains part without affecting GABA 
receptors. Since the first potent GAT-1 inhibitor was reported in the early 1980s [30], several 
compounds have been investigated in clinic trials and one (Tiagabine) has been put on market, 
but inhibitors with a higher potency and selectivity are still desirable. Furthermore, the 
pharmacological profiles of GAT-2 and GAT-3 remain less known, and no highly selective 
and potent inhibitor of the transporters has been discovered until now. 
In our group, my former colleague Dr. Fülep had successfully prepared a series of pyrrolidine 
derivatives with three different N-substituents what are typically used for GABA uptake 
inhibitors. Some of these compounds are potent inhibitors as may be seen from Table 2.1 [36], 
e.g. (S)-98 exhibits a relatively potent inhibition at GAT-1 (IC50 of 0.40 µM) as compared  
 
Table 2.1   The binding test results of pyrrolidine derivatives prepared by Dr. Fülep. 
            H -CH2CH2C=CPh2  
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with (R)-SK&F 89976-A (0.11 µM). Furthermore, a relatively high and selective inhibition of 
(R)-100 at GAT-3 (IC50 3.10 µM) was found to be equivalent to (S)-SNAP-5114. 
It may be seen from the comparison of (R)-SK&F 89976-A (14) with (RS)-cis-SK&F 100591 
(16), the latter is still a potent inhibitor despite of the introduction of hydroxy group in the C-4 
position. Accordingly, the hydroxy group in this position seems to be acceptable for the GAT-
1 transporters. 
Following Dr. Fülep’s work and referring to (RS)-cis-SK&F100591 (16) as well as NNC-05-
2045 (19), my idea was to introduce hydroxy group or hydroxy and p-methoxyphenyl group 
to the C-4 position of the pyrrolidines with 2-carboxylic acid or 2-acetic acid in order to look 
into the impact of these different steric groups on the inhibition at GAT-1 and GAT-3 
transporters. Thereby well-known N-substituents a, b, c, and d, which are typical for GAT-1 
and GAT-3 inhibitors, should be applied for their study. 
Thus, according to the present study it was my intention to prepare the following compounds 
(the general formula 20-23) and to evaluate their biological activity. 
COOH
OMe
OH
N
R
COOH
OH
N
R
COOH
OH
N
R
OMe
COOH
OH
N
R
 
                           20                          21                           22                          23 
 
R   =  H  and  24a-d. 
O
OMe
OMe
OMe
S
S
N
a. b.
c. d.
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4. DISCUSSION OF SYTHETIC METHODS 
 
For my synthetic plan, commercially available L-trans-4-hydroxypyroline [(2S,4R)-25] 
appeared to be useful as a precursor. It bears two optically active centers and is an ideal chiral 
building block. It can be converted into its (2R)-isomer or (4S)-isomer and furthermore the 
carboxylic acid function can be extended to an acetic acid through several different routes. 
The main synthetic routes, which I wanted to explore, are shown below. One arrow doesn’t 
necessarily mean a single step and also the transformation of configurations is not noted here. 
Scheme 1 
N
OH
COOH
H
N
OH
COOCH3
H
 
                               26                                                 25 
N
OH
COOCH3
R
 
N
OH
R
COOH
  
  R  =  24a-b 
 
                               27                                                      28 
N
OH
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Ar
COOH
 
  R  =  24a-b 
N COOCH3
R
O
N
OH
COOCH3
R
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                               29                                          30                                                31  
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Scheme 2 
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                          33                                                 34 
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                           35                                        36                                              37 
Ar = 4-Methoxyphenyl              R    =  24a-d 
O
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c. d.
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Access to compounds of general formula 28: 
From (2S,4R)-25 exhibiting two stereocenters, each with a definite stereochemistry 
compounds 28 would be accessible via the configuration inversion of the respective 
stereocenter followed by esterification, alkylation and final hydrolysis. 
 
Access to compounds of general formula 31: 
Upon oxidation of the hydroxy group of 27, ketone 29 should be obtained. Subsequent 
addition of organometallic reagents to the ketone might yield a mixture of diastereomers 30. 
Separation and final hydrolysis would lead to the single isomers of 31. 
 
Access to compounds of general formula 34: 
An Arndt-Eistert reaction should allow to prolong the carboxylic chain in (2S,4R)-25. The 
accession will require the protection and deprotection of the amino and hydroxy group. Acid-
selective inversion of the configuration of stereocenters would give access to all stereomers.  
 
Access to compounds of general formula 37: 
A procedure similar to the one   for the preparation of 31 should lead to 37 starting from 32. 
 
Synthetic routes to N-unsubstituted derivatives of 28, 31, 34, and 37 are not mentioned here. 
These will be discussed in the sections, which just follow those respectively about N-
substituted derivatives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           3. Discussion of Synthetic Methods                                         - 12 - 
3.1  Preparation of N-substituted 4-hydroxypyrrolidine-2-carboxylic acids 
 
3.1.1 Derivatives of N-substituted (2S)-4-hydroxypyrrolidine-2-carboxylic acids 
 
Keeping the stereochemistry of the starting material unchanged, compound (2S,4R)-25 was 
directly utilized to prepare (2S,4R)-40a-b via esterification of the 2-carboxylic acid, N-
alkylation and final hydrolysis.  
Thus upon the treatment of (2S,4R)-25 in methanol with thionyl chloride, (2S,4R)-38 was 
obtained in 96% yield [37, 38, 39]. The ester (2S,4R)-38 was N-substituted with the bromides of 
24a-b in acetone at room temperature to give (2S,4R)-39a-b in moderate yields [30]. Final 
hydrolysis of the ester function with aqueous 0.85 M KOH at room temperature in ethanol 
afforded (2S,4R)-40a-b in good yields (Table 3.1).  
Scheme 3 
N
OH
COOH
H
SOCl2
MeOH
N
OH
COOCH3H H
+
Cl-
,   0 °C
 
                                                 (2S,4R)-25                                 (2S,4R)-38 Lit.                                 
RBr, 
N
OH
COOCH3
R
K2CO3 KOH
N
OH
R
COOH
0.85 M
C2H5OH,  r.tAcetone,  KI
 
                                               (2S,4R)-39a-b                             (2S,4R)-40a-b 
 
R  =   24a-b.                    a.             b.    -CH2CH2CH=CPh2 -CH2CH2OC(p-MeOC6H4)3
                                               
The inversion of the stereochemistry in the 4-position of 4-hydroxypyrrolidine derivatives has 
been successfully achieved through classic methods: (1) Jones oxidation of the hydroxy group 
followed by reduction with NaBH4 [40]; (2) intramolecular esterification of the hydroxy group 
affected by a proceeding tosylation and subsequent hydrolysis of the resulting lactone [41]. 
Also the Mitsunobu reaction has been widely applied for esterification process with complete 
inversion of the stereochemistry of alcohol function [42], the free alcohol is simply obtained by 
the hydrolysis of the resulting esters. 
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Scheme 4 
N
OH
R
COOH
Ph3P,  DEAD
N
O O
R
THF, 0 °C
N
OH
R
COOH
0.85 M  KOH
EtOH,  r.t
     
       (2S,4R)-40a-b                               (1S,4S)-41a                                (2S,4S)-40a-b 
 
For the Mitsunobu reaction in my performance, (2S,4R)-40a was transformed to the lactone 
(1S,4S)-41a in 85% yield with the desired configuration [43, 44, 45]. Upon the hydrolysis of this 
lactone the stereoisomer (2S,4S)-40a was obtained (Table 3.1). But when the crude product 
from the Mitsunubo reaction of (2S,4R)-40b was purified by flash chromatography (packing: 
Al2O3  pH 7.5±0.5),  (1S,4S)-42b was directly given in a overall 76% yield. 
The Mitsunobu reaction [42] is believed to proceed through the following steps: (1) In the first 
step the addition of triphenylphosphine 43 to diethyl azodicarboxylate 42 gave the quaternary 
phosphonium salt 44; (2) 44 is protonized by RCOOH; (3) Finally an alkoxyphosphonium salt 
46 is formed; (4) 46 undergoes a SN2 type displacement to give 41.   
Scheme 5 
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-
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                                                                      45 
NO
OO
R
Ph3P
 
-
+ N
O O
R
+ Ph3P=O
                                    46                                                 41                          47 
3.1.2  Derivatives of N-substituted (2R)-4-hydroxypyrrolidine-2-carboxylic acids 
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The inversion of the chiral center at the C-2 of (2S,4R)-25 was affected by refluxing the 
starting material in a mixture of acetic anhydride and acetic acid, subsequent hydrolysis with 
aqueous 2 N hydrochloric acid. The recrystallization gave (2R,4R)-25 in 58% yield [46]. The 
recrystallization procedure was considerably simplified by applying triethylamine to 
neutralize the epimeric hydoxyproline salt instead of silver carbonate [47]. 
In analogy to the preparation of (2S,4R)-40a-b, the target compounds (2R,4R)-40a-b (Table 
3.1) were synthesized from (2R,4R)-25 by the esterification of the 2-carboxylic acid, N-
alkylation and final hydrolysis of the ester function.  
Scheme 6  
N
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H
COOH
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2.  2 N HCl N
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H
COOH
TEA3.
SOCl2
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+
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            (2S,4R)-25                               (2R,4R)-25 Lit.                         (2R,4R)-38 Lit. 
RBr,
N
OH
COOCH3
R
K2CO3,  KI
N
OH
R
COOHAcetone,  r.t MeOH,  r.t
1.0 N  NaOH
  
                                                      (2R,4R)-39a-b                         (2R,4R)-40a-b 
  
R   =   24a-b.       a.     b.  -CH2CH2CH=CPh2 -CH2CH2OC(p-MeOC6H4)3
 
The preparation of the stereoisomers (2R,4S)-40a-b were accomplished by performing an 
intermolecular Mitsunobu reaction of (2R,4R)-39a-b followed by the hydrolysis of resulting 
ester (2R,4S)-48a-b. The cleavage in the side chain b by the reactant acetic acid was observed 
and the separation on prep. HPLC was needed for removing side (EtOCONH)2  (see Scheme 
5).  The diastereomeric purity of the product (2R,4S)-39a-b was higher than that were 
reported in the literature [41] for the material that had been obtained by the tosylation of 
hydroxy group followed by hydrolysis under basic conditions. Hydrolysis of (2R,4S)-48a-b 
with aqueous 1.0 N NaOH in methanol at room temperature finally gave (2R,4S)-40a-b in 
medial yields (Table 3.1).  
Scheme 7          
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MeOH,  r.t
1.0 N  NaOH
N
OH
R
COOCH3
Ph3P,  DEAD
AcOH,  THF, N
AcO
COOCH3
R
N
OH
R
COOH0 °C
 
       (2R,4R)-39a-b                            (2R,4S)-48a-b                          (2R,4S)-40a-b    
 
 Table 3.1 The yields of new compounds 39a-b, 40a-b, 41a and 48a-b. 
           R:   a               R:   b      
  Structure  -CH2CH2CH=CPh2  -CH2CH2OC(p-MeOC6H4)3  
    
N
OH
COOCH3
R  
             52% 
      (2S,4R)-39a 
               53% 
         (2S,4R)-39b 
  
N
OH
COOCH3
R  
            41% 
      (2R,4R)-39a 
               33% 
         (2R,4R)-39b 
       
N
O O
R  
           85% 
      (1S,4S)-41a 
          ---------------- 
   
N
ACO
COOCH3
R  
           69% 
      (2R,4S)-48a 
               56% 
        (2R,4S)-48b 
    
N
OH
R
COOH
 
           92% 
      (2S,4R)-40a 
              85% 
        (2S,4R)-40b 
   
N
OH
R
COOH
 
           95% 
      (2S,4S)-40a 
         76% (two steps) 
       (2S,4S)-40b 
   
N
OH
R
COOH
 
            92% 
      (2R,4R)-40a 
               67% 
       (2R,4R)-40b 
  
N
OH
R
COOH
 
           92% 
      (2R,4S)-40a 
               94% 
       (2R,4S)-40b 
 
For all pairs of enantiomers displayed in the Table 3.1, of course, identical data {1H NMR, IR, 
MS} were obtained except for the changes of their optical rotations. Furthermore, all 
compounds that ever have the same pyrrolidine system and vary only in the side chain showed 
high similarities in their 1H NMR spectra (see Table 3.2). The protons of (2S,4R)-40a could 
be unequivocally assigned by H,H-cosy spectra. 
From a comparison of the 1H NMR spectrum of (2S,4S)-40a (Fig.3.1) with that of its 
precursor (2S,4R)-40a (Fig. 3.2), it is evident that the Mitsunobu reaction has indeed led to the 
desired transformation, namely the inversion  at C-4 of the pyrrolidine nucleus. The 1H NMR  
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Fig. 3.1.  The 1H NMR spectrum of (2S,4R)-40a (CD3OD, δ 2.0-7.6).  
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Fig. 3.2.   The 1H NMR spectrum of (2S,4S)-40a (CD3OD, δ 2.0-7.6).  
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data of (2S,4S)-40a-b and (2S,4R)-40a-b are given in the Table 3.2. From these it can be 
easily seen that dependently on the stereochemistry, the NMR data on the pyrrolidine ring 
system are very similar for identical stereochemistry [(2S,4R)-40a and (2S,4R)-40b] or quite 
different for different stereochemistry [(2S,4R)-40a and (2S,4S)-40a]. 
(2S,4R)-40a and (2S,4R)-40b: The chemical shift values of the corresponding protons are very 
close, besides the peaks of the corresponding protons  show the same shape and their coupling 
constants are very close, e.g H-2, H-3, H-5.  
(2S,4R)-40a and (2S,4S)-40a: Significant changes of the chemical shifts have happened 
between the corresponding protons, e.g. H-2 (4.05), H-3 (2.39) and H-5 (3.64) for (2S,4R)-
40a; H-2 (3.79), H-3 (2.48-2.63), H-5 (3.32-3.41) for (2S,4S)-40a. 
 
Table 3.2     Chemical shift and multiplicity of their pyrrolidine ring protons of (2S,4R)-40a-b    
                     and (2S,4S)-40a-b.  
1HNMR 
(CD3OD) 
(2S,4R)-40a 
N
OH
COOH
2
34
5
[α]D22 = -49.2 
(2S,4R)-40b 
N
OH
COOH
O
OMeMeO
OMe
2
34
5
[α]D28  = -24.8 
Proton δ Peak J         Hz δ peak J            Hz 
H-2 
H-3 
H-3 
H-4 
H-5 
H-5 
4.05 
2.09 
2.39 
4.43-4.45 
3.00 
3.64 
dd 
ddd 
ddt 
m 
dt 
dd 
10.6/7.6 
13.7/10.6/4.4 
13.7/7.6/2.0 
 
12.3/1.7 
12.3/4.4 
4.19 
2.15 
2.41 
4.43-4.46 
3.08 
3.40-3.61 
dd 
ddd 
ddt 
m 
br. d 
m 
10.1/7.8 
13.8/10.1/4.7 
13.8/7.8/1.9 
 
12.4 
 
1HNMR 
(CD3OD) 
(2S,4S)-40a  
N
OH
COOH
2
34
5
  [α]D20 = -42.8 
(2S,4S)-40b   [α]D24 = -11.9 
Proton δ Peak J        Hz δ Peak J      Hz 
H-2 
H-3 
H-3 
H-4 
H-5 
H-5 
3.79 
2.15-2.21 
2.48-2.63 
4.36-4.39 
3.03 
3.32-3.41 
dd 
m 
m 
m 
dd 
m 
10.7/4.4 
 
 
 
11.6/3.8 
 
3.98 
2.23-2.29 
2.54 
4.38-4.41 
3.06 
3.23-3.37 
dd 
m 
ddd 
m 
dd 
m 
11.0/4.0 
 
13.9/11.0/4.4 
 
11.6/3.6 
 
2
34
5 N
OH
COOH
O
OMeMeO
OMe
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3.2  Preparation of 4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylic acids and 
their N-substituted derivatives 
 
3.2.1 Attempts towards the synthesis of methyl N-unsubstituted 4-hydroxy-4-(4-
methoxyphenyl)-pyrrolidine-2-carboxylates 
 
In order to get the pyrrolidine derivatives from (2S,4R)-38 or (2R,4R)-38, the following steps 
seemed to be necessary: Protection of the amino function, oxidation of the 4-hydroxy group, 
addition of an organometallic reagent to the ketone and final N-deprotection. To the end the 
following efforts were made. 
Triphenylmethyl group (trityl, Tr) was chosen for N-protection since it is labile to mild acid 
and hydrogenation, and provides an excellent stability for the α-carboxylic acid ester with 
respect to racemization [48, 49]. Selective N-tritylation of (2S,4R)-38 was achieved with trityl 
chloride in 95% yield [50]. Swern oxidation of (2S,4R)-49 led to (2S)-50 in 97% yield. 
However, all attempts to add 4-methoxyphenylmagnesium bromide to 50 at low temperature 
(-78 °C ~ -30 °C) in ether or in THF as solvent, and in the presence of CeCl3 did not meet any 
expectation. A mixture of diastereomers (2S,4R)-51 and (2S,4S)-51 was obtained [(2S,4R)-51 
and (2S,4S)-51: 9% and 18%] when the reaction temperature was raised to –10 °C, though the 
yield remained low and 56% of the starting ketone was recovered. Unfortunately the reaction 
was accompanied by simultaneous addition of the Grignard reagent to the ester group in THF 
with CeCl3. The reason for this is unclear, but it has been reported that when trityl group is 
replaced with a 9-(9-phenylfluorenyl) group, a single diastereomer is achieved as addition 
product in a remarkable yield of 60%. This was thought to be due to a reduction of the steric 
hindrance, when going from a trityl to a 9-(9-phenylfluorenyl) group [51]. 
 
Scheme 8 
N
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COOCH3
H H
+
Cl-
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N
O
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               (2S,4R)-38                                (2S,4R)-49 Lit.                                     (2S)-50 
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3.2.2 Preparation of 4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylic acids 
and their N-substituted derivatives 
 
As already indicated in the Scheme 1 (see page 9), it was my intention to introduce a 4-(4-
methoxyphenyl) group into the C-4 position of 4-hydroxypyrrolidine derivatives via the 
corresponding. These should be accomplished by oxidation of the alcohol and addition of an 
organometallic reagent  
When (2S,4R)-39a-b and (2R,4R)-39a-b underwent Swern oxidation at –78 °C [52], (2S)-52a-b 
and (2R)-52a-b were obtained in 83%-89% yield (Table 3.3). A cleavage of the C-O bond of 
(2S)-52b and (2R)-52b was not observed though this bond is highly sensitive to acid. 
Scheme 9    
N
OH
COOCH3
R
Swern Oxid.
N
O
COOCH3
R
-78 °CTEA,  CH2Cl2,
 
                             (2S,4R)-39a-b                           (2S)-52a-b   
                             (2R,4R)-39a-b                          (2R)-52a-b   
 
Table 3.3  The yields of (2S)-52a-b and (2R)-52a-b by Swern oxidation 
R: a R: b 
Structure 
-CH2CH2CH=CPh2  -CH2CH2OC(p-MeOC6H4)3  
N
O
COOCH3
R  
87% 
(2S)-52a 
83% 
(2S)-52b 
N
O
COOCH3
R  
85% 
(2R)-52a 
89% 
(2R)-52b 
 
It is known for Grignard reagent that additives such as MgBr2 [53], LiClO4 [54], CuX and CeCl3 
[55, 56, 57] lead to a significant change in the reactivity of the organometallic compounds. For 
example, organocerium (III) reagent, generated from the reaction of organolithium or 
Grignard reagent with CeCl3 is more efficient with respect to addition reaction to carbonyl 
groups, especially to sterically encumbered groups. It was recognized that side abnormal 
reactions such as enolization, reduction, condensation, conjugate addition and pinacol 
coupling were suppressed with organocerium (III) reagent. It was found, that especially for N-
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protected 4-oxopyrrolidine derivatives the Grignard reagent in the presence of CeCl3 could 
boost the stereoselectivity [58, 59]. In the absence of CeCl3 as an additive, Grignard additions to 
the C-4 of N-benzyloxylcarbonyl-4-oxopyrrolidine derivatives gave only poor yields 
according to J. E. Bvaldwin and M. Rudolph [60], as enolization became the dominant process.  
 
Therefore in my work these organometallic addition reactions were carried out in two 
different ways either with (4-MeOC6H4)MgBr at –78 °C in ether (A) or with (4-
MeOC6H4)MgBr/CeCl3 at – 60 °C~ -78 °C in THF (B), leading to two distinct results (Table 
3.4): 
Under the condition (A) the cis addition product (cis referred to the ester group) was obtained 
as the major diastereomer and a good diastereoselectivity was achieved [(2S,4S)-53 / (2S,4R)-
53 or (2R,4R)-53 / (2R,4S)-53 range from 92:8 to 85:15 depending on the side chains].  
Under the condition (B) the trans addition product (trans referred to the ester group) was 
formed as the major diastereomer and the ratio for the diastereoselectivity was rather low 
[(2S,4S)-53 / (2S,4R)-53 or (2R,4R)-53 / (2R,4S)-53 from 48:52 to 30:70 for the different side 
chains].  
The configuration determination of the newly generated stereocenter will be discussed in 
section 3.5.1. 
Scheme 10    
N
O
COOCH3
R
N
OH
COOCH3
R
OMe
N
OH
COOCH3
R
OMe
+
ArMgBr
 
        (2S)-52a-b                     (2S,4S)-53a-b              (2S,4R)-53a-b    
        (2R)-52a-b                    (2R,4S)-53a-b               (2R,4R)-53a-b  
-CH2CH2CH=CPh2 -CH2CH2OC(p-MeOC6H4)3a: b:R =
  
For my reactions no remarkable improvement on the diastereoselectivity or yields was 
achieved, when CeCl3 as an additive and THF as a solvent were used. However, in contrast to 
the Grignard reagent that added cis to the ester function, here CeCl3 desired reagent gave rise 
to a trans addition (Table 3.4) 
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Table 3.4   Addition reactions of organometallic reagents to (2S)-52a-b and (2R)-52a-b. 
Ratio of d.s 
Yield 
(isolated ) 
N
     Starting 
material 
solvent 
CeCl3 
equiv. 
Temp. 
°C 
ArMgBr
equiv. (2S,4S)-53 
/(2S,4R)-53 
(2S,4S)-53 (2S,4R)-53 
1 (2S)-52a THF 1.40 -60 1.40 39 : 61 15% 30% 
2 (2S)-52a THF 2.10 -60 2.10 41 : 59 25% 31% 
3 (2S)-52a THF 1.40 -78 1.40 30 : 70 12% 28% 
4 (2S)-52a THF 0.47 -78 1.40 39 : 61 10% 19% 
5 (2S)-52a Et2O ----- -78 1.80 89 : 11 56% 6% 
6 (2S)-52b THF 1.40 -60 1.40 48 : 52 24% 26% 
7 (2S)-52b Et2O ----- -78 1.80 85 : 15 40% 5% 
    
(2R,4R)-53 
/(2R,4S)-53 
(2R,4R)-53 (2R,4S)-53 
8 (2R)-52a THF 1.40 -60 1.40 42 : 58 20% 28% 
9 (2R)-52b THF 1.40 -60 1.40 45 : 55 19% 21% 
 
1. Reaction time: 20 h. 
 
 
According to the description by T. Imamoto, et al. [57], the high efficiency of Grignard 
reagents that were modified with CeCl3 in such addition reactions is due to the high 
oxophilicity of Ce3+, which is supposed to be most important driving force for the promotion 
of carbonyl addition reaction. However this cannot explain the results I obtained with CeCl3 
as an additive. In my cases CeCl3 as an additive resulted in a reversal of the stereoselectivity. 
In contrast to the reactions described in literature [58, 59, 60] My starting materials 52a-b always 
contain an amino group, the Grignard reagent may form a chelate as delineated in Scheme 11, 
which would result in the cis addition product (2S,4S)-53a-b. Alternatively, the Grignard 
reagent may add to the ketofunction by forming a complex as depicted in Scheme 12. In this 
complex (Scheme 12) the ester function at the chiral center of C-2 should direct the 
organometallic reagent to the opposite face. For structural reason, however, this complex 
might give rise only to low asymmetric induction and consequently low diastereoselectivity. 
 
 
Scheme 11 
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Scheme 12 
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                                  (2S)-52a-b                                                      (2S,4R)-53a-b 
                                                                                                                                    
Compared with the transition state in Scheme 12, the one shown in Scheme 11 should prevail 
due to stronger binding with a lone pair of electrons of the amino group, and this would lead 
to (2S,4S)-53a-b as a major diastereomer,  
As CeCl3 and (4-MeOC6H4)MgBr were stirred at 0 °C in THF for one hour, it may be 
assumed that the following reagent 55 was formed: [55] 
Scheme 13 
(p-MeOC6H4)MgBr
CeCl3
(p-MeOC6H4)CeCl2
0 °C,  THF
 
                                   54                                                                      55 
 
The compound 55 is probably less suited to form a chelate similar to that shown for the 
Grignard reagent in Scheme 11. Therefore, the reagent should preferentially react via the 
convenient complex shown in Scheme 14, where the addition to the less barrier face should 
predominate to give (2S,4R)-53a-b from (2S)-52a-b. When the reaction temperature was 
lowered from – 60 °C to – 78 °C, the setereoselectivity slightly rose and the ratio of (2S,4R)-
53a : (2S,4S)-53a increased from 61:39 to 70:30.  
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Scheme 14 
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(2S)-52a                                                    (2S,4R)-53a 
 
When the amino group of the pyrrolidine cycle was protected with Cbz group (in the later 
Section 3.2.3 and 3.4.3), in this case with Grignard reagent (at -60 °C in ether), the (2S,4R) 
addition product was obtained as a major diastereomer. When CeCl3 and THF were used in 
this case, a single (2S,4R)-56 was obtained as a maijor diastereomer (see Scheme 15). These 
results about the addition to the C-4 of these pyrrolidine derivatives are in accord with those 
reported in literature [58, 59, 60].  
Scheme 15  
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In the final step the addition product 53a-b purified to single diastereomers, were subjected to 
an alkaline hydrolysis in methanol or ethanol at room temperature to give the free amino acids 
(2S,4R)-57a-b and (2S,4R)-57a-b, (2R,4S)-57a-b and (2R,4R)-57a-b. The yields for these 
reactions ranged from 74% to 94% (Table 3.5).  
 
Scheme 16  
N
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COOCH3
R
OMe
COOHN
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-
    
                        (2S,4R)-53a-b                                (2S,4R)-57a-b 
                        (2S,4S)-53a-b                                (2S,4S)-57a-b 
                        (2R,4S)-53a-b                                (2R,4S)-57a-b 
                        (2R,4R)-53a-b                               (2R,4R)-57a-b 
 
Table 3.5   The yields of 57a-b from the hydrolysis of 53a-b. 
R:  a R:  b 
Structure 
-CH2CH2CH=CPh2  -CH2CH2OC(p-MeOC6H4)3  
N
OH
OMe
R
COOH
 
74% 
(2S,4S)-57a 
89% 
(2S,4S)-57b 
N
OH
OMe
R
COOH
 
94% 
(2S,4R)-57a 
88% 
(2S,4R)-57b 
N
OH
OMe
R
COOH
 
88% 
(2R,4R)-57a 
89% 
(2R,4R)-57b 
N
OH
OMe
R
COOH
 
84% 
(2R,4S)-57a 
89% 
(2R,4S)-57b 
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3.2.3   Preparation of 4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylic acids 
 
After the organometallic reagents had failed to be added to the C-4 position of the 4-
oxopyrrolidine derivative (2S)-50 (Section 3.2.1), the protected N-trityl group of 50 was 
replaced by a N-Cbz group, which was expected to solve the problem.  
The required starting material (2S)-60 was synthesized according to literature procedures by 
the N-protection of (2S,4R)-25 with CbzCl at 0 °C (yield 90%) [61], by the esterification with 
diazomethane at 0 °C (yield 95%) [62, 63], and finally by Jones’ oxidation (yield 71%) [41]. 
Interestingly, when the last step was performed by Swern oxidation, (2S)-60 was obtained 
only in a very poor yield of 10%-27%.  
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                                          (2S,4R)-62                                         (2S,4R)-63 
 
In the case of (2S)-60, upon (4-MeOC6H4)MgBr (1.05 equiv.) pretreated with CeCl3 (1.05 
equiv.) in THF, only a single diastereomer (2S,4R)-61 was formed (at –60 °C for 4 hours) and 
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18% of the starting (2S)-60 was recycled. In contrast to the addition reactions of (4-
MeOC6H4)MgBr/CeCl3 to (2S)-52a-b and (2R)-52a-b, (1.40 equiv. For 20 hours) were less 
selective, as the addition to the C-4 ketone and to the ester group was occurred (31% yield). 
Hydrolysis of the ester group of (2S,4R)-61 by aq.1.0 N NaOH (1.05 equiv.) gave (2S,4R)-62 
in 88% yield. To avoid a reactive removal of Cbz group, deprotection was performed by 
hydrogenolysis over Pd-C in the presence of triethylamine to afford (2S,4R)-63 in 92% yield. 
Besides, triethylamine improved the solubility of the product in methanol. 
 
The synthetic sequence shown in Scheme 17 was also applicable to (2R,4R)-25 to give 
(2R,4S)-63. 
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3.3 Preparation of 4-hydroxypyrrolidine-2-acetic acids and of their N-substituted 
derivatives 
 
As illustrated in Scheme 2 (see page 10), the 4-hydroxypyrrolidine-2-acetic acid esters 32 are 
key intermediates for the synthesis of N-substituted 4-hydroxypyrrolidine-2-acetic acids 34 
and N-substituted 4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-acetic acids 37. First in the 
following reactions the preparations of the 4-hydroxypyrrolidine-2-acetic acid esters 32 are 
discussed (Section 3.3.1-3.3.2).  
 
3.3.1 Preparation of ethyl (2R,4R)-hydroxypyrrolidine-2-acetate via nucleophilic  
addition of a silyl ketene acetal to hydroxypyrrolidine derived N-acyliminium ions. 
 
Two of the most common methods for the extension of carboxylic acid chain by one carbon 
are based on the Wolf rearrangement and on the Kolbe nitrile synthesis (see below). In both 
cases the configuration of a stereocenter adjacent to the carboxy function is retained. 
Scheme 18 
 
R'COOR'' R'CH2OH
1.   TsCl
2.  NaCN
R'CH2CN R'CH2COOH
NaBH4
 
However, my intention was to accomplish the synthesis of the target compound 64 via N-
acyliminium ions derived from optically active hydroxypyrrolidines like (2S,4R)-58. This 
might also allow the stereoselective construction of the desired compounds as the chiral center 
at C-4 still present in the N-acyliminium ion should give rise to asymmetric induction of a 
hopefully reasonable size. 
Scheme 19 
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                                      (2S,4R)-58                               (2R,4R)-64 
 
For the conversion of (2S,4R)-58 into (2S,4R)-64, the following synthetic steps were 
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necessary: Electrolysis, protection of the 4-hydroxy group, nucleophilic addition to the N-
acyliminium ion and final deprotection (Scheme 19). 
1. Electrolysis: With the advantages of good yields and simple equipment in contrast to 
conventional chemical methods, the electrochemical oxidation of N-acylamines, also known 
as the Ross-Eberson-Nyberg reaction, is a unique approach to α-methoxy amides and α-
methoxy carbamates [64]. Both, α-methoxy amides and carbamates have been shown to be 
versatile synthetic intermediates. 
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Upon their treatment with a Lewis acid such as BF3 and TiCl4, these α-methoxy products, in 
general, give access to N-acyliminium ions, which can be efficiently trapped with appropriate 
nucleophiles (Nu−) to give the α-substituted products. 
In addition to simple amides, N-acylated α-amino acids may be also subjected to anodic 
oxidation reaction, the latter being even more suitable. N-acyliminium ions, which are formed 
during the anodic decarboxylation reaction, are trapped by a solvent such as methanol to give 
the α-methoxylated product in most cases in high yield (Scheme 18) [65, 66, 67]. In my case the 
α-methoxy derivative 69 was obtained from (2S,4R)-58 in 97% yield by anodic oxidation.  
 
Scheme 21 
 
 
 
 
                                                    3. Discussion of Synthetic Methods  - 30 - 
N
COOCH2Ph
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COOH N
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electrolysis, TEA
97%
10 °C
  
                                       (2S,4R)-58                                  69 
 
2. Protection of the 4-hydroxy group: 1-Ethoxy-1-(trimethylsilyloxy)ethene was selected as a 
nucleophile to be added to the N-acyliminium ion that should form from (2S,4R)-69 under the 
influence of a Lewis acid [68]. But despite of extensive variations of the reaction conditions, 
only small amounts of the desired products were obtained as a mixture of two diastereomers 
(determined by MS, IR, CHN analysis and analytical HPLC). As the failure was likely to arise 
from the free hydroxy group in the C-4 position, for this protection, 69 was treated with 
TBDMSCl in the presence of imidazole to provide 70 in 85% yield [69, 70]. 
Scheme 22 
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                                  69                                                            70   
 
3. Nucleophilic addition: For the substitution reactions the mixture of the diastereomers 70 
was employed. While N-acyliminium ions are formed during the course of the reaction, it is 
unlikely that the stereochemistry at the C-2 of 70 will have any influence on diastereomeric 
composition of the final products, which has also been reported by M. Thaning and Lars-G. 
Wistrand [71]. For the transformation process of 70 to (2R,4R)-71 and (2S,4R)-71, a series of 
experiments were made in order to optimize the yield and the stereoselectivity of this process. 
The reaction details are summarized in Table 3.6. 
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Scheme 23 
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                    70                                              cis-(2R,4R)-71          trans-(2S,4R)-71 
 
Table 3.6  Reactions of 70 with nucleophiles in the presence of Lewis acid. 
Yield (isolated) 
No. Nu: 
Addition 
order 
Temp. Time 
Ratio of 
cis/trans 
cis- 
(2R,4R)-71 
trans-
(2S,4R)-71 
1 A (70 + A) + BF3 20 °C 3 h 87:13 8% 54% 
2 A (70 + A) + BF3 -78 °C 4 h 92:8 5% 79% 
3 A (70 + A) + BF3 -78 °C 4 h 87:13 9% 79% 
4 A (70 + A) + TiCl4 -78 °C 16 h 80:20 5% 27% 
5 A (70+ BF3) + A -78 °C 4 h 97:3 1.7% 74% 
6 A (70 + BF3) + A -78 °C 18 h 97:3 1.7% 62% 
7 A (70 + TiCl4) + A -78 °C 16 h 89:11 7% 57% 
8 B (70 + BF3) + B -78 °C 3 h ....... 0 0 
9 B (70 + BF3) + B 20 °C 19 h ........ 0 0 
 
A: 1-Ethoxy-1-(trimethylsilyloxy)ethene, B:  Ethyl bromozincacetate (0.50 M in CH2Cl2); Lewis acid TiCl4 was 
used as a 1.0 M solution in CH2Cl2; the ratio of 70 : Nu : Lewis acid = 1 : 3.15 : 2.1, for all entrances except for 
No. 3 and 5, where the ratio was 1 : 4 : 2.1. 
 
From the results displayed in Table 3.6, the following conclusion can be drawn. 
(1) A raise in temperature and a prolongation of the reaction time led to a decrease in yields, 
possibly because of a cleavage of silyl protective group and Cbz group by the applied Lewis 
acids, compare No.1 with No.2, or No.5 with No.6; No dramatic change of the 
diastereoselectivity occurred when the temperature was varied, which is in concord with 
literature reports [71], compare No.1 with No.2 or with No.3, 
(2) The highest stereoselectivity was achieved when the starting material 70 was first mixed 
with the Lewis acid (15 minutes at –78 °C) before the nucleophile was added. This seems to 
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imply that the reaction may take place along a different pathway (SN2-like reaction, ion pairs 
or free ions as intermediates) and that a more or less free N-acyliminium ion may be 
beneficial for a high stereoselectivity. On the other hand, one undergoes the risk of 
decomposition victim of the protective group when 70 is pretreated with a Lewis acid;  
(3) BF3⋅Et2O appeared to be slightly better for a higher stereoselectivity than TiCl4;  
(4) The Reformasky reagent (ethyl bromozincacetate 0.50 M in CH2Cl2) failed to undergo the 
desired reaction.  
 
In all cases, the cis isomer (Table 3.6) was preferentially formed (for the confirmation of the 
configuration see Section 3.5.2). Philippe Renaud and Dieter Seebach [72] explained this high 
diastereoselectivity as the formation of 72, in which the upper side of the cycle is occupied, 
and therefore the nucleophile preferentially attacks the compound from the bottom. 
  
+
N
H
O
Si
H
O
PhCH2O
CH2=CH(OSiOMe3)(OEt)  
BF3(OMe)
-
                                                                            72  
4. Deprotection:  
(2R,4R)-71 was liberated from the O-silyl group by means of n-Bu4NF in THF at room 
temperature. The resulting compound (2R,4R)-73 (88% yield) [71, 73, 74] was subjected to 
hydrogen over 10% Pd-C in conc. HCl/EtOH to give (2R,4R)-64 (89% yield). 
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3.3.2    Preparation of methyl (2S,4R)-4-hydroxypyrrolidine-2-acetate 
 
3.3.2.1 Attempts of nucleophilic addition to N-acyliminium ions  
 
A synthesis of 76 from 74 has been reported in literature [70, 71]. For this reaction a neighboring 
group effect (Scheme 25) is postulated to explain the observed trans selectivity. 
Scheme 25 
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My idea was to employ 77 as an α-amidoalkylation reagent, which might provide a 
convenient access to the desired 2,4-trans substituted pyrrolidine derivatives. Supposed that a 
similar neighboring group is effective (see 79) as mentioned above, and then the addition 
reaction should proceed for 77 with trans selectivity as well.  
Scheme 26  
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The synthesis of the starting material 77 was easily accomplished by treating 69 with CbzCl 
in the presence of 4-dimethylaminopyridine (yield 68%). A series of amidoalkylation 
reactions were carried out with 77 at –78 °C for 4 h (yields of 3-13%), in which 1-ethoxy-1-
(trimethylsilyloxy)ethene and Lewis acid BF3.Et2O were used. These reactions were 
performed under various conditions and the addition order of the reagent was also changed. 
But in each case only the cis-(2R,4R)-80 and no trans addition product (2S,4R)-80 was found, 
while the yields remained low (3-13%). The cis configuration of (2R,4R)-80 was ascertained 
by the comparison of the analytical data {1H NMR, [α]} of this compound with those of 
(2S,4R)-82 (see Scheme 27 and 34). Possibly, a neighboring predominated group effect 
arising from the carbamate function (similar to the complex 72) predominated as compared to 
the one of the carbonate group in the 4-position of the pyrrolidine ring. 
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3.3.2.2 Preparation of methyl (2S,4R)-4-hydroxypyrrolidine-2-acetate via Wolf 
rearrangement 
 
After the failure to get the trans-(2S,4R)-80 by amidoalkylation reactions with 77 (Scheme 
26), my attention turned to an alternative synthesis. I decided to start from a suitable 
pyrrolidine-2-carboxylic acid derivative with (2S)-configuration [see e.g. (2S,4R)-81] and to 
perform an elongation of the carboxylic acid side chain by a Wolff rearrangement, which is 
known to proceed with retention of configuration and should give the desired product. In 
order to be able to remove both protective groups in a single step by hydrogenation after the 
Wolff rearrangement, (2S,4R)-81 was used as starting material. (2S,4R)-81 was prepared by 
an literature method [44]. But only low yields were obtained from the Wolff rearrangement 
(overall yield of 12%). Evidence for the configuration at C-2 of (2S,4R)-82  that it had been 
retained  came from a comparison of its 1H NMR data with related compounds. 
Scheme 27 
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The acid sensitivity of the carbonate function was blamed to account for the low yield. 
Therefore, instead of the carbonate function a benzyl group seemed to be more appropriate for 
the protection of the hydroxy function. (2S,4R)-58 was treated with NaH and subsequently 
refluxed with benzyl bromide in THF to give (2S,4R)-83 in 90% yield [75]. Then (2S,4R)-83 
was transformed into the diazoketone (2S,4R)-84 (80% yield) by means of (COCl)2 (DMF as 
a catalyst) and diazomethane (at 0 °C). Finally, the rearrangement of 84 initiated by AcOAg-
TEA as a catalyst, gave (2S,4R)-85 in 81% yield.  
Scheme 28 
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Hydrogenolysis over 10% Pd-C under ambient pressure provided the totally deprotected 
amino acid ester (2S,4R)-86 in 90% yield [76, 77, 78]. 
Scheme 29 
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But also a partial deprotection of (2S,4R)-85 could be achieved, when ammonium formate 
was applied as a hydrogen donor in the presence of 10% Pd-C as a catalyst [79, 80]. Then, only 
the Cbz group was removed to yield the amino acid ester (2S,4R)-87 [81]. 
Scheme 30 
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3.3.3   Preparation of 4-hydroxypyrrolidine-2-acetic acids and of their N-substituted 
derivatives 
 
3.3.3.1  Preparation of N-substituted (2R)-4-hydroxypyrrolidine-2-carboxylic acids 
 
In analogy to the preparation of (2S,4R)-40a-b (Scheme 3), (2R,4R)-89a-d were obtained via 
alkylation of (2R,4R)-64 with the corresponding halides of 24a-d and a subsequent hydrolysis 
of the ester group with aqueous 1.0 N NaOH (Table 3.7). 
Furthermore, similar to the preparation of (2R,4S)-40a-b (Scheme 7), the configuration at C-4 
of (2R,4R)-88a-d was inverted by a Mitsunobu reaction. Upon hydrolysis of the products 
(2R,4S)-90a-d with aqueous 1.0 N NaOH the final compounds (2R,4S)-89a-d were obtained 
(Table 3.7). 
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R  =  24a-c,     X  =  Br;                
R  =  24d,        X  =  I.     (see Table 3.7) 
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Fig. 3.3.  The 1H NMR spectrum of (2R,4R)-88a (CDCl3, δ
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Fig. 3.4.     The 1H NMR spectrum of (2R,4R)-88a (CDCl3, δ 
The structures of the compounds mentioned above could be confirmed by the 1H NMR and 
H,H-Cosy spectra in the combination with IR and MS spectra as well as by the combustion of 
analysis. 
For (2R,4R)-88a the locations of the protons were also confirmed by the 1H{13C}-Cosy 
spectra. The 1H NMR spectrum of (2R,4R)-88a is presented as an example in Fig. 3.3 and 3.4.  
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Table 3.7                 The yields of 88a-d, 89a-d and 90a-d. 
R:  a b c d 
 
Structure 
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3.3.3.2   Preparation of N-substituted (2S)-4-hydroxypyrrolidine-2-acetic acids  
 
(2S,4R)-89a-d and (2S,4S)-89a-d were synthesized in analogy to the preparation of (2S,4R)-
40a-b and (2S,4S)-40a-b (Scheme 3 and 4). Thus, they started from (2S,4R)-86 and went 
along (2S,4R)-91a-d and (1S,5S)-92a-d as intermediates. Also the compounds (2S,4R)-94a 
and c were prepared in a similar manner. In this case (2S,4R)-87 as a starting material was N-
alkylated with the bromides of 24a and c to yield (2S,4R)-93a and c, from which the (2S,4R)-
94a and c were obtained.  
Scheme 32 
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R  =  24a-c,   X  =  Br;  R  =  24d,      X  =  I.   (see Table 3.8) 
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                (2S,4R)-87                                  (2S,4R)-93a, c                    (2S,4R)-94a, c 
 
R  =  24a, c  (see Table 3.8) 
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Table 3.8   The yields of 91a-d, 92a-d, 93a-d, 93a and c, 94a and 94c. 
R:  a b c d 
Structure 
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From the synthetic strategy shown above, I had obtained two sets of diastereomers that 
differed with respect to the configuration at C-4 of the pyrrolidine nucleus. 
For these two sets of diastereomers e.g. (2S,4R)-89a-d and (2S,4S)-89a-d, remarked 
differences in 1H NMR spectra for pairs of diastereomeric compounds were observed. In 
Table 3.9 the 1H NMR data of (2S,4R)-89a and (2S,4S)-89a are shown as examples. 
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Table 3.9      Chemical shift values of the partial protons of (2S,4R)-89a and (2S,4S)-89a. 
1H NMR 
(CD3OD) 
(2S,4R)-89a  
N
OH
COOH
2
34
5
[α]D20 = -69.4 (2S,4S)-89a   
N
OH
COOH
2
34
5
 [α]D20 = -51.5 
Proton δ Peak J             Hz δ Peak J                Hz 
H-2 
H-3 
H-3 
H-4 
H-5 
H-5 
H-α 
H-α 
3.74-3.80 
1.93 
2.13 
4.38-4.41 
2.82 
3.46-3.53 
2.46 
2.70 
m 
ddd 
ddt 
m 
d 
m 
dd 
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13.6/11.4/5.1 
13.6/6.5/1.7 
 
12.5 
 
16.5/3.0 
16.5/5.9 
3.46-3.57 
1.71-1.77 
2.46-2.57 
4.35-4.40 
2.92-3.01 
3.17-3.29 
2.46-2.57 
2.63 
m 
m 
m 
m 
m 
m 
m 
dd 
 
 
 
 
 
 
 
16.7/6.3 
  α α 
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3.3.3.3    Preparation of 4-hydroxypyrrolidine-2-acetic acids 
 
The intermediates (2S,4R)-86 and (2R,4R)-73 were employed in the preparation of the free 
amino acids (2S,4R)-97 and (2R,4R)-97. 
 
For the protection of the amino group, (2S,4R)-86 was treated with CbzCl (in the presence of 
4-dimethylaminopyridine) to give the known compound (2S,4R)-95 [73] in 59% yield, which 
was identical with that one from Wolff rearrangement (Scheme 27). In addition, this reaction 
gave (2S,4R)-82 in 19% yield. By a comparison of the analytical data of (2S,4R)-95 and 
(2S,4R)-96 with those in literature [73], also the configuration of (2S,4R)-86 could be deduced. 
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              (2S,4R)-86                                        (2S,4R)-95 Lit.                  (2S,4R)-82 
 
(2S,4R)-95 and (2R,4R)-73 were subjected to 1.0 N NaOH (1.05 equiv.) at room temperature 
in methanol to give (2S,4R)-96 and (2R,4R)-96, and subsequent hydrogenolysis of (2S,4R)-96 
and (2R,4R)-96 over Pd-C gave the respective free amino acids (2S,4R)-97 and (2R,4R)-97 in 
excellent yields. 
Scheme 35 
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Scheme 36 
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                (2R,4R)-73                                 (2R,4R)-96                               (2R,4R)-97      
 
In a manner similar to the preparation of (1S,5S)-90 and (2R,4S)-92 (Scheme 31 and 32), the 
configuration at C-4 of (2S,4R)-96 and (2R,4R)-73 was inverted by a Mitsunobu reaction. In 
order to avoid that the carbamate group is affected during hydrolysis, a readily hydrolyzed 
formyl group was used in place of the acetyl group.  
Scheme 37 
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                  (2R,4R)-73                                            (2R,4S)-99 
 
The controlled hydrolysis of (1S,5S)-98 and (2R,4S)-99, and a subsequent hydrogenolysis 
yielded (2S,4S)-97 and (2R,4S)-97, respectively. 
Scheme 39 
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           (2R,4S)-99                                         (2R,4S)-96                                 (2R,4S)-97    
 
The chemical shift differences of the two diastereomers (2S,4S)-97 and (2S,4R)-97 are 
reflected in Table 3.10. Remarkable differences of the chemical shifts of protons are seen for 
the C-3 and C-α positions.  
 
Table 3.10      Chemical shift values of (2S,4R)-97 and (2S,4S)-97. 
1H NMR 
(CD3OD) 
(2S,4R)-97    
N
OH
COOH
H
2
34
5
  [α]D20 = +1.3 (2S,4S)-97      
N
OH
COOH
H
2
34
5
 [α]D20 = +5.3 
Proton δ Peak J             Hz δ Peak J                Hz 
H-2 
H-3 
H-3 
H-4 
H-5 
H-5 
H-α 
H-α 
4.02-4.08 
1.83 
2.14-2.20 
4.56-4.59 
3.22 
3.43 
2.55 
2.64 
m 
ddd 
m 
m 
dt 
dd 
dd 
dd 
 
14.1/11.4/4.4 
 
 
12.8/1.5 
12.8/4.2 
16.6/7.7 
16.6/5.5 
3.93-3.99 
1.77 
2.55 
4.62-4.65 
3.32 
3.38 
2.72-2.74 
2.72-2.74 
m 
dddd 
ddd 
m 
ddd 
dd 
m 
m 
 
14.2/7.3/3.6/1.4 
14.2/8.8/6.0 
 
12.5/2.4/1.4 
12.5/4.9 
 
 
α  α 
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3.4   Preparation of 4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-acetic acids and of 
their N-substituted derivatives 
 
3.4.1 Preparation of N-substituted 4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-acetic 
acids  
 
As designed in Scheme 2 the four stereoisomers of 104b-c could be prepared from (2S,4R)-
91b-c and (2R,4R)-88b-c in analogy to the preparation of 57a-b (Section 3.2.2) by a synthetic 
sequence: Swern oxidation of the 4-hydroxy group, addition of an organometallic reagent to 
the C-4 position and final hydrolysis. 
Swern oxidation:  
In the first step the 4-oxopyrrolidine-2-acetic acid esters (2S)-100a-c and (2R)-101b-c were 
prepared from (2S,4R)-91a-c and (2R,4R)-88b-c by Swern oxidation. The yields amounted to 
81-92% yields. 
Scheme 41 
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-78 °C TEA,  CH2Cl2,
 
                     (2S,4R)-91a-c                                 (2S)-100a-c   
                     (2R,4R)-88b-c                                 (2R)-101b-c  
(for R and R1  see the following Table 3.11)  
 
Table 3.11   Yields of (2S)-100a-c and (2R)-101b-c obtained by Swern oxidation 
R:  a R:  b R:  c 
Structure 
-CH2CH2CH=CPh2  -CH2CH2OC(p-MeOC6H4)3 -CH2CH2CH=C
S
S
 
N
O
R
COOCH3
 
83% 
(2S)-100a 
81% 
(2S)-100b 
92% 
(2S)-100c 
N
O
R
COOC2H5
 
--------------------- 
87% 
(2R)-101b 
88% 
(2R)-101c 
 
Addition of the organometallic reagent: 
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The addition of the organometallic reagent to (2S)-100b-c and (2R)-101b-c was carried out in 
two different ways. The reaction was either performed at –78 °C in ether without any additive 
(A), or at –78 °C in THF with CeCl3 (B). Further details of the reactions are specified in Table 
3.12 (for the determination of the configuration at C-4 of the products 102b-c and 103b-c see 
Section 3.5.3).  
Scheme 42 
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       R1 = Me:   (2S)-100b-c               (2S,4S)-102b-c            (2S,4R)-102b-c  
       R1 = Et:     (2R)-101b-c              (2R,4S)-103b-c          (2R,4R)-103b-c  
-CH2CH2CH=C
S
S
-CH2CH2OC(C6H4-p-OMe)3b. c.R   =   
  
Table 3.12  Addition reactions of organometallic reagents to (2S)-100b-c and (2R)-101b-c  
Yield (isolated) Recovered (%) 
No. 
Starting 
material 
Solvent 
CeCl3 
equiv. 
ArMgBr
equiv. 
d.s 
(2S,4S)-102 (2S,4R)-102 (2S)-100 
1 (2S)-100b Et2O …… 1.80 81 : 19 47 % 14 % 33 % 
2 (2S)-100b THF 1.40 1.40 17 : 83 5 % 43 % 32 % 
3 (2S)-100c Et2O ……. 1.80 87 : 13 47 % 11 % 24 % 
4 (2S)-100c THF 1.40 1.40 21 : 79 8 % 24 % 41 % 
     d.s (2R,4R)-103 (2R,4S)-103  (2R)-101 
5 (2R)-101b Et2O ……. 1.80 79 : 21 50 % 15 % 31 % 
6 (2R)-101b THF  1.40 1.40  1 % 44 % 26 % 
7 (2R)-101c Et2O ……. 1.80  54 % 10 % 10 % 
8 (2R)-101c THF  1.40 1.40 19 : 81 7 % 25 % 26 % 
 
1. Reaction time: 20 hours; reaction temperature: -78 °C. 
2. For the addition reactions performed with (2S)-100c and (2R)-101c in THF, a side product, possibly formed 
by intermolecular condensation reaction (determined by MS and 1H NMR), was isolated in about 10% yield. 
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By comparison of Table 3.4 with Table 3.12 (for the reactions performed under the same 
conditions), it can be found that the addition reaction of organometallic reagent to (2S)-100b-
c and (2R)-101b-c had proceeded with the same sense of  asymmetric induction as those to 
52a-b (Scheme 10). Only slight changes in the stereoselectivities and yields occurred:  
1) Under condition (A), the stereoselectivity slightly diminished, compare No.5 (89:11) and 
No.7 (85:15) in Table 3.4 with No.3 (87:13), No.1 (81:19) and No.5 (79:21) in Table 3.12. 
2) Under condition (B), however, the stereoselectivity increased to a small extent, compare 
No.3 (30:70) in Table 3.4 with No.2 (17:83), No.4 (21:79), No.8 (19:81) in Table 3.12. 
In accord with my assumptions regarding the reaction mechanism put forth in Section 3.2.2, 
these small variations might be explained as follows: 
As claimed in Section 3.2.2, (4-MeOC6H4)MgBr formed a chelate with (2S)-52a-b in ether. 
The binding of (4-MeOC6H4)MgBr with (2S)-100b-c should be also preferentially located at 
the upper face of the molecule (Scheme 43), which would lead to the cis addition product 
(2S,4S)-102b-c. But this complexation might be a little weaker than that of (2S)-52a-b due to 
the elongated ester side chain, thus, the diastereoselectivity became a little bit lower. 
Scheme 43 
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(2S)-100b-c                                                   (2S,4S)-102b-c 
 
The extension of the carboxylic acid side chain at C-2 also increased its bulkiness and thereby 
its ability to direct the attack to the opposite face as depicted in Scheme 44, thus, leading to a 
slightly enhanced stereoselectivity. 
Scheme 44 
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                         (2S)-100b-c                                              (2S,4R)-102b-c 
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Hydrolysis:  
All stereoisomers 102b-c and 103b-c were subjected to hydrolysis with aq. 1.0 N NaOH in 
methanol at room temperature to yield the free amino acids (2S,4R)-104b-c, (2S,4S)-104b-c, 
(2R,4S)-104b-c and (2R,4R)-104b-c. The yields ranged from 70%-98% (Table 3.13). 
Scheme 45 
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R1   =  Me:     (2S,4R)-102b-c                                    (2S,4R)-104b-c 
                      (2S,4S)-102b-c                                    (2S,4S)-104b-c 
R1  =  Et:       (2R,4S)-103b-c                                    (2R,4S)-104b-c 
                      (2R,4R)-103b-c                                   (2R,4R)-104b-c 
R = 24b-c (see Table 3.13) 
 
Table 3.13  The yields of 104b-c from the hydrolysis of 102b-c and 103b-c series 
R:  b R:  c 
Structure 
-CH2CH2OC(C6H4-p-OMe)3  -CH2CH2CH=C
S
S
 
N
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OMe
COOH
 
73% 
(2S,4S)-104b 
70% 
(2S,4S)-104c 
N
OH
R
OMe
COOH
 
86% 
(2S,4R)-104b 
98% 
(2S,4R)-104c 
N
OH
R
OMe
COOH
 
89% 
(2R,4S)-104b 
82% 
(2R,4S)-104c 
N
OH
R
OMe
COOH
 
93% 
(2R,4R)-104b 
95% 
(2R,4R)-104c 
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3.4.2   Attempts towards preparation of N-substituted 4-oxopyrrolidine-2-acetic acids 
 
4-Oxopyrrolidine-2-acetic acid derivatives were of interest for biological evaluation. 
Therefore, (2S)-100a was subjected to an aqueous hydrolysis with 1.0 N NaOH in methanol at 
room temperature. But the amino acid (2S)-105a could be not obtained after neutralization of 
the reaction mixture. The reaction product had likely undergone reverse Michael reaction, for 
which following pathways may be considered: 
Scheme 46 
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3.4.3  Preparation of N-unsubstituted 4-hydroxy-4-(4-methoxyphenyl)- pyrrolidine-2-
acetic acids 
 
 
A procedure similar to the preparation of 63 series (Scheme 17) was used for the synthesis of 
(2S,4R)-111 from (2S,4R)-95 (Scheme 48) and of (2R,4S)-111 from (2R,4R)-73 (Scheme 49). 
First Jones oxidation of (2S,4R)-95 gave (2S)-108 in 76% yield and then the addition of (4-
MeOC6H4)MgBr/CeCl3 (1.05 equiv.) in THF to (2S)-108 led to (2S,4R)-109 in 25% yield, 
thereby 52% of (2S)-108 was recovered. However, this reaction led to 5% of a side product, 
which came from a simultaneous addition reaction to the ester group. Therefore, an addition 
reaction of a Grignard reagent (1.05 equiv.) to (2S)-108 was carried out at –78 °C (for 4 hours 
in ether) and gave (2S,4R)-109 in low yield (38%). After purification by column 
chromatography and subsequent prep. HPLC, no other stereoisomer could be found but some 
starting material (2S)-108 could be recovered (52%). In the next step (2S,4R)-109 was 
subjected to an hydrolysis with 1.0 N NaOH (1.05 equiv.) to yield (2S,4R)-110 (81%). A final 
hydrogenolysis of (2S,4R)-110 over Pd-C in the presence of triethylamine gave the target 
compound (2S,4R)-111 in 100% yield. 
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Along an analogous synthetic route to the one shown above the enantiomorphic (2R,4S)-111 
was prepared from (2R,4R)-73 via (2R)-112 and (2R,4S)-113. The overall yield (25%) was 
close to the one (overall yield 23%) obtained in the first sequence (Scheme 48). 
Scheme 49 
N
OH
COOC2H5
COOCH2Ph
N
O
COOCH2Ph
COOC2H5
N
OH
COOCH2Ph
OMe
COOC2H5-78 °C, 4 h
37%
Jones Oxid.
Et2O,
(p-MeOC6H4)MgBr
77%
 
      (2R,4R)-73                                 (2R)-112                                           (2R,4S)-113 
COOH
N
OH
COOCH2Ph
OMe
1.0 N  NaOH
MeOH, r.t.
COOH
N
OH
H
OMe
H2, 10% Pd-C
TEA,   MeOH,  r.t.
91% 95%
 
                                                      (2R,4S)-110                                     (2R,4S)-111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                    3. Discussion of Synthetic Methods  - 53 - 
3.5    Determination of the stereochemistry of 4-arylsubstituted pyrrolidine derivatives 
obtained by addition of organometallic reagents to 4-oxopyrrolidines 
 
3.5.1   Determination of the stereochemistry at C-4 of (2S,4R)-53a-b, (2S,4S)-53a-b and 
(2S,4R)-63. 
 
The additions of the organometallic reagent to the C-4 position of (2S)-52a-b and (2R)-52a-b 
described in Section 3.2.2 yielded pairs of diastereomers of 53a-b, from which a pair of 
diastereomers (2S,4R)-53a and (2S,4S)-53a were selected for further investigation of the 
stereochemistry at C-4 of these compounds. The stereochemistry found for (2S,4R)-53a and 
(2S,4S)-53a might finally serve as a basis, on which the stereochemistry of the remaining 
compounds 53a-b, 57a-b and 63 may be deduced. NOE (nuclear overhauser effect) 
technology is a very convenient method for the determination of the relative stereochemistry 
of a compound. According to the known configuration at C-2, NOE measurements for 
(2S,4R)-53a and (2S,4S)-53a might give a solution for their configuration at C-4. 
Unfortunately, the signals in the NOE spectra were too weak and not meaningful with respect 
to the configuration at C-4. But these measurements gave another information, which allowed 
the assignment of the signals that arose from the protons of the two-methoxy groups 
(COOCH3 and ArOCH3) in the 1H NMR spectra. 
 
Each of the 57a-b series must exhibit the same stereochemistry as the corresponding one of 
the 53a-b series, which was obtained from the basic hydrolysis of the formers without any 
influence on the stereochemistry. Thus, I attempted to determine the stereochemistry of these 
hydrolysis products. If one of two diastereomers (2S,4R)-57a and (2S,4S)-57a could be 
transformed to a lactone, then the hydrolysis of the obtained lactone under basic condition 
must give (2S,4R)-57a, which would be identical with one of the two diastereomers used as 
starting materials. Consequently, the stereochemistry of both 57a-b and 53a-b series would 
become known. However, all attempts from (2S,4R)-57a or (2S,4S)-57a employing CDI or 
Ph3P/DEAD or DCC as a dehydrating agent failed to form a lactone. 
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Scheme 50 
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                            (2S,4R)-61                                                      (2S,4R)-114 
 
To eliminate the disturbance from the phenyl groups of the N-substituent in NOE 
measurements, finally I prepared (2S,4R)-114 (100% yield) from (2S,4R)-61 by 
hydrogenation over 10% Pd-C in the presence of triethylamine. The explicit 1H NMR 
spectrum (Fig. 3.5) and the quantitative yield clearly indicate that the configuration at C-4 of 
(2S,4R)-61 remained unchanged through the hydrogenation process. In a preliminary 
experiment, however, when the deprotection reaction had been carried out in methanol in the 
absence of triethylamine, a mixture consisting of 114 and its 4-dehydroxylated product were 
obtained, unluckily, they were not separable. A clear proof from the NOE spectrum of 
(2S,4R)-114 (Fig. 3.6) reveals that the 4-aromatic group is located cis to H-2. 
Fig. 3.5. The 1H NMR spectrum of (2S,4R)-114 (CDCl3). 
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                                                  Fig. 3.6   The NOE spectrum of (2S,4R)-114 (CDCl3). 
 
In analogy to the preparation of (2S,4R)-39 (Scheme 3), (2S,4R)-114 was N-alkylated with the 
bromide of 24a to give (2S,4R)-53a in 53% yield. This product was found to be identical with 
the major diastereomer obtained from the addition reaction of (p-MeOC6H4)MgBr/CeCl3 
(THF) to (2S)-52a by comparison of their analytical data {1H NMR, IR, MS, [α], M.p and 
elementary analysis}. Thus, the second isomer of this pair of diastereomers was 
unequivocally identified as (2S,4S)-53a.  
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Fig. 3.7. The 1H NMR spectrum of (2S,4R)-53a (CDCl3).  
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Fig. 3.8. The 1H NMR spectrum of (2S,4S)-53a (CDCl3). 
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Table 3.14  Chemical shift values of some protons of (2S,4R)-53a and (2S,4S)-53a. 
1HNMR 
(CD3OD) 
(2S,4R)-53a 
N
OH
OMe
COOCH3
2
3
5
[α]D20  = -49.4 (2S,4S)-53a  
N
OH
OMe
COOCH3
2
3
5
 [α]D20  = -1.8 
Proton δ Peak J             Hz δ Peak J                Hz 
H-2 
H-3 
H-3 
H-5 
H-5 
3.38 
2.15 
2.49 
2.63-2.70 
3.09 
dd 
ddd 
dd 
m 
dd 
10.7/3.2 
13.9/3.2/2.0 
13.9/10.7 
 
9.2/2.0 
3.78 
2.34 
2.34 
2.67-2.75 
3.35 
t 
d 
d 
m 
d 
7.7 
7.7 
7.7 
 
10.3 
 
 
Furthermore, the phenomena in the 1H NMR spectra of (2S,4R)-53a and (2S,4S)-53a (Fig. 3.7 
and 3.8, and Table 3.12) support the above conclusions. H-2 (δ 3.38) of (2S,4R)-53a is 
situated at higher field than H-2 (δ 3.78) of (2S,4S)-53a. The aromatic group of (2S,4R)-53a 
might account for the result of a magnetic shielding when it is located cis to H-2. Moreover, 
the hydroxy proton of (2S,4R)-53a was found to be at lower field than that of (2S,4S)-53a, 
which might be attributed to an intramolecular hydrogen bond between the 4-hydroxy group 
and the carbonyl group.   
 
Finally the configuration of the products (2S,4R)-63 and (2R,4S)-63 must be as given. These 
compounds have been prepared from (2S,4R)-61 and (2R,4S)-61, respectively, by a synthetic 
sequence  hydrolysis of the ester function, reductive removal of the Cbz group  that 
should not affect the stereocenters. Thus, the stereochemistry assigned for (2S,4R)-61 and 
(2R,4S)-61 (see Scheme 17) must apply to (2S,4R)-63 and (2R,4S)-63. 
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3.5.2 Elucidation of the stereochemistry of (2S,4R)-86 and (2R,4R)-64. 
 
 The proof for the stereochemistry of (2S,4R)-86 has been presented in section 3.3.3.3. It 
seems reasonable that the relative configuration of (2R,4R)-64 at C-2 can be deduced by a 
comparison of its 1H NMR spectrum with the data of (2S,4R)-86 (Fig.3.9 and 3.10). The 
chemical shifts and coupling constants for some protons of (2S,4R)-86 and (2R,4R)-64 are 
distinctly different. These manifest that 64 must be of cis stereochemistry because (2S,4R)-86 
is trans substituted,  
 
Table 3.15 Chemical shift values of some protons of (2S,4R)-86 and (2R,4R)-64. 
 
1H NMR 
(CD3OD) 
N
OH
COOCH2CH3
H  HCl.
2
34
5
 
(2R,4R)-64      [α]D20 = -34.0 
N
OH
H
COOCH3
HCl.
2
34
5
 
(2S,4R)-86      [α]D20 = +42.8 
Proton δ Peak J             Hz δ Peak J                Hz 
H-2 
H-3 
H-3 
H-4 
H-5 
H-5 
H-α 
H-α 
4.00-4.08 
1.79 
2.43 
4.50-4.53 
3.22 
3.27 
2.92 
2.98 
m 
ddt 
ddd 
m 
dd 
dt 
dd 
dd 
 
14.1/4.7/1.9 
14.1/9.8/5.0 
 
11.9/3.6 
11.9/1.9 
18.0/5.2 
18.0/9.4 
3.99-4.07 
1.71 
2.09 
4.38-4.41 
3.09 
3.25 
2.69 
2.82 
m 
ddd 
ddt 
m 
dd 
dd 
dd 
dd 
 
13.7/11.4/4.0 
13.7/6.4/1.5 
 
12.2/1.5 
12.2/3.7 
18.0/9.9 
18.0/4.0 
  α   α 
N
OH
H
COOCH3
HCl.
2
34
5
(2S,4R)-86 
Fig. 3.9. The 1H NMR spectrum of (2S,4R)-86 (CD3OD). 
  α 
 5 
     CH3 
α
 5 
  α 
  4 
3 
 3  2 
 
                                                    3. Discussion of Synthetic Methods  - 59 - 
  
N
OH
COOCH2CH3
H  HCl.
2
34
5
(2R,4R)-64 
CH2CH3 
α 
α  α 
 
   5/5 
3 
3 4  2 
    CH2CH3
 
   Fig. 3.10. The 1H NMR spectrum of (2R,4R)-64 (CD3OD).  
  
(2S,4R)-82 (see Table 3.16) has been prepared from (2S,4R)-58 via Wolf rearrangement 
(Scheme 27) as well as from (2S,4R)-86 by O,N-protection (Scheme 34) and in both 
processes the configuration (2S,4R) remained unchanged. Thus, the known configuration of 
(2S,4R)-86 must apply to (2S,4R)-82 as well. Finally, the stereochemistry of (2R,4R)-80 
{[α]D20 = +21.2} may be deduced from the configuration of (2S,4R)-82 {[α]D20 = -43.0}. As a 
result of their synthesis (2S,4R)-82 and (2R,4R)-80 must be both of (2R)-configuration at C-4. 
1H NMR spectra of the two compounds are quite different regarding some signals (e.g. H-3 
and H-5), demonstrating the opposite relation of their stereochemistry at C-2. Accordingly, 
(2R,4R)-80 must be of the shown stereochemistry. The following Table 3.16 displays the 1H 
NMR spectra of (2S,4R)-82 and (2R,4R)-80. 
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Table 3.16 Chemical shift values of some protons of (2S,4R)-82 and (2R,4R)-80. 
1H NMR 
(CD OD) 3
 
                   
N
PhCH2OCOO
OCH3
COOCH2Ph
N
PhCH2OCOO
COOC2H5
COOCH2Ph
Proton δ Peak J             Hz δ Peak J                Hz 
H-2 
H-3 
H-3 
H-4 
H-5 
H-5 
H-α 
H-α 
4.45-4.52 
2.25-2.32 
2.49-2.56 
5.31-5.35 
3.79 
3.98 
2.68 
3.06 
m 
m 
m 
m 
dd 
dt 
dd 
 
 
 
 
12.4/5.4 
12.4/2.0 
15.4/8.6 
15.4/3.9 
4.47-4.54 
2.29 
2.49-2.57 
5.30-5.35 
3.72 
3.96 
2.73 
3.13 
 
br. d 
m 
m 
dd 
dd 
dd 
dd 
 
15.4 
 
 
12.6/1.1 
12.6/5.3 
15.2/9.7 
15.2/3.7 
 
 
(2R,4R)-80                [α]  =  +21.2 D20
COα 
            (2S,4R)-82                 [α]  = -43.0 D20
α 
dd 
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3.5.3 Determination of the stereochemistry at C-4 of (2S,4R)-102b-c and (2S,4S)-102b-c 
 
(2S,4R)-109 was transformed into (2S,4R)-115 in 100% yield by hydrogenation over 10% Pd-
C in the presence of triethylamine. Unfortunately, the signal of H-2 (δ 3.61-3.83) overlapped 
with the signal of the ArOCH3 (δ 3.69) in the 1H NMR spectrum of (2S,4R)-115 (CDCl3 or 
CD3OD as solvent), therefore, the NOE experiments could not provide any meaningful 
information. 
Scheme 52 
H2, 10% Pd-C
TEA,   EtOAc
100%
COOCH3
N
OH
COOCH2Ph
OMe
COOCH3
N
OH
H
OMe
  
                (2S,4R)-109                                                      (2S,4R)-115 
 
It is likely practicable that the NOE experiments were performed with (2S,4R)-102c and 
(2S,4S)-102c. In the cases of these two compounds, the NOE signals were too weak to make a 
reliable decision for their stereochemistry. 
There was an alternative way to determine the configuration at C-4 of (2S,4R)-115. (2S,4R)-
111 (Fig. 3.12), prepared from (2S,4R)-109 by hydrolysis of the ester group under basic 
condition and subsequent hydrogenation for N-deprotection (in the presence of triethylamine, 
Scheme 48), possesses the same configuration at C-2 and C-4 as (2S,4R)-115. Owing to its 
poor solubility in common 1H NMR solvents (CDCl3, CD3OD or DMSO-d6), the 1H NMR 
spectrum of (2S,4R)-111 as a sodium salt was taken in CD3OD. Fortunately, H-2 moved to a 
higher field (δ 3.54-3.61), away from the peak (δ 3.77) of CH3OAr (Fig. 3.12). In an NOE 
experiment with (2S,4R)-111, irradiation of the signal pertaining to H-2 enhanced the H-a 
signal of the aromatic group by 2.4%, revealing that H-2 and the phenyl substituent are cis to 
each other (Fig. 3.13). 
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Fig. 3.12. The 1H NMR spectrum of (2S,4R)-111 (CD3OD).  
 
  OCH3 
 2
 a 
H
H
H
N
OH
H
MeO
COONa
2.4%
a
b
2
3
5
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Fig. 3.13   The NOE spectrum of (2S,4R)-111 (CD3OD). 
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Analytical data {1H NMR, IR, MS, [α]} of (2S,4R)-102c obtained by N-alkylation of (2S,4R)-
115 were identical with those of the major isomer formed by an addition of (4-
MeOC6H4)MgBr/CeCl3 (in THF) to (2S)-100c. Therefore, the minor isomer (2S,4S)-102c of 
this addition reaction may be assigned as the shown stereochemistry. The stereochemistry of 
the related compounds  (2S,4R)-102b and (2S,4S)-102b, (2R,4S)-103b-c and (2R,4R)-103b-
c  became known from a comparison of their 1H NMR data with those of (2S,4R)-102c and 
(2S,4S)-102c.  
Scheme 53 
COOCH3
N
OH
H
OMe
RBr,  K2CO3
KI,   acetone,  r.t.
S S
COOCH3
N
OH
OMe
52%
 
                       (2S,4R)-115                                                 (2S,4R)-102c 
R  =  24c 
Table 3.17 chemical shift values of some protons of (2S,4R)-102c and (2S,4S)-102c 
1H 
NMR 
(CD3O
D) 
S S
COOCH3N
OH
OMe
5
2
3
 
(2S,4R)-102c    [α]D20 = +73.1 
S S
COOCH3N
OH
OMe
5
2
3
 
(2S,4S)-102c    [α]D20 = -50.4 
Proton δ Peak J             Hz δ Peak J                Hz 
H-2 
H-3 
H-3 
H-5 
H-5 
H-α 
H-α 
2.90-3.02 
2.09 
2.50-2.60 
2.39-2.46 
3.13 
2.50-2.60 
2.73 
m 
ddd 
m 
m 
dd 
m 
dd 
 
14.2/5.2/2.0 
 
 
9.4/2.0 
 
15.7/3.5 
3.35-3.42 
2.04 
2.27-2.35 
2.67-2.72 
3.35-3.42 
2.27-2.35 
2.67-2.72 
m 
dd 
m 
m 
m 
m 
m 
13.2/9.5 
 
 
 
 
α α 
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The above setereochemical assignment for (2S,4R)-102c and (2S,4S)-102c is also supported 
by the chemical shift values found for H-2. Because of the shielding effect of the aromatic 
group at C-4, H-2 (δ 2.90-3.02) of (2S,4R)-102c is located at higher field in the 1H NMR 
spectrum than H-2 (δ 3.35-3.42) of (2S,4S)-102c. 
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4. DISCUSSION OF THE BIOLOGICAL RESULTS 
 
4.1   Introduction 
 
It is known for a long time that transport proteins for neurotransmitters mediating active 
uptake are present in the synapses in the CNS. As described before (Section 1), so far for 
GABA uptake four characteristic transport proteins have been discovered. The different genes 
as well as the corresponding transport proteins, which can be expressed in mammalian cells, 
have been respectively termed GAT-1, GAT-2, GAT-3 and BGT-1 [32, 33, 34]. It has been 
accepted that GAT-1 and GAT-3 are the most important GABA transporters. The functional 
differences of GAT-1 and GAT-3 are still unknown, but it has been detected that these 
transporters differ with respect to their distribution in distinct regions and subcelluar 
structures of the brain.  
The GABA uptake experiments described below were performed to investigate the potency 
and selectivity of the synthesized compounds with respect to their inhibition of GABA uptake 
mediated by GAT-1 and GAT-3. 
 
 4.2 Procedure and evaluation 
 
 The experimental procedure for the inhibition of GABA uptake was developed on the basis 
of subcellular fractions from frontal cortex and brain stem of bovine brain (Experimental 
Section 5.2.1). Membrane fractions from frontal cortex were utilized to study the inhibitory 
potency of test compounds regarding GAT-1-mediated GABA-uptake. After the incubation of 
the prepared membrane fractions with a test compound, the incubation with [3H] GABA and 
GABA followed. 
To study the inhibitory potency of test compounds regarding GAT-3-mediated GABA-uptake, 
membrane fractions from brain stem were applied. Additionally, the incubation was 
performed in the presence of NNC-711, a GAT-1 selective inhibitor, to block GABA uptake 
mediated by GAT-1 so that the inhibitory effect on GAT-3 mediated GABA-uptake could be 
evaluated (Experimental Section 5.2.2.2). After the incubation of the prepared membrane 
fractions with a test compound, the incubation with [3H] GABA and GABA followed.  
The biological results are listed in Table 4.1, 4.2 and 4.3. All the results of the measurements 
were processed and evaluated in triplicate.  
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 Table 4.1  The inhibition of GABA uptake by 4-hydroxypyrrolidine-2-carboxylic acid 
derivatives: 25 and 40a-b series. 
H 
 
-CH2CH2CH=CPh2  
 
-CH2CH2OC(C6H4-p-OMe)3  
IC50   µM IC50    µM IC50    µM 
 
GAT-1 GAT-3 GAT-1 GAT-3 GAT-1 GAT-3 
N
OH
COOH
R  
4328±708 a 
(2S,4R)-25 
1340±290 b 
(2S,4R)-25 
79.6 a 
(2S,4R)-40a 
> 100 b 
(2S,4R)-40a 
> 100 a 
(2S,4R)-40b 
> 100 b 
(2S,4R)-40b 
N
OH
COOH
R  
 
------------- 
 
------------- 
> 100 a 
(2S,4S)-40a 
> 100 b 
(2S,4S)-40a 
> 100 a 
(2S,4S)-40b 
> 100 b 
(2S,4S)-40b 
N
OH
COOH
R  
 
------------- 
 
------------- 
> 100 a 
(2R,4S)-40a 
> 100 b 
(2R,4S)-40a 
> 100 a 
(2R,4S)-40b 
> 100 b 
(2R,4S)-40b 
N
OH
COOH
R  
> 10 mM a 
(2R,4R)-251 
> 10 mM b 
(2R,4R)-251 
9.4±0.4 a 
(2R,4R)-40a 
313±39 b 
(2R,4R)-40a 
> 100 a 
(2R,4R)-40b 
> 100 b 
(2R,4R)-40b 
 
Note: 
The abbreviations a-f specify the used biological material (for their entire names: see Section 5.2.1). 
 
a.  bfcP2B (from bovine brain) 
b.  bbsP2C (from bovine brain) 
c. pfcP2B (from porcine brain) 
d. pbsP2C (from porcine brain) 
e.   cfcP2B   (from calf brain) 
f. cbsP2C (from calf brain)
 
1.  The concentration of the inhibitory substance was 10 mM for the test.  
2.   If not specified otherwise, the concentration of each test compound was 100 µM.  
3.  Each IC50 was given as mean±SEM. If the IC50 value was larger than 100 µM, no exact value was given.
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Table 4.2 The inhibition of GABA uptake by 4-hydroxypyrrolidine-2-carboxylic acid 
derivatives: 57a-b series, (2S,4R)-63 and (2R,4S)-63. 
H -CH2CH2CH=CPh2  
 
-CH2CH2OC(C6H4-p-OMe)3  
 
IC50   µM IC50    µM IC50    µM 
 
GAT-1 GAT-3 GAT-1 GAT-3 GAT-1 GAT-3 
OMe
N
OH
COOH
R  
------------ ------------- 
> 100 a 
(2S,4S)-57a 
> 100 b 
(2S,4S)-57a 
68.1±4.4 a 
(2S,4S)-57b 
63.3±5.8 b 
(2S,4S)-57b 
OMe
N
OH
COOH
R  
> 100 c 
(2S,4R)-63 
> 100 d 
(2S,4R)-63 
> 100 a 
(2S,4R)-57a 
237±160 b 
(2S,4R)-57a 
45.1±2.7 a 
(2S,4R)-57b 
29.7±0.8 b 
(2S,4R)-57b 
OMe
N
OH
COOH
R  
------------- ------------ 
> 100 e 
(2R,4R)-57a 
> 100 f 
(2R,4R)-57a 
71±1.4 c 
(2R,4R)-57b 
> 100 b 
(2R,4R)-57b 
OMe
N
OH
COOH
R  
> 100 c 
(2R,4S)-63 
> 100 d 
(2R,4S)-63 
> 100 e 
(2R,4S)-57a 
> 100 f 
(2R,4S)-57a 
56±4.3 c 
(2R,4S)-57b 
38.0±5.8 d 
(2R,4S)-57b 
 
 
Note:  
The abbreviations a-f specify the used biological material (for their entire names: see Section 5.2.1. 
 
a.  bfcP2B (from bovine 
brain) 
b.   bbsP2C (from bovine brain) 
c.  pfcP2B from porcine brain) 
d. pbsP2C (from porcine brain) 
e.  cfcP2B    (from calf brain) 
f. fcbsP2C (from calf brain)
 
1. The concentration of the inhibitory substance was 10 mM for the test. 
2. If not specified, the concentration of each test compound was 100 µM.  
3. Each IC50 was given as mean±SEM. If the IC50 value was larger than 100 µM, no exact value was given. 
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Table 4.3  The inhibition of GABA uptake by 4-hydroxypyrrolidine-2-acetic acid derivatives: 
89a-d, 94a and c, and 97 series. 
H -CH2CH2CH=CPh2  
 
-CH2CH2CH=C S
CH3
S
CH3
 
 
-CH2CH2OC(C6H4-p-OMe)3
 
 
N
CH2CH2CH2-  
IC50 µM IC50 µM IC50 µM IC50 µM IC50 µM 
 
GAT-1 GAT-3 GAT-1 GAT-3 GAT-1 GAT-3 GAT-1 
GAT-
3 
GAT-1 GAT-3 
 
N
R
COOH
OH
 
>1.0 mM c 
(2S,4R)- 
97 1 
> 1.0 mM d 
(2S,4R)- 
97 1 
3.29 ±0.54a 
(2S,4R)-
89a 
> 100 b 
(2S,4R)-
89a 
3.15±0.30a 
(2S,4R)- 
89c 
> 100 b 
(2S,4R)-
89c 
> 100 a 
(2S,4R)-
89b 
> 100 b 
(2S,4R)-
89b 
> 100 a 
(2S,4R)-
89d 
> 100 b 
(2S,4R)-
89d 
 
N
R
COOH
OH
 
> 100 c 
(2S,4S)-97 
> 100 d 
(2S,4S)-97 
4.92±0.42 a 
(2S,4S)-
89a 
> 100 b 
(2S,4S)-
89a 
5.14±2.8 c 
(2S,4S)- 
89c 
> 100 b 
(2S,4S)-
89c 
> 100 c 
(2S,4S)-
89b 
58.6±17.1d 
(2S,4S)-
89b 
> 100 e 
(2S,4S)-
89d 
> 100 f 
(2S,4S)-
89d 
 
N
R
COOH
OH
 
>1.0 mM c 
(2R,4S)- 
97 1 
> 1.0 mM d 
(2R,4S)- 
97 1 
28.9±11.6a 
(2R,4S)-
89a 
> 100 f 
(2R,4S)-
89a 
6.56±0.7 a 
(2R,4S)- 
89c 
> 100 b 
(2R,4S)-
89c 
> 100 c 
(2R,4S)-
89b 
19.9±1.1 d 
(2R,4S)-
89b 
> 100 a 
(2R,4S)-
89d 
> 100 b 
(2R,4S)-
89d 
 
N
R
COOH
OH
 
> 100 c 
(2R,4R)-
97 
> 100 d 
(2R,4R)- 
97 
40.7±8 a 
(2R,4R)-
89a 
> 100 b 
(2R,4R)-
89a 
  96.6 a n=1 
(2R,4R)-
89c 
> 100 b 
(2R,4R)-
89c 
> 100 a 
(2R,4R)-
89b 
126±7.0 b 
(2R,4R)-
89b 
> 100 a 
(2R,4R)-
89d 
> 100 b 
(2R,4R)-
89d 
 
N
R
COOH
PhCH2O
 
------------ ------------ 
87.6±11.1a 
(2S,4R)-
94a 
148±33b 
(2S,4R)-
94a 
70±5.8 a 
(2S,4R)- 
94c 
104±16b 
(2S,4R)-
94c 
---------- ---------- ---------- --------- 
  
Note: 
The abbreviations a-f specify the used biological material (for their entire names: see Section 5.2.1). 
 
a.  bfcP2B (from bovine brain) 
b.  bbsP2C (from bovine brain) 
c. pfcP2B  (from porcine brain) 
d. pbsP2C (from porcine brain) 
e.   cfcP2B  (from calf brain) 
f. cbsP2C (from calf brain)
1. The concentration of the inhibitory substance was 10 mM for the test. 
2. If not specified, the concentration of each test compound was 100 µM.  
3. Each IC50 was given as mean±SEM. If the IC50 value was larger than 100 µM, no exact value was given. 
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Table 4.4  The inhibition of GABA uptake by 4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
acetic acid derivatives: 104b-c and 111 series. 
H -CH2CH2CH=C S
CH3
S
CH3
 
-CH2CH2OC(C6H4-p-OMe)3  
IC50   µM IC50    µM IC50    µM 
 
GAT- GAT- GAT-1 GAT- GAT-1 GAT-3 
N CH2COOH
OH
OMe
R  
------------ ------------ 
> 100 c 
(2S,4S)-104c 
122±9 d 
(2S,4S)-104c 
75.2±8.8 c 
(2S,4S)-104b 
78.9±18.5 d 
(2S,4S)-104b 
N CH2COOH
OH
OMe
R  
> 100 c 
(2S,4R)-111 
> 100 d 
(2S,4R)-111 
> 100 c 
(2S,4R)-104c 
124±15 d 
(2S,4R)-104c 
48.4±1.6 c 
(2S,4R)-104b 
66.7±11.2 d 
(2S,4R)-104b
N CH2COOH
OH
OMe
R  
------------ ----------- 
> 100 c 
(2R,4R)-104c
> 100 d 
(2R,4R)-104c 
64.54±3.07 c 
(2R,4R)-104b 
65.4±5.1 d 
(2R,4R)-104b 
N CH2COOH
OH
OMe
R  
> 100 c 
(2R,4S)-111 
> 100 d 
(2R,4S)-111 
89.7 c, n = 1 
(2R,4S)-104c 
> 100 d 
(2R,4S)-104c 
57.3±7.0 c, 
n = 2 
(2R,4S)-104b 
66.1±3.5 d 
(2R,4S)-104b
 
Note 
The abbreviations a-f specify the used biological material (for their entire names: see Section 5.2.1). 
c.      pfcP2B    (from porcine brain) 
d.      psP2C     (from porcine brain) 
 
1. If not described, the concentration of each test compound was 100 µM.  
2. Each IC50 was given as mean±SEM. If the IC50 value was larger than 100 µM, no exact value was given. 
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4.3   Discussion of the biological results 
 
Owing to BSE event, calf brain was temporarily used instead of the bovine brain material for 
the biological tests and finally porcine brain material was chosen. No significant differences 
could be detected for a set of standard GABA uptake inhibitors with respect to their potency 
evaluated with membrane fractions from different species. 
The biological data of the 4-unsubstituted pyrrolidine derivatives mentioned in the following 
discussion are listed in Table 2.1 (page 7) 
Table 4.1 and 4.2: 
Compared with the corresponding 4-unsubstituted pyrrolidines, the stereoisomers of series 
40a-b containing a 4-hydroxy group showed a big loss of inhibitory potency at both GAT-1 
and GAT-3, e.g. (2S,4R)-40a (an IC50 of 79.6 µM at GAT-1) and (2S,4S)-40a (an IC50 > 100 
µM at GAT-1). Thus, they are much weaker than the corresponding compound without a 4-
hydroxy group (IC50 2.56 µM). 
Only (2R,4R)-40a was found to be approximately three-fold less potent at GAT-1 (IC50 9.4 
µM) than the corresponding compound without a 4-hydroxy group (2.97 µM). The known 
compounds (2S,4R)-25 and (2R,4R)-25 showed a very weak inhibitory effect at GAT-1 and 
GAT-3, if any at all.  
The introduction of a 4-methoxyphenyl group into the C-4 position of (2R,4R)-40a (9.4 µM) 
led to a big drop of inhibitory effect for (2R,4S)-57a and (2R,4R)-57a at GAT-1 (IC50 > 100 
µM), but for the rest of the 57a stereoisomers, no significant change in the inhibitory potency 
at GAT-1 or GAT-3 was observed. In one word, a drastic decrease of inhibition at GAT-1 as 
well as GAT-3 occurred for all the stereoisomers of the 40a-b series in contrast to the 
corresponding compounds without any substituent at C-4. 
 
Compared with the 40b series, some of the stereoisomers of the 57b series showed a 
significantly increased inhibition at GAT-1 and GAT-3, e.g. (2S,4R)-57b (an IC50 of 29.7 µM 
at GAT-3) and (2R,4S)-57b (an IC50 of 38.0 µM at GAT-3). But there were no big changes 
about their inhibition at GAT-1 and GAT-3 as compared to the 4-unsubstituted compound 
with the (2S) configuration (23.0 µM at GAT-1) and the 4-unsubstituted compound with the 
(2R) configuration (18.5 µM at GAT-3). But it should be mentioned here that (2R,4S)-57b 
(IC50 38.0 µM) and (2S,4R)-57b (IC50 29.7 µM) are much stronger inhibitors at GAT-3 than 
their isomer (2R,4R)-57b (IC50 > 100 µM), which is actually more or less inactive. In contrast, 
the inhibitory potency of these two compounds at GAT-1 is very close, thus, no significant 
stereoselectivity at GAT-1 is seen. 
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No inhibition at GAT-1 as well as GAT-3 was observed for (2S,4R)-63 and for (2R,4S)-63 at 
a concentration of 100 µM, thus, these compounds are devoid of any significant inhibitory 
potency. 
Table 4.3: 
All the stereoisomers 97 with the 4-hydroxypyrrolidine-2-acetic acid skeletons showed no 
inhibitory potency at GAT-1 and GAT-3, though they were tested up to a rather high 
concentration. On the contrary the 4-unsubstituted compounds with the (2S) configuration 
showed a considerable potency (IC50 74.2 µM at GAT-1). 
After the extension of the 2-carboxylic acid side chains of (2S,4R)-40a and (2S,4S)-40a by 
one carbon, the resulting compounds (2S,4R)-89a and (2S,4S)-89a became more potent 
inhibitors at GAT-1 with IC50 values of 3.29 µM and 4.92 µM, respectively. Interestingly, the 
inhibitory potency displayed by (2S,4S)-89a, (2S,4R)-89a, (2R,4S)-89a and (2R,4R)-89a was 
only one order of magnitude lower than those of the corresponding 4-unsubstituted 
compounds with (2S) configuration (IC50 0.40 µM at GAT-1) and (2R) configuration (3.05 
µM). No significant changes in their inhibitory potency were observed in the 89b series at 
GAT-1 as compared with the 40b series. Due to the introduction of a 4-hydroxy group, the 
89c series showed the same big losses of inhibitory potency at GAT-1 as the 89a series. 
Compounds of the 89a and 89c series with the (2S) configuration showed an about 10-fold 
potency at GAT-1 as those of the 89a and 89c series with the (2R)-configuration except 
(2R,4S)-89c. All these biological results indicate that the introduction of a 4-hydroxy group is 
harmful to the potency of GABA uptake inhibitors, and that the (2S) configuration is crucial 
for the derivatives of the pyrrolidine-2-acetic acids to be potent at GAT-1.  
It was found that the inhibitory potency at GAT-3 for the 89b series had significantly 
increased as compared to the 40b series due to the elongation of the carboxylic acid side chain 
by one carbon; (2R,4S)-89b appears to be the most potent one at GAT-3 (IC50 19.9 µM) 
among the 89a-d series and it is much more potent than its diastereomer (2R,4R)-89b (IC50 > 
126 µM). Furthermore, the stereoisomer of the 89b series with the (2R) configuration 
containing a 4-hydroxy group also showed a big decrease in inhibitory potency at both GAT-1 
(100 µM) and GAT-3 (19.9 µM) as referred to the corresponding 4-unsubstituted compound 
at GAT-1 (67.8 µM) and GAT-3 (3.0 µM). Therefore, the 4-hydroxy group present in the 
compounds of 89b series seems to be detrimental to a potent binding to GAT-3. 
(2S,4S)-89a and (2S,4S)-89c are much weaker at GAT-1 than SK&F 100591 (0.26 µM), 
possibly due to a longer distance between the hydroxyl group and the carboxylic group in 
(2S,4S)-89a and (2S,4S)-89c as compared to SK&F 100591. 
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For the compounds of the 89d series with a carbazole moiety, no inhibition of GAT-1 and 
GAT-3 was observed when tested at the concentrations of 100 µM. 
In (2S,4R)-94a (IC50 87.6 µM at GAT-1) and (2S,4R)-94c (70.0 µM), the substitution of the 4-
hydroxy group by a 4-benzyloxy group led to a weaker potency at GAT-1 by a factor of about 
25 as compared with (2S,4R)-89a (3.29 µM) and (2S,4R)-89c (3.15 µM). In contrast, their 
potency at GAT-3 was not affected by the change of the 4-substituent. 
 
Table 4.4: 
A comparison of the 104c series with the 89c series reveals that the introduction of a 4-
methoxyphenyl group to C-4 gives rise to a sharp drop of the inhibitory potency at GAT-1, 
but a little enhancement at GAT-3 except that (2R,4S)-104c showed no significant variation. 
The situation is different when the 4-methoxyphenyl substituent is introduced into the 89b 
series, in most cases, an increase of the inhibitory potency at both GAT-1 and GAT-3 is seen 
for the 104b series except for (2R,4R)-104b. 
Finally for the basic compounds (2S,4R)-111 and (2R,4S)-111, no inhibitory potency was 
observed at GAT-1 or GAT-3 up to the tested concentration. Thus, they behave the same as 
the compounds of series 97 
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5.    SUMMARY  
 
GABA transporters GAT-1, GAT-2 and GAT-3 are new targets for drug design. The 
substitution of the nitrogen atoms in Nicopetic acid (11), Guvacine (12) and cis-4-
Hydroxynicopetic acid (13) with appropriate bulky lipophilic groups resulted in very potent 
GABA uptake inhibitors for GAT-1 as well as for GAT-3. Pyrrolidine-2-acetic acid 
derivatives with the three N-substituents 24a-c (Scheme 54) also showed a highly potent 
inhibition at GAT-1 and GAT-3, respectively. 
My intention was to investigate how the potency of pyrrolindine-2-carboxylic acid derivatives 
and of pyrrolidine-2-acetic acid derivatives at GAT-1 and GAT-3 is influenced by the 
introduction of a hydroxy group or both of a hydroxy and a (4-methoxy)phenyl group at C-4. 
For this study, the N-substituents 24a-d were chosen. Thus, the four series of pyrrolidine 
derivatives 20-23 shown below were designed as potential GABA uptake inhibitors. 
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L-trans-4-hydroxypyrrolidine [(2S,4R)-25] was chosen as a precursor, from which the four 
key intermediates  (2S,4R)-38, (2R,4R)-38, (2S,4R)-86 and (2R,4R)-64 were synthesized.  
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          (2S,4R)-25              (2S,4R)-38 Lit.          (2R,4R)-38 Lit.          (2S,4R)-86             (2R,4R)-64  
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The known compounds (2S,4R)-38 and (2R,4R)-38 were prepared from (2S,4R)-25 according 
to literature procedures.  
N-protection of (2S,4R)-25 with Cbz group gave (2S,4R)-58 (90% yield). After a series of 
reactions  electrolysis (97% yield), O-silyl protection (85%), nucleophilic addition of 1-
ethoxy-1-(trimethylsilyloxy)ethene (cis-71 79%; trans-71 9%) and finally O-deprotection 
(88%) and N-deprotection (89%)  (2R,4R)-64 was obtained in 46% overall yield [from 
(2S,4R)-25].  
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  (2S,4R)-58 Lit.                              70                                 cis-(2R,4R)-71 (major)                       (2R,4R)-64 
 
After the reaction conditions for the conversion of 70 into 71 have been optimized, the best 
stereoselectivity [a ratio of cis/trans 97:3; yield cis-71 74%, trans-(2S,4R)-71 1.7%] and a 
good yield of 88% (cis 79%, trans 9%) were achieved. BF3⋅Et2O appeared to be slightly better 
for a higher stereoselectivity than TiCl4.  
(2S,4R)-83 was obtained in 90% yield by protecting the hydroxy group of (2S,4R)-58. An 
Arndt-Eistert reaction (64% yield) starting from (2S,4R)-83 followed by a simultaneous N,O-
deprotection (90% yield) of (2S,4R)-85 led to (2S,4R)-86 in 47% overall yield [from (2S,4R)-
25]. 
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          (2S,4R)-83 Lit.                                            (2S,4R)-85                                                    (2S,4R)-86 
 
 
As illustrated in Scheme 58 and 59, (2S,4R)-38 and (2S,4R)-86, (2R,4R)-38 and (2R,4R)-64 
were used as starting materials for the synthesis of the N-substituted target compounds 
(2S,4R)-40a-b, (2S,4S)-40a-b, (2R,4S)-40a-b, (2R,4R)-40a-b, (2S,4R)-89a-d, (2S,4S)-89a-d, 
(2R,4R)-89a-d and (2R,4S)-89a-d. N-alkylation of these four starting materials with the 
halides of 24a-d yielded the corresponding tertiary amines. Mitsunobu reactions gave access 
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to the stereoisomers by inversion of the stereocenter at C-4 of the pyrrolidine ring. Finally 
upon hydrolysis, all the N-substituted pyrrolidine derivatives with a 2-carboxylic acid side 
chain or a 2-acetic acid side chain were obtained. 
Scheme 58 
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                   (2S,4R)-38, n = 0                                (2S,4R)-39a-b                                (2S,4R)-40a-b 
                   (2S,4R)-86, n = 1                                (2S,4R)-91a-d                                (2S,4R)-89a-d 
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                                                                             (1S,5S)-92a-d                                 (2S,4S)-89a-d 
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                      (2R,4R)-38, n = 0                             (2R,4R)-39a-b                             (2R,4R)-40a-b 
                      (2R,4R)-64, n = 1                             (2R,4R)-88a-d                             (2R,4R)-89a-d  
                                                                               (2R,4R)-73, R = Cbz, n = 1           (2R,4R)-96 
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(For the N-substituents 24a-d see page 73) 
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In the same manners (scheme 58 and 59), the series 96 also were synthesized and finally their 
hydrogenolysis over Pd-C provided each of four stereoisomers 97. 
Scheme 60  
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The N-substituted 4-oxopyrrolidine derivatives (2S)-52a-b and (2S)-100a-c (see Scheme 61) 
were prepared (81-92% yields) via Swern oxidation, and fortunately, the acid-sensitive N-
substituent 24b was not affected. The N-Cbz-protected 4-oxopyrrolidine derivatives 60 and 
108 (Scheme 61) were prepared in good yield (71-78%) via Jones’ oxidation, but in low yield 
(10-27%) via Swern oxidation. 
The addition reactions of the organometallic reagents to the N-substituted pyrrolidine 
derivatives 52a-b and (2S)-100b-c were carried out in two different ways. Depending on the 
starting material and the employed organometallic reagent, two different results were 
obtained: Under condition A [(4-MeOC6H4)MgBr at –78 °C in ether] the cis addition product 
(cis refers to the ester group) was formed as the major diastereomer and a good 
diastereoselectivity was achieved (cis/trans addition from 79:21 to 89:11; total yields 45-
65%); Under condition B [(4-MeOC6H4)MgBr/CeCl3 at –78 °C in THF], the trans addition 
product was obtained as a major diastereomer (cis/trans addition from 30:70 to 17:83; total 
yields 32-48%). 
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  (2S,4R)-95 Lit, R = Cbz, n =1         (2S)-108                                     --------------                     (2S,4R)-109 
 
(For the N-substituents 24a-c see page 73) 
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In the case of the N-Cbz-protected pyrrolidine derivative (2S)-60, a single diastereomer 
(2S,4R)-61 was formed in 56% yield under condition B [(4-MeOC6H4)MgBr/CeCl3 in THF at 
– 60 °C for 4 h]. However, for the homologous (2S)-108 under the same conditions, (2S,4R)-
109 (25% yield) and a side product (5%) resulting from a simultaneous addition to the ester 
group were formed. The addition of (4-MeOC6H4)MgBr to (2S)-108 (at –78 °C in ether for 4 
h), however, led to (2S,4R)-109 (38% yield) as a single diastereomer.  
Each of the N-substituted stereoisomers from the reaction above was subjected to a basic 
hydrolysis, which was followed by hydrogenolysis over Pd-C, where necessary, to afford the 
free amino acids (70-98% yields). 
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              (2S,4S)-57a-b,   n = 0                    (2S,4R)-57a-b                          (2S,4R)-63 
              (2S,4S)-104b-c,  n =1                    (2S,4R)-104b-c                        (2S,4R)-111 
 
(For the N-substituents 24a-c see page 73). 
 
Via the similar synthetic procedures as described above, the rest of the stereoisomers (2R,4R)-
57a-b and (2R,4S)-57a-b, (2R,4R)-104b-c and (2R,4S)-104b-c, (2R,4S)-63 and (2R,4S)-111 
were obtained from (2R,4R)-39a-b, (2R,4R)-88b-c, (2R)-60 and (2R,4R)-73. 
 
The relative stereochemistry of the products obtained from the addition of the organometallic 
reagents to the 4-oxopyrrolidine derivatives was determined by chemical correlation and NOE 
measurements.  
Scheme 63 
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                                              (2S,4R)-114                                    (2S,4R)-53a 
                                              (2S,4R)-115                                    (2S,4R)-102c    
(For the N-substituents 24a and c see page 73) 
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NOE experiments performed with (2S,4R)-114 revealed that the phenyl group and H-2 are cis 
to each other. As important signals for the assignment overlapped in the 1H NMR spectrum of 
(2S,4R)-115, the NOE experiments were performed with (2S,4R)-111, which is the sodium 
salt of (2S,4R)-115. The NOE measurement revealed that the phenyl group is located cis to H-
2, thus, (2S,4R)-111 and (2S,4R)-115 being of the stereochemistry shown. 
The N-alkylation of (2S,4R)-114 with the bromide of 24a, and of (2S,4R)-115 with the 
bromide of 24c led to (2S,4R)-53a and (2S,4R)-102c, respectively. With these compounds as 
references, also the stereochemistry of all related compounds differing only in side chain on 
the amino nitrogen could be deduced. 
 
The target compounds obtained in this study were evaluated for their biological activities. 
Membrane fractions from frontal cortex of bovine brain (or porcine brain) were utilized to 
study the inhibitory potency of the test compounds regarding the GAT-1-mediated GABA-
uptake. For the determination of the potency as GAT-3 inhibitors, membrane fractions from 
brain stem of bovine brain (or porcine brain) were used. 
As compared to the corresponding 4-unsubstituted compounds with (2S) configuration (IC50 
2.56 µM at GAT-1) and with (2R) configuration (IC50 18.5 µM), the 40a-b series containing a 
4-hydroxy group showed a significant drop in the inhibitory potency at both GAT-1 and 
GAT-3, only one compound [(2R,4R)-40a] showed  a reasonable potency at GAT-1 (IC50 9.4 
µM) and no one of them for GAT-3 (IC50 > 100 µM). 
(2S,4S)-89a (IC50 3.29 µM at GAT-1) and (2S,4S)-89c (5.14 µM), (2S,4R)-89a (4.92 µM) and 
(2S,4R)-89c (3.15 µM) exhibiting a 4-hydroxypyrrolidine-2-acetic acid skeleton showed an 
inhibitory potency at GAT-1, which was only one order of magnitude lower than the potency 
of corresponding compounds with (2S) configuration without the 4-hydroxy group (with N-
substituent 24a: IC50 0.40 µM and with N-substituent 24c: 0.34 µM). 
(2R,4S)-89b was the most potent inhibitor at GAT-3 (IC50 19.9 µM) of all the stereoisomers 
of series 89a-d and showed a much higher potency than its isomer (2R,4R)-89b (126 µM). 
According to these data a 4-hydroxy group is detrimental to the potency at both GAT-1 and 
GAT-3, and (2S)-configuration of the pyrrolidine-2-acetic acid unit is crucial for a reasonable 
potency at GAT-1.  
As compared to the 40b series, some stereoisomers of the 57b series, the latter exhibiting a 
(4-methoxy)phenyl group at C-4 of the pyrrolidine ring, showed an increased potency as 
inhibitors at GAT-1 and GAT-3 [e.g. (2S,4R)-57b: IC50 29.7 µM at GAT-3; (2R,4S)-57b: IC50 
of 38.0 µM at GAT-3]. In contrast, the introduction of a (4-methoxy)phenyl group into C-4 of 
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the 89b-c series, resulting in the compounds of 104b-c, gave rise to diverse biological results. 
As compared with (2R,4S)-89b,  (2R,4R)-104b displayed a loss of inhibitory potency at GAT-
3 but some enhancement at GAT-1. 
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6.1   Synthetic section 
 
       General remarks 
 
Reagents and solvents: Tetrahydrofuran, toluene, benzene and diisopropylamine were distilled 
from sodium under nitrogen. Acetonitrile was distilled from phosphorus pentoxide and then 
from potassium carbonate. Triethylamine was refluxed with benzoyl chloride and distilled 
under nitrogen. Methanol for anhydrous reactions was distilled from magnesium. Other 
common solvents for recrystallization, column chromatography, analytical HPLC and 
preparative HPLC were always distilled before use. Purchased chemical reagents were used 
without further purification.  
 
Buffer: Aqueous buffer (pH 5.5, 0.42 M and pH 6.6, 0.42 M) was prepared from KH2PO4 and 
KOH. 
  
TLC: TLC plates: silica gel 60 F254 on aluminum sheets (Merck); indicator: the aqueous 
solution containing 5% (NH4)6Mo7O24⋅4H2O, 0.2% Ce(SO4)2⋅4H2O and 5% conc. H2SO4. 
 
Column chromatography (CC): If nothing else is stated, every packing for flash 
chromatography (φ  mm; column length: mm) was silica gel (mesh 230-400, Merck).  
 
Analytical HPLC: Column LiChrospher Si 60 (5 µm, 250 × 4 mm with precolumn 4 × 4 mm), 
Pump L-6000 (Hitachi), UV-VIS Detector L-4000 (275 nm, Merck-Hitachi), Integrator D-
2000 (Merck-Hitachi). 
 
Preparative HPLC: Column LiChrospher Si 60 (7 µm, 250 × 25 mm), Pump L-6200 (Hitachi), 
UV-VIS Detector L-4000 (275 nm, Hitachi), Integrator D-7500 (Merck-Hitachi). 
 
Optical rotations: Polarimeter 241 MC at λ 589 cm-1 of Na light. 
 
Melting points: M.p (uncorrected) were determined with a Büchi 510 Melting Point 
apparatus. 
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Elementary analysis: Elementaranalysator Rapid (Heraeus). 
 
IR spectrum: FI-IR Spectometer 1600 and Paragon 1000 (Perkin Elmer), oily samples as film, 
solid samples as pellets for measurements. 
 
Mass spectra: Mass Spectrometer 5989 A with 59980 B particle beam LC/MS interface 
(Hewlett Packard), method: Chemical ionization (CH5+: CI) (not specified); API 2000 (PE-
Biosystem), method: electric spray ionization (N2). 
 
NMR Spectra: NMR spectra were recorded on JNMR-GX (Jeol, 400 MHz and 500 MHz) 
with TMS as internal standard and integrated with the program of NMR-software Nuts (2D 
Version 5.097, Acorn NMR, 1995). If nothing else is stated, measurements were performed at 
400 MHz at room temperature. 
 
It was not specified that some reactions needed absolute solvents or other absolute conditions, 
or protective gas such as nitrogen. For every reaction, stirring was always necessary despite of 
no mention. 
 
Abbreviations: 
 
Ac                              acetyl 
Cbz                            carboxylate benzyl 
CDI                            carbonyldiimidazole 
DCC                           N,N’-dicyclohexyldiimide 
DEAD                       diethyl azodicarboxylate 
DMAP                       4-(dimethylamino)pyridine 
Decomp.                    decomposition 
DMSO                      dimethyl sulfoxide 
DMF                         dimethyl formamide 
Ether                         diethylether 
Et                              ethyl 
LDA                          lithium diisopropylamide 
Me                             methyl  
Oxid.                         Oxidation 
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prep.                          preparative 
r.t.                               room temperature  
sat.                             saturated 
TBAF                        tetrabutylammonium fluoride  
TEA                           triethylamine 
THF                           tetrahydrofuran  
TLC                           thin layer chromatography 
TMS                          tetramethylsilane 
TMSCl                      trimethylchlorosilane 
TBDMSCl                (tert-butyl)dimethylsilylchloride 
Tr                              triphenyl 
tR                               retention time 
Ph                              phenyl 
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6.1.1    Preparation of the esters of the amino acids  
 
 (2R,4R)-4-Hydroxypyrrolidine-2-carboxylic acid [(2R,4R)-25] 
 
According to ref. [47] 9.30 g (70.9 mmol) of (2S,4R)-25 in 71 ml (76.7 g, 75.1 mmol) of Ac2O 
and 142 ml of AcOH were refluxed for 5.5 h. After the solvent had been distilled off, the 
residual dark oil was refluxed in 180 ml (0.36 mol) of aq. 2 M HCl for 3 h. The reaction 
mixture was decolorized with charcoal. Water was removed under reduced pressure, the 
resulting colorless crystals were dissolved in 21 ml of H2O and the solution was slowly 
neutralized by the addition of 10.4 ml (7.27 g, 72.0 mmol) of TEA in 200 ml of EtOH to give 
colorless crystals. Recrystallization was repeated twice with H2O and EtOH to yield 5.41 g 
(58%) of (2R,4R)-25 as colorless crystals. – M.p. 250-256 °C (decomp.). – [α]D20 = +59.3 (c = 
2.00, H2O). {ref. [47]: M.p. 250-254 °C; [α]D23 = +58.6 (c = 2.0, H2O)}. 
 
Methyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate hydrochloride [(2S,4R)-38] 
 
According to ref. [37] A solution of 4.5 g (34.3 mmol) of (2S,4R)-25 and 2.80 ml (4.57 g, 38.4 
mmol) of SOCl2 in 45 ml of MeOH was stirred at r.t. for 15 h and then 60 ml of Et2O was 
added to give 5.50 g (96%) of (2S,4R)-38 as colorless crystals. – M.p. 168-171 °C (MeOH). – 
[α]D20 = -21.3 (c = 1.00, MeOH). {ref. [37]: M.p. 168-170 °C (MeOH); [α]D20 = -19.5 (c = 1, 
MeOH)}. 
 
Methyl (2R,4R)-4-hydroxypyrrolidine-2-carboxylate hydrochloride [(2R,4R)-38] 
 
According to ref. [37] To a mixture of 2.03 g (15.5 mmol) of (2R,4R)-25 in 23 ml of MeOH, 
1.20 ml (1.94 g, 16.3 mmol) of SOCl2 was added at r.t. The mixture was stirred at r.t. for 1 h, 
then refluxed for 4 h and finally cooled down. 25 ml of iPr2O was added and the mixture gave 
2.43 g (86%) of (2R,4R)-38 as colorless crystals. – M.p. 120-122 °C. – [α]D20 = +9.8 (c = 
1.00, MeOH). {ref. [82]: M.p. 121-123 °C}. 
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(2S,4R)-1-Benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid [(2S,4R)-58]  
 
As described by ref. [41]: To a solution of 1.31 g (10 mmol) of (2S,4R)-25 in 5.0 ml (10 mmol) 
of aq. 2.0 M NaOH, 1.41 ml (1.70 g, 10.0 mmol) of CbzCl and 5.0 ml (10 mmol) of aq. 2.0 M 
NaOH were by turn added at 0 °C within 45 min. The mixture was stirred overnight, and then 
acidified to pH 1-2 with aq. 4.0 M HCl and finally extracted with EtOAc. Combined extract 
was dried (Na2SO4) and evaporated. Yield: 2.39 g (90%); colorless oil. – [α]D20  = -44.1 (c = 
1.00, MeOH). {ref. [61]:  [α]D24 = -41 (c = 1.0, MeOH)} 
 
Benzyl (2R,4R)-4-hydroxy-2-methoxypyrrolidine-1-carboxylate [(2R,4R)-69] and  
benzyl (2S,4R)-4-hydroxy-2-methoxypyrrolidine-1-carboxylate [(2S,4R)-69] 
N
COOCH2Ph
OH
OMe N
COOCH2Ph
OH
OMe
 
                                           (2R,4R)-69                        (2S,4R)-69 
 
In 60 ml of MeOH containing 145 mg (1.44 mmol) of TEA, 1.90 g (7.17 mmol) of (2S,4R)-58 
was electrolyzed at 10~15 °C at the voltage of 13 v, a slim stick of platinum as an anode and a 
wire grate of platinum as a cathode) until no bubble appeared on the surface of platinum wire 
in 7 h. After MeOH was removed (T < 25 °C), the resulting oil was subjected to analytical 
HPLC (the ratio of d.s = 41:59; respective tR = 9.4 min, 10.5 min; n-heptane/EtOAc, 40:60; 
1.5 ml/min) and purificated by CC (φ 40 × 245; iPr2O/EtOH, 92:8) gave 1.74 g (97%) of 69. It 
was possible to get optically pure diastereomers via the above CC. 
 
Major diastereomer: Colorless oil. TLC: Rf  = 0.36 (iPr2O/EtOH, 9:1). – [α]D20 = +1.2 (c = 
1.76,  EtOH). – 1H NRM (CDCl3): Two rotamers δ = 1.91-2.01 (m, 1 H, NCHCH2), 2.15-2.19 
(m, 1 H, NCHCH2), 3.23, 3.37 (2s, 3 H, OCH3), 3.45-3.49, 3.67-3.71 (m, 2 H, NCH2), 4.60-
4.64 (m, 1 H, CHOH), 5.11-5.31 (m, 3 H, NCH and OCH2Ph), 7.29-7.36 (m, 5 H, Haromat). – 
IR: ~ν  = 3429, 2947, 2834, 1704, 1416, 1088, 774, 698 cm-1. – MS; m/z (%): 252 (1) [M+1]+, 
220 (92), 176 (100), 91 (62), 86 (29). – C13H17NO4 (251.28): calcd. C 62.14, H 6.82, N 5.57; 
found C 62.00, H 7.00, N 5.53. 
Minor diastereomer: Colorless oil. TLC: Rf = 0.27 (iPr2O/EtOH, 9:1). – [α]D20  = -31.7 (c = 
1.20,  EtOH). – 1H NMR (CDCl3): two rotamers δ = 1.91-1.97 (m, 1 H, NCHCH2), 2.12-2.18 
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(m, 1 H, NCHCH2), 3.10-3.24, 3.58-3.71 (m, 2 H, NCH2), 3.31-3.44 (m, 3 H, OCH3), 4.34-
4.37 (m, 1 H, CHOH), 5.13-5.38 (m, 3 H, NCH and OCH2Ph), 7.30-7.38 (m, 5 H, Haromat). – 
IR: ~ν  = 3466, 2946, 2834, 1708, 1410, 1084, 754, 699 cm-1. – MS; m/z (%): 252 (1) [M+1]+, 
220 (100), 176 (100), 91 (79), 86 (52). – C13H17NO4 (251.28): calcd. C 62.14, H 6.82, N 5.57; 
found C 61.98, H 6.85, N 5.70.  
 
Benzyl (2R,4R)-4-(tert-butyl)dimethylsilyloxy-2-methoxypyrrolidine-1-carboxylate 
[(2R,4R)-70] and 
benzyl (2S,4R)-4-(tert-butyl)dimethylsilyloxy-2-methoxypyrrolidine-1-carboxylate 
[(2S,4R)-70]  
N
COOCH2Ph
OMe
O
Si
N
COOCH2Ph
OMe
O
Si
 
 
                                       (2R,4R)-70                              (2S,4R)-70 
 
To a solution of 0.986 g (3.93 mmol) of 27 and 0.401 g (5.89 mmol) of imidazole in 14 ml of 
CH2Cl2, a solution of 0.770 g (5.11 mmol) of TBDMSCl in 6 ml of CH2Cl2 was added at r.t. 
After stirring for 16 h, the mixture was washed with H2O, dried (Na2SO4), and then 
evaporated to afford colorless oil. Purification by CC (φ 25 × 95; n-heptane/EtOAc, 7:1) gave 
1.22 g (85%) of 70 as colorless oil and separation by prep. HPLC (n-heptane/EtOAc, 7:1; 12 
ml/min) gave pure diastereomers.  
 
Diastereomer I: Colorless oil. – tR = 24.6 min. – TLC: Rf  = 0.35 (n-heptane/EtOAc, 7:1). – 
[α]D20  = -10.9 (c = 0.82, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 0.11 (s, 3 H, SiCH3), 
0.12 (s, 3 H, SiCH3), 0.93 [s, 9 H, SiC(CH3)3], 2.00 (dt, J = 13.9/1.5 Hz, 1 H, NCHCH2), 2.35 
(dt, J = 13.9/6.4 Hz, 1 H, NCHCH2), 3.41-3.45 (m, 4 H, NCH2 and 3 H of OCH3), 3.99 (dd, J 
= 11.2/6.6 Hz, 1 H, NCH2), 4.44-4.49 (m, 1 H, CHOSi), 5.24 (d, J = 12.6 Hz, 1 H, CH2Ph), 
5.28 (d, J = 12.6 Hz, 1 H, CH2Ph), 5.36 (dd, J = 6.4/1.5 Hz, 1 H, NCH), 7.25-7.44 (m, 5 H, 
Haromat). – IR: ~ν  = 3034, 2930, 2857, 1714, 1410, 1098, 837, 775, 698 cm-1. – MS; m/z (%): 
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364 (1) [M-1]+, 334 (65), 290 (74), 264 (23), 234 (21), 158 (22), 91 (100). – C19H31NO4Si 
(365.55): calcd. C 62.43, H 8.55, N 3.83; found C 62.33, H 8.73, N 3.94.  
 
Diastereomer II: Colorless oil. – tR  = 21.6 min. – TLC: Rf = 0.42 (n-heptane/EtOAc, 7:1). – 
[α]D20 = +14.4 (c = 1.07, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 0.10 (s, 3 H, SiCH3), 
0.11 (s, 3 H, SiCH3), 0.91 [s, 9 H, SiC(CH3)3], 2.00 (dd, J = 12.9/7.2 Hz, 1 H, NCHCH2), 2.20 
(ddd, J = 12.9/5.8/1.5 Hz, 1 H, NCHCH2), 3.38 (s, 3 H, OCH3), 3.50 (dd, J = 11.1/5.2 Hz, 1 
H, NCH2), 3.72 (dd, J = 11.1/6.3 Hz, 1 H, NCH2), 4.66-4.73 (m, 1 H, CHOSi), 5.25 (d, J = 
12.7 Hz, 1 H, CH2Ph), 5.29 (d, J = 12.7 Hz, 1 H, CH2Ph), 5.38 (dd, J = 7.2/1.5 Hz, 1 H, 
NCH), 7.26-7.35, 7.42-7.44 (m, 5 H, Haromat). – IR: ~ν  = 3040, 2954, 2991, 1714, 1408, 1096, 
900, 777, 698 cm-1. – MS; m/z (%): 364 (1) [M-1]+, 334 (49), 290 (61), 264 (19), 234 (19), 
158 (22), 91 (22). – C19H31NO4Si (365.55): calcd. C 62.43, H 8.55, N 3.83; found C 62.59, H 
8.64, N 3.93.  
 
Benzyl (2S,4R)-4-(benzyloxycarbonyl)oxy-2-methyoxypyrrolidine-1-carboxylate 
[(2S,4R)-77] and  
benzyl (2R,4R)-4-(benzyloxycarbonyl)oxy-2-methyoxypyrrolidine-1-carboxylate 
[(2R,4R)-77] 
N
COOCH2Ph
PhCH2OCOO
OMe N
COOCH2Ph
PhCH2OCOO
OMe
 
                                           (2R,4R)-77                                 (2S,4R)-77 
 
To a solution of 518 mg (2.06 mmol) of 69 and 377 mg (3.07 mmol) of DMAP in 20 ml of 
CH2Cl2, 0.407 ml (493 mg, 2.89 mmol) of CbzCl was added at 0 °C. The mixture was stirred 
at 0 °C for 19 h, and then neutralized with aq. 1.2 N HCl to ~ pH 8, finally washed with 
water. The CH2Cl2 layer was separated, dried (MgSO4), and evaporated to give yellow oil. 
The two diastereomers were obtained by CC (φ 25 × 250; EtOAc/n-heptane, 1:4). 
 
Major diastereomer: 322 mg (41%); colorless oil. – TLC: Rf = 0.22 (EtOAc/n-heptane, 1:3). – 
[α]D20 = -25.6 (c = 1.00, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 2.26 (dt, J = 13.9/5.9 
Hz, 1 H, NCHCH2), 2.41 (ddd, J = 13.9/6.6/2.0 Hz, 1 H, NCHCH2), 3.37 (s, 3 H, OCH3), 
3.83-3.85 (m, 2 H, NCH2), 5.22 (d, J = 12.6 Hz, 1 H, OCOOCH2Ph), 5.22 (s, 2 H, 
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NCOOCH2Ph), 5.27 (d, J = 12.6 Hz, 1 H, OCOOCH2Ph), 5.36-5.42 (m, 1 H, NCH2CHO), 
5.45 (dd, J = 5.9/2.0 Hz, 1 H, NCH), 7.25-7.42 (m, 10 H, Haromat). – IR: ~ν = 3034, 2950, 1746, 
1714, 1410, 1270, 1085, 792, 753, 698 cm-1. – MS; m/z (%): 354 (1) [M-OCH3]+, 202 (100), 
158 (34), 91 (66). – C21H23NO6 (385.42): calcd. C 65.44, H 6.02, N 3.63; found C 65.17, H 
6.08, N 3.63.  
 
Minor diastereomer: 228 mg (27%); colorless oil. – TLC: Rf = 0.32 (EtOAc/n-heptane, 1:3). – 
[α]D20 = +16.5 (c = 1.00, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 2.32 (br. d, J = 14.8 
Hz, 1 H, NCHCH2), 2.39 (dt, J = 14.8/5.5 Hz, 1 H, NCHCH2), 3.40 (s, 3 H, OCH3), 3.70 (dd, 
J = 12.5/2.5 Hz, 1 H, NCH2), 4.08 (dd, J = 12.5/6.4 Hz, 1 H, NCH2), 5.22 (s, 2 H, 
NCOOCH2Ph), 5.26 (d, J = 4.4, 2 H, OCOOCH2Ph), 5.29-5.34 (m, 1 H, NCH2CHO), 5.41 
(dd, J = 5.5/1.0 Hz, 1 H, NCH), 7.26~7.44 (m, 10 H, Haromat). – IR: ~ν = 3034, 2950, 1747, 
1714, 1416, 1265, 1085, 791, 754, 698 cm-1. – MS; m/z (%): 354 (1) [M-OCH3]+, 202 (100), 
158 (33), 91 (77). – C21H23NO6 (385.42): cal. C 65.44, H 6.02, N 3.63; found C 65.24, H 
6.05, N 3.63.  
 
1-Ethoxy-1-(trimethylsilyloxy)ethene (116) 
 
According to ref. [82] To a solution of 3.08 ml (22.0 mmol) of iPr2NH in 20 ml of THF, 13.8 
ml (1.6 M in n-heptane, 22 mmol) of n-BuLi was added at –5 °C. After stirring for 20 min at 
0 °C, the mixture was cooled down to –78°C, and then 2.95 ml (1.76 g, 20.0 mmol) of EtOAc 
was added. After 30 min, 3.00 ml (2.58 g, 24.0 mmol) of TMSCl was added and stirring was 
continued for 1 h. The mixture was poured into a mixture of 100 ml of pentane and 40 ml of 
H2O. The organic layer was washed with H2O, dried (MgSO4) and then distilled under 
reduced pressure (75-80 °C/118-122 mbr). Yield: 1.73 g (51%) (Si-O/Si-C = 75:25, purity 
75%, determined by 1H NMR); colorless liquid. 
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General procedure (GP1) 
 
A) 
To a solution of 70 (1 equiv.) and the nucleophile (116 or ethyl bromozincacetate, 3.2-4.0 
equiv.) in CH2Cl2 (3 ml/mmol), the solution of Lewis acid (BF3·Et2O or TiCl4, 2.1 equiv.) was 
added at the temperature given. The mixture was allowed to stir at this temperature for the 
time given, before it was quenched with aq. 5% K2CO3 (2.3-2.6 equiv.). The organic layer 
was separated and the aqueous layer was extracted with CH2Cl2. The combined extracts were 
dried (MgSO4) and concentrated to yield a colorless oil. The ratio of d.s was determined by 
analytical HPLC gave Purification by CC and separation by prep. HPLC yielded pure 
diastereomers. 
 
B) 
To a solution of 70 (1 equiv.) in CH2Cl2 (3 ml/mmol), Lewis acid (BF3·Et2O or TiCl4, 2.1 
equiv.) was added. After this mixture had been stirred for 15 min, the nucleophile (116 or 
ethyl bromozincacetate, 3.2-4.0 equiv.) was added. This mixture was allowed to stir at this 
temperature for the time given. The reaction mixture was quenched with aq. 5% K2CO3 (2.3-
2.6 equiv.). The organic layer was separated and the aqueous layer was extracted with 
CH2Cl2. the combined extract was dried (MgSO4) and concentrated to yield a colorless oil. 
Assay on analytical HPLC gave the ratio of d.s. Purification by CC and separation by prep. 
HPLC yielded pure diastereomers. 
 
Ethyl (2R,4R)-1-benzyloxycarbonyl-4-(tert-butyl)dimethylsilyloxypyrrolidine-2-acetate 
[(2R,4R)-71] and 
ethyl (2S,4R)-1-benzyloxycarbonyl-4-(tert-butyl)dimethylsilyloxypyrrolidine-2-acetate 
[(2S,4R)-71]   
N
COOCH2Ph
COOC2H5
O
Si
N
COOCH2Ph
COOC2H5
O
Si
   
                               cis-(2R,4R)-71                                trans-(2S,4R)-71                
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2)     According to GP1-A from 124 mg (0.339 mmol) of 70, 228 mg (purity: 75%, 1.07 
mmol) of 116 and 101 mg (0.711 mmol) of BF3·Et2O in 3 ml of CH2Cl2; reaction: at –78 °C 
for 4 h; 3.2 ml (2.3 mmol) of aq. 5% K2CO3; analytical HPLC (n-heptane/EtOAc, 7:1; 1.5 
ml/min) cis/trans = 92:8 (cis tR = 10.8 min, trans tR = 8.8 min). Purification by CC (φ 12 × 
220; n-heptane/EtOAc, 9:1) and separation by prep. HPLC (n-heptane/EtOAc, 7:1; 12.0 
ml/min) gave (2R,4R)-71 (tR = 31.7 min) and (2S,4R)-71 (tR = 26.8 min). 
 
(2R,4R)-71: 113 mg (79%); colorless oil. – TLC: Rf = 0.40 (n-heptane/EtOAc, 3:1). – [α]D20 = 
+13.0 (c = 1.02, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 0.13 (s, 3 H, SiCH3), 0.14 (s, 3 
H, SiCH3), 0.94 [s, 9 H, C(CH3)3], 1.25 (t, J = 7.0 Hz, 3 H, CH2CH3), 2.04 (dt, J = 13.5/2.4 
Hz, 1 H, CH2CHCH2COO), 2.32 (ddd, J = 13.5/8.1/5.4 Hz, 1 H, CH2CHCH2COO), 2.91 (dd, 
J = 15.1/9.6 Hz, 1 H, CH2COO), 3.18 (dd, J = 15.1/4.0 Hz, 1 H, CH2COO), 3.50 (ddd, J = 
11.4/2.9/1.1 Hz, 1 H, NCH2), 3.82 (dd, J = 11.4/5.4 Hz, 1 H, NCH2), 4.14-4.22 (m, 2 H, 
CH2CH3), 4.43-4.53 (m, 2 H, CHOSi and NCH), 5.26 (s, 2 H, CH2Ph), 7.24-7.45 (m, 5 H, 
Haromat). – IR: ~ν  = 3034, 2955, 2858, 1738, 1704, 1415, 1357, 1098, 838, 775, 698 cm-1. – 
MS; m/z (%): 422 (36) [M+1]+, 364 (8), 314 (7), 163 (7), 91 (100). – C22H35NO5 (421.61): 
calcd. C 62.67, H 8.37, N 3.32; found C 62.47, H 8.28, N 3.25. 
 
(2S,4R)-71: 7 mg (5%); colorless oil. – TLC: Rf = 0.43 (n-heptane/EtOAc, 3:1). – [α]D20 = -
40.3 (c = 1.00, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 0.06 (s, 6 H, 2 SiCH3), 0.90 [s, 9 
H, Si(CH3)3], 1.24 (t, J = 7.0 Hz, 3 H, CH2CH3), 2.06-2.12 (m, 1 H, CH2CHCH2COO), 2.22-
2.28 (m, 1 H, CH2CHCH2COO), 2.62 (dd, J = 15.1/8.5 Hz, 1 H, CH2COO), 3.08 (dd, J = 
15.1/2.2 Hz, 1 H, CH2COO), 3.62 (dt, J = 11.3/2.2 Hz, 1 H, NCH2), 3.69 (br. d, J = 11.3 Hz, 1 
H, NCH2), 4.17 (q, J = 7.0 Hz, 2 H, CH2CH3), 4.50-4.56 (m, 2 H, NCH and CHOSi), 5.23 (d, 
J = 12.9 Hz, 1 H, CH2Ph), 5.27 (d, J = 12.9 Hz, 1 H, CH2Ph), 7.25-7.43 (m, 5 H, Haromat). – 
IR: ~ν  = 3034, 2955, 2857, 1735, 1705, 1413, 1110, 838, 776, 697 cm-1. – MS; m/z (%): 422 
(72)  [M+1]+, 378 (13), 314 (16), 91 (100). – C22H35NO5 (421.61): calcd. C 62.67, H 8.37, N 
3.32; found C 62.48, H 8.47, N 3.36. 
 
1)    According to GP1-A from 124 mg (0.339 mmol) of 70 and 228 mg (purity: 75%, 1.07 
mmol) of 116 in 3 ml of CH2Cl2, 101 mg (0.711 mmol) of BF3·Et2O; reaction: at 20 °C for 3 
h; 3.2 ml (2.3 mmol) of aq. 5% K2CO3; analytical HPLC (n-heptane/EtOAc, 88/12; 1.5 
ml/min) cis/trans = 87:13 (cis tR = 9.4 min, trans tR = 7.6 min); purification by CC (φ 12 × 
200; n-heptane/EtOAc, 87.5:12.5) and separation by prep. HPLC (n-heptane/EtOAc, 
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87.5:12.5; 12 ml/min). Yield: 11 mg (8%) of (2S,4R)-71 (tR = 23.5 min) and 77 mg (54%) of 
(2R,4R)-71 (tR = 27.3 min).  
 
3) According to GP1-A from 3.00 (8.20 mmol) of 70 and 8.60 g (purity: 61%, 32.8 mmol) of 
116 in 83 ml of CH2Cl2, 2.43 g (17.2 mmol) of BF3·Et2O; reaction: at –78 °C for 4 h; 66.7 ml 
(48.3 mmol) of aq. 5% K2CO3; analytical HLPC (n-heptane/EtOAc, 88/12; 1.3 ml/min) 
cis/trans = 87:13 (cis tR = 12.0 min, trans tR = 9.5 min); purification by CC (n-
heptane/EtOAc, 88:12) and separation by prep. HPLC (n-heptane/EtOAc, 88:12; 12 ml/min). 
Yield: 314 mg (9%) of (2S,4R)-71 (tR = 27.0 min) and  2.72 g (79%) of (2R,4R)-71 (tR = 32.7 
min). 
 
4) According to GP1-A from 124 mg (0.339 mmol) of 70 and 228 mg (purity: 75%, 1.07 
mmol) of 116 in 3 ml of CH2Cl2, 0.71 ml (1.0 M in CH2Cl2, 0.71 mmol) of TiCl4; reaction: at 
–78 °C for 48 h; 3.5 ml (2.5 mmol) of aq. 5% K2CO3; analytical HPLC (n-heptane/EtOAc, 
87.5/12.5; 1.3 ml/min) cis/trans = 80:20 (cis tR = 13.1 min, trans tR = 10.1 min); purification 
by CC (φ 18 × 230; n-heptane/EtOAc, 87.5:12.5) and separation by prep. HPLC (n-
heptane/EtOAc, 87.5:12.5; 12 ml/min). Yield: 7 mg (5%) of (2S,4R)-71  and 38 mg (27%) of 
(2R,4R)-71. 
 
5)  According to GP1-B from 124 mg (0.339 mmol) of 70 and 101 mg (0.711 mmol) of 
BF3·Et2O in 3 ml of CH2Cl2, 357 mg (purity: 61%, 1.36 mmol) of 116; reaction: at -78 °C for 
4 h; 3.2 ml (2.3 mmol) of aq. 5% K2CO3; analytical HPLC (n-heptane/EtOAc, 88/12; 1.3 
ml/min) cis/trans = 97:3 (cis tR = 12.3 min, trans tR = 9.6 min); purification by CC (φ 18 × 
220; n-heptane/EtOAc, 88:12) and separation by prep. HPLC (n-heptane/EtOAc, 88:12; 12 
ml/min). Yield: 2.4 mg (1.7%) of (2S,4R)-71 (tR = 27.6 min) and 106 mg (74%) of (2R,4R)-71 
(tR = 33.0 min). 
 
6) According to GP1-B from 124 mg (0.339 mmol) of 70 and 101 mg (0.711 mmol) of 
BF3·Et2O in 3 ml of CH2Cl2, 228 mg (purity: 75%, 1.07 mmol) of 116; reaction: at -78 °C for 
18 h; 3.2 ml (2.3 mmol) of aq. 5% K2CO3; analytical HPLC (n-heptane/EtOAc, 87.5:12.5; 1.3 
ml/min) cis/trans = 97:3 (cis tR = 12.6 min, trans tR = 10.2 min); purification by CC (φ 18 × 
240; n-heptane/EtOAc, 87.5:12.5) and separation by prep. HPLC (n-heptane/EtOAc, 88:12; 
12 ml/min). Yield: 2.5 mg (2%) of (2S,4R)-71 (tR = 26.6 min) and 89 mg (62%) of (2R,4R)-71 
(tR = 30.8 min). 
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7) According to GP1-B from 124 mg (0.339 mmol) of 70 and 0.71 ml (1.0 M in CH2Cl2, 
0.71 mmol) of TiCl4 in 3 ml of CH2Cl2, 228 mg (purity: 75%, 1.07 mmol) of 116; reaction: at 
-78 °C for 16 h; 3.2 ml (2.3 mmol) of aq. 5% K2CO3; analytical HPLC (n-heptane/EtOAc, 
87.5:12.5; 1.3 ml/min) cis/trans = 89:19 (cis tR = 11.72 min, trans tR = 9.40 min); purification 
by CC (φ 18 × 245; n-heptane/EtOAc, 87.5:12.5) and separation by prep. HPLC (n-
heptane/EtOAc, 88:12; 12 ml/min). Yield: 10 mg (7%) of (2S,4R)-71 (tR = 23.2 min) and 82 
mg (57%) of (2R,4R)-71 (tR = 27.7 min). 
 
Ethyl (2R,4R)-1-benzyloxycarbonyl-4-(benzyloxycarbonyl)oxypyrrolidine-2-acetate 
[(2R,4R)-80] 
COOC2H5
N
PhCH2OCOO
COOCH2Ph
 
 
1)     According to GP1-A from 131 mg (0.339 mmol) of 77, 400 mg (purity: 57%, 1.42 
mmol) of 116 and 101 mg (0.711 mmol) of BF3·Et2O in 3 ml of CH2Cl2; reaction: at –78 °C 
for 4 h; 3.2 ml (2.3 mmol) of aq. 5% K2CO3. Purification by CC (φ 25 × 210; iso-
hexane/acetone, 4:1) and separation by prep. HPLC (n-heptane/EtOAc, 7:3; 12 ml/min) gave 
(2R,4R)-80. And 36 mg (24%) of the starting material 77 (tR = 28.5 min) was recycled. 
 
(2R,4R)-80: 19 mg (13%); colorless oil. – tR = 26.5 min. – TLC: Rf = 0.33 (n-heptane/ EtOAc, 
3:1). – [α]D 20 = +21.2 (c = 0.50, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 1.22 (t, J = 7.1 
Hz, 3 H, CH2CH3), 2.29 (br. d, J = 15.4 Hz, 1 H, CH2CHCH2COO), 2.49-2.57 (m, 1 H, 
CH2CHCH2COO), 2.73 (dd, J = 15.2/9.7 Hz, 1 H, CH2COO), 3.13 (dd, J = 15.2/3.7 Hz, 1 H, 
CH2COO), 3.72 (dd, J = 12.6/1.1 Hz, 1 H, NCH2CHO),  3.96 (dd, J = 12.6/5.3 Hz, 1 H, 
NCH2CHO), 4.15 (q, J = 7.1 Hz, 2 H, CH2CH3), 4.47-4.54 (m, 1 H, NCH), 5.23-5.29 (m, 4 H, 
CH2Ph), 5.30-5.35 (m, 1 H, NCH2CHO), 7.26-7.44 (m, 10 H, Haromat). – IR: ~ν = 3034, 2956, 
1732, 1705, 1498, 1415, 1268, 770, 752, 698 cm-1. – MS; m/z (%): 442 [M+1]+ (100), 398 
(14), 181 (14), 154 (37). – C24H27NO7 (441.48): calcd. C 65.29, H 6.16, N 3.17; found C 
65.24, H 6.16, N 3.17. 
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2)    According to GP1-B from 131 mg (0.339 mmol) of 77, 101 mg (0.711 mmol) of 
BF3·Et2O; 400 mg (purity: 57%, 1.42 mmol) of 116 in 3 ml of CH2Cl2; reaction: at –78 °C for 
4 h; 3.2 ml (2.3 mmol) of aq. 5% K2CO3. Purification by CC (φ 25 × 200; iso-hexane/acetone, 
4:1) and separation by prep. HPLC (n-heptane/EtOAc, 7:3; 12 ml/min) gave 5.6 mg (4%) of 
(2R,4R)-80 (tR = 27.2 min). And 20 mg (15%) of the starting material 77 (tR = 28.7 min) was 
recycled. 
 
Ethyl (2R,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-acetate [(2R,4R)-73]   
N
COOCH2Ph
OH
COOC2H5
 
To a solution of 90 mg (0.21 mmol) of (2R,4R)-71 in 2 ml of THF, 0.26 ml (1.0 M in THF, 
0.26 mmol) of TBAF was added, then resulting solution was stirred at r.t. for 4.5 h. 2.0 ml of 
0.1% K2CO3 was added. The organic layer was separated, dried (Na2SO4), and evaporated to 
give pale yellow oil, which was purified by CC (φ 12 × 100; iPr2O/EtOH, 95:5). Yield: 58 mg 
(88%); colorless oil. – TLC: Rf = 0.54 (iPr2O/EtOH, 9:1). – [α]D22 = +23.4 (c = 0.7, EtOAc). – 
1H NMR (C6D5NO2, 120 °C): δ = 1.24 (t, J = 7.1 Hz, 3 H, CH2CH3),  2.09 (dtd, J = 
13.8/3.1/1.3 Hz, 1 H, CH2CHCH2COO), 2.39 (ddd, J = 13.8/8.4/5.6 Hz, 1 H, 
CH2CHCH2COO), 2.60 (s, 1 H, OH), 2.93 (dd, J = 15.4/9.2 Hz, 1 H, CH2COO), 3.17 (dd, J = 
15.4/4.1 Hz, 1 H, CH2COO), 3.57 (ddd, J = 11.8/2.9/1.3 Hz, 1 H, NCH2), 3.83 (dd, J = 
11.8/5.4 Hz, 1 H, NCH2), 4.17 (q, J = 7.1 Hz, 2 H, CH2CH3), 4.41-4.48 (m, 1 H, NCH), 4.54-
4.58 (m, 1 H, CHOH), 5.25 (s, 2 H, CH2Ph), 7.25-7.45 (m, 5 H, Haromat). – IR: ~ν  = 3442, 
3034, 2944, 1731, 1682, 1416, 1119, 770, 750, 698 cm-1. – MS; m/z (%): 308 (93) [M+1]+, 
264 (44), 262 (36), 172 (23), 91 (100). – C16H21NO5 (307.35): calcd. C 62.53, H 6.89, N 4.56; 
found C 62.39, H 6.92, N 4.49. 
 
Ethyl (2R,4R)-4-hydroxypyrrolidine-2-acetate hydrochloride [(2R,4R)-64] 
 
N
OH
COOC2H5
H HCl.
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To a solution of 187 mg (0.608 mmol) of (2R,4R)-73 in 10 ml of EtOH, 93 mg (0.087 mmol) 
of 10% Pd-C and 55 µl (0.66 mmol) of aq. 37% HCl were added. The mixture was 
hydrogenated at r.t. under ambient pressure for 2 h, and then filtrated and finally concentrated. 
The residue was recrystallized from EtOH/iPr2O. Yield: 114 mg (89%); colorless crystals. – 
M.p. 150-151 °C (EtOH/iPr2O). – [α]D20 = -34.0 (c = 1.00, EtOH). – 1H NMR (CD3OD): δ = 
1.29 (t, J = 7.4 Hz, 3 H, CH2CH3), 1.79 (ddt, J = 14.1/4.7/1.9 Hz, 1 H, CH2CHCH2COO), 
2.43 (ddd, J = 14.1/9.8/5.0 Hz, 1 H, CH2CHCH2COO), 2.92 (dd, J = 18.0/5.2 Hz, 1 H, 
CH2COO), 2.98 (dd, J = 18.0/9.4 Hz, 1 H, CH2COO), 3.22 (dd, J = 11.9/3.6 Hz, 1 H, NCH2), 
3.27 (dt, J = 11.9/1.9 Hz, 1 H, NCH2), 4.00-4.08 (m, 1 H, NCH), 4.21 (q, J = 7.4 Hz, 2 H, 
CH2CH3), 4.50-4.53 (m, 1 H, CHOH). – IR: ~ν  = 3303, 2934, 2758, 1721, 1585, 1259, 1104, 
1033 cm-1. – MS; m/z (%): 174 (100). – C8H16ClNO3 (209.67): calcd. C 45.83, H 7.69, N 
6.68, Cl 16.91; found C 45.76, H 7.72, N 6.64, Cl 16.68. 
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(2S,4R)-4-Benzyloxy-1-benzyloxycarbonylpyrrolidine-2-carboxylic acid [(2S,4R)-83]  
 
According to ref. [75]: To a solution of 5.0 g (19 mmol) of (2S,4R)-58 in 200 ml of THF, 1.61 
g (55~60% in oil, 40 mmol) of NaH was added at r.t, the mixture was stirred over night and 
then 7.42 g (43.4 mmol) of benzyl bromide was added. After refluxing for 11.5 h, the reaction 
mixture was cooled down, quenched with ice-water and extracted with 300 ml of n-heptane. 
The aqueous layer was acidified with aq. 2 M HCl to pH 1~2 and extracted with Et2O (4 × 
100 ml). The combined extracts were dried (MgSO4) and concentrated. Yield: 6.07 g (90%); 
colorless oil. – [α]D20 = -34.9 (c = 1.27, EtOH). {ref. [75]: [α]D20 = -23.2 (c = 0.2, EtOH)} 
 
Benzyl (2S,4R)-4-benzyloxy-2-diazoacetylpyrrolidine-1-carboxylate [(2S,4R)-84]  
N
PhCH2O
COCHN2
COOCH2Ph
 
To a solution of 3.90 g (11.0 mmol) of (2S,4R)-83 and 50 µl of DMF as a catalyst in 26 ml of 
CH2Cl2 2.10 g (16.5 mmol) of (COCl)2 was added at 0 °C. After the mixture had been stirred 
for 1 h at 0 °C, the solvent was removed under vacuo to afford the acid chloride as a yellow 
oil. To a solution of 2.22 g (52.8 mmol) of CH2N2 in 150 ml of Et2O the acid chloride was 
diluted in 4.5 ml of Et2O and slowly added at 0 °C. After the resulting yellow solution had 
been stirred for 1 h, excessive CH2N2 was decomposed by the addition of AcOH and then the 
mixture was neutralized with aq. 1% K2CO3, dried (Na2SO4) and evaporated to give a yellow 
oil. Purification by CC (φ 45 × 230; iso-hexane/acetone, 7:3). Yield: 3.33 g (80%); yellow oil. 
– TLC: Rf  = 0.41 (n-heptane/acetone, 3:2). – [α]D20 = -55.5 (c = 1.00, EtOAc). – 1H NMR 
(CDCl3, -30 °C): Two rotamers (the chemical shift small one to the large one 43:57) δ = 2.01-
2.07, 2.10-2.16 (m, 1 H, NCHCH2), 2.30-2.37, 2.41-2.48 (m, 1 H, NCHCH2), 3.55-3.59, 3.61-
3.65 (m, 1 H, NCH2), 3.69-3.73, 3.88-3.92 (m, 1 H, NCH2), 4.14-4.23 (m, 1 H, NCH2CHO), 
4.37-4.53 (m, 3 H, NCH and PhCH2OCH), 5.00-5.23 (m, 2 H, PhCH2OCO), 5.26, 5.54 (s, 1 
H, CHN2), 7.28-7.38 (m, 10 H, Haromat). – IR: ~ν  = 3090, 3033, 2943, 2107, 1704, 1650, 1416, 
1357, 1119, 770, 740, 698 cm –1. – MS; m/z (%): 380 (2) [M+1]+, 352 (100), 310 (34), 266 
(29), 181 823), 107 (5). – C21H21N3O4 (379.42): calcd. C 66.48, H 5.58, N 11.08; found C 
66.82, H 5.71, N 10.63.       
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Methyl (2S,4R)-4-benzyloxy-1-benzyloxycarbonylpyrrolidine-2-acetate [(2S,4R)-85]  
N
PhCH2O
COOCH2Ph
COOCH3
 
To a solution of 390 mg (1.03 mmol) of (2S,4R)-84  in 3 ml of MeOH, a solution of 17 mg 
(0.10 mmol) of AgOAc and 61 mg (0.61 mmol) of TEA in 1.5 ml of MeOH was added at r.t. 
The mixture turned to be brown within a few minutes, and then was warmed to 60 °C for 30 
min. The reaction mixture was decolorized with charlcoal and concentrated. The resulting oil 
was purified by CC (φ 15 × 210; n-heptane/acetone, 3:1). Yield: 317 mg (81%); colorless oil. 
– TLC: Rf  = 0.45 (n-heptane/acetone, 3:2). – [α]D20 = -33.8 (c = 0.95, EtOAc). – 1H NMR 
(C6D5NO2, 120 °C): δ = 2.07-2.13 (m, 1 H, CH2CHCH2COO), 2.41-2.47 (m, 1 H, 
CH2CHCH2COO), 2.62 (dd, J = 15.4/8.4 Hz, 1 H, CH2COO), 3.07 (dd, J = 15.4/3.7 Hz, 1 H, 
CH2COO), 3.62 (dd, J = 11.8/4.8 Hz, 1 H, NCH2), 3.66 (s, 3 H, CH3), 3.91 (br. d, J = 11.8 Hz, 
1 H, NCH2), 4.24-4.29 (m, 1 H, NCH2CHO), 4.50-4.54 (m, 1 H, NCH), 4.56 (s, 2 H, 
PhCH2OCH), 5.26 (s, 2 H, COOCH2Ph), 7.25-7.45 (m, 10 H, Haromat). – IR: ~ν  = 3092, 3034, 
2109, 1746, 1712, 1644, 1416, 1125, 770, 754, 698 cm1. – MS; m/z (%): 384 (22) [M+1]+, 
340 (26), 248 (32), 148 (17), 91 (100). – C22H25NO5 (383.44): calcd. C 68.91, H 6.57, N 3.65; 
found C 68.80, H 6.59, N 3.52. 
 
Methyl (2S,4R)-4-hydroxypyrrolidine-2-acetate hydrochloride [(2S,4R)-86] 
N
OH
COOCH3
H HCl.
 
To a solution of 325 mg (0.848 mmol) of (2S,4R)-85 and 80 µl (0.96 mmol) of aq. 37% HCl 
in 10 ml of MeOH , 162 mg (0.153 mmol) of 10% Pd-C was added. The mixture was 
hydrogenated under ambient pressure at r.t. for 5 d, then filtrated. The filtrate was evaporated 
and its residue was dissolved in a small amount of MeOH and then crystallized from iPr2O. 
Yield: 149 mg (90%); colorless crystals. – M.p. 116-117 °C. – [α]D20 = +42.8 (c = 0.43, 
MeOH). – 1H NMR (CD3OD): δ = 1.71 (ddd, J = 13.7/11.4/4.0 Hz, 1 H, CH2CHCH2COO), 
2.09 (ddt, J = 13.7/6.4/1.5 Hz, 1 H, CH2CHCH2COO), 2.69 (dd, J = 18.0/9.9 Hz, 1 H, 
CH2COO), 2.82 (dd, J = 18.0/4.0 Hz, 1 H, CH2COO), 3.09 (dd, J = 12.2/1.5 Hz, 1 H, NCH2), 
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3.25 (dd, J = 12.2/3.7 Hz, 1 H, NCH2), 3.62 (s, 3 H, CH3), 3.99-4.07 (m, 1 H, NCH), 4.38-
4.41 (m, 1 H, CHOH). – IR: ~ν  = 3333, 2955, 1735, 1588, 1202, 1163 cm-1. – MS; m/z (%): 
160 (100), 142 (8). – C7H14ClNO3 (195.46): calcd. C 42.97, H 7.21, N 7.16, Cl 18.12; found 
C 42.78, H 7.42, N 7.16, Cl 18.16. 
 
Methyl (2S,4R)-4-benzyloxypyrrolidine-2-acetate hydrochloride [(2S,4R)-87] 
N
PhCH2O
COOCH3
H . HCl
 
1) To a solution of 298 mg (0.778 mmol) of (2S,4R)-85 and 196 mg (3.11 mmol) of 
HCOONH4 in 5 ml of MeOH, 100 mg (0.047 mmol) of 5% Pd-C was added. The mixture was 
hydrogenated at r.t. under ambient pressure for 2 h, then filtrated and evaporated. The 
resulting residue was dissolved in a small amount of H2O and the mixture was extracted with 
Et2O. the combined extract was dried (Na2SO4) and concentrated to give an oil, which was 
bubbled by dry HCl gas in iPr2O to give 151 mg (70%) of (2S,4R)-87 as colorless crystals. – 
M.p. 128-129 °C (iPr2O). – [α]D20 = +18.4 (c = 1.02, MeOH). – 1H NMR (CD3OD): δ = 1.71 
(ddd, J = 14.0/11.5/4.0 Hz, 1 H, CH2CHCH2COO), 2.33-2.39 (m, 1 H, CH2CHCH2COO), 
2.71 (dd, J = 18.0/9.9 Hz, 1 H, CH2COO), 2.86 (dd, J = 18.0/4.0 Hz, 1 H, CH2COO), 3.28 
(dd, J = 12.7/3.8 Hz, 1 H, NCH2CHO), 3.36 (br. d, J = 12.7 Hz, 1 H, NCH2CHO), 3.63 (s, 3 
H, CH3), 3.96-4.04 (m, 1 H, NCH), 4.22-4.25 (m, 1 H, NCH2CHO), 4.45 (s, 2 H, CH2Ph), 
7.15-7.27 (m, 5 H, Haromat). – IR: ~ν  = 3456, 3031, 2900, 2732, 1735, 1209, 1166, 740, 700 
cm-1. – MS; m/z (%): 250 (100), 176 (9), 143 (5), 119 (1). – C14H20ClNO3 (285.77): calcd. C 
58.84, H 7.05, N 4.90, Cl 12.41; found C 58.67, H 7.22, N 4.91, Cl 12.57.    
 
2) To a solution of 300 mg (0.783 mmol) of (2S,4R)-85 and 24 mg (0.23 mmol) of TEA in 15 
ml of MeOH, 150 mg (0.141 mmol) of 10% Pd-C was added. The mixture was hydrogenated 
under ambient pressure at r.t. for 23 h, and then filtrated and evaporated. The resulting residue 
was bubbled by dry HCl gas in iPr2O to give 203 mg (91%) of (2S,4R)-87. 
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6.1.2 Preparation of alkyl halides 
 
Cyclopropyldiphenylmethanol (117) 
 
To a solution of 5.70 g (0.115 mmol) of ethyl cyclopropanecarboxylate in 85 ml of THF, 
PhMgBr, prepared from 18.0 g (0.115 mmol) of C6H5Br and 2.80 g (0.115 mmol) of Mg 
powder in 90 ml of THF, was added at 0 °C. The mixture was allowed to stir at r.t. for 1 h and 
sat. aq. NH4Cl was added. Organic layer was isolated, and dried (Na2SO4) and evaporated. 
The residual oil was crystallized to give 9.19 g (82%) of 117 as colorless crystals. – M.p. 82-
84 °C (petroleum ether). {ref. [83]: M.p. 82-83 °C}. 
 
4-Bromo-1,1-dipheny-1-butene (118) 
 
According to ref. [35]: 7.40 g (33 mmol) of 117 in 10 ml of CH2Cl2 was treated with 30 ml 
(0.26 mol) of 47% hydrobromic acid at 0 °C for 4 h. The mixture was extracted with CH2Cl2, 
washed with sat. NaHCO3, H2O, dried (Na2SO4) and evaporated to give 8.63 g (86%) of 118 
as colorless oil. 
 
Tris(4-methoxyphenyl)methanol  (119) 
 
According to ref. [84]: To a solution of 6.65 g (40 mmol) of methyl 4-methoxybenzoate in 105 
ml of THF 4-methoxyphenyl magnesium bromide, prepared from 2.07 g (86.0 mmol) of Mg 
and 15.7 g (84.0 mmol) of 4-methoxyphenylbromide, was added at 0 °C. The mixture was 
stirred at r.t. for 3 h and the reaction was quenched with sat. aq. NH4Cl. The organic layer was 
separated, dried (Na2SO4) and concentrated to yield an oil, which was crystallized from iPr2O 
to give 11.5 g (82%) of 119 as colorless crystals. – M.p. 81-84 °C (n-heptane). {ref. [85]: M.p. 
82-82.5 °C (n-pentane)}. 
 
1-Bromo-2-[tris(4-methoxyphenyl)]methoxyethane (120) 
 
According to ref. [85]: Tris(4-methoxyphenyl)chloromethane as violet solid was prepared from  
4.15 g (11.8 mmol) of 119 and 2.04 g (1.85 ml, 26.0 mmol) of AcCl in 20 ml of CH2Cl2. 1.56 
g (0.880 ml, 11.8 mmol) of 2-bromoethanol was dropwise added at 0 °C to the solution of the 
above violet solid in 20 ml of CH2Cl2, and followed by the addition of 1.74 g  (17.2 mmol) of 
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TEA. After 1 h, this mixture was washed with H2O, and dried (Na2SO4) and concentrated to 
yield a yellow oil. Purification by CC (Al2O3, mesh 70-230, pH 9.5 ± 0.5; n-heptane/EtOAc, 
9:1) gave 4.87 g (90%) of 120 [35] as colorless oil. 
 
2-Bromo-3-methylthiophene (121) 
 
According to ref. [86]: To a solution of 4.80 ml (4.91 g, 50.0 mmol) of 3-methylthiophene in 
38 ml of EtOAc, a suspension of 9.53 g (52.0 mmol) of NBS in 61 ml of EtOAc-CHCl3 (1:1, 
v/v) was stepwise added at r.t. within 12 min. After 1.5 h, the mixture was washed with aq. 
1% K2CO3, dried (MgSO4), and finally evaporated. The residual oil was purified by 
azeotropic distillation. Yield: 7.13 g (81%); yellow oil.  
 
Cyclopropyldi(3-methyl-2-thienyl)methanol (122) [18] 
 
To a solution of 3-methyl-2-thienylmagnesium bromide in 50 ml of Et2O, which was prepared 
from 7.10 g (40.1 mmol) of 121 and 1.01 g (42.1 mmol) of Mg in 60 ml of Et2O, 1.89 ml 
(1.83 g, 16.0 mmol) of ethyl cyclopropanecarboxylate in 10 ml of Et2O was slowly added 
below 10 °C. The mixture was stirred over night and then quenched with aq. sat. NH4Cl. The 
organic layer was isolated, dried (MgSO4), and concentrated. Yield: 4.1 g (39%); yellow oil. 
 
4-Bromo-1,1-di(3-methyl-2-thienyl)-1-butene (123) 
 
According to ref. [62]: To a solution of 4.08 g (12.5 mmol) of 122 and 6 ml of AcOH, 30 ml 
(0.56 mmol) of aq. 47% HBr was added at 0-5 °C. The resulting mixture was stirred for 1.5 h, 
and then diluted with 80 ml of H2O and extracted with Et2O (2 × 40 ml). The combined 
extracts were washed, in turn, with H2O, aq. 1% K2CO3, H2O, dried (Na2SO4), and 
evaporated. The residue was purified by CC (φ 25 × 100, n-heptane). Yield 3.93 g (78%); 
yellow oil.   
 
9-(3-Chloropropyl)carbazole (124) 
 
According to ref. [87]: To a solution of 13.8 g (82.8 mmol) of carbazole and 15.8 g (101 mmol) 
of 1-bromo-3-chloropropane in 180 ml of DMF, 16.2 g (405 mmol) of NaOH powder was 
slowly added. The mixture was stirred at r.t. for 3 h, and then mixed with 500 ml of ice-water 
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and extracted with iPr2O (2 × 200 ml). The combined extracts were washed with H2O, dried 
(MgSO4), and evaporated. The residue was purified by CC (φ 50 × 200; n-heptane/EtOAc, 
75:25). Yield: 13.6 g (68%); slightly yellow oil. 
 
9-(3-Iodopropyl)carbazole (125) 
 
A mixture of 8.0 g (33 mmol) of 124 and 10 g (60 mmol) of KI was stirred in 100 ml of 
acetone at r.t. for 15 d, and then filtrated and evaporated. Yield: 8.2 g; yellow oil [purity: 70% 
(w/w); I/Cl = 1.6:1 (mol/mol), determined by 1H NMR]. 
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6.1.3   Preparation of N-Substituted pyrrolidine derivatives 
 
General procedure 2 (GP2) [30] 
 
The respective alkyl halide RX (1.0 equiv.) and KI (0.2 equiv.) were added to a mixture of the 
pyrrolidine derivative (1.0 equiv. hydrochloride) and K2CO3 (5.0 equiv.) in acetone (4~8 
ml/mmol). It was stirred at r.t. for the time indicated. Inorganic salts were removed by 
filtration and the filtrate was evaporated in vacuuo. The residue was purified by CC. 
 
Methyl (2S,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-carboxylate 
[(2S,4R)-39a]  
N
OH
COOCH3
 
According to GP2 from 50 mg (0.30 mmol) of KI, 454 mg (1.50 mmol) of 118, 274 mg (1.0 
mmol) of (2S,4R)-38 and 691 mg (5.0 mmol) of K2CO3 in 8 ml of acetone; reaction time: 144 
h; purification by CC (φ 20 × 310; n-heptane/acetone, 4:1). Yield: 273 mg (52%); colorless 
oil. – TLC: Rf = 0.39 (n-heptane/acetone, 3:2). – [α]D20 = -53.3 (c = 0.6, EtOAc). – 1H NMR 
(CDCl3): δ = 2.03 (ddd, J = 13.7/7.6/3.1 Hz, 1 H, NCHCH2), 2.19 (dd, J = 13.7/7.6 Hz, 1 H, 
NCHCH2), 2.30 (q, J = 7.5 Hz, 2 H, NCH2CH2), 2.41 (dd, J = 10.1/3.6 Hz, 1 H, 
NCH2CHOH), 2.62 (dt, J = 12.2/7.5 Hz, 1 H, NCH2CH2), 2.82 (dt, J = 12.2/7.5 Hz, 1 H, 
NCH2CH2), 3.33 (dd, J = 10.1/5.5 Hz, 1 H, NCH2CHOH), 3.53 (t, J = 7.6 Hz, 1 H, NCH), 
3.67 (s, 3 H, OCH3), 4.40-4.45 (m, 1 H, CHOH), 6.07 (t, J = 7.5 Hz, 1 H, =CHCH2), 7.15-
7.38 (m, 10 H, Haromat). – IR: ~ν = 3418, 3055, 2949, 1738, 1443, 763, 701 cm-1. – MS; m/z 
(%): 352 (67) [M+1]+, 351 (100), 207 (18), 129 (58).  – C22H25NO3 (351.45): calcd. C 75.19, 
H 7.17, N 4.00; found C 74.83, H 7.22, N 3.94. 
The oily product described above was treated in acetone with anhydrous HCl to give its 
hydrochloride as colorless crystals. – M.p. 125-127 °C (acetone). – [α]D20  = -39.9 ( c = 1.00, 
EtOH). – 1H NMR (CD3OD): δ = 2.20 (ddd, J = 13.6/12.4/4.3 Hz, 1 H, NCHCH2), 2.45 (dd, J 
= 13.6/7.2 Hz, 1 H, NCHCH2), 2.51-4.61 (m, 2 H, NCH2CH2), 3.19 (d, J = 12.4 Hz, 1 H, 
NCH2CHOH), 3.34-3.41 (m, 1 H, NCH2CH2), 3.54-3.62 (m, 1 H, NCH2CH2), 3.76 (dd, J = 
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12.4/4.3 Hz, 1 H, NCH2CHOH), 3.85 (s, 3 H, OCH3), 4.50-4.54 (m, 1 H, CHOH), 4.61 (dd, J 
= 12.4/7.2 Hz, 1 H, NCH), 6.09 (t, J = 7.2 Hz, 1 H, =CHCH2), 7.18-7.47 (m, 10 H, Haromat). – 
IR: ~ν = 3254, 2935, 1749, 772, 703 cm-1. – MS; m/z (%): 353 (27), 352 (100) [M-Cl]+, 158 
(13). – C22H26ClNO3 (387.91): calcd. C 68.12, H 6.76, N 3.61; found C 68.15, H 6.85, N 3.49.  
 
Methyl (2R,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-carboxylate 
[(2R,4R)-39a] 
N
OH
COOCH3
 
According to GP2 from 50 mg (0.30 mmol) of KI, 936 mg (3.09 mmol) of 118, 549 mg (3.00 
mmol) of (2R,4R)-38, 2.07 g (15.0 mmol) of K2CO3 in 12 ml of acetone; reaction time: 72 h; 
purification by CC (φ 25 × 260; n-heptane/EtOAc, 3:2). Yield: 432 mg (41%); colorless oil. – 
TLC: Rf  = 0.28 (n-heptane/EtOAc, 3:2). – [α]D20 = +45.4 (c = 1.00, EtOAc). – 1H NMR 
(CDCl3): δ = 1.92 (ddt, J = 14.2/3.6/1.5 Hz, 1 H, NCHCH2), 2.30 (q, J = 7.5 Hz, 2 H, 
NCH2CH2), 2.29-2.37 (m, 1 H, NCHCH2), 2.58 (dd, 1 H, J = 9.9/4.0 Hz, NCH2CHOH), 2.63 
(dt, J = 12.0/7.5 Hz, 1 H, NCH2CH2), 2.81 (dt, J = 12.0/7.5 Hz, 1 H, NCH2CH2), 3.00 (dt, J = 
9.9/1.5 Hz, 1 H, NCH2CHOH), 3.26 (dd, J = 9.9/3.6 Hz, 1 H, NCH), 3.70 (s, 3 H, OCH3), 
4.23-4.26 (m, 1 H, CHOH), 6.08 (t, J = 7.5 Hz, 1 H, =CHCH2), 7.16-7.40 (m, 10 H, Haromat). – 
IR:  ~ν = 3424, 3023, 2950, 1732, 1598, 1494, 1443, 1203, 1075, 867, 764, 700 cm-1.– MS; m/z 
(%): 352 (100) [M+1]+, 320 (34), 158 (39). – C22H25NO3 (351.45): calcd. C 75.19, H 7.17, N 
4.00; found C 74.90, H 7.18, N 3.82. 
 
Methyl (2S,4R)-4-hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylate [(2S,4R)-39b] 
 
According to GP2 from 50 mg (0.30 mmol) of KI, 682 mg (1.49 mmol) of 120, 273 mg (1.49 
mmol) of (2S,4R)-38, 680 mg (6.85 mmol) of K2CO3 in 6 ml of acetone; reaction time: 72 h; 
purification by CC (Al2O3, pH 7.5, mesh 70-230; φ 20 × 250; n-heptane/acetone, 2:1). Yield: 
414 mg (53%); colorless oil. – TLC: Rf  = 0.16 (n-heptane/acetone, 3:2). – [α]D22 = -24.5 (c = 
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0.55, EtOH). – 1H NMR (CDCl3): δ = 2.00-2.07 (m, 1 H, NCHCH2), 2.16 (ddt, J = 
13.6/7.2/3.3 Hz, 1 H, NCHCH2), 2.57 (dd, J = 10.2/3.4 Hz, 1 H, NCH2CHOH), 2.83 (m, 1 H, 
NCH2CH2), 2.95 (m, 1 H, NCH2CH2), 3.20 (t, J = 6.1 Hz, 2 H, NCH2CH2), 3.38 (dd, J = 
10.2/5.4 Hz, 1 H, NCH2CHOH), 3.64-3.66 (m, 1 H, NCH), 3.65 (s, 3 H, COOCH3), 3.78 (s, 9 
H, ArOCH3), 4.40-4.44 (m, 1 H, CHOH), 6.83-6.79 (m, 6 H, Haromat), 7.29-7.33 (m, 6 H, 
Haromat). – IR: ~ν = 3418, 3031, 2952, 1740, 1608, 1582, 1504, 1250, 1035, 828 cm-1. – MS 
(ESI+); m/z (%): 522 [M+1]+ (1), 333 (67), 266 (22), 146 (42). – C30H35NO7  (521.61): calcd. 
C 69.08, H 6.76, N 2.69; found C 68.85, H 7.04, N 2.65.  
 
Methyl (2R,4R)-4-hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylate [(2R,4R)-39b]  
N
OH
O
MeO OMe
OMe
COOCH3
 
According to GP2 from 42 mg (0.25 mmol) of KI, 1.14 g (2.50 mmol) of 120, 458 mg (2.50 
mmol) of (2R,4R)-38, 1.73 g (12.5 mmol) of K2CO3 in 12 ml of acetone; reaction time: 72 h; 
purification by CC (φ 25 × 220; n-heptane/acetone, 3:2). Yield: 429 mg (33%); colorless oil. – 
TLC: Rf  = 0.32 (n-heptane/acetone, 3:2). – [α]D20  = +30.8 (c = 1.45, EtOH). – 1H NMR 
(CDCl3): δ = 1.88-1.93 (m, 1 H, NCHCH2), 2.32 (ddd, J = 14.2/10.0/5.9 Hz, 1 H, NCHCH2), 
2.67 (dd, J = 9.9/4.1 Hz, 1 H, NCH2CHOH), 2.79 (dt, J = 12.4/6.0 Hz, 1 H, NCH2CH2), 2.94 
(dt, J = 12.4/6.0 Hz, 1 H, NCH2CH2), 3.03 (s, 1 H, OH), 3.06 (dt, J = 9.9/1.4 Hz, 1 H, 
NCH2CHOH), 3.12-3.21 (m, 2 H, NCH2CH2), 3.38 (dd, J = 10.0/3.9 Hz, 1 H, NCH), 3.66 (s, 
3 H, COOCH3), 3.77 (s, 9 H, ArOCH3), 4.20-4.24 (m, 1 H, CHOH), 6.78-6.82 (m, 6 H, 
Haromat), 7.28-7.32 (m, 6 H, Haromat). – IR: ~ν = 3444, 2952, 2836, 1732, 1607, 1504, 1249, 
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1034, 827, 787 cm-1. – MS (ESI+); m/z (%): 522 (1), 333 (100). – C30H35NO7 (521.61): calcd. 
C 69.08, H 6.76, N 2.69; found C 69.41, H 7.16, N 2.48. 
 
Methyl (2S,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-carboxylate [(2S,4R)-53a] 
N
OH
OMe
COOCH3
 
According to GP2 from 76 mg (0.30 mmol) of (2S,4R)-114, 93 mg (0.30 mmol) of 118, 167 
mg (0.906 mmol) of K2CO3 and 10 mg of KI in 3 ml of acetone; reaction time: 2 d; 
purification by CC (φ 18 × 240; n-heptane/EtOAc, 7:3). Yield: 73 mg (53%); colorless 
crystals. – M.p. 106-107 °C (iPr2O). – TLC: Rf = 0.23 (n-heptane/EtOAc, 7:3). – [α]D20 = -
47.8 (c = 0.95, CHCl3). – 1H NMR (CDCl3, 500 MHz): δ = 2.15 (ddd, J = 13.9/3.2/2.1 Hz, 1 
H, NCHCH2), 2.26 (q, J = 7.5 Hz, 2 H, NCH2CH2), 2.49 (dd, J = 13.9/10.8 Hz, 1 H, 
NCHCH2), 2.64-2.69 (m, 2 H, NCH2CH2 and NCH2CO), 2.80 (dt, J = 12.0/7.5 Hz, 1 H, 
NCH2CH2), 3.08 (dd, J = 9.1/2.1 Hz, 1 H, NCH2CO), 3.37 (dd, J = 10.8/3.2 Hz, 1 H, NCH), 
3.67 (s, 3 H, COOCH3), 3.73 (s, 3 H, ArOCH3), 3.91 (s, 1 H, OH), 6.05 (t, J = 7.5 Hz, 1 H, 
=CHCH2), 6.79-6.82 (m, 2 H, Haromat), 7.10-7.33 (m, 12 H, Haromat). – IR: ~ν  = 3474, 3060, 
2955, 1720, 1608, 1515, 1274, 1031, 834, 770, 752, 720 cm-1. – MS; m/z (%): 458 (58) 
[M+1]+, 440 (66), 426 (33), 380 (46), 264 (100), 207 (93), 167 (71), 109 (8). – C29H31NO4 
(457.57): calcd. C 76.12, H 6.83, N 3.06; found C 76.15, H 7.04, N 3.04. All analytical data 
were identical with those of one diastereomer which was prepared via the organometallic 
addition to (2S)-52a. 
 
Ethyl (2R,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-acetate [(2R,4R)-
88a]  
 
According to GP2 from 92 mg (0.44 mmol) of (2R,4R)-64, 132 mg (0.439 mmol) of 118, 298 
mg (2.16 mmol) of K2CO3 and 10 mg of KI in 2.7 ml of acetone; purification by CC (φ 18 × 
230; n-heptane/acetone, 3:1). Yield: 115 mg (69%); colorless oil. – TLC: Rf = 0.39 (n- 
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heptane/acetone, 3:2). – [α]D20 = +58.9 (c = 0.85, EtOAc). – 1H NMR (CDCl3, 500 MHz): δ = 
1.20 (t, J = 7.1 Hz, 3 H, CH2CH3), 1.69 (ddt, J = 14.3/6.1/1.7 Hz, 1 H, CH2CHCH2COO), 
2.16 (dd, J = 10.0/4.2 Hz, 1 H, NCH2CHOH), 2.23-2.33 (m, 3 H, NCH2CH2 and 2 H of 
NCH2CH2), 2.37 (ddd, J = 14.3/9.2/6.5 Hz, 1 H, CH2CHCH2COO), 2.43 (dd, J = 15.3/7.8 Hz, 
1 H, CH2COO), 2.62 (dd, J = 15.3/3.3 Hz, 1 H, CH2COO), 2.63-2.70 (m, 2 H, NCH and OH), 
2.80-2.90 (m, 1 H, NCH2CH2), 2.99 (d, J = 10.0 Hz, 1 H, NCH2CHOH), 4.05-4.15 (m, 3 H, 
CHOH and 2 H of CH2CH3), 6.05-6.09 (m, 1 H, =CHCH2), 7.14-7.37 (m, 10 H, Haromat). – 13C 
{1H} (decoupling: X-freq. 1H 500 MHz; Y-freq. 13C 125.8 MHz): δ = 14.2 (CH3), 28.8 
(NCH2CH2), 38.8 (CH2COO), 40.9 (1 C, CH2CHCH2COO), 53.3 (NCH2CH2), 59.5 (NCH), 
60.4 (OCH2CH3), 62.1 (NCH2CHO), 70.1 (CHOH), 127.0, 127.1 (2 C, Caromat), 127.3 
(=CHCH2), 128.2, 128.3 (4 C, Caromat), 129.9 (4 C, Caromat), 140.0 (2 C, C=CHCH2), 142.5 
142.7 (2 C, Caromat), 172.3 (COO). – IR: ~ν  = 3415, 3025, 2976, 1731, 1598, 1444, 1031, 762, 
702 cm-1. – MS; m/z (%): 380 (82) [M+1]+, 334 (100), 292 (17), 186 (43), 140 (18). – 
C24H29NO3 (379.50): calcd. C 75.96, H 7.70, N 3.69; found C 75.64, H 7.74, N 3.57. 
 
Ethyl (2R,4R)-4-hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
acetate [(2R,4R)-88b] 
N
OH
COOC2H5
O
OMeMeO
OMe
 
According to GP2 from 136 mg (0.608 mmol) of (2R,4R)-64, 278 mg (0.608 mmol) of 120, 
420 mg (3.04 mmol) of K2CO3 and 15 mg of KI in 4 ml of acetone; purification by CC (φ 18 
× 250; n-heptane/acetone, 3:1). Yield: 175 mg (52%); colorless oil. – TLC: Rf = 0.32 (n-
heptane/acetone, 3:2). – [α]D20 = +22.5 (c = 1.65, EtOAc). – 1H NMR (CDCl3): δ = 1.20 (t, J 
= 7.1 Hz, 3 H, CH2CH3), 1.69 (ddt, J = 14.2/6.2/1.7 Hz, 1 H, CH2CHCH2COO), 2.29 (dd, J = 
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10.1/4.2 Hz, 1 H, NCH2CHOH), 2.38 (ddd, J = 14.2/9.5/6.6 Hz, 1 H, CH2CHCH2COO), 2.41-
2.48 (m, 2 H, NCH2CH2 and CH2COO), 2.64 (dd, J = 15.8/3.4 Hz, 1 H, CH2COO), 2.70-2.77 
(m, 1 H, NCH), 2.96 (dt, J = 12.6/6.3 Hz, 1 H, NCH2CH2), 3.05 (br. d, J = 10.1 Hz, 1 H, 
NCH2CHOH), 3.12 (dt, J = 9.5/5.8 Hz, 1 H, NCH2CH2), 3.19 (dt, J = 9.5/6.1 Hz, 1 H, 
NCH2CH2), 3.77 (s, 9 H, ArOCH3), 4.01-4.14 (m, 2 H, CH2CH3), 4.13-4.18 (m, 1 H, CHOH), 
6.79-6.82 (m, 6 H, Haromat), 7.30-7.33 (m, 6 H, Haromat). – IR: ~ν  = 3440, 2955, 2875, 1731, 
1607, 1506, 1250, 1035, 828, 732 cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 227 (5), 186 (8). – 
C32H39NO7 (549.66): calcd. C 69.92, H 7.15, N 2.55; found C 69.70, H 7.31, N 2.42. 
 
Ethyl (2R,4R)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxypyrrolidine-2-
acetate [(2R,4R)-88c]  
N
OH
COOC2H5
S S
 
According to GP2 from 92 mg (0.44 mmol) of (2R,4R)-64, 143 mg (0.439 mmol) of 123, 298 
mg (2.16 mmol) of K2CO3 and 10 mg of KI in 2.7 ml of acetone; purification by CC (φ 18 × 
230; n-heptane/acetone, 2:1). Yield: 95 mg (52%); yellow oil. – TLC: Rf = 0.32 (n-
heptane/acetone, 3:2). – [α]D20 = +69.8 (c = 0.80, EtOAc). – 1H NMR (CDCl3): δ = 1.23 (t, J 
= 7.3 Hz, 3 H, CH2CH3), 1.69 (ddt, J = 14.3/6.1/1.7 Hz, 1 H, CH2CHCH2COO), 1.99 (s, 3 H, 
thienyl-CH3), 2.04 (s, 3 H, thienyl-CH3), 2.20 (dd, J = 10.0/4.1 Hz, 1 H, NCH2CHOH), 2.25-
2.40 (m, 4 H, NCH2CH2, CH2CHCH2COO and 2 H of NCH2CH2), 2.43 (dd, J = 15.4/ 7.8 Hz, 
1 H, CH2COO), 2.52 (br. s, 1 H, OH), 2.62-2.72 (m, 2 H, NCH and CH2COO), 2.81-2.92 (m, 
1 H, NCH2CH2), 3.01 (br. d, J = 10.0 Hz, 1 H, NCH2CHOH), 4.05-4.18 (m, 3 H, CHOH and 
2 H of CH2CH3), 6.03-6.07 (m, 1 H, =CHCH2), 6.75 (d, J = 5.2 Hz, 1 H, SCH), 6.84 (d, J = 
5.2 Hz, 1 H, SCH), 7.04 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.21 (d, J = 5.2 Hz, 1 H, SCH=CH). 
– IR: ~ν  = 3433, 2937, 1732, 1456, 1156, 1032, 711, 668 cm-1. – MS; m/z (%): 420 (29) 
[M+1]+, 374 (35), 186 (57), 140 (100). – C22H29NO3S2 (419.60): calcd. C 62.98, H 6.97, N 
3.34, S 15.28; found C 62.87, H 6.95, N 3.28, S 15.31.  
 
Ethyl (2R,4R)-1-[3-(9-carbazolyl)-1-propyl]-4-hydroxypyrrolidine-2-acetate [(2R,4R)-
88d] 
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According to GP2 from 122 mg (0.528 mmol) of (2R,4R)-64, 279 mg (purity: 70.0%, 0.528 
mmol) of 125 and 400 mg (2.91 mmol) of K2CO3 in 3 ml of acetone; purification by CC (φ 18 
× 260; n-heptane/acetone, 1:3). Yield: 193 mg (87%); colorless oil. – TLC: Rf  = 0.31 (n-
heptane/acetone, 3:2). – [α]D20  = +56.8 (c = 0.96, EtOAc). – 1H NMR (CDCl3, 500 MHz): δ 
= 1.23 (t, J = 7.2 Hz, 3 H, CH2CH3), 1.74 (ddt, J = 14.3/6.2/1.7 Hz, 1 H, CH2CHCH2COO), 
1.99-2.14 (m, 2 H, CHNCH2CH2), 2.21 (dd, J = 10.0/4.1 Hz, 1 H, NCH2CHOH), 2.23-2.29 
(m, 1 H, CH2NCH), 2.38-2.46 (m, 2 H, CH2CHCH2COO and CH2COO), 2.56 (dd, J = 
15.6/3.6 Hz, 1 H, CH2COO), 2.64-2.71 (m, 1 H, NCH), 2.84 (ddd, J = 15.9/8.7/7.3 Hz, 1 H, 
CH2NCH), 3.11 (br. d, J = 10.0 Hz, 1 H, NCH2CHOH), 4.07-4.17 (m, 2 H, CH2CH3), 4.19-
4.23 (m, 1 H, CHOH), 4.28-4.35 (m, 1 H, CH2-carbazole), 4.42-4.49 (m, 1 H, CH2-carbazole), 
7.25 (ddd, J = 8.0/6.9/1.1 Hz, 2 H, Haromat),  7.44 (br. d, J = 8.0 Hz, 2 H, Haromat), 7.49 (ddd, J 
= 8.0/6.9/1.1 Hz, 2 H, Haromat), 8.12 (br. d, J = 8.0 Hz, 2 H, Haromat). – IR: ~ν  = 3427, 3052, 
2938, 1732, 1597, 1454, 1326, 751, 725, 616 cm-1. – MS; m/z (%): 381 (27) [M+1]+, 363 (4), 
335 (100), 293 (12), 180 (8), 140 (8). – C23H28N2O3 (380.49): calcd. C 72.60, H 7.42, N 7.36; 
found C 72.27, H 7.65, N 7.13. 
 
Methyl (2S,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-acetate [(2S,4R)-
91a] 
N
OH
COOCH3
 
 
According to GP2 from 81 mg (0.41 mmol) of (2S,4R)-86, 129 mg (0.426 mmol) of 118, 228 
mg (1.65 mmol) of K2CO3 and 10 mg of KI; reaction time: 3 d; purification by CC (φ 18 × 
230; iso-hexane/acetone, 3:1). Yield: 89 mg (59%); colorless oil. – TLC: Rf = 0.31 (n-
heptane/acetone, 3:2). – [α]D20 = -72.8 (c = 0.87, CHCl3). – 1H NMR (CDCl3): δ = 1.83 (ddd, 
J = 13.6/8.4/7.0 Hz, 1 H, CH2CHCH2COO), 1.93 (ddd, J = 13.6/7.0/3.1 Hz, 1 H, 
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CH2CHCH2COO), 2.16 (dd, J = 10.1/4.4 Hz, 1 H, NCH2CHOH), 2.19-2.33 (m, 3 H, 
CH2COO and 2 H of  NCH2CH2), 2.39 (ddd, J = 12.0/8.8/4.9 Hz, 1 H, NCH2CH2), 2.58 (dd, J 
= 15.0/4.2 Hz, 1 H, CH2COO), 2.81 (dt, J = 12.0/7.3 Hz, 1 H, NCH2CH2), 3.02-3.09 (m, 1 H, 
NCH), 3.29 (dd, J = 10.1/6.0 Hz, 1 H, NCH2CHOH), 3.62 (s, 3 H, OCH3), 4.29-4.35 (m, 1 H, 
CHOH ), 6.06 (t, J = 7.2 Hz, 1 H, =CHCH2), 7.14-7.37 (m, 10 H, Haromat). – IR: ~ν  = 3064, 
3023, 2950, 1738, 1598, 1443, 763, 701 cm-1. – MS; m/z (%): 366 (57) [M+1]+, 292 (17), 172 
(100). – C23H27NO3 (365.47): calcd. C 75.59, H 7.45, N 3.83; found C 75.31, H 7.30, N 3.63. 
 
Methyl (2S,4R)-4-hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
acetate [(2S,4R)-91b] 
N
OH
O
COOCH3
OMeMeO
OMe
 
According to GP2 from 195 mg (1.00 mmol) of (2S,4R)-86, 457 mg (1.00 mmol) of 120, 690 
mg (5.00 mmol) of K2CO3 and 16 mg of KI in 3 ml of acetone; reaction time: 3 d; purification 
by CC (φ 18 × 230, n-heptane/acetone, 7:3). Yield: 210 mg (39%); colorless oil. – TLC: Rf  = 
0.25  (n-heptane/acetone, 3:2). – [α]D20 = -28.2 (c = 1.00, EtOAc). – 1H NMR (CDCl3): δ = 
1.81 (ddd, J = 13.5/8.4/7.0 Hz, 1 H, CH2CHCH2COO), 1.95 (ddd, J = 13.5/7.0/3.1 Hz, 1 H, 
CH2CHCH2COO), 2.23 (dd, J = 15.0/9.1 Hz, 1 H, CH2COO), 2.32 (dd, J = 10.4/4.4 Hz, 1 H, 
NCH2CHOH), 2.56-2.66 (m, 2 H, CH2COO and NCH2CH2), 2.93 (dt, J = 12.6/6.3 Hz, 1 H, 
NCH2CH2), 3.10-3.20 (m, 3 H, NCH and 2 H of NCH2CH2), 3.36 (dd, J = 10.4/5.8 Hz, 1 H, 
NCH2CHOH), 3.63 (s, 3 H, COOCH3), 3.77 (s, 9 H, ArOCH3), 4.33-4.38 (m, 1H, CHOH), 
6.78-6.82 (m, 6 H, Haromat), 7.30-7.34 (m, 6 H, Haromat). – IR: ~ν  = 3444, 3036, 2950, 1735, 
1608, 1504, 1435, 1173, 1033, 829 cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 227 (76), 204 
(52), 186 (16), 172 (60), 130 (12), 79 (37). – C31H37NO7 (535.64): calcd. C 69.51, H 6.96, N 
2.62; found C 69.58, H 7.28, N 2.63. 
 
Methyl (2S,4R)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxypyrrolidine-2-
acetate [(2S,4R)-91c] 
 
According to GP2 from 94 mg (0.48 mmol) of (2S,4R)-86, 156 mg (0.480 mmol) of 123, 330  
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mg (2.40 mmol) of K2CO3 and 11 mg of KI in 3 ml of acetone; reaction time: 3 d; purification 
by CC (φ 20 × 300; n-heptane/acetone, 3:1). Yield: 80 mg (41%); slight yellow oil. – TLC: Rf 
= 0.32 (n-heptane/acetone 2:3). – [α]D20 = -84.6 (c = 1.00, EtOAc). – 1H NMR (CDCl3): δ = 
1.83 (ddd, J = 13.5/8.3/7.1 Hz, 1 H, CH2CHCH2COO), 1.95 (ddd, J = 13.5/7.1/3.2 Hz, 1 H, 
CH2CHCH2COO), 2.00 (s, 3 H, thienyl-CH3), 2.03 (s, 3 H, thienyl-CH3), 2.16-2.32 (m, 4 H, 
NCH2CHOH, CH2COO and 2 H of NCH2CH2), 2.41 (ddd, J = 11.9/8.2/5.0 Hz, 1 H, 
NCH2CH2), 2.62 (dd, J = 15.0/4.0 Hz, 1 H, CH2COO), 2.83 (dt, J = 11.9/8.2 Hz, 1 H, 
NCH2CH2), 3.05-3.12 (m, 1 H, NCH), 3.33 (dd, J = 10.2/6.1 Hz, 1 H, NCH2CHOH), 3.65 (s, 
3 H, OCH3), 4.32-4.37 (m, 1 H, CHOH), 6.04 (t, J = 7.3 Hz, 1 H, =CHCH2), 6.75 (d, J = 5.1 
Hz, 1 H, SCH), 6.83 (d, J = 5.1 Hz, 1 H, SCH), 7.04 (d, J = 5.1 Hz, 1 H, SCH=CH), 7.20 (d, J 
= 5.1 Hz, 1 H, SCH=CH). – IR: ~ν  = 3410, 3100, 2949, 1738, 1436, 713 cm-1. – MS; m/z (%): 
406 (46) [M+1]+, 388 (4), 332 (10), 172 (100), 158 (2). – C21H27NO3S2 (405.57): calcd. C 
62.19, H 6.71, N 3.45, S 15.81; found C 62.43, H 6.99, N 3.35, S 15.64. 
 
Methyl (2S,4R)-1-[3-(9-carbazolyl)-1-propyl]-4-hydroxypyrrolidine-2-acetate [(2S,4R)-
91d] 
N
N
OH
COOCH3
 
 
According to GP2 from 166 mg (0.847 mmol) of (2S,4R)-86, 406 mg (purity: 70.0%, 0.847 
mmol) of 125, 574 mg (1.24 mmol) of K2CO3 in 3.5 ml of acetone; reaction time: 3 d; 
purification by CC (φ 18 × 240; n-heptane/acetone, 3:1). Yield: 170 mg (57%); yellowish oil. 
– TLC: Rf = 0.21 (n-heptane/acetone, 3:2). – [α]D20 = -51.0 (c = 1.05, EtOAc). – 1H NMR 
(CDCl3, 500 MHz): δ = 1.89 (ddd, J = 13.6/8.2/7.0 Hz, 1 H, CH2CHCH2COO), 1.94-2.11 (m, 
3 H, CH2CHCH2COO and 2 H of CHNCH2CH2), 2.17-2.24 (m, 2 H, CH2COO and 
NCH2CHOH), 2.38 (ddd, J = 12.0/7.1/4.7 Hz, 1 H, CH2NCH), 2.50 (dd, J = 15.0/4.9 Hz, 1 H, 
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CH COO), 2.78 (dt, J = 12.0/7.9 Hz, 1 H, CH NCH), 3.05-3.11 (m, 1 H, NCH), 3.40 (dd, J = 
10.2/6.0 Hz, 1 H, NCH CHOH), 3.61 (s, 3 H, OCH ), 4.30 (dt, J = 14.9/7.4 Hz, 1 H, CH -
carbazole), 4.37-4.43 (m, 2 H, CHOH and CH -carbazole), 7.23 (t, J = 7.4 Hz, 2 H, H ), 
7.41 (br. d, J = 7.9 Hz, 2 H, H ), 7.44-7.47 (m, 2 H, H ), 8.10 (br. d, J = 7.9 Hz, 2 H, 
H ). – IR:  = 3417, 3051, 2949, 1732, 1597, 1454, 1327, 752, 725, 682 cm . – MS; m/z 
(%): 367 (100) [M+1] , 293 (24), 180 (6), 172 (10), 97 (3). – C H N O  (366.46): calcd. C 
72.11, H 7.15, N 7.64; found C 72.56, H 7.46, N 7.53. 
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2 2
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2 aromat
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~ν
+
Methyl (2S,4R)-4-benzyloxy-1-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-acetate [(2S,4R)-
93a]  
N
O
COOCH3
 
According to GP2 from 207 mg (0.723 mmol) of (2S,4R)-87,  239 mg (0.723 mmol) of 118, 
200 mg (1.43 mmol) of K CO  and 12 mg of KI in 6 ml of CH CN; reaction time: 3 d; 
purification by CC (φ 18 × 240; n-heptane/EtOAc, 1:3). Yield: 147 mg (45%); colorless oil. – 
TLC: R  = 0.17 (n-heptane/EtOAc, 3:1). – [α]  = -60.0 (c = 1.34, EtOAc). – H NMR 
(CDCl ): δ = 1.73 (dt, J = 13.3/7.9 Hz, 1 H, CH CHCH COO), 2.05 (ddd, J = 13.3/7.4/3.3 Hz, 
1 H, CH CHCH COO), 2.14-2.24 (m, 4 H, CH COO, NCH CHO and 2 H of NCH CH ), 
2.27-2.34 (m, 1 H, NCH CH ), 2.54 (dd, J = 14.6/3.8 Hz, 1 H, CH COO), 2.73-2.81 (m, 1 H, 
NCH CH ), 2.91-2.98 (m, 1 H, NCH), 3.26 (dd, J = 10.1/6.4 Hz, 1 H, NCH CHO), 3.57 (s, 3 
H, OCH ), 3.97-4.02 (m, 1 H, NCH CHO), 4.33 (d, J = 12.0 Hz, 1 H, CH Ph), 4.40 (d, J = 
12.0 Hz, 1 H, CH Ph), 6.01 (t, J = 7.4 Hz, 1 H, =CHCH ), 7.09-7.31 (m, 15 H, H ). – IR: 
 = 3056, 3028, 2948, 1737, 1443, 1098, 762, 737, 699 cm . – MS; m/z (%): 456 (32) 
[M+1] , 382 (9), 262 (100), 175 (11), 148 (25), 91 (61).  – C H NO  (455.60): calcd. C 
79.09, H 7.30, N 3.07; found C 78.73, H 7.38, N 3.09.  
2
20 1
-1
+
3 3
f D
3 2 2
2 2 2 2 2 2
2 2 2
2 2 2
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Methyl (2S,4R)-4-benzyloxy-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]pyrrolidine-2-
acetate [(2S,4R)-93c] 
 
According to GP2 from 69 mg (0.21 mmol) of (2S,4R)-87, 68 mg (0.21 mmol) of 123, 145 
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N
O
S S
COOCH3
 
mg (1.05 mmol) of K2CO3 and 10 mg of KI in 3 ml of acetone; purification by CC (φ 18 × 
200; n-heptane/acetone, 6:1). Yield: 53 mg (51%); colorless oil. – TLC: Rf = 0.21 (n-
heptane/EtOAc, 3:1). – [α]D21 = -43.5 (c = 1.19, EtOAc). – 1H NMR (CDCl3): δ = 1.72 (dt, J 
= 13.4/8.1 Hz, 1 H, CH2CHCH2COO), 1.94 (s, 3 H, theinyl-CH3), 1.97 (s, 3 H, thienyl-CH3), 
2.05 (ddd, J = 13.4/7.1/3.2 Hz, 1 H, CH2CHCH2COO), 2.12-2.26 (m, 4 H, NCH2CHO, 
CH2COO and 2 H of NCH2CH2), 2.27-2.34 (m, 1 H, NCH2CH2), 2.56 (dd, J = 14.8/4.1 Hz, 1 
H, CH2COO), 2.77 (dt, J = 11.5/8.1 Hz, 1 H, NCH2CH2), 2.91-2.98 (m, 1 H, NCH), 3.28 (dd, 
J = 9.9/6.2 Hz, 1 H, NCH2CHO), 3.58 (s, 3 H, OCH3), 3.97-4.02 (m, 1 H, NCH2CHO), 4.34 
(d, J = 12.0 Hz, 1 H, CH2Ph), 4.40 (d, J = 12.0 Hz, 1 H, CH2Ph), 5.97 (t, J = 7.2 Hz, 1 H, 
=CHCH2), 6.69 (d, J = 5.2 Hz, 1 H, SCH), 6.76 (d, J = 5.2 Hz, 1 H, SCH), 6.98 (d, J = 5.2 Hz, 
1 H, SCH=CH), 7.13 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.20-7.28 (m, 5 H, Haromat). – IR: ~ν  = 
3050, 3030, 2949, 1736, 1702, 1413, 1112, 769, 735, 697 cm-1. – MS; m/z (%): 496 (4) 
[M+1]+, 384 (34), 340 (32), 248 (36), 91 (100), 79 (37). – C28H33NO3S2 (495.70): calcd. C 
67.85, H 6.71, N 2.83; found C 67.85, H 6.60, N 3.06. 
 
Methyl (2S,4R)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxy-
phenyl)pyrrolidine-2-acetate [(2S,4R)-102c]  
N
OH
OMe
COOCH3
S S
 
According to GP2 from 10 mg (0.038 mmol) of (2S,4R)-115, 12 mg (0.038 mmol) of 123, 26 
mg (0.19 mmol) of K2CO3 and 3 mg KI in 1.5 ml of acetone; purification by CC (φ 12 × 110; 
iso-hexane/acetone, 85:15). Yield: 11 mg (57%). – M.p. 96-98 (iPr2O). – TLC: Rf = 0.33 (n-
heptane/acetone, 3:2). – [α]D20 = -82 (c = 0.29, CHCl3). All other analytical data (1H NMR, 
IR, MS) were identical with that prepared from (2S)-100c (Section 5.1.7) 
 
                                                          6. Experimental Section……………    ………….. - 112 - 
6.1.4 Stereochemical inversions of the 4-hydroxy groups of pyrrolidine 
derivatives by Mitsunobu reaction 
 
General procedure 3 (GP3) [42, 43, 44, 45] 
 
To a solution of the N-substituted or N-protected 4-hydroxy pyrrolidine derivative (1 equiv.) 
and Ph3P (1.0-1.5 equiv.) in THF (10-50 ml/mmol), DEAD (1.2-1.5 equiv.) was added at 0 
°C. The resulting yellow solution was stirred for 10 min and then AcOH or HCOOH (1.05-
1.50 equiv.) was added at 0 °C (for intramolecular Mitsunobu reaction no additoinal acid was 
used). Stirring was continued at 0 °C for the time given. The solvent was evaporated in vacuo. 
and the residual oil was purified by CC. Some compounds needed separation on prep. HPLC. 
 
(1S,4S)-5-(4,4-Diphenylbut-3-en-1-yl)-2-oxa-5-azabicyclo[2,2,1]heptane-3-one [(1S,4S)-
41a]  
N
O
O
 
According to GP3 from 195 mg (0.578 mmol) of (2S,4R)-40a and 304 mg (1.16 mmol) of 
Ph3P, 151 mg (0.867 mmol) of DEAD in 10 ml of THF; reaction time: 13 h; purification by 
CC (φ 20 × 250; n-heptane/acetone, 4:1). Yield: 157 mg (85%); colorless crystals. – TLC: Rf 
= 0.23 (n-heptane/acetone, 3:2). – M.p. 85-86 °C (n-heptane/acetone, 4:1). – [α]D21 = -60.7 (c 
= 0.84, EtOH). – 1H NMR (CDCl3): δ = 1.85 (dd, J = 10.5/1.6 Hz, 1 H, NCHCH2), 1.92-2.08 
(m, 1 H, NCHCH2), 2.15 (dd, J = 10.6/1.2 Hz, 1 H, NCH2CHO), 2.17-2.31 (m, 2 H, 
NCH2CH2), 2.43 (dt, J = 11.8/6.6 Hz, 1 H, NCH2CH2), 2.68 (dt, J = 11.8/7.1 Hz, 1 H, 
NCH2CH2), 3.22 (dd, J = 10.6/0.9 Hz, 1 H, NCH2CHO), 3.48 (br. s, 1 H, NCH), 4.78 (br. s, 1 
H, NCH2CHO), 6.02 (t, J = 7.3 Hz, 1 H, =CHCH2), 7.09-7.30 (m, 10 H, Haromat). – IR: ~ν = 
3053, 1766, 1089, 926, 774, 757 cm-1. – MS; m/z (%): 320 (100) [M+1]+, 274 (11), 207 (10). 
– C21H21NO2 (319.40): calcd. C 78.97, H 6.63, N 4.39; found C 78.92, H 6.71, N 4.36. 
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Methyl (2R,4S)-4-acetoxy-1-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-carboxylate 
[(2R,4S)-48a] 
 
According to GP3 from 120 mg (0.352 mmol) of (2R,4R)-39a, 134 mg (0.513 mmol) of Ph3P, 
243 µl (38-40% in PhCH3, 0.513 mmol) of DEAD, 29 mg (0.51 mmol) of AcOH in 5 ml of 
THF; reaction time: for 6 h; purification by CC (φ 25 × 220; n-heptane/EtOAc, 3:1) and 
further separation on prep. HPLC (n-heptane/EtOAc, 75:25; tR = 29.6 min; 12 ml/min). Yield: 
92 mg (69%); colorless oil. – TLC: Rf = 0.26 (n-heptane/EtOAc, 1:3). – [α]D20 = +43.1 (c = 
1.02, EtOAc). – 1H NMR (CDCl3): δ = 2.02 (s, 3 H, CH3COO), 2.12 (ddd, J = 13.9/7.5/2.9 
Hz, 1 H, NCHCH2), 2.25-2.33 (m, 3 H, NCHCH2 and 2 H of NCH2CH2), 2.50 (dd, J = 
10.8/3.3 Hz, 1 H, NCH2CHO),  2.59 (dt, J = 12.0/7.6 Hz, 1 H, NCH2CH2), 2.79 (dt, J = 
12.0/8.0 Hz, 1 H, NCH2CH2), 3.43 (dd, J = 10.8/6.2 Hz, 1 H, NCH2CHO), 3.49 (t, J = 7.5 Hz, 
1 H, NCH), 3.68 (s, 3 H, COOCH3), 5.17-5.22 (m, 1 H, NCH2CHO), 6.06 (t, J = 7.4 Hz, 1 H, 
=CHCH2), 7.14-7.38 (m, 10 H, Haromat). – IR: ~ν = 3055, 2951, 1738, 1718, 1495, 1243, 762, 
702 cm-1. – MS; m/z (%): 394 (64) [M+1]+, 334 (11), 200 (100), 140 (8). – C24H27NO4 
(393.48): calcd. C 73.25, H 6.92, N 3.56; found C 73.04, H 6.83, N 3.79. 
 
Methyl (2R,4S)-4-acetoxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylate [(2R,4S)-48b]  
N
CH3COO
COOCH3
N
CH3COO
COOCH3
O
MeO OMe
OMe
 
According to GP3 from 100 mg (0.192 mmol) of (2R,4R)-39b and 79 mg (0.29 mmol) of 
Ph3P, 139 µl (38-40% in PhCH3, 0.288 mmol) of DEAD, 13 mg (0.22 mmol) of AcOH in 3.5 
ml of THF; reaction time: 4 h; purification by CC (φ 18 × 260; n-heptane/acetone, 3:1) and 
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further separation on prep. HPLC (n-heptane/EtOAc, 60:40; tR = 29.2 min; 12 ml/min,). 
Yield: 60 mg (56%); colorless oil. – TLC: Rf  = 0.35 (n-heptane/acetone, 3:2). – [α]D20  = 
+21.3 (c = 1.10, EtOAc). – 1H NMR (CDCl3): δ = 2.02 (s, 3 H, CH3COO), 2.12 (ddd, J = 
13.9/7.5/3.0 Hz, 1 H, NCHCH2), 2.27 (dt, J = 13.9/7.5 Hz, 1 H, NCHCH2), 2.64 (dd, J = 
11.0/3.3 Hz, 1 H, NCH2CHO), 2.79 (dt, J = 12.6/6.2 Hz, 1 H, NCH2CH2), 2.89-2.94 (m, 1 H, 
NCH2CH2), 3.19 (t, J = 6.2 Hz, 2 H, NCH2CH2), 3.48 (dd, J = 11.0/6.2 Hz, 1 H, NCH2CHO), 
3.59 (t, J = 7.5 Hz, 1 H, NCH), 3.67 (s, 3 H, COOCH3), 3.78 (s, 9 H, ArOCH3), 5.17-5.21 (m, 
1 H, NCH2CHO), 6.78-6.81 (m, 6 H, Haromat), 7.29-7.32 (m, 6 H, Haromat). – IR: ~ν = 3036, 
2836, 1738, 1732, 1608, 1505, 1249, 1035, 828, 681 cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 
232 (12), 227 (35), 200 (42), 140 (10). – C32H37NO8 (563.65): calcd. C 68.19, H 6.62, N 2.49; 
found C 67.96, H 6.58, N 2.48. 
 
Ethyl (2R,4S)-4-acetoxy-1-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-acetate [(2R,4S)-90a]  
N
CH3COO
COOC2H5
 
According to GP3 from 50 mg (0.13 mmol) of  (2R,4R)-88a and 52 mg (0.20 mmol) of Ph3P 
in 2 ml of THF, 94 µl (38-40% in PhCH3, 0.20 mmol) of DEAD and 11 mg (0.18 mmol) of 
AcOH; reaction time: 23 h; purification (φ 18 × 220; n-heptane/EtOAc, 3:1) and separation by 
prep. HPLC (tR = 37.8 min; n-heptane/EtOAc, 75:25; 12 ml/min). Yield: 40 mg (72%); 
colorless oil. – TLC: Rf  = 0.27 (n-heptane/EtOAc, 3:1). – [α]D20 = +57.9 (c = 0.98, EtOAc). – 
1H NMR (CDCl3): δ = 1.24 (t, J = 7.0 Hz, 3 H, CH2CH3), 1.89 (ddd, J = 13.9/9.0/7.6 Hz, 1 H, 
CH2CHCH2COO), 2.01 (s, 3 H, CH3COO), 2.06 (ddd, J = 13.9/6.6/2.6 Hz, 1 H, 
CH2CHCH2COO), 2.17-2.40 (m, 5 H, NCH2CHO, NCH2CH2, CH2COO and 2 H of 
NCH2CH2), 2.61 (dd, J = 15.0/4.2 Hz, 1 H, CH2COO), 2.80-2.87 (m, 1 H, NCH2CH2), 2.97-
3.04 (m, 1 H, NCH), 3.42 (dd, J = 10.8/6.4 Hz, 1 H, NCH2CHO), 4.05-4.17 (m, 2 H, 
CH2CH3), 5.06-5.11 (m, 1 H, NCH2CHO), 6.06 (t, J = 7.2 Hz, 1 H, =CHCH2), 7.14-7.38 (m, 
10 H, Haromat). – IR: ~ν  = 3056, 2979, 1740, 1732, 1495, 1369, 1256, 763, 702 cm-1. – MS; 
m/z (%): 422 (46), [M+1]+, 362 (10), 334 (13), 228 (100), 168 (10), 115 (4). – C26H31NO4 
(421.54): calcd. C 74.08, H 7.41, N 3.32; found C 74.16, H 7.38, N 3.32. 
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Ethyl (2R,4S)-4-acetoxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
acetate [(2R,4S)-90b] 
N
COOC2H5
O
OMeMeO
OMe
CH3COO
 
According to GP3 from 147 mg (0.267 mmol) of (2R,4R)-88b and 105 mg (0.401 mmol) of 
Ph3P in 5 ml of THF, 190 µl (38-40% in PhCH3, 0.40 mmol) of DEAD and 19 mg (0.32 
mmol) of AcOH; reaction time: 2 h; purification by CC (φ 25 × 220; n-heptane/acetone, 3:1) 
and separation by prep. HPLC (n-heptane/EtOAc, 60:40; tR = 32.1 min; 12 ml/min). Yield: 50 
mg (32%); colorless oil. – TLC: Rf = 0.37 (n-heptane/acetone, 3:2). – [α]D20 = +23.4 (c = 
1.51, EtOAc). – 1H NMR (CDCl3): δ = 1.23 (t, J = 7.2 Hz, 3 H, CH2CH3), 1.86 (ddd, J = 
13.9/9.1/7.4 Hz, 1 H, CH2CHCH2COO), 2.01 (s, 3 H, CH3COO), 2.06 (ddd, J = 13.9/6.6/2.6 
Hz, 1 H, CH2CHCH2COO), 2.21 (dd, J = 15.1/9.1 Hz, 1 H, CH2COO), 2.34 (dd, J = 10.9/4.4 
Hz, 1 H, NCH2CHO), 2.48-2.55 (m, 1 H, NCH2CH2), 2.65 (dd, J = 15.1/4.1 Hz, 1 H, 
CH2COO), 2.90-2.97 (m, 1 H, NCH2CH2), 3.03-3.18 (m, 3 H, NCH and 2 H of NCH2CH2), 
3.46 (dd, J = 10.9/6.3 Hz, 1 H, NCH2CHO), 3.78 (s, 3 H, ArOCH3), 4.06-4.14 (m, 2 H, 
CH2CH3), 5.06-5.12 (m, 1 H, NCH2CHO), 6.78-6.82 (m, 6 H, Haromat), 7.29-7.33 (m, 6 H, 
Haromat). – IR: ~ν  = 2980, 1733, 1608, 1508, 1249, 828 cm-1. – MS; m/z (%): 406 (12), 333 
(100) [Ar3C]+, 287 (20), 258 (5), 184 (22), 94 (37). – C34H41NO8 (591.70): calcd. C 69.02, H 
6.99, N 2.37; found C 69.02, H 7.38, N 2.31. 
 
Ethyl (2R,4S)-4-acetoxy-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]pyrrolidine-2-acetate 
[(2R,4S)-90c]  
N
CH3COO
S S
COOC2H5
 
According to GP3 from 117 mg (0.279 mmol) of (2R,4R)-88c and 108 mg (0.419 mmol) of 
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Ph3P in 4 ml of THF, 199 µl (38-40% in toluene, 0.42 mmol) of DEAD and 24 mg (0.40 
mmol) of AcOH; reaction time: 3 h; purification by CC (φ 25 × 220; n-heptane/EtOAc, 4:1) 
nd separation by prep. HPLC (n-heptane/EtOAc, 75:25; tR = 27.3 min; 12 ml/min). Yield: 81 
mg (63%); colorless oil. – TLC: Rf = 0.38 (n-heptane/EtOAc, 3:1). – [α]D20 = +86.8 (c = 0.94, 
EtOAc). – 1H NMR (CDCl3): δ = 1.24 (t, J = 7.1 Hz, 3 H, CH2CH3), 1.87 (ddd, J = 
13.9/9.0/7.6 Hz, 1 H, CH2CHCH2COO), 2.00-2.09 (m, 10 H, 1 H of CH2CHCH2COO, 3 H of 
CH3COO and 6 H of thienyl-CH3), 2.18-2.42 (m, 5 H, NCH2CHO, NCH2CH2, CH2COO and 
2 H of NCH2CH2), 2.63 (dd, J = 15.1/4.2 Hz, 1 H, CH2COO), 2.83 (dt, J = 11.5/8.1 Hz, 1 H, 
NCH2CH2), 2.97-3.05 (m, 1 H, NCH), 3.44 (dd, J = 10.8/6.4 Hz, 1 H, NCH2CHO), 4.12 (q, J 
= 7.1 Hz, 2 H, CH2CH3), 5.06-5.11 (m, 1 H, NCH2CHO), 6.02 (t, J = 7.2 Hz, 1 H, =CHCH2), 
6.75 (d, J = 5.1 Hz, 1 H, SCH), 6.83 (d, J = 5.1 Hz, 1 H, SCH), 7.05 (d, J = 5.1 Hz, 1 H, 
SCH=CH), 7.20 (d, J = 5.1 Hz, 1 H, SCH=CH). – IR: ~ν  = 3105, 2978, 1738, 1732, 1369, 
1244, 713 cm-1. – MS; m/z (%): 462 (12) [M+1]+, 402 (2), 374 (4), 228 (100), 111 (5). – 
C24H31NO4S2 (461.64): calcd. C 62.44, H 6.77, N 3.03, S 13.89; found C 62.31, H 7.00, N 
2.96, S 13.56. 
 
Ethyl (2R,4S)-4-acetoxy-1-[3-(9-carbazolyl)-1-propyl]pyrrolidine-2-acetate [(2R,4S)-90d] 
N
N
CH3COO
COOC2H5
 
According to GP3 from 110 mg (0.289 mmol) of (2R,4R)-88d and 152 mg (0.578 mmol) of 
Ph3P in 4 ml of THF, 269 µl (38-40% in PhCH3, 0.58 mmol) of DEAD and 26 mg (0.43 
mmol) of AcOH; reaction time: 3 h; purification by CC (φ 18 × 210; n-heptane/acetone, 4:1) 
and separation by prep. HPLC (n-heptane/EtOAc, 60:40; tR = 34.2 min; 12 ml/min). Yield: 
104 mg (85%); colorless oil. – TLC: Rf = 0.43 (n-heptane/acetone, 3:2). – [α]D20 = +43.6 (c = 
1.04, EtOAc). – 1H NMR (CDCl3, 500 MHz): δ = 1.22 (t, J = 7.1 Hz, 3 H, CH2CH3), 1.93-
2.12 (m, 7 H, CH2CHCH2COO, CHNCH2CH2 and CH3COO), 2.19 (dd, J = 15.0/8.6 Hz, 1 H, 
CH2COO), 2.29 (dd, J = 10.8/4.3 Hz, 1 H, NCH2CHO), 2.32-2.35 (m, 1 H, CH2NCH), 2.48 
(dd, J = 15.0/4.4 Hz, 1 H, CH2COO), 2.77 (dt, J = 12.1/7.8 Hz, 1 H, CH2NCH), 3.00-3.05 (m, 
1 H, NCH), 3.53 (dd, J = 10.8/6.3 Hz, 1 H, NCH2CHO), 4.08 (q, J = 7.1 Hz, 2 H, CH2CH3), 
4.29-4.35 (m, 1 H, CH2-carbazole), 4.37-4.43 (m, 1 H, CH2-carbazole), 5.14-5.18 (m, 1 H, 
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NCH2CHO), 7.21-7.25 (m, 2 H, Haromat), 7.41-7.42 (m, 2 H, Haromat), 7.45-7.48 (m, 2 H, 
Haromat), 8.09-8.11 (m, 2 H, Haromat). – IR: ~ν  = 3051, 2978, 1737, 1732, 1597, 1246, 751, 725 
cm-1. – MS; m/z (%): 423 (100) [M+1]+, 363 (13), 335 (25), 275 (11), 228 (9), 180 (12). – 
C25H30N2O4 (422.53): calcd. C 71.07, H 7.16, N 6.63; found C 71.01, H 7.29, N 6.54. 
 
(1S,5S)-6-(4,4-Diphenylbut-3-en-1-yl)-2-oxa-6-azabicyclo[3,2,1]octane-3-one [(1S,5S)-
92a] 
N
O
CH2
O
 
According to GP3 from 97 mg (0.27 mmol) of (2S,4R)-91a and 112 mg (0.411 mmol) of Ph3P 
in 5 ml of THF, 198 µl (38-40% in PhCH3, 0.41 mmol) of  DEAD; reaction time: 4 h; 
purification by CC (φ 18 × 24; n-heptane/acetone, 3:1) and separation by prep. HPLC (n-
heptane/EtOAc, 1:1; tR = 35.8 min; 12 ml/min). Yield: 65 mg (76%); colorless crystals. – 
M.p. 72-74 °C. – TLC: Rf = 0.41 (n-heptane/acetone, 3:2). – [α]D20  = +4.6 (c = 1.00, EtOAc). 
– 1H NMR (CDCl3, 500 MHz): δ = 1.98 (br. s, 2 H, CH2CHCH2COO), 2.26 (q, J = 7.3 Hz, 2 
H, NCH2CH2), 2.43 (dd, J = 18.6/3.7 Hz, 1 H, CH2COO), 2.67-2.78 (m, 3 H, CH2COO and 2 
H of NCH2CH2), 2.95 (d, J = 11.9 Hz, 1 H, NCH2CHO), 3.06 (dd, J = 11.9/3.7 Hz, 1 H, 
NCH2CHO), 3.37-3.41 (m, 1 H, NCH), 4.84-4.86 (m, 1 H, NCH2CHO), 6.09 (t, J = 7.3 Hz, 1 
H, =CHCH2), 7.15-7.39 (m, 10 H, Haromat). – IR: ~ν  = 3054, 2969, 1732, 1598, 1494, 1372, 
1203, 1068, 770, 702 cm-1. – MS; m/z (%): 334 (100) [M+1]+, 140 (40), 91 (3). – C22H23NO2 
(333.43): calcd. C 79.25, H 6.95, N 4.20; found C 79.14, H 7.10, N 4.08. 
 
(1S,5S)-6-{2-[Tris(4-methoxyphenyl)methoxy]-1-ethyl}-2-oxa-6-azabicyclo[3,2,1]octane-
3-one [(1S,5S)-92b]  
 
According to GP3 from 96 mg (0.18 mmol) of (2S,4R)-91b and 97 mg (0.37 mmol) of Ph3P in 
4 ml of THF, 174 µl (38-40% in toluene, 0.37 mmol) of DEAD; reaction time: 4 h; 
purification by CC (φ 18 × 240; n-heptane/acetone, 3:1) and separation by prep. HPLC (tR =  
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N
CH2
O
O
OMeMeO
OMe
O
 
32.4 min; n-heptane/EtOAc, 8:2; 12 ml/min). Yield: 43 mg (46%); colorless oil. – TLC: Rf 
=0.27 (n-heptane/acetone, 3:2). – [α]D20  = +2.4 (c = 0.55, EtOAc). – 1H NMR (CDCl3): δ = 
1.99 (br. s,  2 H, CH2CHCH2COO), 2.47 (dd, J = 18.6/3.5 Hz, 1 H, CH2COO), 2.82-2.88 (m, 
3 H, CH2COO, NCH2CH2 and NCH2CHO), 3.07 (d, J = 12.0 Hz, 1 H, NCH2CHO), 3.14-3.18 
(m, 3 H, NCH2CH2 and 2 H of NCH2CH2), 3.48-3.51 (m, 1 H, NCH), 3.78 (s, 9 H, ArOCH3), 
4.85-4.87 (m, 1 H, NCH2CHO), 6.79-6.83 (m, 6 H, Haromat), 7.28-7.32 (m, 6 H, Haromat). – IR: 
~ν  = 3049, 2943, 1737, 1595, 1453, 753, 726 cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 227 
(10), 172 (12), 109 (2). – C30H33NO6 (503.59): calcd. C 71.55, H 6.61, N 2.78; found C 71.17, 
H 6.66, N 2.73.   
 
(1S,5S)-6-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-2-oxa-6-azabicyclo[3,2,1]octane-3-
one [(1S,5S)-92c] 
N
O
CH2
O
S S
 
According to GP3 from 111 mg (0.284 mmol) of (2S,4R)-91c and 154 mg (0.568 mmol) of 
Ph3P in 6 ml of THF, 269 µl (38-40% in  PhCH3, 0.57 mmol) of DEAD;  reaction time: 4 h; 
purification by CC (φ 18 × 250; n-heptane/acetone, 3:1) and separation by prep. HPLC (tR = 
42.7 min; n-heptane/EtOAc, 35:65; 12 ml/min). Yield: 74 mg (70%); colorless oil. – TLC: Rf 
= 0.38 (n-heptane/acetone, 3:2). – [α]D22 = +6.9 (c = 1.00, EtOAc). – 1H NMR (CDCl3): δ = 
1.97-2.00 (m, 2 H, CH2CHCH2COO), 2.00 (s, 3 H, thienyl-CH3), 2.03 (s, 3 H, thienyl-CH3), 
2.28 (q, J = 7.3 Hz, 2 H, NCH2CH2), 2.45 (dd, J = 18.7/3.7 Hz, 1 H, CH2COO), 2.68-2.81 (m, 
3 H, CH2COO and 2 H of NCH2CH2), 2.97 (br. d, J = 11.9 Hz, 1 H, NCH2CHO), 3.06 (dd, J 
= 11.9/3.7 Hz, 1 H, NCH2CHO), 3.38-3.41 (m, 1 H, NCH), 4.85-4.87 (m, 1 H, NCH2CHO), 
6.06 (t, J = 7.3 Hz, 1 H, =CHCH2), 6.76 (d, J = 5.2 Hz, 1 H, SCH), 6.84 (d, J = 5.2 Hz, 1 H, 
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SCH), 7.05 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.21 (d, J = 5.2 Hz, 1 H, SCH=CH). – IR: ~ν  = 
3103, 2946, 1738, 1444, 1204, 858, 834, 715 cm-1. – MS; m/z (%): 374 (32) [M+1]+, 307 (3), 
172 (5), 140 (100). – C20H23NO2S2 (373.53): calcd. C 64.31, H 6.17, N 3.75, S 17.18; found C 
64.24, H 6.31, N 3.70, S 16.94.   
 
(1S,5S)-6-[3-(9-Carbazolyl)-1-propyl]-2-oxa-6-azabicyclo[3,2,1]octane-3-one [(1S,5S)-
92d] 
N
N
CH2
O
O
 
According to GP3 from 142 mg (0.403 mmol) of (2S,4R)-91d and 212 mg (0.806 mmol) of 
Ph3P in 8 ml of THF, 383 µl (38-40% in PhCH3, 0.81 mmol) of DEAD; reaction time: 3 h; 
purification by CC (φ 30 × 230; n-heptane/acetone, 3:2) and separation by prep. HPLC (tR = 
36.0 min; n-heptane/EtOAc, 20:80; 16.5 ml/min). Yield: 55 mg (41%); colorless oil. – TLC: 
Rf = 0.31 (n-heptane/acetone, 3:2). – [α]D20 = +6.2 (c = 0.97, EtOAc). – 1H NMR (CDCl3): δ 
= 1.95-2.07 (m, 4 H, CH2CHCH2COO and CHNCH2CH2), 2.41-2.51 (m, 2 H, CH2COO and 
CH2NCH), 2.58-2.64 (m, 1 H, CH2NCH), 2.73-2.79 (m, 1 H, CH2COO), 3.00 (br. d, J = 11.8 
Hz, 1 H, NCH2CHO), 3.06 (dd, J = 11.8/3.5 Hz, 1 H, NCH2CHO), 3.28-3.31 (m, 1 H, NCH), 
4.36-4.49 (m, 2 H, CH2-carbazole), 4.8-4.91 (m, 1 H, NCH2CHO), 7.21-7.26 (m, 2 H, Haromat), 
7.41-7.48 (m, 4 H, Haromat), 8.09-8.12 (m, 2 H, Haromat). – IR: ~ν  = 3036, 2952, 1738, 1607, 
1505, 1249, 1034, 827, 628 cm-1. – MS; m/z (%): 335 (100) [M+1]+, 293 (5), 180 (7), 140 (7). 
– C21H22N2O2 (334.42): calcd. C 75.42, H 6.63, N 8.38; found C 75.05, H 6.83, N 8.05. 
 
Benzyl (1S,5S)-2-oxa-6-azabicyclo[3,2,1]octane-3-one-6-carboxylate [(1S,5S)-98] 
N
O
COOCH2Ph
O
 
According to GP3 from 290 mg (1.04 mmol) of (2S,4R)-96, 491 mg (1.87 mmol) of Ph3P in 
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25 ml of THF, 886 µl (38-40% in PhCH3, 1.9 mmol) of DEAD; reaction time: 7 h; 
purification by CC (φ 25 × 250; n-heptane/acetone, 3:1) and separation by prep. HPLC (tR = 
53.8 min; n-heptane/EtOAc/iso-propanol, 55:45:1.0; 12 ml/min). Yield: 191 mg (70%); 
colorless oil. – TLC: Rf = 0.26 (n-heptane/acetone, 3:2). – [α]D20 = -63.4 (c = 1.22, CHCl3). – 
1H NMR (C6D5NO2, 120 °C): δ = 2.19 (br. s, 2 H, CH2CHCH2COO), 2.70-2.77 (m, 1 H, 
CH2COO), 3.04 (br. d, J = 18.5 Hz, 1 H, CH2COO), 3.67-3.71 (m, 1 H, NCH2), 3.88 (d, J = 
12.2 Hz, 1 H, NCH2), 4.52 (br. s, 1 H, NCH), 5.06 (br. s, 1 H, NCH2CHO), 5.24 (br. s, 2 H, 
CH2Ph), 7.25-7.44 (m, 5 H, Haromat). – IR: ~ν  = 3035, 2955, 1747, 1709, 1417, 1360, 1206, 
1069, 767, 699 cm-1. – MS; m/z (%): 262 (100) [M+1]+, 218 (14), 105 (7). – C14H15NO4 
(261.28): calcd. C 64.36, H 5.79, N 5.36; found C 64.31, H 5.90, N 5.34. 
 
Ethyl (2R,4S)-1-benzyloxycarbonyl-4-formyloxypyrrolidine-2-acetate [(2R,4S)-99]  
N
HCOO
COOC2H5
COOCH2Ph
 
According to GP3 from 106 mg (0.345 mmol) of (2R,4R)-73 and 135 mg (0.517 mmol) of 
Ph3P in 5 ml of THF, 245 µl (38-40% in PhCH3, 0.72 mmol) of DEAD; reaction time: 16 h; 
purification by CC (φ 25 × 210; n-heptane/acetone, 3:1) and separation by prep. HPLC (tR = 
22.7 min; n-heptane/EtOAc/iso-propanol, 78:22:0.8; 12 ml/min). Yield: 92 mg (80%); 
colorless oil. – TLC: Rf = 0.40 (n-heptane/acetone, 3:2). – [α]D20 = +36.4 (c = 1.64, CHCl3). – 
1H NMR (C6D5NO2, 120 °C): δ = 1.21-1.26 (m, 3 H, CH2CH3), 2.25-2.33 (m, 1 H, 
CH2CHCH2COO), 2.41-2.49 (m, 1 H, CH2CHCH2COO), 2.64-2.72 (m, 1 H, CH2COO), 3.04-
3.10 (m, 1 H, CH2COO), 3.75-3.80 (m, 1 H, NCH2), 3.89 (d, J = 12.1 Hz, 1 H, NCH2), 4.13-
4.20 (m, 2 H, CH2CH3), 4.45-4.52 (m, 1 H, NCH), 5.26 (s, 2 H, CH2Ph), 5.45-5.49 (m, 1 H, 
NCH2CHO), 7.27-7.36, 7.40-7.44 (m, 5 H, Haromat), 8.03 (s, 1 H, HCOO). – IR: ~ν  = 3030, 
2982, 1728, 1705, 1416, 1174, 770, 699 cm-1. – MS; m/z (%): 308 (79), 264 (31), 225 (63), 
187 (16), 174 (26), 105 (100). – C17H21NO6 (335.36): calcd. C 60.89, H 6.31, N 4.18; found C 
60.55, H 6.40, N 4.27. 
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6.1.5  4-Oxopyrrolidine derivatives from Swern oxidation or Jones’    
oxidation 
 
 
General procedure 4 (GP4)  
 
A) [52, 58]  
To a solution of (COCl)2 (1.5 equiv.) in CH2Cl2 (3~9 ml/mmol), DMSO (3 equiv.) was added 
at –78 °C over several minutes to give the oxidizing reagent. After 15 min the respective 
derivative of 4-hydroxypyrrolidine (1 equiv.) in CH2Cl2 (5~9 ml/mmol) was added to the 
above solution at –78 °C. After the mixture had been stirred between –78 °C ~ -70 °C for 15 
min (10 min for the derivatives with side chain b), TEA (3.10-3.25 equiv.) was added. The 
reaction mixture was allowed to stir at r.t. for 15 min (10 min for the derivative with side 
chain b). After water and aq. dilute KOH or NaOH (3.2 equiv.) were added, the organic layer 
was isolated, the aqueous phase was extracted with CH2Cl2. The combined organic layers 
were washed with water, and then dried (MgSO4) and evaporated. The residual oil was 
purified by CC. 
 
B) [41] 
To a solution of the respective derivative of N-protected 4-hydroxypyrroline (1 equiv.) in 
acetone (15 ml), 2.67 M chromic acid in aq. H2SO4 (8.50 equiv.) was added at r.t. over 5 min. 
The brown mixture was stirred at r.t. for 30 min and excessive oxidizing agent was destroyed 
by addition of MeOH (9 equiv.). The supernatant was decanted, diluted by CH2Cl2 (70 ml), 
washed with sat. aq. NH4Cl, dried (MgSO4) and evaporated. The residual oil was purified by 
CC. 
 
Methyl (2S)-4-oxo-1-triphenylmethylpyrrolidine-2-carboxylate [(2S)-50] 
Tr
N
O
COOCH3
 
Accordingbto GP4-A form 397 mg (6.00 mmol) of (COCl)2  and 0.426 ml (469 mg, 6.00 
mmol) of DMSO in 8 ml of CH2Cl2, 775 mg (2.00 mmol) of (2S,4R)-49 in 5 ml of CH2Cl2; 
679 mg (6.60 mmol) of TEA, no strong base was used; purification by CC (φ 25 × 100; n-
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heptane/acetone, 4:1). Yield: 703 mg (97%), slightly yellow foam. – [α]D20 = +83.4 (c = 1.22, 
EtOAc). – 1H NMR (CDCl3): δ = 1.11 (ddd, J = 18.7/10.2/1.6 Hz, 1 H, NCHCH2), 1.87 (dt, J 
= 18.7/1.2 Hz, 1 H, NCHCH2), 3.52 (dd, J = 19.8/0.7 Hz, 1 H, NCH2), 3.76 (s, 3 H, OCH3), 
3.82 (d, J = 19.8 Hz, 1 H, NCH2), 4.25 (d, J = 10.0 Hz, 1 H, CHCOO), 7.10-7.31 (m, 9 H, 
Haromat), 7.54-7.57 (m, 6 H, Haromat). – IR: ~ν = 3058, 2925, 1750, 1489, 1448, 1205, 746, 711 
cm-1. –  MS; m/z  (%): 243 (100)  [Ph3C]+. – C25H23NO3 (385.46): calcd. C 77.90, H 6.02, N 
3.63; found  C 77.39, H 6.30, N 3.26. 
 
Methyl (2S)-1-(4,4-diphenylbut-3-en-1-yl)-4-oxopyrrolidine-2-carboxylate [(2S)-52a]  
N
O
COOCH3
 
According to GP4-A from 227 mg (2.91 mmol) of DMSO and 193 mg (1.46 mmol) of 
(COCl)2 in 4.5 ml of CH2Cl2, 357 mg (0.970 mmol) of (2S,4R)-39a in 1.5 ml of CH2Cl2; 304 
mg (3.00 mmol) of TEA, 3.7 ml (3.2 mmol) of aq. 0.85 M KOH; purification by CC (φ 20 × 
250; n-heptane/acetone, 4:1). Yield: 312 mg (87%); colorless oil. – TLC: Rf  = 0.15 (n-
heptane/acetone, 4:1). – [α]D25 = -32.4 (c = 1.26, EtOH). – 1H NMR (CDCl3): δ = 2.26 (q, J = 
7.4 Hz, 2 H, NCH2CH2), 2.43 (dd, J = 18.0/5.5 Hz, 1 H, NCHCH2), 2.54-2.62 (m, 2 H, 
NCHCH2 and NCH2CH2), 2.77 (dt, J = 12.1/7.4 Hz, 1 H, NCH2CH2), 2.91 (d, J = 17.2 Hz,  1 
H, NCH2CO), 3.29 (d, J = 17.2 Hz, 1 H, NCH2CO), 3.65 (s, 3 H, OCH3), 3.70 (dd, J = 7.8/5.5 
Hz, 1 H, NCH), 6.03 (t, J = 7.4 Hz, 1 H, =CHCH2), 7.07-7.34 (m, 10 H, Haromat). – IR: ~ν = 
3055, 3023, 2951, 1761, 1737, 762, 702 cm-1. – MS; m/z (%): 350 (100) [M+1]+, 207 (7), 156 
(72). – C22H23NO3 (349.43): calcd. C 75.62, H 6.64, N 4.01; found C 75.79, H 6.75, N 3.73. 
 
Methyl (2R)-1-(4,4-diphenylbut-3-en-1-yl)-4-oxopyrrolidine-2-carboxylate [(2R)-52a] 
N
O
COOCH3
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According to GP4-A from 62 mg (0.79 mmol) of DMSO and 50 mg (0.40 mmol) of (COCl)2 
in 2 ml of CH2Cl2, 92 mg (0.26 mmol) of (2R,4R)-39a in 2 ml of CH2Cl2; 83 mg (0.82 mmol) 
of TEA, 0.80 ml (0.80 mmol) of aq. 1.0 M NaOH; purification by CC (φ 18 × 230; n-
heptane/EtOAc, 4:1). Yield: 78 mg (85%); colorless oil. – TLC: Rf = 0.28 (n-heptane/EtOAc, 
3:1). – [α]D20  = +33.2 (c = 0.60, EtOH). The spectra (1H NMR, IR, and MS) were identical 
with those of (2S)-52a. – C22H23NO3 (349.43): calcd. C 75.62, H 6.64, N 4.01; found C 75.51, 
H 6.66, N 3.87. 
 
Methyl (2S)-4-oxo-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylate [(2S)-52b] 
N
O
COOCH3
O
MeO OMe
OMe
 
According to GP4-A from 72 mg (0.92 mmol) of DMSO and 61 mg (0.46 mmol) of (COCl)2 
in 2 ml of CH2Cl2, 160 mg (0.307 mmol) of (2S,4R)-39b in 1.5 ml of CH2Cl2; 108 mg (1.07 
mmol) of TEA, 1.2 ml (1.0 mmol) of aq. 0.85 M KOH; purification by CC (Al2O3, pH 7.5 ± 
0.5; φ 20 × 180; n-heptane/EtOAc, 1:1). Yield: 132 mg (83 %); colorless viscous oil. – TLC: 
Rf = 0.40 (n-heptane/acetone, 3:2). – [α]D29 = -6.4 (c = 1.83, EtOAc). – 1H NMR (CDCl3): δ = 
2.48 (dd, J = 18.0/5.5 Hz, 1 H, NCHCH2), 2.65 (dd, J = 18.0/7.8 Hz, 1 H, NCHCH2), 2.83 (dt, 
J = 13.0/5.7 Hz, 1 H, NCH2CH2), 2.94 (dt, J = 13.0/5.7 Hz, 1 H, NCH2CH2), 3.13 (d, J = 17.4 
Hz, 1 H, NCH2CO), 3.24 (t, J = 5.7 Hz, 2 H, NCH2CH2), 3.44 (d, J = 17.4 Hz, 1 H, 
NCH2CO), 3.72 (s, 3 H, COOCH3), 3.78 (s, 9 H, ArOCH3), 3.84 (dd, J = 7.8/5.5 Hz, 1 H, 
NCH), 6.79-6.83 (m, 6 H, Haromat), 7.29-7.32 (m, 6 H, Haromat). – IR: ~ν = 2953, 2840, 1754, 
1604, 1504, 1254, 1028, 797 cm-1. – MS; m/z (%): 333 (79) [Ar3C]+, 335 (19), 334 (59), 333 
(79), 227 (100), 186 (5), 158 (62). – C30H33NO7 (519.59): calcd. C 69.35, H 6.40, N 2.70; 
found C 69.53, H 6.59, N 2.33. 
 
Methyl (2R)-4-oxo-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylate [(2R)-52b] 
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N
O
COOCH3
O
MeO OMe
OMe
 
According to GP4-A from 93 mg (1.2 mmol) of DMSO and 75 mg (0.59 mmol) of (COCl)2 in 
5 ml of CH2Cl2, 206 mg (0.395 mmol) of (2R,4R)-39b in 5 ml of CH2Cl2; 132 mg (1.30 
mmol) of TEA, 1.2 ml (1.2 mmol) of aq. 1.0 M NaOH; purification (φ 18 × 230; n-
heptane/acetone, 3:1). Yield: 183 mg (89%); colorless oil. – TLC: Rf = 0.40 (n-
heptane/acetone, 3:2). – [α]D 20 = +4.3 (c = 1.5, EtOAc). The spectra (1H NMR, IR, and MS) 
were identical with those of (2S)-52b. – C30H33NO7 (519.59): calcd. C 69.35, H 6.40, N 2.70; 
found C 69.42, H 6.75, N 2.82.  
 
Methyl (2S)-1-benzyloxycarbonyl-4-oxopyrrolidine-2-carboxylate [(2S)-60] [61] 
 
1) According to GP4-A from 148 mg (2.25 mmol) of (COCl)2 and 352 mg (4.50 mmol) of 
DMSO in 6 ml of CH2Cl2, 419 mg (1.50 mmol) of (2S,4R)-58; 465 mg (4.70 mmol) of TEA, 
no strong base (NaOH or KOH) in use; purification by CC (φ 30 × 230; n-heptane/acetone, 
3:1). Yield: 110 mg (26%); colorless oil. – [α]D20 = +17.8 (c = 1.10, CHCl3) {ref. [41]: [α]D20 = 
+18.5 (c = 1.0, CHCl3)}. 
 
2) According to GP4-B from 500 mg (1.79 mmol) of (2S,4R)-58 in 28 ml of acetone, 1.90 ml 
(15.2 mmol) of 2.67 M chromic acid in aq. H2SO4. Yield: 354 mg (71%); colorless oil.  
 
Methyl (2R)-1-benzyloxycarbonyl-4-oxopyrrolidine-2-carboxylate [(2R)-60] [75] 
 
According to GP4-B from 800 mg (2.87 mmol) of (2R,4R)-58, 3.04 ml (24.3 mmol) of 2.67 
M chromic acid in aq. H2SO4. Yield: 623 mg (78%); colorless oil. – [α]D20 = -18.8 (c = 1.31, 
CHCl3) {ref. [41]: [α]D20 = -19.4 (c = 1.0, CHCl3)}. 
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Methyl (2S)-1-(4,4-diphenylbut-3-en-1-yl)-4-oxopyrrolidine-2-acetate [(2S)-100a] 
N
O
COOCH3
 
According to GP4-A from 54 mg (0.42 mmol) of (COCl)2 and 66 mg (0.85 mmol) of DMSO  
in 1.5 ml of CH2Cl2, 103 mg (0.282 mmol) of (2S,4R)-91a  in 1.5 ml of CH2Cl2; 101 mg (1.01 
mmol) of TEA, 0.90 ml (0.90 mmol) of aq. 1.0 M NaOH; purification by CC (φ 18 × 210; n-
heptane/acetone, 4:1). Yield: 86 mg (83%); colorless oil. – TLC: Rf = 0.43  (n-
heptane/acetone, 3:2). – [α]D20  = +63.5 (c = 1.06, EtOAc). – 1H NMR (CDCl3): δ = 2.21-2.38 
(m, 4 H, CH2COO, NCH2CH2, and 2 H of NCH2CH2), 2.43 (dd, J = 15.4/8.7 Hz, 1 H, 
CH2CHCH2COO), 2.57-2.63 (m, 2 H, CH2COO and NCH2CO), 2.78 (dd, J = 15.4/3.8 Hz, 1 
H, CH2CHCH2COO), 2.98 (dt, J = 11.5/7.8 Hz, 1 H, NCH2CH2), 3.15-3.22 (m, 1 H, NCH), 
3.32 (d, J = 17.5 Hz, 1 H, NCH2CO), 3.66 (s, 3 H, OCH3), 6.09 (t, J = 7.3 Hz, 1 H, =CHCH2), 
7.14-7.39 (m, 10 H, Haromat). – IR: ~ν  = 3055, 2951, 1760, 1738, 1598, 1495, 1442, 768, 702, 
631 cm-1. – MS; m/z (%): 364 (63) [M+1]+, 290 (17), 183 (10), 170 (100) 134 (17), 91 (7). – 
C23H25NO3 (363.46): calcd. C 76.00, H 6.93, N 3.85; found C 75.72, H 7.04, N 3.79.  
 
Methyl (2S)-4-oxo-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-acetate 
[(2S)-100b] 
N COOCH3
O
O
OMeMeO
OMe
 
According to GP4-A from 65 mg (0.51 mmol) of (COCl)2 and 80 mg (1.0 mmol) of DMSO in 
3 ml of CH2Cl2, 183 mg (0.342 mmol) of (2S,4R)-91b in 3 ml of CH2Cl2; 114 mg (1.14 
mmol) of TEA, 1.1 ml (1.1 mmol) of aq. 1.0 M NaOH; purification by CC (φ 18 × 200; n-
heptane/acetone, 3:2). Yield: 148 mg (81%); colorless oil. – TLC: Rf = 0.40  (n-
heptane/acetone, 3:2). – [α]D20 = -45.2 (c = 0.95, EtOAc). – 1H NMR (CDCl3): δ = 2.23 (dd, J 
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= 18.4/9.3 Hz, 1 H, CH2COO), 2.41 (dd, J = 15.5/8.8 Hz, 1 H, CH2CHCH2COO), 2.49 (dt, J = 
12.7/5.7 Hz, 1 H, NCH2CH2), 2.60 (dd, J = 18.4/6.7 Hz, 1 H, CH2COO), 2.79 (d, J = 17.7 Hz, 
1 H, NCH2CO), 2.82 (dd, J = 15.5/3.8 Hz, 1 H, CH2CHCH2COO), 3.01-3.07 (m, 1 H, 
NCH2CH2), 3.12-3.28 (m, 3 H, NCH and 2 H of NCH2CH2), 3.45 (d, J = 17.7 Hz, 1 H, 
NCH2CO), 3.65 (s, 3 H, COOCH3), 3.77 (s, 9 H, ArOCH3), 6.78-6.84 (m, 6 H, Haromat), 7.28-
7.32 (m, 6 H, Haromat). – IR: ~ν  = 3035, 2953, 1756, 1738, 1607, 1506, 1249, 1175, 1034, 828 
cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 227 (45), 202 (24), 170 (19), 160 (14), 128 (9). – 
C31H35NO7 (533.62): calcd. C 69.78, H 6.61, N 2.62; found C 69.29, H 6.75, N 2.54.  
 
Ethyl (2R)-4-oxo-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-acetate 
[(2R)-101b] 
N COOC2H5
O
O
OMeMeO
OMe
 
According to GP4-A from 69 mg (0.54 mmol) of (COCl)2 and 85 mg (1.0 mmol) of DMSO in 
2 ml of CH2Cl2, 149 mg (0.271 mmol) of (2R,4R)-88b in 2.5 of ml CH2Cl2; 121 mg (1.19 
mmol) of TEA, 1.1 ml (1.1 mmol) of aq. 1.0 M NaOH; purification by CC (φ 18 × 100; n-
heptane/acetone, 3:2). Yield: 130 mg (87%); pale yellow oil. – TLC: Rf = 0.40 (n-
heptane/acetone, 3:2). – [α]57820 = +56.9 (c = 1.53, EtOAc). – 1H NMR (CDCl3): δ = 1.23 (t, J 
= 7.2 Hz, 1 H, CH2CH3), 2.23 (dd, J = 18.4/9.3 Hz, 1 H, CH2COO), 2.40 (dd, J = 15.5/8.8 Hz, 
1 H, CH2CHCH2COO), 2.48 (dt, J = 12.7/5.7 Hz, 1 H, NCH2CH2), 2.60 (dd, J = 18.4/6.7 Hz, 
1 H, CH2COO), 2.79 (d, J = 17.7 Hz, 1 H, NCH2CO), 2.81 (dd, J =15.5/3.8 Hz, 1 H, 
CH2CHCH2COO), 3.02-3.08 (m, 1 H, NCH2CH2), 3.13-3.29 (m, 3 H, NCH and 2 H of 
NCH2CH2), 3.45 (d, J = 17.7 Hz, 1 H, NCH2CO), 3.77 (s, 9 H, ArOCH3), 4.06-4.17 (m, 2 H, 
CH2CH3), 6.79-6.82 (m, 6 H, Haromat), 7.29-7.23 (m, 6 H, Haromat). – IR: ~ν  = 3031, 2955, 
1760, 1732, 1608, 1505, 1250, 1176, 1034, 828  cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 198 
(6), 184 (4), 89 (5). – C32H37NO7 (547.65): calcd. C 70.18, H 6.81, N 2.56; found C 69.98, H 
6.79, N 2.43. 
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Methyl (2S)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-oxopyrrolidine-2-acetate [(2S)-
100c] 
N
O
COOCH3
S S
 
According to GP4-A from 56 mg (0.44 mmol) of (COCl)2 and 69 mg (0.87 mmol) of DMSO 
in 2.5 ml of CH2Cl2, 118 mg (0.291 mmol) of (2S,4R)-91c in 2.5 ml f CH2Cl2; 98 mg (0.96 
mmol) of TEA, 0.92 ml (0.92 mmol) of aq. 1.0 M NaOH; purification by CC (φ 18 × 260; n-
heptane/acetone, 3:1). Yield: 108 mg (92%); slightly yellow oil. – TLC: Rf  = 0.28 (n-
heptane/acetone, 4:1). –[α]D20 = +68.3 (c = 0.75, EtOAc). – 1H NMR (CDCl3, 500 MHz): δ = 
2.00 (s, 3 H, thienyl-CH3), 2.02 (s, 3 H, thienyl-CH3), 2.23-2.43 (m, 5 H, CH2COO, 
NCH2CH2, CH2CHCH2COO and 2 H of NCH2CH2), 2.59-2.66 (m, 2 H, NCH2CO and 
CH2COO), 2.80 (dd, J = 15.4/3.9 Hz, 1 H, CH2CHCH2COO), 2.99 (dt, J = 11.6/7.9 Hz, 1 H, 
NCH2CH2), 3.17-3.23 (m, 1 H, NCH), 3.35 (d, J = 17.5 Hz, 1 H, NCH2CO), 3.67 (s, 3 H, 
OCH3), 6.05 (t, J = 7.3 Hz, 1 H, =CHCH2), 6.76 (d, J = 5.2 Hz, 1 H, SCH), 6.84 (d, J = 5.2 
Hz, 1 H, SCH), 7.05 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.21 (d, J = 5.2 Hz, 1 H, SCH=CH). – 
IR: ~ν  = 3104, 2950, 1760, 1732, 1435, 715 cm-1. – MS; m/z (%): 404 (30) [M+1]+, 330 (4), 
247 (3), 170 (100), 156 (8), 79 (3). – C21H25NO3S2 (403.56): calcd. C 62.50, H 6.24, N 3.47; 
found C 62.25, H 5.97, N 3.40.  
 
Ethyl (2R)-1-[4,4-di(3-methyl-thienyl)but-3-en-1-yl]-4-oxopyrrolidine-2-acetate [(2R)-
101c] 
N
O
COOC2H5
S S
 
According to GP4-A from 140 mg (1.10 mmol) of (COCl)2  and 173 mg (2.20 mmol) of 
DMSO in 3 ml of CH2Cl2, 230 mg (0.548 mmol) of (2R,4R)-88c in 3 ml of CH2Cl2; 246 mg 
(2.42 mmol) of TEA, 2.3 ml (2.3 mmol) of aq. 1.0 M NaOH; purification by CC (φ 25 × 170; 
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n-heptane/acetone, 3:1). Yield: 201 mg (88%); yellow oil. –TLC: Rf = 0.45 (n-
heptane/acetone, 3:2). – [α]D20 = -59.4 (c = 2.00, EtOAc). – 1H NMR (CDCl3, 500 MHz): δ = 
1.25 (t, J = 7.2 Hz, 1 H, CH2CH3), 2.00 (s, 3 H, thienyl-CH3), 2.02 (s, 3 H, thienyl-CH3), 
2.22-2.42 (m, 5 H, CH2COO, NCH2CH2, CH2CHCH2COO and 2 H of NCH2CH2), 2.59-2.66 
(m, 2 H, NCH2CO and CH2COO), 2.80 (dd, J = 15.4/3.9 Hz, 1 H, CH2CHCH2COO), 2.99 (dt, 
J = 11.6/7.9 Hz, 1 H, NCH2CH2), 3.17-3.23 (m, 1 H, NCH), 3.35 (d, J = 17.5 Hz, 1 H, 
NCH2CO), 4.09-4.18 (m, 2 H, CH2CH3), 6.05 (t, J = 7.3 Hz, 1 H, =CHCH2), 6.76 (d, J = 5.2 
Hz, 1 H, SCH), 6.84 (d, J = 5.2 Hz, 1 H, SCH), 7.05 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.21 (d, J 
= 5.2 Hz, 1 H, SCH=CH). – IR: ~ν  = 3100, 2974, 1759, 1732, 1184, 1027, 714 cm-1. – MS; 
m/z (%): 418 (46) [M+1]+, 329 (9), 225 (48), 184 (100), 165 (26), 105 (78). – C22H 27NO3S2 
(417.59): calcd. C 63.28, H 6.52, N 3.35, S 15.35; found C 63.20, H 6.53, N 3.20, S 14.92. 
 
Methyl (2S)-1-benzyloxycarbonyl-4-oxopyrrolidine-2-acetate [(2S)-108] 
N
O
COOCH3
COOCH2Ph
 
According to GP4-B from 300 mg (1.02 mmol) of (2S,4R)-95 in 16 ml of acetone, 1.08 ml 
(8.7 mmol) of 2.67 M chromic acid in aq. H2SO4; purification by CC (φ 25 × 200; n-
heptane/acetone, 3:1). Yield: 225 mg (76%); colorless crystals. – M.p. 53-54 °C. – TLC: Rf = 
0.36 (n-heptane/acetone, 3:2). – [α]D20 = +10.7 (c = 1.06, CHCl3). – 1H NMR (C6D5NO2, 120 
°C): δ = 2.59 (d, J = 18.4 Hz, 1 H, CH2COO), 2.83-2.99 (m, 3 H, CH2COO and 2 H of 
CH2CHCH2COO), 3.63 (s, 3 H, OCH3), 3.88 (d, J = 18.1 Hz, 1 H, NCH2), 4.02 (d, J = 18.1 
Hz, 1 H, NCH2), 4.75-4.82 (m, 1 H, NCH), 5.27 (s, 2 H, CH2Ph), 7.27-7.44 (m, 5 H, Haromat). 
– IR: ~ν  = 3033, 1765, 1732, 1698, 1416, 1106, 742, 700 cm-1. – MS; m/z (%): 292 (100) 
[M+1]+, 248 (45), 156 (25), 119 (3). – C15H17NO5 (291.31): calcd. C 61.85, H 5.88, N 4.81; 
found C 61.77, H 6.07, N 4.74.         
 
Ethyl (2R)-1-benzyloxycarbonyl-4-oxopyrrolidine-2-acetate [(2R)-112] 
N
O
COOC2H5
COOCH2Ph
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According to GP4-B from 192 mg (0.625 mmol) of (2R,4R)-73, 0.69 ml (5.5 mmol) of 2.67 
M chromic acid in aq. H2SO4; purification by CC (φ 25 × 210; n-heptane/acetone, 3:1). Yield: 
147 mg (77%); colorless oil. – TLC: Rf = 0.36 (n-heptane/acetone, 3:2). – [α]D20 =  -11.3 (c = 
1.38, CHCl3). – 1H NMR (CDCl3): δ = 1.66-1.70 (m, 3 H, CH2CH3), 3.06-3.12 (m, 1 H, 
CH2COO), 3.31-3.37 (m, 1 H, CH2COO), 3.39-3.47 (m, 2 H, CH2CHCH2COO), 4.36 (d, J = 
18.6 Hz, 1 H, NCH2), 4.50 (d, J = 18.6 Hz, 1 H, NCH2), 4.58-4.64 (m, 2 H, CH2CH3), 5.23-
5.29 (m, 1 H, NCH), 5.74 (s, 2 H, CH2Ph), 7.72-7.84 (m, 5 H, Haromat). – IR: ~ν  = 3031, 2982, 
1766, 1732, 1698, 1416, 1027, 768, 740, 699 cm-1. – MS; m/z (%): 306 (100) [M+1]+, 262 
(30), 198 (3), 170 (15). – C16H19NO5 (305.34): calcd. C 62.94, H 6.27, N 4.59; found 62.76, H 
6.28, N 4.55. 
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6.1.6  Organometallic addition reaction to the C-4 positions of 4-
oxopyrrolidine derivatives 
 
General procedure 5 (GP5) 
 
A) [51, 55, 56, 57, 59, 60] 
To a mixture of 266 mg (11.1 mmol) of Mg in 22 ml of THF, 1.43 ml (2.08 g, 11.1 mmol) of 
4-MeOC6H5Br was added over 40 min at r.t. to give a gray solution of 4-MeOC6H4MgBr 
(0.48 M) in THF , which was stored in a freezer at –35 °C.  
CeCl3⋅7H2O was heated at 140 °C under high vacuo for 3.5 h to yield anhydrous CeCl3 as 
white powder. 
Anhydrous CeCl3 (0.33-2.0 equiv.) was dried in vacuo with a heatgun for 15 min and then 
cooled to 0 °C. THF (10-20 ml/mmol) and 4-MeOC6H4MgBr (1.0-2.1 equiv.) in THF were 
added and the resulting white suspension was stirred for 1 h at 0 °C and then cooled down to 
the temperature given. A solution of the respective 4-oxopyrrolidine (1 equiv.) in THF (10-20 
ml/mmol) was added. Stirring was continued at the same temperature for the time given. The 
reaction was quenched with aq. sat. NH4Cl. The organic layer was separated and the aqueous 
layer was extracted with Et2O. The combined organic phases were dried (MgSO4) and 
concentrated. The resulting oil was subjected to analytical HPLC, purified by CC and finally 
separated by prep. HPLC. Thereby some starting ketone was also recovered. 
 
B) [58] 
To a mixture of 266 mg (11.1 mmol) of Mg in 25 ml of Et2O, 1.43 ml (2.08 g, 11.1 mmol) of 
4-MeOC6H4Br was added over 40 min at r.t. to give 4-MeOC6H4MgBr (0.44 M) in Et2O, 
which was stored at –35 °C. 
To a solution of the respective 4-oxopyrrolidine (1 equiv.) in Et2O (35 ml/mmol), a solution 
of 4-MeOC6H4MgBr (1.80 equiv.) in Et2O was dropwise added at the temperature given. 
Stirring was continued at the temperature for the time given. The reaction was quenched with 
aq. sat. NH4Cl. The organic layer was separated and the aqueous layer was extracted with 
Et2O. The combined organic phases were dried (MgSO4) and concentrated. The resulting oil 
was subjected to analytical HPLC, purified by CC and finally separated by prep. HPLC. 
Thereby some starting ketone was also recovered. 
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Methyl (2S,4R)-4-hydroxy-4-(4-methoxyphenyl)-1-triphenylmethylpyrrolidine-2-
carboxylate [(2S,4R)-51] and 
methyl (2S,4S)-4-hydroxy-4-(4-methoxyphenyl)-1-triphenylmethylpyrrolidine-2-
carboxylate [(2S,4S)-51] 
Tr
N
OH
COOCH3
OMe
Tr
N
OH
COOCH3
OMe
         
                                           (2S,4R)-51                            (2S,4S)-51 
 
Accodording GP5-B from 2.61 ml (2.74 mmol) of 4-MeOC6H4MgBr (1.05 M in Et2O) was 
added to 530 mg (1.38 mmol) of (2S)-50 in 60 ml of Et2O; reaction: at –10 °C fro 15 h. 
Purification by CC (φ 25 × 240; n-heptane/EtOAc, 3:1,) and separation on prep. HPLC (n-
heptane/EtOAc, 85:15; 12 ml/min) gave pure diastereomers. 299 mg (55%) of (2S)-50 was 
recycled. 
 
The minor ds: 58 mg (9%); colorless crystals. – tR = 34.1 min. – M.p: 65-67 °C. – [α]D20 = 
+28.3 (c = 0.70, EtOAc). – TLC: Rf = 0.26 (n-heptane/EtOAc, 2:1). – 1H NMR (CDCl3): δ = 
1.59 (dd, J = 13.5/10.3 Hz, 1 H, NCHCH2), 1.79 (dd, J = 13.5/1.1 Hz, 1 H, NCHCH2), 2.78 
(d, J = 10.7 Hz, 1 H, NCH2), 3.57-3.61 (m, 1 H, NCH2), 3.57 (s, 3 H, COOCH3), 3.66 (s, 3 H, 
ArOCH3), 3.98 (dd, J = 10.3/1.1 Hz, 1 H, CHCOO), 5.06 (s, 1 H, OH), 6.64-6.67 (m, 2 H, 
Haromat), 6.89-6.93 (m, 2 H, Haromat), 7.10-7.14 (m, 3 H, Haromat), 7.19-7.24 (m, 6 H, Haromat), 
7.50-7.54 (m, 6 H, Haromat). – IR: ~ν = 3445, 3056, 2951, 1739, 1610, 1514, 1251, 1177, 832, 
745, 712 cm-1. – MS; m/z (%): 310 (10), 243 (100) [Ph3C]+, 165 (50), 135 (21). – C32H31NO4 
(493.60): calcd. C 77.87, H 6.33, N 2.84; found C 77.74, H 6.62, N 2.67. 
 
The major ds: 118 mg (18%); colorless crystals. – tRT = 41.7 min. – M.p: 108-110 °C. – [α]D20 
= -59.1 (c = 1.16, EtOAc). – TLC: Rf = 0.22 (n-heptane/EtOAc, 2:1). – 1H NMR (CDCl3): δ = 
2.14 (ddd, J = 13.2/6.9/2.2 Hz, 1 H, NCHCH2), 2.45 (dd, J = 13.2/9.2 Hz, 1 H, NCHCH2), 
3.19 (d, J = 13.0/2.2 Hz, 1 H, NCH2), 3.42 (s, 3 H, COOCH3), 3.76 (s, 3 H, ArOCH3), 3.97 (d, 
J = 13.0 Hz, 1 H, NCH2), 4.07 (dd, J = 9.2/6.9 Hz, 1 H, CHCOO), 6.79-6.83 (m, 2 H, Haromat), 
7.18-7.22 (m, 3 H, Haromat), 7.29-7.33 (m, 8 H, Haromat), 7.60-7.63 (m, 6 H, Haromat). – IR: ~ν = 
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3446, 3056, 3031, 2951, 1722, 1611, 1515, 1448, 1253, 1178, 832, 746, 712 cm-1. – MS; m/z 
(%): 354 (4), 243 (100) [Ph3C]+, 165 (41). – C32H31NO4 (493.60): calcd. C 77.87, H 6.33, N 
2.84; found C 77.58, H 6.66, N 2.80.   
 
Methyl (2S,4S)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-carboxylate [(2S,4S)-53a] and 
methyl (2S,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-carboxylate [(2S,4R)-53a] 
N
OH
COOCH3
OMe
N
OH
COOCH3
OMe
 
                                   (2S,4S)-53a                                        (2S,4R)-53a 
 
1) According to GP5-A from 99 mg (0.40 mmol) of anhydrous CeCl3 and 0.83 ml (0.48 M in 
THF, 0.40 mmol) of 4-MeOC6H4MgBr in 5 ml of THF; 100 mg (0.286 mmol) of (2S)-52a in 
5 ml of THF; reaction: at –60 °C for 20 h. Analytical HPLC (n-heptane/EtOAc/iso-propanol, 
88:12:0.77; 1.3 ml/min) d.s: (2S,4R) / (2S,4S) = 61:39 [(2S,4R) tR = 21.4 min, (2S,4S) tR = 26.8 
min]. Purification by CC (φ 18 × 240; n-heptane/EtOAc, 75:25) and separation by prep. 
HPLC (n-heptane/EtOAc/iso-propanol, 90:10:1.0; 12 ml/min) yielded (2S,4R)-53a (tR = 40.8 
min) and (2S,4S)-53a (tR = 49.3 min). 
 
(2S,4R)-53a: 39 mg (30%); colorless crystals. – M.p. 105-106 °C (iPr2O). – TLC: Rf = 0.23 
(n-heptane/EtOAc, 70:30). – [α]D20  = -49.4 (c = 0.815, CHCl3). – 1H NMR (CDCl3): δ = 2.15 
(ddd, J = 13.9/3.2/2.0 Hz, 1 H, NCHCH2), 2.25 (q, J = 7.5 Hz, 2 H, NCH2CH2), 2.49 (dd, J = 
13.9/10.7 Hz, 1 H, NCHCH2), 2.63-2.70 (m, 2 H, NCH2CH2 and NCH2CO), 2.80 (dt, J = 
12.1/7.5 Hz, 1 H, NCH2CH2), 3.09 (dd, J = 9.2/2.0 Hz, 1 H, NCH2CO), 3.38 (dd, J = 10.7/3.2 
Hz, 1 H, NCH), 3.66 (s, 3 H, COOCH3), 3.72 (s, 3 H, ArOCH3), 3.92 (s, 1 H, OH), 6.05 (t, J 
= 7.5 Hz, 1 H, =CHCH2), 6.78-6.81 (m, 2 H, Haromat.), 7.09-7.33 (m, 12 H, Haromat.). –  IR: ~ν = 
3471, 3026, 2956, 2808, 1720, 1604, 1509, 1248, 770, 694 cm-1. – MS; m/z (%): 458 (19) 
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[M+1]+, 440 (25), 426 (85), 381 (35), 380 (100), 207 (96), 171 (38). – C29H31NO4 (457.57): 
calcd. C 76.12, H 6.83, N 3.06; found C 76.03, H 6.89, N 3.09. 
 
(2S,4S)-53a: 20 mg (15%); colorless crystals. – M.p. 103-104 °C (iPr2O). – TLC: Rf  = 0.18 
(n-heptane/EtOAc, 70:30). – [α]D20  = -1.8 (c = 1.00, CHCl3). – 1H NMR (CDCl3): δ = 2.27 
(q, J = 7.5 Hz, 2 H, NCH2CH2), 2.34 (d, J = 7.7 Hz, 2 H, NCHCH2), 2.67-2.75 (m, 2 H, 
NCH2CH2 and NCH2CO), 2.85 (dt, J = 12.0/7.5 Hz, 1 H, NCH2CH2), 3.35 (d, J = 10.3 Hz, 1 
H, NCH2CO), 3.63 (s, 3 H, COOCH3), 3.71 (s, 3 H, ArOCH3), 3.78 (t, J = 7.7 Hz, 1 H, NCH), 
6.05 (t, J = 7.5 Hz, 1 H, =CHCH2), 6.76-6.81 (m, 2 H, Haromat.), 7.09-7.37 (m, 12 H, Haromat.). – 
IR: ~ν = 3424, 3025, 2948, 1742, 1610, 1518, 1248, 762, 700 cm-1. – MS; m/z (%): 458 (55) 
[M+1]+, 440 (100), 264 (82), 246 (86), 183 (15). – C29H31NO4 (457.57): calcd. C 76.12, H 
6.83, N 3.06; found C 76.23, H 6.86, N 2.92. 
 
2) According to GP5-A from 222 mg (0.901 mmol) of CeCl3 and 1.88 ml (0.48 M in THF, 
0.90 mmol) of 4-MeOC6H4MgBr in 8 ml of THF; 150 mg (0.429 mmol) of (2S)-52a in 6 ml 
of THF; reaction: at –60 °C for 20 h; analytical HPLC d.s: (2S,4R) / (2S,4S)  = 59:41 [(2S,4R) 
tR = 21.7 min, (2S,4S) tR = 26.8 min]; prep. HPLC yield: 60 mg (31%) of (2S,4R)-53a (tR = 
40.7 min) and 48 mg (25%) of (2S,4S)-53a (tR = 48.8 min). 
 
3) According to GP5-A from 148 mg (0.601 mmol) of CeCl3 and 1.25 ml (0.48 M in THF, 
0.60 mmol) of 4-MeOC6H4MgBr in 8 ml of THF; 150 mg (0.429 mmol) of (2S)-52a in 7 ml 
of THF; reaction: at –78 °C for 20 h; analytical HPLC d.s: (2S,4R) / (2S,4S) = 70:30 [(2S,4R) 
tR = 22.8 min, (2S,4S) tR = 28.4 min]; prep. HPLC yield: 54 mg (28%) of (2S,4R)-53a (tR = 
39.7 min) and 24 mg (12%) of (2S,4S)-53a (tR = 49.5 min). 
 
4) According to GP5-A from 50 mg (0.20 mmol) of CeCl3 and 1.37 ml (0.48 M in THF, 0.60 
mmol) of 4-MeOC6H4MgBr in 8 ml of THF; 150 mg (0.429 mmol) of (2S)-52a in 7 ml of 
THF; reaction: at –78 °C for 20 h; analytical HPLC d.s: (2S,4R) / (2S,4S) = 61:39 [(2S,4R) tR 
= 21.9 min, (2S,4S) tR = 29.0 min]; prep. HPLC yield: 37 mg (19%) of (2S,4R)-53a (tR = 37.4 
min) and 19 mg (10%) of (2S,4S)-53a (tR = 49.2 min). 
 
 
5) According to GP5-B from 150 mg (0.429 mmol) of (2S)-52a in 15 ml of Et2O, 1.76 ml 
(0.44 M in Et2O, 0.77 mmol) of 4-MeOC6H4MgBr; reaction: at –78 °C for 20 h; analytical 
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HPLC d.s: (2S,4R) / (2S,4S) = 89:11 [(2S,4R) tR = 23.1 min, (2S,4S) tR = 28.4 min]; prep. 
HPLC yield: 12 mg (6%) of (2S,4R)-53a (tR = 39.0 min) and 109 mg (56%) of (2S,4S)-53a (tR 
= 53.6 min).  
 
Methyl (2R,4R)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-carboxylate [(2R,4R)-53a]  and  
methyl (2R,4S)-1-(4,4-diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-carboxylate [(2R,4S)-53a]  
 
N
OH
COOCH3
OMe
N
OH
COOCH3
OMe
 
                                     (2R,4R)-53a                             (2R,4S)-53a 
 
8) According to GP5-A from 315 mg (1.28 mmol) of CeCl3 and 2.67 ml (0.48 M in THF, 1.3 
mmol) of 4-MeOC6H4MgBr in 14 ml of THF; 320 mg (0.915 mmol) of (2R)-52a in 10 ml of 
THF; reaction: at –60 °C for 20 h; analytical HPLC (n-heptane/EtOAc/iso-propanol, 
88:12:0.77; 1.3 ml/min) d.s: (2R,4S) / (2R,4R) = 58:42 [(2R,4S) tR = 21.8 min, (2R,4R) tR = 
27.2 min]. Purification by CC (φ 25 × 290; n-heptane/EtOAc, 3:1) and separation by prep. 
HPLC (n-heptane/EtOAc/iso-propanol, 86:14:0.9; 12 ml/min) yielded (2R,4S)-53a (tR = 26.0 
min) and (2R,4R)-53a (tR = 37.1 min); 25 mg of (2R)-52a was recovered. 
 
(2R,4S)-53a: 116 mg (28%); colorless crystals. – M.p. 105-107 °C (iPr2O). – TLC: Rf = 0.23 
(n-heptane/EtOAc, 7:3).– [α]D20  = +47.9 (c = 0.90, CHCl3). The spectra (1H NMR, IR, and 
MS) were identical with those of (2S,4R)-53a. – C29H31NO4 (457.57): calcd. C 76.12, H 6.83, 
N 3.06; found C 76.03, H 6.86, N 3.02. 
 
(2R,4R)-53a: 82 mg (20%); colorless crystals. – M.p. 103-104 °C (iPr2O). – TLC: Rf = 0.18 
(n-heptane/EtOAc, 7:3). – [α]D20 = +1.6  (c = 0.80, CHCl3). The spectra (1H NMR, IR, and 
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MS) were identical with those of (2S,4S)-53a. – C29H31NO4 (457.57): calcd. C 76.12, H 6.83, 
N 3.06; found 76.07, H 6.83, N 3.09. 
 
Methyl (2S,4S)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)-methoxy]-
1-ethyl}pyrrolidine-2-carboxylate [(2S,4S)-53b] and  
methyl (2S,4R)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)-methoxy]-
1-ethyl}pyrrolidine-2-carboxylate [(2S,4R)-53b] 
 
N
OH
OMe
O
OMeMeO
OMe
COOCH3N
OH
OMe
O
OMeMeO
OMe
COOCH3
 
                                       (2S,4S)-53b                                  (2S,4R)-53b                    
 
6) According to GP5-A from 130 mg (0.527 mmol) of CeCl3 and 0.80 ml (0.67 M in THF, 
0.53 mmol) of 4-MeOC6H4MgBr in 5 ml of THF; 196 mg (0.377 mmol) of (2S)-52b in 6 ml 
of THF; reaction: at –60 °C for 20 h; analytical HPLC (n-heptane/EtOAc, 50:50; 1.3 ml/min) 
d.s: (2S,4S)-53b / (2S,4R)-53b = 48:52 [(2S,4S) tR = 7.6 min, (2S,4R) tR = 11.9 min]. 
Purification by CC (φ 20 × 320; n-heptane/EtOAc, 3:2) and separation by prep. HPLC (n-
heptane/EtOAc, 55:45; 12 ml/min) afforded (2S,4S)-53b (tR = 19.7 min) and (2S,4R)-53b (tR 
= 24.6 min). 
 
(2S,4S)-53b: 57 mg (24%); colorless viscous oil. – TLC: Rf = 0.19 (n-heptane/EtOAc, 1:1). – 
[α]D20 = -7.1 (c = 1.10, acetone). – 1H NMR (CDCl3): δ = 2.34-2.44 (m, 2 H, NCHCH2), 2.54 
(s, 1 H, OH), 2.94-3.00 (m, 2 H, NCH2CO and NCH2CH2), 3.04-3.10 (m, 1 H, NCH2CH2), 
3.17-3.26 (m, 2 H, NCH2CH2), 3.49 (d, J = 10.7 Hz, 1 H, NCH2CO), 3.69 (s, 3 H, COOCH3), 
3.78 (s, 9 H, ArOCH3), 3.79 (s, 3 H, Ar‘OCH3), 3.94 (t, J = 7.6 Hz, 1 H, NCH), 6.79-6.83 (m, 
6 H, Haromat), 6.85-6.88 (m, 2 H, Haromat), 7.31-7.34 (m, 6 H, Haromat), 7.38-7.42 (m, 2 H, 
Haromat). – MS; m/z (%): 333 (100) [Ar3C]+, 296 (15), 227 (38). – IR: ~ν = 3478, 3036, 2953, 
1738, 1608, 1583, 1505, 1251, 1036, 829 cm-1. – C37H41NO8 (627.73): calcd. C 70.80, H 
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6.58, N 2.23; found C 70.33, H 7.07, N 2.22.  
      
(2S,4R)-53b: 62 mg (26%); colorless viscous oil. – TLC: Rf = 0.23 (n-heptane/EtOAc, 1:1). – 
[α]D20 = -22.7 (c = 1.66, acetone). – 1H NMR (CDCl3): δ = 2.23 (dt, J = 13.9/3.0 Hz, 1 H, 
NCHCH2), 2.56 (dd, J = 13.9/10.7 Hz, 1 H, NCHCH2), 2.87-2.95 (m, 2 H, NCH2CO and 
NCH2CH2), 2.98-3.05 (m, 1 H, NCH2CH2),  3.19-3.24 (m, 3 H, NCH2CO and  2 H of 
NCH2CH2), 3.63 (dd, J = 10.7/3.0 Hz, 1 H, NCH), 3.71 (s, 3 H, COOCH3), 3.79 (s, 9 H, 
ArOCH3), 3.81 (s, 3 H, Ar‘OCH3), 6.81-6.84 (m, 6 H, Haromat), 6.86-6.90 (m, 2 H, Haromat), 
7.31-7.35 (m, 6 H, Haromat), 7.37-7.40 (m, 2 H, Haromat). – MS; m/z (%): 333 (100) [Ar3C]+, 296 
(11), 227 (34). – IR: ~ν = 3476, 3036, 2950, 1733, 1608, 1582, 1508, 1250, 1034, 829 cm-1. – 
C37H41NO8 (627.73): calcd. C 70.80, H 6.58, N 2.23; found C 70.51, H 6.62, N 2.15. 
 
7) According to GP5-B from 113 mg (0.218 mmol) of (2S)-52b in 6 ml of Et2O and 0.78 ml 
(0.50 M in Et2O, 0.39 mmol) of 4-MeOC6H4MgBr; reaction: at –78 °C for 20 h; analytical 
HPLC (n-heptane/EtOAc/iso-propanol, 70:30:1.0; 1.3 ml/min) d.s: (2S,4S) / (2S,4R) = 85:15 
[(2S,4S) tR = 17.7 min, (2S,4R) tR = 23.5 min]; purification by CC (φ 18 × 230; n-
heptane/acetone, 2:1) and separation by prep. HPLC (n-heptane/EtOAc, 60:40; 12 ml/min) 
gave 55 mg (40%) of (2S,4S)-53b (tR = 31.1 min) and 7 mg (5%) of (2S,4R)-53b (tR = 45.2 
min). 
 
Methyl (2R,4S)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)-methoxy]-
1-ethyl}pyrrolidine-2-carboxylate [(2R,4S)-53b] and  
methyl (2R,4R)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)-methoxy]-
1-ethyl}pyrrolidine-2-carboxylate [(2R,4R)-53b] 
N
OH
OMe
O
OMeMeO
OMe
COOCH3 N
OH
OMe
O
OMeMeO
OMe
COOCH3
  
                                        (2R,4S)-53b                                 (2R,4R)-53b 
 
                                                          6. Experimental Section……………    ………….. - 137 - 
9) According to GP5-A from 165 mg (0.669 mmol) of CeCl3 and 1.40 ml (0.48 M in THF, 
0.67 mmol) of 4-MeOC6H4MgBr in 10 ml of THF; 248 mg (0.478 mmol) of (2R)-52b in 10 
ml of THF; reaction: at –60 °C for 20 h. Analytical HPLC (n-heptane/EtOAc/iso-propanol, 
70:30:1.0; 1.3 ml/min) d.s: (2R,4R) / (2R,4S) = 45:55 [(2R,4R) tR = 17.5 min, (2R,4S) tR = 
22.9 min]. Purification by CC (φ 25 × 265; n-heptane/acetone, 2:1) and separation by prep. 
HPLC (n-heptane/EtOAc, 60:40; 12 ml/min) yielded (2R,4R)-53b (tR = 29.3 min) and 
(2R,4S)-53b (tR = 43.7 min); 19 mg of the starting ketone was recovered. 
 
(2R,4R)-53b: 57 mg (19%); colorless viscous oil. – TLC: Rf = 0.19 (n-heptane/EtOAc, 50:50). 
– [α]D23 = +7.6 (c = 0.93, acetone). The spectra (1H NMR, IR, and MS) were identical with 
those of (2R,4R)-53b. – (C37H41NO8 (627.73): calcd. C 70.80, H 6.58, N 2.23; found C 70.47, 
H 6.62, N 2.13. 
(2R,4S)-53b: 63 mg (21%); colorless oil. – TLC: Rf = 0.23 (n-heptane/EtOAc, 50:50). – 
[α]D24 = +22.9 (c = 1.12, acetone). The spectra (1H NMR, IR, and MS) were identical with 
those of (2S,4R)-53b. – C37H41NO8 (627.73): calcd. C 70.80, H 6.58, N 2.23; found C 70.61, 
H 6.58, N 2.15.   
 
Methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
carboxylate [(2S,4R)-61] 
N
OH
OMe
COOCH3
COOCH2Ph
 
According to GP5-A from 330 mg (1.34 mmol) of CeCl3 and 2.80 ml (0.48 M in THF, 1.34 
mmol) of 4-MeOC6H4MgBr in 20 ml of THF, 354 mg (1.28 mmol) of (2S)-60 in 5 ml of 
THF; reaction: at – 60 °C for 4.5 h; purification by CC (φ 25 × 270; n-heptane/acetone, 3:1). 
61 mg of the starting ketone was recovered. Yield: 276 mg (56%); colorless oil. – TLC: Rf = 
0.35 (n-heptane/acetone, 3:2). – [α]D20 = -23.5 (c = 1.36, EtOAc). – 1H NMR (C6D5NO2, 120 
°C): δ = 2.51 (dd, J = 13.6/1.8 Hz, 1 H, NCHCH2), 2.83 (ddd, J = 13.6/9.7/1.5 Hz, 1 H, 
NCHCH2), 3.78-3.81 (m, 6 H, COOCH3 and ArOCH3), 3.93 (dd, J = 11.4/1.5 Hz, 1 H, 
NCH2), 4.07 (dd, J = 11.4/1.3 Hz, 1 H, NCH2), 4.77 (dd, J = 9.7/1.3 Hz, 1 H, NCH), 5.23 (d, J 
= 12.6 Hz, 1 H, PhCH2), 5.32 (d, J = 12.6 Hz, 1 H, PhCH2), 6.89-6.94 (m, 2 H, Haromat), 7.27-
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7.50 (m, 7 H, Haromat). – IR: ~ν = 3438, 3063, 2951, 1756, 1706, 1610, 1514, 1418, 1251, 832, 
770, 699 cm-1. – MS; m/z (%): 385 (2) [M+1]+, 368 (62), 324 (100), 250 (18), 234 (21), 135 
(18), 91 (90). – C21H23NO6 (385.42): calcd. C 65.44, H 6.02, N 3.63; found C 65.11, H 6.19, 
N 3.70.   
 
Methyl (2R,4S)-1-benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
carboxylate [(2R,4S)-61] 
N
OH
OMe
COOCH3
COOCH2Ph
 
According to GP5-A from 399 mg (1.62 mmol) of CeCl3 and 3.38 ml (0.48 M in THF, 1.62 
mmol) of 4-MeOC6H4MgBr in 25 ml of THF, 427 mg (1.54 mmol) of (2R)-60; reaction: at –
60 °C for 5.5 h; purification by CC (φ 30 × 250; n-heptane/acetone, 3:1). 84 mg of the starting 
ketone was recovered. Yield: 265 mg (45%); colorless oil. – TLC: Rf = 0.35 (n-heptane/ 
acetone, 3:2). – [α]D20 = +24.8 (c = 1.08, EtOAc). The spectra (1H NMR, IR, and MS) were 
identical with those of (2S,4R)-61. – C21H23NO6 (385.42): calcd. C 65.44, H 6.02, N 3.63; 
found C 65.48, H 6.16, N 3.57. 
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Methyl (2S,4R)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-
ethyl}pyrrolidine-2-acetate [(2S,4R)-102b] and  
methyl (2S,4S)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-
ethyl}pyrrolidine-2-acetate [(2S,4S)-102b] 
  
N
OH
OMe
COOCH3
O
OMeMeO
OMe
N
OH
OMe
COOCH3
O
OMeMeO
OMe
 
                                      (2S,4R)-102b                                (2S,4S)-102b        
 
1) According to GP5-B from 115 mg (0.216 mmol) of (2S)-100b in 11 ml of Et2O, 0.88 ml 
(0.44 M in Et2O, 0.39 mmol) of 4-MeOC6H4MgBr; reaction: at –78 °C for 20 h; analytical 
HPLC (n-heptane/EtOAc/iso-propanol, 54:45:1.2; 1.3 ml/min) d.s: (2S,4S) / (2S,4R) = 81:19 
[(2S,4S) tR = 9.1 min, (2S,4R) tR = 13.8 min]. Purification by CC (φ 25 × 210; n-
heptane/acetone, 3:1) and separation by prep. HPLC (n-heptane/EtOAc/iso-propanol, 
54:45:1.2; 12 ml/min) yielded (2S,4S)-102b (tR = 19.4 min) and (2S,4R)-102b (tR = 29.0 min). 
38 mg of (2S)-100b was recovered. 
 
(2S,4S)-102b: 65 mg (47%); colorless oil. – TLC: Rf = 0.28 (n-heptane/EtOAc/iso-propanol, 
54:45:1.2). – [α]D20 = -14.4 (c = 0.95, acetone). – 1H NMR (CDCl3): δ = 2.05 (dd, J = 
13.0/9.6 Hz, 1 H, CH2CHCH2COO), 2.28-2.37 (m, 2 H, CH2CHCH2COO and CH2COO), 
2.69-2.77 (m, 2 H, NCH2CH2 and CH2COO), 2.82 (d, J = 10.9 Hz, 1 H, NCH2CO), 2.99-3.06 
(m, 1 H, NCH2CH2), 3.10-3.20 (m, 2 H, NCH2CH2), 3.43 (d, J = 10.9 Hz, 1 H, NCH2CO), 
3.44-3.51 (m, 1 H, NCH), 3.63 (s, 3 H, COOCH3), 3.77 (s, 9 H, Ar’OCH3), 3.79 (s, 3 H, 
ArOCH3), 6.78-6.82 (m, 6 H, Haromat), 6.83-6.86 (m, 2 H, Haromat), 7.31-7.35 (m, 6 H, Haromat), 
7.36-7.40 (m, 2 H, Haromat). – IR: ~ν  = 3462, 3030, 2951, 1732, 1608, 1581, 1509, 1249, 1176, 
1034, 829 cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 260 (14), 227 (41), 186 (5), 101 (12). – 
C38H43NO8 (641.77): calcd. C 71.12, H 6.75, N 2.18; found C 71.10, H 6.86, N 2.11.  
 
(2S,4R)-102b: 20 mg (14%); colorless oil. – TLC: Rf = 0.23 (n-heptane/EtOAc/iso-propanol, 
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54:45:1.2). – [α]D20 = -36.8 (c = 0.88, acetone). – 1H NMR (CDCl3): δ = 2.08 (ddd, J = 
14.1/5.2/1.8 Hz, 1 H, CH2CHCH2COO), 2.51-2.61 (m, 4 H, CH2CHCH2COO, CH2COO, 
NCH2CH2 and NCH2CO), 2.72 (dd, J = 16.0/3.5 Hz, 1 H, CH2COO), 2.99-3.08 (m, 2 H, 
NCH2CH2 and NCH), 3.12-3.25 (m, 3 H, NCH2CO and 2 H of NCH2CH2), 3.55 (s, 1 H, OH), 
3.64 (s, 3 H, COOCH3), 3.77 (s, 9 H, Ar’OCH3), 3.79 (s, 3 H, ArOCH3), 6.80-6.88 (m, 8 H, 
Haromat), 7.30-7.34 (m, 6 H, Haromat), 7.35-7.39 (m, 2 H, Haromat). – IR: ~ν  = 3481, 3000, 1732, 
1607, 1580, 1508, 1248, 1034, 829 cm-1. – MS; m/z (%): 334 (41), 333 (100) [Ar3C]+, 280 
(16), 260 (12), 227 (100), 218 (25), 101 (7). – C38H43NO8 (641.77): calcd. C 71.12, H 6.75, N 
2.18; found C 71.06, H 7.08, N 2.14.           
 
2) According to GP5-A from 110 mg (0.45 mmol) of CeCl3 and 0.93 ml (0.48 M in THF, 0.45 
mmol) of 4-MeOC6H4MgBr in 8 ml of THF; 170 mg (0.320 mmol) of (2S)-100b in 4 ml of 
THF; reaction: at –78 °C for 20 h; analytical HPLC (n-heptane/EtOAc/iso-propanol, 
54:45:1.2; 1.3 ml/min) d.s: (2S,4S) / (2S,4R) = 17:83 [(2S,4S) tR = 10.0 min, (2S,4R) tR = 14.1 
min]; purification by CC (φ 25 × 220; n-heptane/acetone, 3:1) and separation by prep. HPLC 
yielded 11 mg (5%) of (2S,4S)-102b (tR = 20.4 min) and 88 mg (43%) of (2S,4R)-102b (tR = 
28.0 min). 35 mg of (2S)-100b was recovered. 
 
Ethyl (2R,4R)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-
ethyl}pyrrolidine-2-acetate [(2R,4R)-103b] and 
ethyl (2R,4S)-4-hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-
ethyl}pyrrolidine-2-acetate [(2R,4S)-103b]  
N
OH
COOC2H5
OMe
O
OMeMeO
OMe
N
OH
COOC2H5
OMe
O
OMeMeO
OMe
 
                                         (2R,4R)-103b                                 (2R,4S)-103b         
 
1) According to GP5-B from 185 mg (0.338 mmol) of (2R)-101b in 12 ml of Et2O, 1.38 ml 
(0.44 M in Et2O, 0.61 mmol) of 4-MeOC6H4MgBr; reaction: at –78 °C for 20 h; analytical 
 
                                                          6. Experimental Section……………    ………….. - 141 - 
HPLC (n-heptane/EtOAc/iso-propanol, 60:40:1.2; 1.3 ml/min) d.s: (2R,4R) / (2R,4S) = 79:21 
[(2R,4R) tR = 10.5 min, (2R,4S) tR = 12.4 min]. Purification by CC (φ 25 × 230; n-
heptane/acetone, 3:2) and separation by prep. HPLC (n-heptane/EtOAc/iso-propanol, 
60:40:0.88; 12 ml/min) yielded (2R,4R)-103b (tR = 22.5 min) and (2R,4S)-103b (tR = 31.3 
min). 58 mg of (2R)-101b was recovered. 
 
(2R,4R)-103b: 111 mg (50%); colorless oil. – TLC: Rf = 0.31 (n-heptane/acetone, 3:2). – 
[α]D20 = +14.6 (c = 2.18, EtOAc). – 1H NMR (CDCl3): δ = 1.25 (t, J = 7.1 Hz, 3 H, CH2CH3), 
2.10 (br. s, 1 H, OH), 2.05 (dd, J = 13.1/9.7 Hz, 1 H, CH2CHCH2COO), 2.28-2.35 (m, 2 H, 
CH2CHCH2COO and CH2COO), 2.67-2.77 (m, 2 H, NCH2CH2 and CH2COO), 2.82 (d, J = 
10.8 Hz, 1 H, NCH2CO), 3.00-3.07 (m, 1 H, NCH2CH2), 3.10-3.20 (m, 2 H, NCH2CH2), 3.42 
(d, J = 10.8 Hz, 1 H, NCH2CO), 3.44-3.51 (m, 1 H, NCH), 3.77 (s, 9 H, Ar’OCH3), 3.79 (s, 3 
H, ArOCH3), 4.05-4.13 (m, 2 H, CH2CH3), 6.77-6.81 (m, 6 H, Haromat), 6.82-6.86 (m, 2 H, 
Haromat), 7.31-7.35 (m, 6 H, Haromat), 7.36-7.40 (m, 2 H, Haromat). – IR: ~ν  = 3492, 2933, 1729, 
1608, 1508, 1249, 1034, 828 cm-1. – MS; m/z (%): 333 (100) [Ar3C]+, 227 (52), 105 (24). – 
C39H45NO8 (655.80): calcd. C 71.43, H 6.92, N 2.14; found C 71.17, H 6.92, N 2.08. 
 
(2R,4S)-103b: 33 mg (15%); colorless oil. – TLC: Rf = 0.31 (n-heptane/acetone, 3:2). – [α]D20 
= +36.5 (c = 0.85, EtOAc). – 1H NMR (CDCl3): δ = 1.22 (t, J = 7.2 Hz, 3 H, CH2CH3), 2.08 
(dd, J = 14.1/5.2/1.8 Hz, 1 H, CH2CHCH2COO), 2.51-2.60 (m, 4 H, CH2CHCH2COO, 
CH2COO, NCH2CH2 and NCH2CO), 2.72 (dd, J = 15.9/3.3 Hz, 1 H, CH2COO), 2.99-3.08 (m, 
2 H, NCH2CH2 and NCH), 3.12-3.25 (m, 3 H, NCH2CO and 2 H of NCH2CH2), 3.54 (s, 1 H, 
OH), 3.77 (s, 9 H, Ar’OCH3), 3.79 (s, 3 H, ArOCH3), 4.05-4.16 (m, 2 H, CH2CH3), 6.80-6.88 
(m, 8 H, Haromat), 7.30-7.34 (m, 6 H, Haromat), 7.35-7.39 (m, 2 H, Haromat). – IR: ~ν  = 3462, 
3036, 2952, 1728, 1608, 1508, 1249, 1176, 1034, 828 cm-1. – MS; m/z (%): 333 (100) 
[Ar3C]+, 324 (10), 227 (55), 105 (74). – C39H45NO8 (655.80): calcd. C 71.43, H 6.92, N 2.14; 
found C 71.43, H 7.17, N 2.05. 
 
 
2) According to GP5-A from 76 mg (0.31 mmol) of CeCl3 and 0.63 ml (0.48 M in THF, 0.30 
mmol) of 4-MeOC6H4MgBr in 5 ml of THF, 119 mg (0.217 mmol) of (2R)-101b in 4 ml of 
THF; reaction: at –78 °C for 20 h. Purification by CC (φ 25 × 260; iso-hexane/acetone, 3:1) 
and separation by prep. HPLC (n-heptane/EtOAc/iso-propanol, 60:40:0.88; 12 ml/min.) 
yielded 2 mg (1%) of (2R,4R)-103b (tR = 23.0 min) and 63 mg (44%) of (2R,4S)-103b (tR = 
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30.4 min). 20 mg of (2R)-101b was recovered. 
 
Methyl (2S,4R)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxy-
phenyl)pyrrolidine-2-acetate [(2S,4R)-102c] and  
methyl (2S,4S)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxy-
phenyl)pyrrolidine-2-acetate [(2S,4S)-102c] 
 
N
OH
OMe
COOCH3
S S
N
OH
OMe
COOCH3
S S
 
                                     (2S,4R)-102c                         (2S,4S)-102c 
 
1) According to GP5-B from 136 mg (0.337 mmol) of (2S)-100c in 17 ml of Et2O, 1.53 ml 
(0.44 M in Et2O, 0.67 mmol) of 4-MeOC6H4MgBr; reaction: at -78 °C for 20 h; analytical 
HPLC (n-heptane/EtOAc/iso-propanol, 75:25:0.5; 1.3 ml/min) d.s: (2S,4S) / (2S,4R) = 87:13 
[(2S,4S) tR = 17.0 min, (2S,4R) tR = 20.5 min]. Purification by CC (φ 25 × 200; n-
heptane/acetone, 3:1) and separation by prep. HPLC (n-heptane/EtOAc/iso-propanol, 
75:25:0.5; 12 ml/min) yielded (2S,4S)-102c (tR = 36.5 min) and (2S,4R)-102c (tR = 49.6 min). 
33 mg of (2S)-100c was recovered. 
 
(2S,4S)-102c: 81 mg (47%); colorless oil. – TLC: Rf = 0.36 (n-heptane/acetone, 3:2). – [α]D20 
= -50.4 (c = 1.09, CHCl3). – 1H NMR (CDCl3): δ = 2.00 (s, 3 H, thienyl-CH3), 2.02 (s, 3 H, 
thienyl-CH3), 2.04 (dd, J = 13.2/9.5 Hz, 1 H, CH2CHCH2COO), 2.27-2.35 (m, 4 H, 
CH2CHCH2COO, CH2COO and 2 H of NCH2CH2), 2.54-2.61 (m, 1 H, NCH2CH2), 2.67-2.72 
(m, 2 H, CH2COO and NCH2CO), 2.90 (dt, J = 12.0/8.0 Hz, 1 H, NCH2CH2), 3.35-3.42 (m, 2 
H, NCH2CO and NCH), 3.64 (s, 3 H, COOCH3), 3.78 (s, 3 H, ArOCH3), 6.09 (t, J = 7.2 Hz, 1 
H, =CHCH2), 6.76 (d, J = 5.2 Hz, 1 H, SCH), 6.82-6.86 (m, 3 H, SCH and 2 H of Haromat), 
7.05 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.19 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.37-7.41 (m, 2 H, 
Haromat). – IR: ~ν  = 3493, 3090, 2950, 1732, 1613, 1514, 1249, 833, 713 cm-1. – MS; m/z (%): 
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512 (13) [M+1]+, 494 (10), 480 (2), 278 (100), 260 (24), 248 (10), 101 (2). – C28H33NO4S2 
(511.70): calcd. C 65.72, H 6.50, N 2.74, S 12.53; found C 65.97, H 6.84, N 2.56, S 12.35. 
  
(2S,4R)-102c: 19 mg (11%); colorless crystals. – M.p. 99-100 °C (iPr2O). – TLC: Rf = 0.33 
(n-heptane/acetone, 3:2). – [α]D20 = +73.1 (c = 1.00, CHCl3). – 1H NMR (CDCl3): δ = 2.00 (s, 
3 H, thienyl-CH3), 2.03 (s, 3 H, thienyl-CH3), 2.09 (ddd, J = 14.2/5.2/2.0 Hz, 1 H, 
CH2CHCH2COO), 2.29-2.37 (m, 2 H, NCH2CH2), 2.39-2.46 (m, 2 H, NCH2CH2 and 
NCH2CO), 2.50-2.60 (m, 2 H, CH2CHCH2COO and CH2COO), 2.73 (dd, J = 15.7/3.5 Hz, 1 
H, CH2COO), 2.90-3.02 (m, 2 H, NCH2CH2 and NCH), 3.13 (dd, J = 9.4/2.0 Hz, 1 H, 
NCH2CO), 3.42 (s, 1 H, OH), 3.66 (s, 3 H, COOCH3), 3.79 (s, 3 H, ArOCH3), 6.08 (t, J = 7.2 
Hz, 1 H, =CHCH2), 6.76 (d, J = 5.2 Hz, 1 H, SCH), 6.83 (d, J = 5.2 Hz, 1 H, SCH), 6.84-6.88 
(m, 2 H, Haromat), 7.05 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.20 (d, J = 5.2 Hz, 1 H, SCH=CH), 
7.36-7.40 (m, 2 H, Haromat). – MS; m/z (%): 512 (14), 494 (15), 480 (5), 420 (18), 278 (100), 
260 (43), 248 (12), 186 (6). – IR: ~ν  = 3523, 3090, 2938, 1731, 1514, 1511, 1246, 1167, 838, 
806, 710 cm-1. – C28H33NO4S2 (511.70): calcd. C 65.72, H 6.50, N 2.74, S 12.53; found C 
66.07, H 6.70, N 2.70, S 12.48. 
 
2) According to GP5-A from 127 mg (0.521 mmol) of CeCl3 and 1.1 ml (0.48 M in THF, 0.52 
mmol) of 4-MeOC6H4MgBr in 8 ml of THF, 150 mg (0.372 mml) of (2S)-100c in 7 ml of 
THF; reaction: at –78 °C for 20 h; analytical HPLC (n-heptane/EtOAc/iso-propanol, 
75:25:0.5; 1.3 ml/min) d.s: (2S,4S) / (2S,4R) = 21:79 [(2S,4S) tR = 16.7 min, (2S,4R) tR 19.6 
min;]. Purification by CC (φ 25 × 230; n-heptane/acetone, 3:1) and separation by prep. HPLC 
(n-heptane/EtOAc/iso-propanol, 75:25:0.5; 12 ml/min) yielded 16 mg (8%) of (2S,4S)-102c 
(tR = 39.1 min), and 45 mg (24%) of (2S,4R)-102c  (tR = 46.2 min). 52 mg of (2S)-100c was 
recovered. 
 
Ethyl (2R,4S)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxy-
phenyl)pyrrolidine-2-acetate [(2R,4S)-103c] and 
ethyl (2R,4R)-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxy-
phenyl)pyrrolidine-2-acetate [(2R,4R)-103c] 
 
1) According to GP5-A from 117 mg (0.280 mmol) of (2R)-101c in 10 ml of Et2O, 1.2 ml 
(0.44 M in Et2O, 0.51 mmol) of 4-MeOC6H4MgBr; reaction: at –78 °C for 20 h. Purification 
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N
OH
COOC2H5
SS
OMe
N
OH
COOC2H5
SS
OMe
                                    (2R,4S)-103c                        (2R,4R)-103c 
 
by CC (φ 25 × 210; n-heptane/acetone, 3:1) and separation by prep. HPLC (n-heptane/ 
EtOAc/iso-propanol, 80:20:0.5; 12 ml/min) yielded (2R,4R)-103c (tR = 38.6 min) and 
(2R,4S)-103c (tR = 45.9 min). 12 mg of (2R)-101c was recovered.  
 
(2R,4R)-103c: 79 mg (54%); colorless oil. – TLC: Rf = 0.36 (n-heptane/acetone, 3:2). – [α]D20 
= +51.0 (c = 1.07, CHCl3). – 1H NMR (CDCl3): δ = 1.23 (t, J = 7.1 Hz, 3 H, CH2CH3), 2.00 
(s, 3 H, thienyl-CH3), 2.02 (s, 3 H, thienyl-CH3), 2.00-2.07 (m, 1 H, CH2CHCH2COO), 2.26-
2.34 (m, 4 H, CH2COO, CH2CHCH2COO and 2 H of NCH2CH2), 2.53-2.61 (m, 1 H, 
NCH2CH2), 2.65-2.72 (m, 2 H, CH2COO and NCH2CO), 2.91 (dt, J = 12.0/8.0 Hz, 1 H, 
NCH2CH2), 3.34-3.42 (m, 2 H, NCH2CO and NCH), 3.78 (s, 3 H, ArOCH3), 4.11 (q, J = 7.1 
Hz, CH2CH3), 6.09 (t, J = 7.2 Hz, 1 H, =CHCH2), 6.76 (d, J = 5.2 Hz, 1 H, SCH), 6.82-6.87 
(m, 3 H, SCH and Haromat), 7.05 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.19 (d, J = 5.2 Hz, 1 H, 
SCH=CH), 7.37-7.41 (m, 2 H, Haromat). – IR: ~ν  = 3482, 3061, 2932, 1732, 1611, 1513, 833, 
714 cm-1. – MS; m/z (%): 526 (18) [M+1]+, 508 (22), 292 (100), 274 (56), 105 (21). – 
C29H35NO4S2 (525.73): calcd. C 66.25, H 6.71, N 2.66, S 12.20; found C 66.50, H 6.79, N 
2.51, S 11.89. 
 
(2R,4S)-103c: 14 mg (10%); colorless oil. – TLC: Rf = 0.36 (n-heptane/acetone, 3:2). – [α]D20 
= -77.9 (c = 0.67, CHCl3). – 1H NMR (CDCl3): δ = 1.24 (t, J = 7.3 Hz, 3 H, CH2CH3), 1.99 (s, 
3 H, thienyl-CH3), 2.03 (s, 3 H, thienyl-CH3), 2.09 (ddd, J = 14.2/5.2/2.0 Hz, 1 H, 
CH2CHCH2COO), 2.30-2.37 (m, 2 H, NCH2CH2), 2.39-2.46 (m, 2 H, NCH2CH2 and 
NCH2CO), 2.50-2.60 (m, 2 H, CH2CHCH2COO and CH2COO), 2.73 (dd, J = 15.7/3.5 Hz, 1 
H, CH2COO), 2.90-3.02 (m, 2 H, NCH2CH2 and NCH), 3.12 (dd, J = 9.4/2.0 Hz, 1 H, 
NCH2CO), 3.43 (s, 1 H, OH), 3.79 (s, 3 H, ArOCH3), 4.09-4.17 (m, 2 H, CH2CH3), 6.07 (t, J 
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= 7.2 Hz, 1 H, =CHCH2), 6.76 (d, J = 5.0 Hz, 1 H, SCH), 6.82-6.88 (m, 3 H, SCH and 2 H of 
Haromat), 7.05 (d, J = 5.0 Hz, 1 H, SCH=CH), 7.20 (d, J = 5.0 Hz, 1 H, SCH=CH), 7.36-7.40 
(m, 2 H, Haromat). – IR: ~ν  = 3468, 3061, 2932, 1713, 1611, 1513, 833, 713 cm-1. – MS; m/z 
(%): 527.1 (100) [M+1]+, 526.7 (80), 508 (63), 494.3 (18), 420 (29). – C29H35NO4S2 (525.73): 
calcd. C 66.25, H 6.71, N 2.66, S 12.20; found C 66.28, H 6.86, N 2.56, S 11.99. 
 
2) According to GP5-A from 146 mg (0.601 mmol) of CeCl3 and 1.30 ml (0.48 M in THF, 
0.60 mmol) of 4-MeOC6H4MgBr in 12 ml of THF, 176 mg (0.421 mmol) of (2R)-101c in 6 
ml of THF; reaction: at –78 °C for 20 h; analytical HPLC  d.s: (2R,4R) / (2R,4S) = 19:81 
[(2R,4R) tR = 13.9 min, (2R,4S) tR = 17.7 min; n-heptane/EtOAc/iso-propanol, 75:25:0.5; 1.3 
ml/min]. Purification by CC (φ 25 × 200; iso-hexane/acetone, 3:1) and separation by prep. 
HPLC (n-heptane/EtOAc/iso-propanol, 80:20:0.5, 12 ml/min.) yielded 16 mg (7%) of 
(2R,4R)-103c (tR = 40.5 min), and 55 mg (25%) of (2R,4S)-103c (tR = 45.6 min). 46 mg of 
(2R)-101c was recovered. 
 
Methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
acetate [(2S,4R)-109] 
N
OH
COOCH2Ph
OMe
COOCH3
 
1) According to GP5-B from 168 mg (0.611 mmol) of (2S)-108 in 30 ml of Et2O, 1.53 ml 
(0.44 M in Et2O, 0.67 mmol) of 4-MeOC6H4MgBr; reaction: at –78 °C for 4 h; purification by 
CC (φ 25 × 220; n-heptane/acetone, 80:20) and separation by prep. HPLC (n-
heptane/EtOAc/iso-propanol, 78:22:0.5; tR = 64.2 min; 12 ml/min). 91 mg of (2S)-108 was 
recovered. Yield: 92 mg (38%); colorless oil. – TLC: Rf = 0.35 (n-heptane/acetone, 3:2). – 
[α]D20 = -29.1 (c = 0.95, CHCl3). – 1H NMR (C6D5NO2, 120 °C): δ = 2.40 (d, J = 13.7 Hz, 1 
H, CH2CHCH2COO), 2.68 (dd, J = 13.7/9.1 Hz, 1 H, CH2CHCH2COO), 2.78 (s, 1 H, OH), 
3.17 (dd, J = 15.4/3.3 Hz, 1 H, CH2COO), 3.32 (dd, J = 15.4/3.3 Hz, 1 H, CH2COO), 3.70 (s, 
3 H, ArOCH3), 3.76 (s, 3 H, COOCH3), 3.90-4.00 (m, 1 H, NCH), 4.56-4.64 (m, 1 H, 
CHOH), 5.29, 5.34 (2s, 2 H, CH2Ph), 6.86-6.91 (m, 2 H, Haromat), 7.25-7.48 (m, 7 H, Haromat). 
– IR: ~ν  = 3440, 3031, 2952, 1734, 1700, 1610, 1515, 1416, 1252, 832, 771, 698 cm-1. – MS; 
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m/z (%): 382 (100), 368 (78), 338 (31), 324 (83), 15 (11). – C22H25NO6 (399.45): calcd. C 
66.15, N 3.51, H 6.31; found C 66.45, N 3.44, H 6.67. 
 
2) According to GP5-A from 193 mg (0.784 mmol) of CeCl3, 1.63 mmol (0.48 M in THF, 
0.78 mmol) of 4-MeOC6H4MgBr in 10 ml of THF, 198 mg (0.680 mmol) of (2S)-108 in 5 ml 
of THF; reaction: at –60 °C for 20 h; purification by (φ 25 × 230; n-heptane/acetone, 3:1) and 
separation by prep. HPLC (n-heptane/EtOAc/iso-propanol, 78:22:0.5; tR = 64.6 min; 12 
ml/min). 22 mg of (2S)-108 was recovered. Yield: 91 mg (34%). 
 
Ethyl (2R,4S)-1-benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
acetate [(2R,4S)-113] 
N
OH
COOC2H5
COOCH2Ph
OMe
 
According to GP5-B from 120 mg (0.393 mmol) of (2R)-112 and 0.94 ml (0.44 M in Et2O, 
0.41 mmol) of 4-MeOC6H4MgBr in 20 ml of Et2O; reaction: at –78 °C for 20 h; purification 
by CC (φ 25 × 195; n-heptane/acetone, 3:1) and separation by prep. HPLC (n-
heptane/EtOAc/iso-propanol, 78:22:0.5; tR = 47.4 min; 12 ml/min). 54 mg of (2R)-112 was 
recovered. Yield: 60 mg (37%); colorless oil. – TLC: Rf = 0.35 (n-heptane/acetone, 3:2). – 
[α]D20 = +26.1 (c = 1.05, CHCl3). – 1H NMR (C6D5NO2, 120 °C): δ = 1.22-1.29 (m, 3 H, 
CH2CH3), 2.43 (d, J = 13.7 Hz, 1 H, CH2CHCH2COO), 2.65-2.72 (m, 1 H, CH2CHCH2COO), 
2.80 (s, 1 H, OH), 3.18 (dd, J = 15.4/3.3 Hz, 1 H, CH2COO), 3.27-3.34 (m, 1 H, CH2COO), 
3.76, 3.78 (2s, 3 H, ArOCH3), 3.91-4.00 (m, 1 H, NCH), 4.17-4.24 (m, 2 H, CH2CH3), 4.57-
4.65 (m, 1 H, CHOH), 5.30, 5.34 (2s, 2 H, CH2Ph), 6.86-6.90 (m, 2 H, Haromat), 7.26-7.48 (m, 
7 H, Haromat). – IR: ~ν  = 3440, 3034, 2954, 1730, 1700, 1610, 1416, 831, 770, 698 cm-1. – MS; 
m/z (%): 396 (43), 368 (34), 324 (42), 105 (15). – C23H27NO6 (413.48): calcd. C 66.81, H 
6.58, N 3.39; found C 66.95, H 6.77, N 3.20. 
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 6.1.7    Hydrolysis of ester functions of N-protected pyrrolidine derivatives 
 
General procedure 6 (GP6): 
 
The respective ester (1 equiv.) was hydrolyzed with 1.0 M NaOH (2.05-4.10 equiv.) in MeOH 
(10-50 ml/mmol) at r.t. for the time given. After MeOH had been removed in vacuo, the 
residue was dissolved in a small amount of water and then acidified to pH 1-2 with aq. 1.0 M 
HCl. The mixture was extracted with CH2Cl2 and the combined extracts were dried (Na2SO4) 
and evaporated to yield the carboxylic acid. 
 
 (2S,4R)-1-Benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylic 
acid [(2S,4R)-62] 
N
OH
OMe
COOCH2Ph
COOH
 
According to GP6 from 131 mg (0.340 mmol) of (2S,4R)-61, 1.02 ml (1.02 mmol) of aq. 1.0 
M NaOH in 4 ml of MeOH; reaction time: 3 h. Yield: 111 mg (88%); colorless foam. – M.p. 
62-65 °C. – [α]D20 = -25.0 (c = 1.00, MeOH). – 1H NMR (C6D5NO2, 120 °C): δ = 2.74-2.89 
(m, 2 H, NCHCH2), 3.77 (s, 3 H, ArOCH3), 3.91 (d, J = 11.0 Hz, 1 H, NCH2), 4.09 (d, J = 
11.0 Hz, 1 H, NCH2), 4.88 (d, J = 9.4 Hz, 1 H, NCH), 5.29-5.36 (m, 2 H, CH2Ph), 6.89-6.93 
(m, 2 H, Haromat), 7.26-7.52 (m, 7 H, Haromat). – IR: ~ν = 3420, 3060, 2955, 1705, 1611, 1516, 
1425, 1252, 832, 771, 698 cm-1. – MS; m/z (%): 370 (1) [M-1]+, 355 (10), 354 (46), 310 
(100), 236 (14), 220 (45), 218 (38), 174 (15), 135 (16). – C20H21NO6 (371.40): calcd. C 64.68, 
H 5.70, N 3.77; found C 64.85, H 5.42, N 3.53. 
 
(2R,4S)-1-Benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylic 
acid [(2R,4S)-62] 
N
OH
OMe
COOCH2Ph
COOH
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According to GP6 from 107 mg (0.278 mmol) of (2R,4S)-61, 0.83 ml (0.83 mmol) of aq. 1.0 
M NaOH in 4.2 ml of MeOH; reaction time: 4 h. Yield: 83 mg (80%); colorless foam. – M.p. 
58-62 °C. – [α]D20 = +25.8 (c = 0.64, MeOH). The spectra (1H NMR, IR, and MS) were 
identical with those of (2S,4R)-62. – C20H21NO6 (371.40): calcd. C 64.68, H 5.70, N 3.77; 
found C 64.74, H 5.93, N 3.56. 
 
(2S,4R)-1-Benzyloxycarbonyl-4-hydroxypyrrolidine-2-acetic acid [(2S,4R)-96]  
 
According to GP6 from 312 mg (1.06 mmol) of (2S,4R)-95. Yield: 290 mg (98%); colorless 
oil. – [α]D20 = -61.2 (c = 1.22, MeOH). All its analytical data were identical with those in the 
literature [40]. {ref. [40]: [α]D20 = - 62.4 (c = 3, MeOH)}. 
 
(2R,4R)-1-Benzyloxycarbonyl-4-hydroxypyrrolidine-2-acetic acid [(2R,4R)-96] 
N
OH
COOH
COOCH2Ph
 
According to GP6 from 86 mg (0.28 mmol) of (2R,4R)-73, 0.57 ml (0.57 mmol) of aq. 1.0 M 
NaOH in 3 ml of MeOH; reaction time: 23 h. Yield: 75 mg (91%); colorless oil. – [α]D20 = 
+17.2 (c = 1.41, MeOH). – 1H NMR (C6D5NO2, 120 °C): δ = 2.11-2.17 (m, 1 H, 
CH2CHCH2COO), 2.37-2.46 (m, 1 H, CH2CHCH2COO), 3.04 (dd, J = 15.8/8.9 Hz, 1 H, 
CH2COO), 3.28 (dd, J = 15.8/3.1 Hz, 1 H, CH2COO), 3.59-3.67 (m, 1 H, NCH2), 3.79-3.85 
(m, 1 H, NCH2), 4.44-4.51 (m, 1 H, NCH), 4.57-4.62 (m, 1 H, CHOH), 5.27 (s, 2 H, CH2Ph), 
7.25-7.46 (m, 5 H, Haromat). – IR: ~ν  = 3296, 2956, 1716, 1498, 1069, 769 cm-1. – MS; m/z 
(%): 279 (10) M+, 262 (100), 250 (17), 218 (20), 158 (7), 151 (12), 105 (16). – C14H17NO5 
(279.30): calcd. C 60.21, H 6.14, N 5.02; found C 60.41, H 6.34, N 4.82. 
 
(2S,4S)-1-Benzyloxycarbonyl-4-hydroxypyrrolidine-2-acetic acid [(2S,4S)-96] 
N
OH
COOH
COOCH2Ph
 
According to GP6 from 98 mg (0.38 mmol) of (1S,5S)-98, 0.77 ml (0.77 mmol) of aq. 1.0 M 
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NaOH in 8.3 ml of MeOH; reaction time: 4 d. Yield: 98 mg (94%); colorless oil. – [α]D20 = -
17.6 (c = 1.03, MeOH). The spectra (1H NMR, IR, and MS) were identical with those of 
(2R,4R)-45. – C14H17NO5 (279.30): calcd. C 60.21, H 6.14, N 5.02; found C 60.41, H 6.62, N 
4.86. 
 
(2R,4S)-1-Benzyloxycarbonyl-4-hydroxypyrrolidine-2-acetic acid [(2R,4S)-96] 
N
OH
COOH
COOCH2Ph
 
According to GP6 from 73 mg (0.22 mmol) of (2R,4S)-99, 0.89 ml (0.89 mmol) of aq. 1.0 M 
NaOH in 9.1 ml of MeOH; reaction time: 3 d. Yield: 60 mg (98%); colorless oil. – [α]D20 = 
+59.6 (c = 1.05, MeOH). – 1H NMR (C6D5NO2, 120 °C): δ = 2.10-2.20 (m, 1 H, 
CH2CHCH2COO), 2.36-2.44 (m, 1 H, CH2CHCH2COO), 2.72 (dd, J = 15.6/8.2 Hz, 1 H, 
CH2COO), 3.20 (dd, J = 15.6/3.8 Hz, 1 H, CH2COO), 3.70 (dd, J = 11.5/4.4 Hz, 1 H, NCH2), 
3.79 (d, J = 11.5 Hz, 1 H, NCH2), 4.53-4.62 (m, 2 H, CHOH and NCH), 5.25 (s, 2 H, CH2Ph), 
7.24-7.45 (m, 5 H, Haromat). – IR: ~ν  = 3423, 3032, 2926, 1704, 1418, 749 cm-1. – MS; m/z 
(%): 280 (44) [M+1]+, 250 (20), 236 (100), 146 (58), 128 (29). – C14H17NO5 (279.30): calcd. 
C 60.21, H 6.14, N 5.02; found C 60.37, H 6.65, N 4.87. 
 
(2S,4R)-1-Benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-acetic acid 
[(2S,4R)-110] 
 
N
OH
COOCH2Ph
OMe
COOH
 
According to GP6 from 93 mg (0.23 mmol) of (2S,4R)-109 and 0.48 ml (0.48 mmol) of aq. 
1.0 M NaOH in 4.5 ml of MeOH; reaction time: 4 d. Yield: 73 mg (81%); colorless foam. – 
[α]D20 = -30.0 (c = 0.80, MeOH). – 1H NMR (C6D5NO2, 120 °C): δ = 2.40-2.51 (m, 1 H, 
CH2CHCH2COO), 2.68-2.74 (m, 1 H, CH2CHCH2COO), 3.27 (dd, J = 16.0/8.9 Hz, 1 H, 
CH2COO), 3.41 (dd, J = 16.0/3.8 Hz, 1 H, CH2COO), 3.77 (s, 3 H, ArOCH3), 3.93 (d, J = 
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11.5 Hz, 1 H, NCH2), 4.00 (d, J = 11.5 Hz, 1 H, NCH2), 4.59-4.68 (m, 1 H, NCH), 5.26-5.33 
(m , 2 H, CH2Ph), 6.85-6.91 (m, 2 H, Haromat), 7.25-7.51 (m, 7 H, Haromat). – IR: ~ν  = 3424, 
3031, 2954, 1702, 1677, 1611, 1421, 832, 770, 698 cm-1. – MS; m/z (%): 368 (80), 324 (100), 
300 (46), 256 (70), 234 (48), 174 (31). – C21H23NO6 (385.42): calcd. C 65.44, H 6.02, N 3.63; 
found C 65.22, H 6.14, N 3.40.      
 
(2R,4S)-1-Benzyloxycarbonyl-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-acetic acid 
[(2R,4S)-110] 
N
OH
COOCH2Ph
OMe
COOH
 
According to GP6 from 40 mg (0.097 mmol) of (2R,4S)-112 and 0.20 ml (0.20 mmol) of aq. 
1.0 M NaOH in 2.8 ml of MeOH; reaction: 4 d. Yield: 34 mg (91%); colorless foam. – [α]D20 
= +29.2 (c = 0.49, MeOH). The spectra (1H NMR, IR, and MS) were identical with those of 
(2S,4R)-56. – C21H23NO6 (385.42): calcd. C 65.44, H 6.02, N 3.63; found C 65.56, H 6.32, N 
3.37. 
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6.1.8   N-Deprotection of pyrrolidine derivatives by hydrogenolysis 
 
General procedure 8 (GP8) 
 
A) To a solution of the respective N-protected pyrrolidine (1 equiv.) and TEA (0.33-20 
equiv.) in MeOH or EtOAc (40-50 ml/mmol)), 10% Pd-C (0.5-1.0 to the substrate, w/w) was 
added. This mixture was subjected to hydrogen at r.t. under ambient pressure for the time 
given. The reaction mixture was filtrated and evaporated to give its N-deprotected amine. 
 
B) General procedure B (GP8-B) was identical with A (GP8-A) except that no TEA was 
used. 
  
(2S,4R)-4-Hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylic acid [(2S,4R)-63] 
N
OH
H
COOH
OMe
 
According to GP8-A from 140 mg (0.377 mmol) of (2S,4R)-62 and 12 mg (0.12 mmol) of 
TEA in 17 ml of MeOH, 70 mg (0.066 mmol) of 10% Pd-C; reaction time: 1.5 h. Yield: 82 
mg (92%); colorless crystals. – M.p. 244-247 °C (MeOH, decomp.). – [α]D20 = +0.7 (c = 0.45, 
H2O). – 1H NMR (D2O): δ = 2.47 (dt, J = 14.0/2.2 Hz, 1 H, NCHCH2), 2.63 (dd, J = 14.0/11.0 
Hz, 1 H, NCHCH2), 3.40 (d, J = 12.2, 1 H, NCH2), 3.55 (dd, J = 12.2/2.2 Hz, 1 H, NCH2), 
3.67 (s, 3 H, ArOCH3), 4.23 (dd, J = 11.0/2.2 Hz, 1 H, NCH), 6.85-6.89 (m, 2 H, Haromat), 
7.26-7.30 (m, 2 H, Haromat). – IR: ~ν = 3383, 3040, 2950, 1614, 1516, 1404, 1255, 830 cm-1. – 
MS; m/z (%): 237 (11) M+, 234 (25), 220 (100), 208 (38), 190 (63), 174 (69), 151 (55), 109 
(15). – C12H15NO4 (237.26): calcd. C 60.75, H 6.37, N 5.90; C12H15NO4·0.2MeOH: calcd. C 
60.13, H 6.53, N 5.74; found C 60.00, H 6.47, N 5.76.    
          
(2R,4S)-4-Hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylic acid [(2R,4S)-63] 
N
OH
OMe
H
COOH
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According to GP8-A from 66 mg (0.17 mmol) of (2R,4S)-62 and 5.8 mg (0.056 mmol) of 
TEA in 8 ml of EtOAc, 33 mg (0.031 mmol) of 10% Pd-C; reaction time: 4 h. Yield: 38 mg 
(96%); colorless crystals. – M.p. 244-246 °C (MeOH, decomp.). – [α]D20 = -0.9 (c = 0.76, 
H2O). The spectra (1H NMR (500 MHz), IR, and MS) were identical with those of (2R,4S)-
63. – C12H15NO4·0.4MeOH: calcd. C 59.56, H 6.69, N 5.60; found C 59.32, H 6.54, N 5.68. 
 
Methyl (2S,4R)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-carboxylate [(2S,4R)-114] 
N
OH
OMe
COOCH3
H
Ha'
Ha
Hb'
Hb
 
According to GP8-A from 144 mg (0.374 mmol) of (2S,4R)-61 and 11 mg (0.11 mmol) of 
TEA in 15 ml of EtOAc, 74 mg (0.070 mmol) of 10% Pd-C; reaction time: 6 h. Yield: 94 mg 
(100%); colorless crystals. – TLC: Rf = 0.25 (iPr2O/MeOH, 4:1). – M.p. 96-97 °C (EtOAc). – 
[α]D20 = +27.3 ( c = 1.00, CHCl3). – 1H NMR (CDCl3, NOE for the determination of the C-4 
configuration): δ = 2.35 (dt, J = 13.7/2.5 Hz, 1 H, NCHCH2), 2.51 (dd, J = 13.7/10.0 Hz, 1 H, 
NCHCH2), 3.07 (br. s, 1 H, OH), 3.10 (d, J = 11.8 Hz, 1 H, NCH2), 3.27 (dd, J = 11.8/2.1 Hz, 
1 H, NCH2), 3.77 (s, 3 H, COOCH3), 3.79 (s, 3 H, ArOCH3), 3.99 (dd, J = 10.0/2.5 Hz, 1 H, 
NCH), 6.85-6.88 (m, 2 H, Ha and Ha’), 7.33-7.37 (m, 2 H, Hb and Hb’). – IR: ~ν  = 3303, 3034, 
2954, 1740, 1612, 1514, 1256, 1115, 831 cm-1. – MS; m/z (%): 252 (7) [M+1]+, 235 (15), 234 
(100), 220 (10), 192 (10), 135 (4). – C13H17NO4 (251.29): calcd. C 62.14, H 6.82, N 5.57; 
found C 62.11, H 6.97, N 5.53. 
 
(2S,4R)-Hydroxypyrrolidine-2-acetic acid [(2S,4R)-97] 
N
OH
COOH
H
 
According to GP8-B from 76 mg (0.27 mmol) of (2S,4R)-96 and 38 mg (0.036 mmol) of 10% 
Pd-C in 10 ml of MeOH; reaction time: 1 h. Yield: 35 mg (89%); colorless crystals. – M.p. 
238-240 °C (decomp.). – [α]D20 = +1.3 (c = 0.31, H2O). – 1H NMR (D2O): δ = 1.83 (ddd, J = 
14.1/11.4/4.4 Hz, 1 H, CH2CHCH2COO), 2.14-2.20 (m, 1 H, CH2CHCH2COO), 2.55 (dd, J = 
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16.6/7.7 Hz, 1 H, CH2COO), 2.64 (dd, J = 16.6/5.5 Hz, 1 H, CH2COO), 3.22 (dt, J = 12.8/1.5 
Hz, 1 H, NCH2), 3.43 (dd, J = 12.8/4.2 Hz, 1 H, NCH2), 4.02-4.08 (m, 1 H, NCH), 4.56-4.59 
(m, 1 H, CHOH). – IR: ~ν  = 3231, 2931, 2783, 1643, 1558, 1401, 732, 666 cm-1. – MS; m/z 
(%): 146 (100) [M+1]+, 145 (19), 128 (17), 102 (8). – C6H11NO3 (145.16): calcd. C 49.65, H 
7.64, N 9.65; found C 49.37, H 7.62, N 9.44.   
 
(2R,4S)-4-Hydroxypyrrolidine-2-acetic acid [(2R,4S)-97] 
N
OH
COOH
H
 
According to GP8-B from 50 mg (0.18 mmol) of (2R,4S)-96 and 25 mg of 10% Pd-C in 8 ml 
of MeOH; reaction time 1 h. Yield: 24 mg (92%); colorless crystals. – M.p. 235-237 °C 
(MeOH, decomp.). – [α]D20 = -2.6 (c = 0.23, H2O). The spectra (1H NMR, IR, and MS) were 
identical with those of (2S,4R)-97. – C6H11NO3 (145.16): calcd. C 49.65, H 7.63, N 9.65; 
found C 49.10, H 7.50, N 9.49. 
 
(2R,4R)-4-Hydroxypyrrolidine-2-acetic acid [(2R,4R)-97] 
N
OH
COOH
H
 
According to GP8-B from 59 mg (0.21 mmol) of (2R,4R)-96 and 30 mg of 10% Pd-C in 10 
ml of MeOH, reaction time: 1 h. Yield: 31 mg (100%); colorless crystals. – M.p. 210-212 °C 
(MeOH, decomp.). – [α]D20 = -4.8 (c = 0.33, H2O). – 1H NMR (D2O): δ = 1.77 (dddd, J = 
14.2/7.3/3.6/1.4 Hz, 1 H, CH2CHCH2COO), 2.55 (ddd, J = 14.2/8.8/6.0 Hz, 1 H, 
CH2CHCH2COO), 2.72-2.74 (m, 2 H, CH2COO), 3.32 (ddd, J = 12.5/2.4/1.4 Hz, 1 H, NCH2), 
3.38 (dd, J =12.5/4.9 Hz, 1 H, NCH2), 3.93-3.99 (m, 1 H, NCH), 4.62-4.65 (m, 1 H, CHOH). 
– IR: ~ν  = 3175, 2958, 1662, 1560, 1412, 1089, 722 cm-1. – MS; m/z (%): 146 (100) [M+1]+. – 
C6H11NO3 (145.16): calcd. C 49.65, H 7.63, N 9.65; found C 49.71, H 7.91, N 9.47.   
 
 
(2S,4S)-4-Hydroxypyrrolidine-2-acetic acid [(2S,4S)-97] 
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N
OH
COOH
H
 
According to GP8-B from 80 mg (0.29 mmol) of (2S,4S)-96 and 40 mg of 10% Pd-C in 8 ml 
of MeOH; reaction time 1 h. Yield: 41 mg (99%); colorless crystals. – M.p. 238-240 °C 
(MeOH, decomp.). – [α]D20 = +5.3 (c = 0.32, H2O). The spectra [1H NMR (500 MHz), IR, 
and MS] were identical with those of (2R,4R)-97. – C6H11NO3 (145.16): calcd. C 49.65, H 
7.63, N 9.65; found C 49.27, H 7.75, N 9.73.      
 
(2S,4R)-4-(4-Methoxyphenyl)-4-hydroxypyrrolidine-2-acetic acid [(2S,4R)-111] 
N
OH
H
COOH
OMe
 
According to GP8-A from 59 mg (0.15 mmol) of (2S,4R)-110, 0.20 ml (1.4 mmol) of TEA in 
5 ml of MeOH, 40 mg (0.038 mmol) of 10% Pd-C; reaction time: 3 h. Yield: 38 mg (100%); 
colorless crystals. – M.p. 261-262 °C (MeOH, decomp.). – [α]D20 = +5.6 (c = 0.50, 0.05 M 
NaOH in MeOH). – 1H NMR (its sodium salt in CD3OD, 500 MHz; NOE): δ =  1.93 (ddd, J = 
13.9/6.4/1.8 Hz, 1 H, CH2CHCH2COO), 2.43 (dd, J = 13.9/9.3 Hz, 1 H, CH2CHCH2COO), 
2.51 (dd, J = 15.4/6.8 Hz, 1 H, CH2COO), 2.60 (15.4/5.4 Hz, 1 H, CH2COO), 2.90 (d, J = 
12.0 Hz, 1 H, NCH2), 3.04 (dd, J = 12.0/1.8 Hz, 1 H, NCH2), 3.54-3.61 (m, 1 H, NCH),  3.77 
(s, 3 H, ArOCH3), 6.85-6.89 (m, 2 H, Haromat), 7.38-7.41 (m, 2 H, Haromat). – IR: ~ν  =  3424, 
3147, 2958, 1648, 1610, 1548, 1412, 1250, 1099, 828 cm-1. – MS; m/z (%): 252 (8) [M+1]+, 
235 (18), 234 (100), 192 (16), 174 (46), 135 (18), 102 (16). – C13H17NO4 (251.29): calcd. C 
62.14, H 6.82, N 5.57; found C 61.62, H 6.68, N 5.45. 
 
(2R,4S)-4-Hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-acetic acid [(2R,4S)-111] 
N
OH
H
COOH
OMe
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According to GP8-A from 73 mg (0.19 mmol) of (2R,4S)-110 and 0.50 ml (3.5 mmol) of TEA 
in 10 ml of MeOH, 38 mg (0.036 mmol) of 10% Pd-C; reaction time: 1 h. Yield: 45 mg 
(95%); colorless crystals. – M.p. 251-253 °C (MeOH, decomp.). – [α]D20 = -5.1 (c = 0.685, 
0.04 M NaOH in MeOH). The spectra [1H NMR (its sodium salt), IR, and MS] were identical 
with those of (2S,4R)-111. – C13H17NO4 (251.29): calcd. C 62.14, H 6.82, N 5.57; found C 
62.11, H 7.08, N 5.31. 
 
Methyl (2S,4R)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-acetic acid [(2S,4R)-115] 
N
OH
OMe
COOCH3
H
 
According to GP8-A from 40 mg (0.10 mmol) of (2S,4R)-109 and 1.0 ml (7.0 mml) of TEA in 
5 ml of EtOAc, 20 mg of 10% Pd-C (0.019 mmol); reaction time: 1 h. Yield: 26 mg (100%); 
colorless crystals. – TLC: Rf = 0.27 (iPr2O/MeOH, 4:1). – M.p. 83-84 °C (iPr2O). – [α]D20 = + 
5.4 (c = 0.59, CHCl3). – 1H NMR (CDCl3, NOE): δ = 1.90 (ddd, J = 14.1/5.7/2.0 Hz, 1 H, 
CH2CHCH2COO), 2.47 (dd, J = 14.1/9.6 Hz, 1 H, CH2CHCH2COO), 2.69 (dd, J = 16.3/5.7 
Hz, 1 H, CH2COO), 2.75 (dd, J = 16.3/7.5 Hz, 1 H, CH2COO), 3.10 (d, J = 11.0 Hz, 1 H, 
NCH2), 3.22 (dd, J = 11.0/2.0 Hz, 1 H, NCH2), 3.28 (br. s, 2 H, NH and OH), 3.61-3.83 (m, 1 
H, NCH), 3.69 (s, 3 H, ArOCH3), 3.77 (s, 3 H, COOCH3), 6.85-6.89 (m, 2 H, Haromat), 7.36-
7.39 (m, 2 H, Haromat). – IR: ~ν = 3305, 3063, 1733, 1610, 1252, 828 cm-1.  – MS; m/z (%): 266 
(37) [M+1]+, 248 (100), 192 (14), 158 (14). – C14H19NO4 (265.32): calcd. C 63.38, H 7.22, N 
5.28; found  
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6.1.9   Hydrolysis of ester functions of N-substituted pyrrolidine derivatives and of 
related lactone derivatives 
 
General procedure 7 (GP7) 
 
The respective ester (1 equiv.) was hydrolyzed in EtOH or MeOH (10-50 ml/mmol) at r.t. 
with aq. 0.85 M KOH or 1.0 M NaOH (3 equiv.; 6 equiv. for the derivatives with two ester 
groups) and for the time given. The mixture was neutralized with aq. 1.0 M HCl to pH 7 
before buffer (pH 6.6 or pH 5.5) was added. 
Two diferent procedures were used to isolate the final compounds: 
A): The mixture was evaporated and the residue was purified by CC and recrystallization. 
B): The mixture was diluted with some water to give white crystal; the product was collected 
by filtration. 
 
(2S,4R)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-carboxylic acid [(2S,4R)-
40a] 
N
OH
COOH
 
According to GP7-A from 185 mg (0.527 mmol) of (2S,4R)-39a, 1.85 ml (1.58 mmol) of aq. 
0.85 M KOH in 7 ml of EtOH; reaction time: 1.5 h; 1 ml (pH 6.6) of buffer; purification by 
CC (φ 20 × 74; n-heptane/EtOAc, 1:1 → EtOH) and recrystallization in acetone. Yield: 170 
mg (96%); colorless crystals. – M.p. 162-165 °C (acetone). – [α]D22 = −49.2 (c = 0.85, EtOH). 
– 1H NMR (CD3OD): δ = 2.09 (ddd, J = 13.7/10.6/4.4 Hz, 1 H, NCHCH2), 2.39 (ddt, J = 
13.7/7.6/1.9 Hz, 1 H, NCHCH2), 2.55 (q, J = 7.6 Hz, 2 H, NCH2CH2), 3.00 (dt, J = 12.3/1.9 
Hz, 1 H, NCH2CHOH), 3.35 (dt, J = 12.4/7.6 Hz, 1 H, NCH2CH2), 3.46 (dt, J = 12.4/7.6 Hz, 
1 H, NCH2CH2), 3.64 (dd, J = 12.3/4.4 Hz, 1 H, NCH2CHOH), 4.05 (dd, J = 10.6/7.6 Hz, 1 
H, NCH), 4.43-4.45 (m, 1 H, CHOH), 6.09 (t, J = 7.6 Hz, 1 H, =CHCH2), 7.17-7.43 (m, 10 H, 
Haromat). – IR: ~ν = 3424, 3051, 2858, 1628, 1394, 775, 702 cm-1. – MS; m/z (%): 338 (100) 
[M+1]+, 274 (68), 144 (39). – C21H23NO3 (337.42): calcd. C 74.75, H 6.87, N 4.15; found C 
74.61, H 7.07, N 4.09.  
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(2R,4S)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-carboxylic acid [(2R,4S)-
40a]  
N
OH
COOH
 
According to GP7-A from 85 mg (0.21 mmol) of (2R,4S)-48a, 1.26 ml (1.26 mmol) of aq. 1.0 
M NaOH in 6 ml of EtOH; reaction time: 3 d; 3 ml of buffer (pH 6.6); purification by CC (φ 
12 × 100, EtOH) and recrystallization in EtOH/iPr2O. Yield: 65 mg (92%); colorless crystals. 
– M.p. 181-184 °C (EtOH/iPr2O). – [α]D20 = +50.6 (c = 0.93, EtOH). The spectra (1H NM, IR, 
and MS) were identical with those of (2S,4R)-40a. – C21H23NO3 (337.43)⋅H2O: calcd. C 
70.96, H 7.09, N 3.94; found C 71.07, H 7.12, N 3.95. 
 
(2R,4R)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-carboxylic acid [(2R,4R)-
40a]  
N
OH
COOH
 
 
According to GP7-A from 68 mg (0.19 mmol) of (2R,4R)-39a, 0.58 ml (0.58 mmol) of aq. 1.0 
M NaOH in 3 ml of EtOH; reaction time: 3 h; 1 ml (pH 6.6) of buffer; purification by CC (φ 
12 × 100, EtOH) and recrystallization in C6H6/iPr2O. Yield: 58 mg (92%); colorless crystals. 
– M.p. 112-116 °C (C6H6/iPr2O). – [α]D20 = +43.1 (c = 0.90, EtOH). – 1H NMR (CD3OD, 500 
MHz): δ = 2.15-2.21 (m, 1 H, NCHCH2), 2.48-2.63 (m, 3 H, NCHCH2 and 2 H of 
NCH2CH2), 3.03 (dd, J = 11.5/3.8 Hz, 1 H, NCH2CHOH), 3.18-3.24 (m, 1 H, NCH2CH2), 
3.32-3.41 (m, 2 H, NCH2CH2 and NCH2CHOH), 3.79 (dd, J = 10.6/4.4 Hz, 1 H, NCH), 4.36-
4.39 (m, 1 H, CHOH), 6.07 (dd, J = 7.9/6.9 Hz, 1 H, =CHCH2), 7.17-7.44 (m, 10 H, Haromat). 
– IR: ~ν = 3274, 3053, 2851, 1633, 1494, 1400, 764, 702, 632 cm-1. – MS; m/z (%): 338 (36) 
[M+1]+, 320 (40), 274 (16), 213 (100), 195 (87), 183 (10), 126 (61), 91 (10). – C21H23NO3 
(337.42): calcd. C 74.75, H 6.87, N 4.15; C21H23NO3·1.2H2O: calcd. C 70.25, H 7.13, N 3.90; 
found C 69.99, H 6.95, N 3.83.   
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(2S,4S)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-carboxylic acid [(2S,4S)-
40a] 
N
OH
COOH
 
According to GP7-A from 157 mg (0.491 mmol) of (1S,4S)-41a, 2.1 ml (1.8 mmol) of aq. 
0.85 M KOH in 12 ml of EtOH; reaction time: 40 min; 2.5 ml of buffer (pH 6.6); purification 
(φ  20 × 70; n-heptane/acetone, 1:1 → EtOH) and recrystallization in acetone. Yield: 158 mg 
(95%); colorless crystals. – M.p. 138-140 °C (acetone). – [α]D24  = -42.8 (c = 1.00, EtOH). 
The spectra (1H NMR, IR, and MS) were identical with those of (2R,4R)-40a. – C21H23NO3 
(337.42): calcd. C 74.75, H 6.87, N 4.15; found C 74.65, H 7.12, N 4.01. 
 
(2S,4R)-4-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylic acid [(2S,4R)-40b] 
N
OH
COOH
O
OMeMeO
OMe
 
According to GP7-A from 299 mg (0.574 mmol) of (2S,4R)-39b, 1.7 ml (1.5 mmol) of aq. 
0.85 M KOH in 23 ml of EtOH; reaction time: 4 h. 2.0 ml of buffer (pH 6.6); purification by 
CC (φ 25 × 70; Al2O3, pH 7.5; n-heptane/acetone, 3:2→EtOH/H2O, 4:1) and recrystallization 
in acetone. Yield: 243 mg (85%); colorless crystals. – M.p. 142-144 °C (acetone). – [α]D28  = -
24.8 (c = 1.12, EtOH). – 1H NMR (CD3OD): δ = 2.15 (ddd, J = 13.8/10.1/4.7 Hz, 1 H, 
NCHCH2), 2.41 (ddt, J = 13.8/7.8/1.9 Hz, 1 H, NCHCH2), 3.08 (br. d, J = 12.4 Hz, 1 H, 
NCH2CHOH), 3.29-3.35 (m, 1 H, NCH2CH2), 3.40-3.61 (m, 4 H, NCH2CH2, NCH2CHOH 
and 2 H of NCH2CH2), 3.76 (s, 9 H, ArOCH3), 4.19 (dd, J = 10.1/7.8 Hz, 1 H, NCH), 4.43-
4.46 (m, 1 H, CHOH), 6.85-6.88 (m, 6 H, Haromat), 7.32-7.36 (m, 6 H, Haroma). – IR: ~ν = 3464, 
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3213, 1640, 1607, 1509, 831 cm-1. – MS (ESI); m/z (%): 333 (100). – C29H33NO7 (507.58): 
calcd. C 68.62, H 6.55, N 2.76; found C 68.54, H 6.79, N 2.60. 
 
(2R,4S)-4-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylic acid [(2R,4S)-40b] 
N
OH
COOH
O
OMeMeO
OMe
 
According to GP7-A from 80 mg (0.14 mmol) of (2R,4S)-48b, 0.85 ml (0.85 mmol) of aq. 1.0 
M NaOH in 3.5 ml of MeOH; reaction time: 3 d. 0.8 ml of buffer (pH 6.6); purification by 
recrystallization in C6H6/iPr2O. Yield: 68 mg (94%); colorless crystals. – M.p. 135-137 °C 
(C6H6/iPr2O). – [α]D20 = +20.6 (c = 0.90, EtOH). The spectra (1H NMR, IR, and MS) were 
identical with those of (2S,4R)-40b. – C29H33NO7 (507.58): calcd. C 68.62, H 6.55, N 2.76; 
C29H33NO7⋅H2O (525.60): calcd. C 66.27, H 6.71, N 2.67; found C 64.99, H 6.50, N 2.76. 
 
(2R,4R)-4-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylic acid [(2R,4R)-40b] 
N
OH
COOH
O
OMeMeO
OMe
  
According to GP7-A from 66 mg (0.13 mmol) of (2R,4R)-39b, 0.38 ml (0.38 mmol) of aq. 1.0 
M NaOH in 2.5 ml of EtOH; reaction time: 2 h; purification by CC (φ 12 × 110; Al2O3, pH 7 
± 0.5; EtOH/H2O, 4:1) and recrystallization (petroleum ether). Yield: 43 mg (67%); colorless 
crystals. – M.p. 126-130 °C (petroleum ether). – [α]D20 = +12.1 (c = 0.7, EtOH). – 1H NMR 
(CD3OD): δ = 2.23-2.29 (m, 1 H, NCHCH2), 2.54 (ddd, J = 13.9/11.0/4.4 Hz, 1 H, NCHCH2), 
3.06 (dd, J = 11.6/3.6 Hz, 1 H, NCH2CHOH), 3.23-3.37 (m, 3 H, NCH2CHOH and 2 H of 
NCH2CH2), 3.51-3.61 (m, 2 H, NCH2CH2), 3.77 (s, 9 H, OCH3), 3.98 (dd, J = 11.0/4.0 Hz, 1 
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H, NCH), 4.38-4.41 (m, 1 H, CHOH), 6.86-6.90 (m, 6 H, Haromat), 7.34-7.38 (m, 6 H, Haromat). 
– IR: ~ν = 3414, 2956, 1638, 1608, 1250, 1176, 1033, 828 cm-1. – MS (ESI); m/z (%): 333 
(100), 185 (9), 149 (14). – C29H33NO7 (507.58): calcd. C 68.62, H 6.55, N 2.76; 
C29H33NO7·H2O (525.60): calcd. C 66.27, H 6.71, N 2.67; found C 66.26, H 6.77, N 2.59. 
 
(2S,4S)-4-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-
carboxylic acid  [(2S,4S)-40b] 
N
OH
COOH
O
OMeMeO
OMe
 
According to GP2 from 151 mg (0.298 mmol) of (2S,4R)-40b and 161 mg (0.596 mmol) of 
PPh3, (67 mg, 0.39 mmol) of DEAD in 6.5 ml of THF; reaction time: 20 h. Purification by CC 
(Al2O3, pH 7.5 ±0.5; φ 25 × 180; gradient elution, n-heptane/acetone, 2:1 → EtOH/H2O, 4:1) 
directly yielded (2S,4S)-40b. Yield: 115 mg (76% for two steps); colorless crystals. – M.p. 
147-149 °C (EtOH/H2O). – [α]D24  = -11.9 (c = 0.75, EtOH). The spectra (1H NMR, IR, and 
MS) were identical with those of (2R,4R)-40b.  – C29H33NO7 (507.58): calcd. C 68.62, H 
6.55, N 2.76; found C 68.73, H 6.72, N 2.48. 
 
(2S,4S)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
carboxylic acid  [(2S,4S)-57a] 
N
OH
OMe
COOH
 
According to GP7-A from 50 mg (0.11 mmol) of (2S,4S)-53a, 0.39 ml (0.33 mmol) of aq. 
0.85 M KOH in 1.7 ml of EtOH; reaction time: 1 h; purification by CC (φ 10 × 70, gradient 
elution, iPr2O → EtOH). Yield: 36 mg (74%); colorless crystals. – M.p. 173-175 °C (MeOH). 
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– [α]D20  = -28.0 (c = 0.64, MeOH). – 1H NMR (CD3OD): δ = 2.42 (dd, J = 13.3/12.0 Hz, 1 H, 
NCHCH2), 2.57 (q, J = 7.6 Hz, 2 H, NCH2CH2), 2.65 (ddd, J = 13.3/6.7/2.0 Hz, 1 H, 
NCHCH2), 3.26-3.33 (m, 1 H, NCH2CO), 3.36-3.40 (m, 1 H, NCH2CH2), 3.55 (dt, J = 
12.2/7.6 Hz, 1 H, NCH2CH2), 3.68 (d, J = 12.3 Hz, 1 H, NCH2CO), 3.78 (s, 3 H, ArOCH3), 
4.25 (dd, J = 12.0/6.7 Hz, 1 H, NCH), 6.12 (t, J = 7.6 Hz, 1 H, =CHCH2), 6.90-6.93 (m, 2 H, 
Haromat), 7.17-7.44 (m, 12 H, Haromat). – IR: ~ν = 3254, 3023, 2960, 2862, 1622, 1516, 1260, 
834, 764, 700 cm-1. – MS; m/z (%): 444 (6) [M+1]+, 382 (42), 381 (34), 380 (92), 207 (100), 
188 (39), 127 (15). – C28H29NO4 (443.54): calcd. C 75.82, H 6.59, N 3.16; found C 76.04, H 
6.84, N 3.06. 
 
(2R,4R)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
carboxylic acid [(2R,4R)-57a]  
N
OH
OMe
COOH
 
According to GP7-A from 62 mg (0.14 mmol) of (2R,4R)-53a, 0.42 ml (0.42 mmol) of aq. 1 
M NaOH in 3.6 ml of MeOH; reaction time: 12 h; purification by recrystallization from 
MeOH. Yield: 56 mg (94%); colorless crystals. – M.p. 179-181 °C (MeOH). – [α]D20  = +28.0 
(c = 0.50, MeOH). The spectra (1H NMR, IR, and MS) were identical with those of (2S,4S)-
57a. – C H NO  (443.54)·H O: C 72.86, H 6.77, N 3.03; found C 72.77, H 6.57, N 2.95. 28 29 4 2
 
(2S,4R)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
carboxylic acid  [(2S,4R)-57a]          
 
N
OH
OMe
COOH
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According to GP7-B from 20 mg (0.044 mmol) of (2S,4R)-53a, 0.15 ml (0.13 mmol) of aq. 
0.85 M KOH in 1 ml of EtOH; reaction time: 1 h; purification by CC ( φ 10 × 80, gradient 
elution iPr2O → EtOH). Yield: 17 mg (88%); colorless crystals. – M.p. 168-173 °C. – [α]D20 
= -39.3 (c = 0.81, MeOH). – 1H NMR (CD3OD): δ = 2.54-2.71 (m, 3 H, NCHCH2 and 2 H of 
NCH2CH2), 2.92 (dd, J = 13.5/11.4 Hz, 1 H, NCHCH2), 3.33-3.53 (m, 3 H, NCH2CO and 2 H 
of NCH2CH2), 3.62 (dd, J = 11.2/1.8 Hz, 1 H, NCH2CO), 3.78 (s, 3 H, ArOCH3), 4.39 (dd, J 
= 11.4/1.8 Hz, 1 H, NCH), 6.09 (t, J = 7.5 Hz, 1 H, =CHCH2), 6.90-6.95 (m, 2 H, Haromat), 
7.16-7.45 (m, 12 H, Haromat). – IR: ~ν = 3431, 3022, 2955, 2835, 1612, 1515, 1252, 832, 764, 
702 cm-1. – MS; m/z (%): 444 (5) [M+1]+, 426 (47), 381 (33), 380 (100), 207 (87), 75 (67). – 
C28H29NO4 (443.54): calcd. C 75.82, H 6.59, N 3.16; found: C 75.71, H 6.82, N 2.96;  
 
(2R,4S)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxy-4-(4-methoxyphenyl)pyrrolidine-2-
carboxylic acid [(2R,4S)-57a] 
N
OH
OMe
COOH
 
According to GP7-A from 88 mg (0.19 mmol) of (2R,4S)-53a, 0.57 ml (0.57 mmol) of aq. 1 
M NaOH in 6 ml of MeOH; reaction time: 12 h; purification by recrystallization from 
MeOH/iPr2O. Yield: 72 mg (84%); colorless crystals. – M.p. 165-170 °C (MeOH/iPr2O). – 
[α]D20 = +40.4 (c = 1.55, MeOH). The spectra (1H NMR, IR, and MS) were identical with 
those of (2R,4S)-57a. – C28H29NO4·0.4H2O: C 74.56, H 6.62, N 2.92; found C 74.61, H 6.66, 
N 3.11. 
 
(2S,4R)-4-Hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}-
pyrrolidine-2-carboxylic acid [(2S,4R)-57b] 
 
According to GP7-B from 62 mg (0.099 mmol) of (2S,4R)-53b, 0.47 ml (0.40 mmol) of aq. 
0.85 M KOH in 2 ml of EtOH; reaction time: 3.5 h; 2.0 ml of buffer (pH 6.6). Yield: 54 mg 
(89%); colorless crystals. – M.p. 105-108 °C. – [α]D20 = +1.5 (c = 1.15, MeOH). – 1H NMR 
(CD3OD): δ = 2.48 (dd, J = 13.5/2.1 Hz, 1 H, NCHCH2), 2.75 (dd, J = 13.5/11.5 Hz, 1 H,  
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N
OH
COOH
OMe
O
OMeMeO
OMe
 
NCHCH2), 3.16-3.22 (m, 2 H, NCH2CO), 3.25-3.32 (m, 2 H, NCH2CH2), 3.49-3.62 (m, 2 H, 
NCH2CH2), 3.67 (s, 9 H, ArOCH3), 3.70 (s, 3 H, Ar’OCH3), 4.06 (dd, J = 11.5/2.1 Hz, 1 H, 
NCH), 6.77-6.84 (m, 8 H, Haromat), 7.22-7.25 (m, 2 H, Haromat), 7.28-7.32 (m, 6 H, Haromat). – 
IR: ~ν = 3421, 2999, 2955, 2830, 1637, 1609, 1509, 1251, 1034, 830 cm-1. – MS (ESI); m/z 
(%): 614 [M+1]+ (4), 333 (100). – C36H39NO8·H2O: calcd. C 68.45, H 6.54, N 2.22; found C 
68.62, H 6.40, N 2.18.  
 
(2R,4S)-4-Hydroxy-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}-
pyrrolidine-2-carboxylic acid [(2R,4S)-57b]  
N
OH
OMe
COOH
O
OMeMeO
OMe
 
According to GP7-B from 60 mg (0.096 mmol) of (2R,4S)-53b, 0.29 ml (0.29 mmol) of aq. 
1.0 M NaOH  in 3 ml of MeOH; reaction time: 3 h; 0.5 ml of buffer (pH 6.6). Yield: 52 mg 
(89%); colorless crystals. – M.p. 158-160 °C (MeOH/H2O). – [α]D20 = -1.6 (c = 0.75, MeOH). 
The spectra (1H NMR, IR, and MS) were identical with those of (2S,4R)-57b. – 
C36H39NO8·0.5H2O calcd. C 69.44, H 6.68, N 2.25; found: C 69.31, H 6.51, N 2.17.   
 
(2S,4S)-4-Hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}-
pyrrolidine-2-carboxylic acid [(2S,4S)-57b] 
 
According to GP7-B from 30 mg (0.048 mmol) of (2S,4S)-53b, 0.39 ml (0.33 mmol) of aq. 
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N
OH
COOH
OMe
O
OMeMeO
OMe
 
0.85 M KOH in 1 ml of EtOH; reaction time: 1.75 h; 1 ml of buffer (pH 6.6). Yield: 26 mg 
(89%); colorless crystals. – M.p. 138-139 °C (EtOH/H2O). – [α]D20 = -3.9 (c = 0.85, MeOH). 
– 1H NMR (CD3OD): δ = 2.32 (dd, J = 13.3/11.6 Hz, 1 H, NCHCH2),  2.57 (ddd, J = 
13.3/7.1/1.5 Hz, 1 H, NCHCH2), 3.14 (dd, J = 12.5/2.1 Hz, 1  H, NCH2CO), 3.30-3.51 (m, 5 
H, NCH2CO and 2 H of NCH2CH2 and 2 H of NCH2CH2), 3.65 (s, 9 H, Ar’OCH3), 3.69 (s, 3 
H, ArOCH3), 4.29 (dd, J = 11.6/7.1 Hz, 1 H, NCH), 6.73-6.76 (m, 6 H, Haromat), 6.78-6.81 (m, 
2 H, Haromat), 7.23-7.27 (m, 8 H, Haromat). – IR: ~ν = 3425, 2839, 1630, 1609, 1509, 1250, 1175, 
830 cm-1. – MS (ESI); m/z (%): 614 [M+1]+ (6), 333 (100). – C36H39NO8  (613.71): calcd. C 
70.46, H 6.41, N 2.28; found C 70.18, H 6.62, N 2.35. 
  
(2R,4R)-4-Hydroxy-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}-
pyrrolidine-2-carboxylic acid [(2R,4R)-57b] 
N
OH
OMe
COOH
O
OMeMeO
OMe
 
According to GP7-B from 56 mg (0.089 mmol) of (2R,4R)-53b, 0.27 ml (0.27 mmol) of aq. 
1.0 M NaOH in 3 ml of MeOH; reaction time: 5 h; 0.5 ml of buffer (pH 6.6). Yield: 48 mg 
(88%); colorless crystals. – M.p. 158-160 °C (MeOH/H2O). – [α]D20 = +3.6 (c = 0.50, 
MeOH). The spectra (1H NMR, IR, and MS) were identical with those of (2S,4S)-57b. – 
C36H39NO8·0.3H2O calcd. C 69.84, H 6.45, N 2.26; found C 69.76, H 6.67, N 2.15. 
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(2R,4R)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-acetic acid   [(2R,4R)-
89a] 
N
OH
COOH
 
According to GP7-A from 53 mg (0.14 mmol) of (2R,4R)-88a, 0.42 ml (0.42 mmol) of aq. 1.0 
M NaOH in 2 ml of MeOH; reaction time: 41 h; 1 ml of buffer (pH 5.5); purification by CC 
(φ 12 × 100, MeOH). Yield: 41 mg (84%); colorless crystals. – M.p. 70-76 °C (MeOH/iPr2O). 
– [α]D20 = +52.2 (c = 0.50, MeOH). – 1H NMR (CD3OD): δ = 1.71-1.77 (m, 1 H, 
CH2CHCH2COO), 2.46-2.57 (m, 4 H, CH2COO, CH2CHCH2COO and 2 H of NCH2CH2), 
2.63 (dd, J = 16.7/6.3 Hz, 1 H, CH2COO), 2.92-3.01 (m, 2 H, NCH2CH2 and NCH2CHO), 
3.17-3.29 (m, 1 H, NCH2CHO), 3.46-3.57 (m, 2 H, NCH2CH2 and NCH), 4.35-4.40 (m, 1 H, 
CHOH), 6.02 (t, J = 7.3 Hz, 1 H, =CHCH2), 7.14-7.40 (m, 10 H, Haromat). – IR: ~ν  = 3388, 
3055, 2952, 1608, 1444, 1361, 773, 701 cm-1. – MS; m/z (%): 352 (23) [M+1]+, 334 (100), 
292 (10), 158 (11), 140 (18), 89 (7), 75 (22) cm-1. – C22H25NO3 (351.45)·1.0 H2O: calcd. C 
71.52, H 7.37, N 3.79; found C 71.72, H 7.01, N 3.49. 
 
(2S,4S)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-acetic acid [(2S,4S)-89a] 
N
OH
COOH
 
According to GP7-A from 60 mg (0.18 mmol) of (1S,5S)-92a, 0.54 ml (0.54 mmol) of aq. 1.0 
M NaOH in 3 ml of MeOH; reaction time: 20 h; 0.7 ml of buffer (pH 6.6); purification by CC 
(φ 12 × 110, MeOH) and recrystallization from C6H6. Yield: 49 mg (78%); colorless crystals. 
– M.p. 95-97 °C (C6H6). – [α]D20 = -51.5 (c = 0.47, MeOH). The spectra (1H NMR, IR, and 
MS) were identical with those of (2R,4R)-89a. 
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(2R,4S)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-acetic acid [(2R,4S)-89a] 
N
OH
COOH
 
According to GP7-A from 36 mg (0.085 mmol) of (2R,4S)-90a, 0.51 ml (0.51 mmol) of aq. 
1.0 M NaOH in 4.5 ml of MeOH; reaction time: 3 d; 0.3 ml of buffer (pH 6.6); purification by 
recrystallization (C6H6/iPr2O). Yield: 28 mg (93%); colorless crystals. – M.p. 57-60 °C 
(C6H6/iPr2O). – [α]D20 = +65.6 (c = 0.5, MeOH). – 1H NMR (CD3OD): δ = 1.93 (ddd, J = 
13.6/11.4/5.1 Hz, 1 H, CH2CHCH2COO), 2.13 (ddt, J = 13.6/6.5/1.7 Hz, 1 H, 
CH2CHCH2COO), 2.46 (dd, J = 16.5/3.0 Hz, 1 H, CH2COO), 2.56 (q, J = 7.4 Hz, 2 H, 
NCH2CH2), 2.70 (dd, J = 16.5/5.9 Hz, 1 H, CH2COO), 2.82 (d, J = 12.5 Hz, 1 H, NCH2CHO), 
3.03-3.10 (m, 1 H, NCH2CH2), 3.46-3.53 (m, 2 H, NCH2CH2 and NCH2CHO), 3.74-3.80 (m, 
1 H, NCH), 4.38-4.41 (m, 1 H, CHOH), 6.09 (t, J = 7.4 Hz, 1 H, =CHCH2), 7.21-7.46 (m, 10 
H, Haromat). – IR: ~ν  = 3295, 3055, 1718, 1624, 1444, 1396, 764, 702 cm-1. – MS; m/z (%): 352 
(19) [M+1]+, 334 (26), 279 (26), 207 (47), 195 (35), 183 (95), 158 (39), 145 (100), 91 (31). – 
C22H25NO3 (351.45).1.3 H2O; calcd. C 70.50, H 7.42, N 3.74; found C 70.34, H 7.47, N 3.53.      
 
(2S,4R)-1-(4,4-Diphenylbut-3-en-1-yl)-4-hydroxypyrrolidine-2-acetic acid [(2S,4R)-89a] 
N
OH
COOH
 
According to GP7-A from 50 mg (0.14 mmol) of (2S,4R)-91a, 0.42 ml (0.42 mmol) of aq. 1.0 
M NaOH in 3 ml of EtOH; reaction time: 3 h; 2 ml of  buffer (pH 6.6); purification by CC (φ 
10 × 70, EtOH). Yield: 40 mg (83%); colorless oil. – [α]D20 = -69.4 (c = 0.95, MeOH). The 
spectra (1H NMR, IR, and MS) were identical with those of (2R,4S)-89a. – C22H25NO3 
(351.45): calcd. C 75.19, H 7.17, N 4.00; found C 74.70, H 7.48, N 3.79. 
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(2R,4R)-4-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-acetic 
acid [(2R,4R)-89b] 
N
OH
O
COOH
OMeMeO
OMe
 
According to GP7-A from 54 mg (0.098 mmol) of (2R,4R)-88b, 0.30 ml (0.30 mmol) of aq. 
1.0 M NaOH in 2 ml of MeOH; reaction time: 2 d; purification by CC (Al2O3, pH 7.0 ± 0.5, 
mesh 0.05-0.15 mm; φ 12 × 70; MeOH/H2O, 7:3) and recrystallization (C6H6/iPr2O). Yield: 
40 mg (78%); colorless crystals. – M.p. 85-88 °C. – [α]D20 = +17.9 (c = 0.90, MeOH). – 1H 
NMR (CD3OD): δ = 1.83 (ddd, J = 13.4/9.0/4.3 Hz, 1 H, CH2CHCH2COO), 2.50-2.62 (m, 2 
H, CH2COO and CH2CHCH2COO), 2.74 (dd, J = 16.7/6.2 Hz, 1 H, CH2COO), 2.98-3.04 (m, 
1 H, NCH2CH2), 3.14 (dd, J = 11.9/5.7 Hz, 1 H, NCH2CHO), 3.28-3.34 (m, 1 H, NCH2CHO), 
3.39-3.60 (m, 4 H, NCH2CH2, NCH and 2 H of NCH2CH2), 3.77 (s, 9 H, ArOCH3), 4.41-4.46 
(m, 1 H, CHOH), 6.85-6.89 (m, 6 H, Haromat), 7.32-7.36 (m, 6 H, Haromat). – IR: ~ν  = 3420, 
3050, 3025, 2933, 1607, 1508, 1250, 1176, 1034, 828 cm-1. – MS (ESI+); m/z (%): 522 
[M+1]+ (6), 333 (100). – C30H35NO7 (521.61)·1.0 H2O: calcd. C 66.78, H 6.91, N 2.60; found 
C 66.93, H 6.71, N 2.46. 
 
(2S,4S)-4-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-acetic 
aicd [(2S,4S)-89b] 
N
OH
COOH
O
OMeMeO
OMe
 
According to GP7-A from 112 mg (0.227 mmol) of  (1S,5S)-92b, 0.67 ml (0.67 mmol) of aq. 
1.0 M NaOH in 7.3 ml of MeOH; reaction time: 2 d; purification by recrystallization from 
MeOH/iPr2O. Yield: 102 mg (96%); colorless powder. – M.p. 95-103 °C (C6H6/iPr2O). – 
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[α]D20 = -16.8 (c = 0.75, MeOH). The spectra (1H NMR, IR, and MS) were identical with 
those of (2R,4R)-89b. – C30H35NO7 (521.61): calcd. C 69.08, H 6.76, N 2.69; found 
 
(2R,4S)-4-hydroxy-1-{2-[Tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-acetic acid 
[(2R,4S)-89b] 
N
OH
COOH
O
OMeMeO
OMe
 
According to GP7-A from 70 mg (0.12 mmol) of (2R,4S)-90b, 0.71 ml (0.71 mmol) of aq. 1.0 
m NaOH in 6.3 ml of MeOH; reaction time: 48 h; purification by recrystallization 
(C6H6/iPr2O). Yield: 52 mg (85%); colorless crystals. – M.p. 98-105 °C (C6H6/iPr2O). – 
[α]D20 = +31.5 (c = 0.60, MeOH). – 1H NMR (CD3OD): δ = 1.93 (ddd, J = 13.5/11.5/4.6 Hz, 
1 H, CH2CHCH2COO), 2.12 (ddt, J = 13.5/6.5/1.6 Hz, 1 H, CH2CHCH2COO), 2.39 (dd, J = 
16.9/2.4 Hz, 1 H, CH2COO), 2.72 (dd, J = 16.9/5.3 Hz, 1 H, CH2COO), 3.00 (dt, J =12.6/1.6 
Hz, 1 H, NCH2CHO), 3.10-3.16 (m, 1 H, NCH2CH2), 3.38-3.53 (m, 4 H, NCH2CHO, 
NCH2CH2 and 2 H of NCH2CH2), 3.75 (s, 9 H, ArOCH3), 3.79-3.86 (m, 1 H, NCH), 4.39-
4.43 (m, 1 H, CHOH), 6.83-6.87 (m, 6 H, Haromat), 7.29-7.33 (m, 6 H, Haromat). – IR: ~ν  = 3398, 
2933, 1607, 1506, 1251, 1176, 1033, 828, 583 cm-1. – MS (ESI+); m/z (%): 522 [M+1]+ (16), 
333 (100). – C30H35NO7 (521.61)·0.8 H2O: calcd. C 67.22, H 6.88, N 2.61; found C 67.34, H 
7.19, N 2.45. 
 
(2S,4R)-4-Hydroxy-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}pyrrolidine-2-acetic 
acid [(2S,4R)-89b] 
N
OH
O
OMeMeO
OMe
COOH
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According to GP7-A from 149 mg (0.279 mmol) of (2S,4R)-91b, 0.85 ml (0.85 mmol) of aq. 
1.0 M NaOH in 5 ml of MeOH; reaction time: 4 h; 2.5 ml of buffer (pH 6.6); purification by 
CC (Al2O3, pH 7 ± 0.5; φ 12 × 100; H2O/MeOH, 1:4) and recrystallization from 
C6H6/petroleum ether. Yield: 120 mg (83%); colorless crystals. – M.p. 95-103 °C 
(C6H6/petroleum ether). – [α]D20 = -33.2 (c = 1.00, MeOH). The spectra (1H NMR, IR, and 
MS) were identical with those of (2R,4S)-89b.  – C30H35NO7·0.5 H2O: calcd. C 67.90, H 6.84, 
N 2.64; found C 68.01, H 7.11, N 2.33. 
 
(2R,4R)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxypyrrolidine-2-acetic acid 
[(2R,4R)-89c] 
N
OH
S S
COOH
 
According to GP7-A from 47 mg (0.12 mmol) of (2R,4R)-88c, 0.56 ml (0.56 mmol) of aq. 1.0 
M NaOH in 2 ml of MeOH; reaction time: 2 d; purification by CC (φ 12 × 120, MeOH) and 
recrystallization (C6H6/petroleum ether). Yield: 43 mg (95%); slightly yellow powder. – M.p. 
69-74 °C (C6H6/petroleum ether). – [α]D20 = +34.8 (c = 0.46, MeOH). – 1H NMR (CD3OD): δ 
= 1.72-1.78 (m, 1 H, CH2CHCH2COO), 1.97 (s, 3 H, thienyl-CH3), 2.03 (s, 3 H, theinyl-CH3), 
2.46-2.60 (m, 5 H, CH2CHCH2COO, 2 H of CH2COO and 2 H of NCH2CH2), 2.95-3.04 (m, 1 
H, NCH2CH2), 3.08 (dd, J = 11.9/5.5 Hz, 1 H, NCH2CHO), 3.30-3.60 (m, 3 H, NCH2CHO, 
NCH2CH2 and NCH), 4.38-4.44 (m, 1 H, NCH2CHO), 6.05 (t, J = 7.3 Hz, 1 H, =CHCH2), 
6.78 (d, J = 5.2 Hz, 1 H, SCH), 6.91 (d, J = 5.2 Hz, 1 H, SCH), 7.16 (d, J = 5.2 Hz, 1 H, 
SCH=CH), 7.35 (d, J = 5.2 Hz, 1 H, SCH=CH). – IR: ~ν  = 3396, 3105, 2921, 1591, 1399, 
1097, 713 cm-1. – MS; m/z (%): 392 (12) [M+1]+, 374 (24), 328 (25), 263 (19), 223 (49), 183 
(18), 165 (40), 140 (100), 127 (41), 91 (10). – C20H25NO3S2 (391.54)·0.8 H2O: calcd. C 59.17, 
H 6.60, N 3.45; found C 59.29, H 6.42, N 3.10.       
 
(2S,4S)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxypyrrolidine-2-acetic acid 
[(2S,4S)-89c] 
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N
OH
COOH
S S
 
According to GP7-A from 67 mg (0.18 mmol) of (1S,5S)-92c, 0.54 ml (0.54 mmol) of aq. 1.0 
M NaOH in 4.5 ml of MeOH; reaction time: 25 h; 1 ml of buffer (pH 6.6); purification by CC 
(φ 12 × 100, MeOH) and rescrystallization from MeOH/iPr2O. Yield: 59 mg (84%); colorless 
powder. – M.p. 72-78 °C (C6H5/iPr2O). – [α]D20 = -34.4 (c = 0.52, MeOH). The spectra (1H 
NMR, IR, and MS) were identical with those of (2R,4R)-89c. – C20H25NO3S2·1.1 H2O: calcd. 
C 58.39, H 6.67, N 3.40; found C 58.33, H 6.64, N 3.08. 
 
(2R,4S)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxypyrrolidine-2-acetic acid 
[(2R,4S)-89c] 
N
OH
S S
COOH
 
According to GP7-A from 70 mg (0.15 mmol) of (2R,4S)-90c, 0.91 ml (0.91 mmol) of aq. 1.0 
M NaOH in 4 ml of MeOH; reaction time: 3 d; 1.5 ml of buffer (pH 6.6); purification by CC 
(φ 12 × 110, MeOH). Yield: 56 mg (94%); pale yellow powder. – M.p. 58-62 °C 
(C6H6/iPr2O). – [α]D20 = +57.5 (c = 0.52, MeOH). – 1H NMR (CD3OD): δ = 1.87-1.94 (m, 1 
H, CH2CHCH2COO), 1.99 (s, 3 H, thienyl-CH3), 2.04 (s, 3 H, thienyl-CH3), 2.13 (dd, J = 
13.6/6.5 Hz, 1 H, CH2CHCH2COO), 2.49 (dd, J = 16.6/3.2 Hz, 1 H, CH2COO), 2.50-2.61 (m, 
2 H, NCH2CH2), 2.63 (dd, J = 16.6/6.0 Hz, 1 H, CH2COO), 2.85 (br. d, J = 12.1 Hz, 1 H, 
NCH2CHO), 2.99-3.05 (m, 1 H, NCH2CH2), 3.42 (dt, J = 12.4/8.2 Hz, 1 H, NCH2CH2), 3.60 
(dd, J = 12.1/4.9 Hz, 1 H, NCH2CHO), 3.68-3.76 (m, 1H, NCH), 4.40-4.43 (m, 1H, CHOH), 
6.05 (t, J = 7.4 Hz, 1 H, =CHCH2), 6.77 (d, J = 5.2 Hz, 1 H, SCH), 6.91 (d, J = 5.2 Hz, 1 H, 
SCH), 7.15 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.36 (d, J = 5.2 Hz, 1 H, SCH=CH). – IR: ~ν  = 
3380, 3102, 2921, 1588, 1401, 834, 713 cm-1. – MS; m/z (%): 392 (45) [M+1]+, 374 (13), 330 
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(14), 306 (13), 247 (25), 174 (37), 158 (100), 140 (39), 97 (13 ), 87 (50). – C22H25NO3S2 
(391.54)·1.0 H2O: calcd. C 58.65, H 6.65, N 3.42; found C 58.75, H 6.80, N 3.48.   
 
(2S,4R)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxypyrrolidine-2-acetic acid 
[(2S,4R)-89c] 
N
OH
S S
COOH
 
According to GP7-A from 90 mg (0.22 mmol) of (2S,4R)-91c, 0.67 ml (0.67 mmol) of aq. 1.0 
M NaOH in 3.5 ml of MeOH; reaction time: 3 h; 2 ml of buffer (pH 6.6); purification by CC 
(φ 12 × 100, MeOH). Yield: 80 mg (92%); yellow foam. – M.p. 74-80 °C (C6H6/iPr2O). – 
[α]D20 = -58.3 (c = 1.00, MeOH). The spectra (1H NMR, IR, and MS) were identical with 
those of (2R,4S)-89c. – C20H25NO3S2·1.0 H2O (391.54): calcd. C 58.65, H 6.65, N 3.42; found 
C 58.75, H 6.89, N 3.18. 
 
(2R,4R)-1-[3-(9-Carbazolyl)-1-propyl]-4-hydroxypyrroidine-2-acetic acid [(2R,4R)-89d] 
N
N
OH
COOH
 
According to GP7-A from 88 mg (0.23 mmol) of (2R,4R)-88d, 0.70 ml (0.70 mmol) of aq. 1.0 
M NaOH in 3 ml of MeOH; reaction time: 14 h; 1 ml of buffer (pH 5.5); purification by CC 
(φ 12 × 100, MeOH) and recrystallization (MeOH/EtOAc). Yield: 73 mg (90%); colorless 
crystals. – M.p. 93-97 °C (MeOH/EtOAc). – [α]D20  = +31.2 (c = 0.26, MeOH). – 1H NMR 
(CD3OD): δ = 1.71-1.78 (m, 1 H, CH2CHCH2COO), 2.18-2.32 (m, 2 H, CHNCH2CH2), 2.43-
2.51 (m, 1 H, CH2CHCH2COO), 2.58-2.62 (m, 2 H, CH2COO), 2.90-3.02 (m, 2 H, CH2NCH 
and NCH2CHO), 3.41-3.55 (m, 3 H, NCH, CH2NCH and NCH2CHO), 4.34-4.51 (m, 3 H, 
CHOH and 2 H of CH2-carbazole), 7.17-7.21 (m, 2 H, Haromat), 7.46-7.53 (m, 4 H, Haromat), 
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8.05-8.08 (m, 2 H, Haromat). – IR: ~ν  = 3385, 3049, 2946, 1595, 1454, 1387, 753, 726 cm-1. – 
MS; m/z (%): 353 (2) [M+1]+, 335 (100), 289 (21), 275 (16), 180 (19), 168 (18), 159 (17), 151 
(21). – C21H24N2O3 (352.44):  calcd. C 71.57, H 6.86, N 7.95; found 
 
(2S,4S)-1-[3-(9-Carbazolyl)-1-propyl]-4-hydroxypyrrolidine-2-acetic acid [(2S,4S)-89d] 
N
N
OH
COOH
 
According to GP7-A from 54 mg (0.16 mmol) of (1S,5S)-92d, 0.49 ml (0.49 mmol) of aq. 1 
M NaOH in 4.5 ml of MeOH; reaction time: 12 h; purification by CC (φ 12 × 90; 
CH3OH/H2O, 9:1) and recrystallization in MeOH/EtOAc. Yield: 54 mg (95%); colorless 
crystals. – M.p. 102-108 °C (MeOH/EtOAc). – [α]D20 = -31 (c = 0.51, MeOH). The spectra 
(1H NMR, IR, and MS) were identical with those of (2R,4R)-89d. – C21H24N2O3·1.0 H2O 
(370.46): calcd. C 68.09, H 7.05, N 7.56; found 
 
(2R,4S)-1-[3-(9-Carbazolyl)-1-propyl]-4-hydroxypyrrolidine-2-acetic acid [(2R,4S)-89d]  
N
N
OH
COOH
 
According to GP7-A from 94 mg (0.22 mmol) of (2R,4S)-90d, 1.3 ml (1.3 mmol) of aq. 1.0 M 
NaOH in 6.5 ml of MeOH; reaction time: 3 d; purification by recrystallization (MeOH/iPr2O). 
Yield: 73 mg (93%); colorless crystals. – M.p. 175-177 °C (MeOH/iPr2O). – [α]D22 = +44.4 (c 
= 0.80, MeOH). – 1H NMR (CD3OD, 500 MHz): δ = 1.93 (ddd, J = 13.7/11.3/4.7 Hz, 1 H, 
CH2CHCH2COO), 2.13 (ddt, J = 13.7/6.4/1.7 Hz, 1 H, CH2CHCH2COO), 2.21-2.37 (m, 2 H, 
CHNCH2CH2), 2.45 (dd, J = 16.5/3.0 Hz, 1 H, CH2COO), 2.65 (dd, J = 16.5/6.0 Hz, 1 H, 
CH2COO), 2.93 (br. d, J = 12.4 Hz, 1 H, NCH2CHO), 2.96-3.03 (m, 1 H, CH2NCH), 3.36-
3.42 (m, 1 H, CH2NCH), 3.64-3.74 (m, 2 H, NCH2CHO and NCH), 4.39-4.43 (m, 1 H, 
CHOH), 4.45-4.55 (m, 2 H, CH2-carbazole), 7.21-7.26 (m, 2 H, Haromat), 7.49-7.55 (m, 2 H, 
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Haromat), 7.62-7.67 (m, 2 H, Haromat), 8.08-8.10 (m, 2 H, Haromat). – IR:  ~ν  = 3405, 3053, 2949, 
1594, 1401, 752, 725 cm-1. – MS; m/z (%): 353 (3) [M+1]+, 305 (38), 291 (100), 267 (14), 
225 (21), 180 (7), 168 (24). – C21H24N2O3 (370.46)·1.0 H2O: calcd. C 68.09, H 7.05, N 7.56; 
found C 67.91, H 6.77, N 7.37. 
 
(2S,4R)-1-[3-(9-Carbazolyl)-1-propyl]-4-hydroxypyrrolidine-2-acetic acid [(2S,4R)-89d] 
 
N
N
OH
COOH
 
According to GP7-A from 105 mg (0.286 mmol) of (2S,4R)-91d, 0.86 ml (0.86 mmol) of aq. 
1.0 M NaOH in 4 ml of MeOH; reaction time: 6 h; 1.5 ml of buffer (pH 6.6); purification by 
CC (φ 12 × 100, MeOH) and recrystallization from MeOH/iPr2O. Yield: 89 mg (88%); 
colorless crystals. – M.p. 207-209 °C (MeOH/iPr2O). – [α]D20 = -43.5 (c = 0.93, MeOH). The 
spectra (1H NMR, IR, and MS) were identical with those of (2R,4S)-89d. – C21H24N2O3 
(352.44): calcd. C 71.57, H 6.86, N 7.95; found C 71.21, H 6.79, N 7.91. 
 
(2S,4R)-4-Benzyloxy-1-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-acetic acid [(2S,4R)-94a] 
 
N
O
COOH
 
According to GP7-B from 40 mg (0.088 mmol) of (2S,4R)-93a, 0.26 ml (0.26 mmol) of aq. 
1.0 M NaOH  in 1.5 ml of MeOH; reaction time: 4 h; 2 ml of buffer (pH 6.6). The residue was 
dissolved in C6H6, then filtrated, finally concentrated. Yield: 37 mg (95%); colorless oil. – 
[α]D20  = -79.0 (c = 1.24, MeOH). – 1H NMR (CD3OD): δ = 1.90 (ddd, J = 13.9/11.5/4.8 Hz, 1 
H, CH2CHCH2COO), 2.37-2.41 (m, 1 H, CH2CHCH2COO), 2.44 (dd, J = 17.0/2.9 Hz, 1 H, 
CH2COO), 2.51-2.57 (m, 2 H, NCH2CH2), 2.74 (dd, J = 17.0/5.3 Hz, 1 H, CH2COO), 3.03-
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3.12 (m, 2 H, NCH2CHO and NCH2CH2), 3.44-3.50 (m, 1 H, NCH2CH2), 3.53 (dd, J = 
12.8/4.8 Hz, 1 H, NCH2CHO), 3.74-3.80 (m, 1 H, NCH), 4.20-4.24 (m, 1 H, NCH2CHO), 
4.44 (d, J = 11.9 Hz, 1 H, CH2Ph), 4.53 (d, J = 11.9 Hz, 1 H, CH2Ph), 6.07 (t, J = 7.4 Hz, 1 H, 
=CHCH2), 7.17-7.43 (m, 15 H, Haromat). – IR: ~ν  = 3394, 3030, 2932, 1698, 1595, 1397, 1094, 
764, 736, 699 cm-1.  – MS; m/z (%): 444 (19) [M+1]+, 443 (69), 382 (14), 274 (19), 248 (100), 
91 (78). – C29H31NO3 (441.57)·0.4 H2O: calcd. C 77.62, H 7.14, N 3.12; found C 77.53, H 
7.00, N 2.80. 
 
(2S,4R)-4-Benzyloxy-1-[4,4-di(3-methyl-2-thienyl)but-3-en-1-yl]pyrrolidine-2-acetic acid 
[(2S,4R)-94c] 
N
O
S S
COOH
 
According to GP7-B from 39 mg (0.079 mmol) of (2S,4R)-93c and 0.32 ml (0.32 mmol) of 
aq. 1.0 M NaOH in 2 ml of MeOH; purification by CC (φ 12 × 70, MeOH). Yield: 36 mg 
(95%); yellow oil. – [α]D20 = -53.8 (c = 1.03, MeOH). – 1H NMR (CD3OD): δ = 1.87 (ddd, J 
= 13.9/11.0/5.6 Hz, 1 H, CH2CHCH2COO), 1.98 (s, 3 H, thienyl-CH3), 2.01 (s, 3 H, thienyl-
CH3), 2.35 (dd, J = 13.9/6.3 Hz, 1 H, CH2CHCH2OO), 2.46-2.60 (m, 4 H, NCH2CH2 and  
CH2COO), 2.92-2.98 (m, 2 H, NCH2CHO and NCH2CH2), 3.32-3.38 (m, 1 H, NCH2CH2), 
3.57-3.67 (m, 2 H, NCH2CHO and NCH), 4.20-4.23 (m, 1 H, NCH2CHO), 4.46 (d, J = 11.8 
Hz, 1 H, CH2Ph), 4.54 (d, J = 11.8 Hz, 1 H, CH2Ph), 6.05 (t, J = 7.4 Hz, 1 H, =CHCH2), 6.77 
(d, J = 5.2 Hz, 1 H, SCH), 6.89 (d, J = 5.2 Hz, 1 H, SCH), 7.15 (d, J = 5.2 Hz, 1 H, 
SCH=CH), 7.25-7.37 (m, 6 H, Haromat). – IR: ~ν  = 3407, 3056, 3021, 2922, 1592, 1093, 698 
cm-1. – MS; m/z (%): 482 (49) [M+1]+, 422 (10), 336 (40), 248 (100), 91 (35). – C27H31NO3S2 
(481.68)·1.0 H2O: calcd. C 64.90, H 6.70, N 2.80; found C 64.70, H 6.37, N 2.90. 
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(2S,4R)-4-Hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}-
pyrrolidine-2-acetic acid [(2S,4R)-104b] 
N
OH
COOH
OMe
O
OMeMeO
OMe
 
According to GP7-A from 115 mg (0.179 mmol) of (2S,4R)-102b, 0.54 ml (0.54 mmol) of aq. 
1.0 M NaOH in 4.5 ml of MeOH; reaction time: 48 h; purification by recrystallization from 
C6H6/iPr2O. Yield: 97 mg (86%); colorless powder. – M.p. 106-111 °C (C6H6/iPr2O). – [α]D20 
= -20.5 (c = 0.81, MeOH). – 1H NMR (CD3OD, 500 MHz): δ = 2.19 (ddd, J = 14.1/6.0/1.4 
Hz, 1 H, CH2CHCH2COO), 2.70 (dd, J = 16.5/4.1 Hz, 1 H, CH2COO), 2.74-2.82 (m, 2 H, 
CH2CHCH2COO and CH2COO), 3.19-3.25 (m, 1 H, NCH2CH2), 3.33 (d, J = 11.1 Hz, 
NCH2CO), 3.44-3.49 (m, 3 H, NCH2CO and 2 H of NCH2CH2), 3.62-3.67 (m, 1 H, 
NCH2CH2), 3.74 (s, 9 H, Ar’OCH3), 3.78 (s, 3 H, ArOCH3), 3.87-3.93 (m, 1 H, NCH), 6.83-
6.86 (m, 6 H, Haromat), 6.89-6.92 (m, 2 H, Haromat), 7.31-7.38 (m, 8 H, Haromat). – IR: ~ν  = 3421, 
3037, 2956, 1608, 1580, 1508, 1251, 1176, 1034, 829 cm-1. – MS (ESI+): m/z (%): 628 
(M+1]+ (51), 333 (100). – C37H41NO8 (627.74)·0.7 H2O: calcd. C 69.40, H 6.67, N 2.19; found 
C 69.45, H 6.94, N 2.19. 
 
(2R,4S)-4-Hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}-
pyrrolidine-2-acetic acid [(2R,4S)-104b] 
 
N
OH
COOH
OMe
O
OMeMeO
OMe
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According to GP7-A from 125 mg (0.191 mmol) of (2R,4S)-103b, 0.58 ml (0.58 mmol) of aq. 
1.0 M NaOH in 6.4 ml of MeOH; reaction time: 48 h; purification by CC (φ 18 × 120; 
MeOH-H2O, 4:1) and recrystallization from C6H6/iPr2O. Yield: 107 mg (89%); colorless 
crystal. – M.p. 116-122 °C (C6H6/iPr2O). – [α]D20 = +20.3 (c = 0.69, MeOH). The spectra (1H 
NMR, IR, and MS) were identical with those of (2S,4R)-104b. – C37H41NO8 (627.74)·0.6 
H2O: calcd. C 69.60, H 6.66, N 2.19; found C 69.50, H 6.75, N 2.08. 
 
(2S,4S)-4-Hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)methoxy]-1-ethyl}-
pyrrolidine-2-acetic acid [(2S,4S)-104b] 
N
OH
COOH
OMe
O
OMeMeO
OMe
 
According to GP7-A from 70 mg (0.11 mmol) of (2S,4S)-102b, 0.33 ml (0.33 mmol) of aq. 
1.0 M NaOH in 2.7 ml of MeOH; reaction time: 48 h; purification by CC (φ 12 × 90; MeOH-
H2O, 4:1) and recrystallization from C6H6/iPr2O. Yield: 50 mg (73%); colorless powder. – 
M.p. 117-121 °C (C6H6/iPr2O). – [α]D20 = -9.4 (c = 0.50, MeOH). – 1H NMR (CD3OD): δ = 
2.28-2.42 (m, 2 H, CH2CHCH2COO), 2.46 (dd, J = 16.9/1.5 Hz, 1 H, CH2COO), 2.85 (dd, J = 
16.9/5.1 Hz, CH2COO), 3.23 (dd, J = 12.4/1.5 Hz, 1 H, NCH2CO), 3.30-3.34 (m, 1 H, 
NCH2CH2), 3.38 (d, J = 12.4 Hz, 1 H, NCH2CO), 3.43-3.68 (m, 3 H, NCH2CH2 and 2 H of 
NCH2CH2), 3.74 (s, 9 H, Ar’OCH3), 3.79 (s, 3 H, ArOCH3), 4.05-4.12 (m, 1 H, NCH),  6.84-
6.88 (m, 6 H, Haromat), 6.90-6.94 (m, 2 H, Haromat), 7.31-7.37 (m, 8 H, Haromat). – IR: ~ν  = 3422, 
3037, 2957, 1608, 1509, 1251, 1177, 1034, 829 cm-1. – MS (ESI+); m/z (%): 628 [M+1]+ (26) 
333 (100). – C37H41NO8 (627.74)·0.8 H2O: calcd. C 69.21, H 6.69, N 2.18; found C 69.22, H 
6.78, N 2.02. 
 
(2R,4R)-4-Hydroxy-4-(4-methoxyphenyl)-1-{2-[tris(4-methoxyphenyl)]methoxy-1-
ethyl}pyrrolidine-2-acetic acid [(2R,4R)-104b] 
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N
OH
COOH
OMe
O
OMeMeO
OMe
 
According to GP7-A from 42 mg (0.065 mmol) of (2R,4R)-103b, 0.20 ml (0.20 mmol) of aq. 
1.0 M NaOH in 3 ml of MeOH; reaction time: 2 d; purification by recrystallization from 
C6H6/iPr2O. Yield: 38 mg (93%); colorless powder. – M.p. 110-117 °C (C6H6/iPr2O). – [α]D20 
= +9.5 (c = 0.62, MeOH). The spectra [1H NMR (500 MHz), IR, and MS] were identical with 
those of (2S,4S)-104b. – C37H41NO8 (627.74)·0.9 H2O: calcd. C 69.01, H 6.67, N 2.18; found 
C 68.85, H 6.56, N 2.21. 
 
(2S,4R)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-acetic acid [(2S,4R)-104c] 
 
N
OH
OMe
COOH
S S
 
 
 
According to GP7-A from 83 mg (0.16 mmol) of (2S,4R)-102c, 0.49 ml (0.49 mmol) of aq. 
1.0 M NaOH  in 4.5 ml of MeOH; reaction time: 3 d; purification by CC (φ 12 × 110, MeOH) 
and recrystallization from C6H6/iPr2O. Yield: 56 mg (70%); colorless powder. – M.p. 73-76 
°C (C6H6/iPr2O). – [α]D20 = -37.9 (c = 0.61, MeOH). – 1H NMR (CD3OD, 500 MHz): δ = 
1.96 (s, 3 H, thienyl-CH3), 2.02 (s, 3 H, thienyl-CH3), 2.13-2.18  (m, 1 H, CH2CHCH2COO), 
2.60 (q, J = 7.4 Hz, 2 H, NCH2CH2), 2.69-2.81 (m, 3 H, CH2CHCH2COO and 2 H of 
CH2COO), 3.08-3.12 (m, 1 H, NCH2CH2), 3.18-3.22 (m, 1 H, NCH2CO), 3.54-3.62 (m, 2 H, 
NCH2CH2 and NCH2CO), 3.77 (s, 3 H, ArOCH3), 3.86-3.90 (m, 1 H, NCH), 6.04 (t, J = 7.4 
Hz, 1 H, =CHCH2), 6.78 (d, J = 5.2 Hz, 1 H, SCH), 6.88-6.93 (m, 3 H, SCH and 2 H of 
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Haromat), 7.16 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.34 (d, J = 5.2 Hz, 1 H, SCH=CH), 7.38-7.40 
(m, 2 H, Haromat). – IR: ~ν  = 3385, 3102, 2953, 1609, 1515, 1400, 1251, 1034, 832, 714 cm-1. – 
MS; m/z (%): 498 (100) [M+1]+, 480 (47), 434 (62), 276 (12), 186 (13). – C27H31NO4S2 
(497.67)·0.5 H20: calcd. C 64.00, H 6.37, N 2.76; found C 63.84, H 6.67, N 2.54.  
  
(2R,4S)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-acetic acid [(2R,4S)-104c] 
N
OH
OMe
COOH
S S
 
According to GP7-A from 87 mg (0.17 mmol) of (2R,4S)-103c, 0.50 ml (0.50 mmol) of aq. 
1.0 M NaOH in 4.5 ml of MeOH; reaction time: 2 d; purification by recrystallization from 
C6H6/iPr2O. Yield: 68 mg (82%); slightly yellow powder. – M.p. 69-73 °C (C6H6/iPr2O). – 
[α]D20 = +34.0 (c = 0.85, MeOH). The spectra [1H NMR (500 MHz), IR, and MS] were 
identical with those of (2S,4R)-104c. – C27H31NO4S2 (497.67)·0.6 H2O: calcd. C 63.78, H 
6.38, N 2.75, S 12.61; found C 63.60, H 6.38, N 2.67, S 12.43. 
 
(2S,4S)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-acetic acid [(2S,4S)-104c] 
 
N
OH
OMe
COOH
S S
 
According to GP7-A from 60 mg (0.12 mmol) of (2S,4S)-102c, 0.35 ml (0.35 mmol) of aq. 
1.0 M NaOH in 3.6 ml of MeOH; reaction time: 3 d; purification by recrystallization from 
 
                                                          6. Experimental Section……………    ………….. - 179 - 
C6H6/iPr2O. Yield: 57 mg (98%); colorless powder. – M.p. 73-76 °C (C6H6/iPr2O). – [α]D20 = 
-38.6 (c = 0.70, MeOH). – 1H NMR (CD3OD, 500 MHz): δ = 1.98 (s, 3 H, thienyl-CH3), 2.03 
(s, 3 H, thienyl-CH3), 2.24-2.31 (m, 1 H, CH2CHCH2COO), 2.39 (ddd, J = 13.3/6.0/1.9 Hz, 1 
H, CH2CHCH2COO), 2.51 (dd, J = 16.7/2.3 Hz, 1 H, CH2COO), 2.61 (q, J = 7.4 Hz, 2 H, 
NCH2CH2), 2.79 (dd, J = 16.7/5.8 Hz, CH2COO), 3.25-3.31 (m, 2 H, NCH2CH2 and 
NCH2CO), 3.52-3.61 (m, 1 H, NCH2CH2), 3.64 (d, J = 12.4 Hz, 1 H, NCH2CO), 3.77 (s, 3 H, 
ArOCH3), 4.05-4.12 (m, 1 H, NCH), 6.07 (t, J = 7.4 Hz, 1 H, =CHCH2), 6.77 (d, J = 5.2 Hz, 1 
H, SCH), 6.89-6.92 (m, 3 H, SCH and 2 H of Haromat), 7.15 (d, J = 5.2 Hz, 1 H, SCH=CH), 
7.34-7.39 (m, 3 H, SCH=CH and Haromat). – IR: ~ν  = 3420, 3102, 2926, 1610, 1514, 1382, 
1250, 1034, 833, 715 cm-1. – MS: m/z (%): 498 (17) [M+1]+, 480 (20), 420 (53), 412 (34), 
264 (62), 236 (95), 178 (41), 146 (100), 128 (35). – C27H31NO4S2 (497.67)·0.5 H20: calcd. C 
64.00, H 6.37, N 2.76; found C 64.27, H 6.59, N 2.47. 
 
(2R,4R)-1-[4,4-Di(3-methyl-2-thienyl)but-3-en-1-yl]-4-hydroxy-4-(4-methoxyphenyl)-
pyrrolidine-2-acetic acid [(2R,4R)-104c] 
N
OH
OMe
COOH
S S
 
According to GP7-A from 61 mg (0.12 mmol) of (2R,4R)-103c, 0.35 ml (0.35 mmol) of aq. 
1.0 M NaOH in 4 ml of MeOH; reaction time: 2 d; purification by recrystallization from 
C6H6/iPr2O. Yield: 55 mg (95%); slight yellow powder. – M.p. 70-74 °C (C6H6/iPr2O). – 
[α]D20 = +40.1 (c = 0.7, MeOH). The spectra [1H NMR (500 MHz), IR, and MS] were 
identical with those of (2S,4S)-104c. – C27H31NO4S2 (497.67)·0.9 H2O: calcd. C 65.11, H 
6.43, N 2.73; found C 65.09, H 6.24, N 2.64. 
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6.1.10   Miscellaneous  
 
Methyl (2S,4R)-4-hydroxy-1-triphenylmethylpyrrolidine-2-carboxylate [(2S,4R)-49] [45] 
 
1.00 g (5.51 mmol) of (2S,4R)-38 was dissolved in 55 ml of CH2Cl2 containing 1.34 g (13.3 
mmol) of TEA to give a clear solution, and then 1.54 g (5.51 mmol) of TrCl was added at 0~5 
°C. After the mixture had been stirred at this temperature for 20 min, the organic layer was 
washed with H2O (3 × 60 ml), dried (Na2SO4), and evaporated to give a viscous oil, which 
was recrystallized from 4 ml of iPr2O and 8 ml of petroleum ether. Yield: 2.03 g (95%); 
colorless crystals. – M.p. 139-142 °C. – [α]D20 = -26.2 (c = 1.01, MeOH)  {ref. [45]: M.p: 144-
145 °C; [α]D30 = -24.2 (c = 1.00, MeOH)}. 
 
(2R,4R)-1-Benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid [(2R,4R)-58] 
 
As described by ref. [61] from 7.41 g (56.6 mmol) of (2R,4R)-25 in 28 ml (57 mmol) of aq. 2.0 
M NaOH, 7.98 ml (9.62 g, 56.6 mmol) of CbzCl and 28 ml (57 mmol) of aq. 2.0 M NaOH. 
Yield: 12.0 g (80%); colorless crystals. – M.p. 106-110 °C. – [α]D22 = +27.1 (c = 1.00, 
CHCl3) {ref. [41]: M.p. 110.5-11.5 °C (EtOAc/petroleum ether); [α]D20 = +26.3 (c = 1.0, 
CHCl3)}. 
 
Methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate [(2S,4R)-59]  
 
As described by ref. [62, 63]: To a solution of 1.86 g (7.00 mmol) of (2S,4R)-58 in 25 ml of 
EtOAc, 3.0 g (7.2 mmol) of CH2N2 in 20 ml of Et2O was slowly added at 0 °C until yellow 
color persisted in 15 min. Excessive CH2N2 was decomposed by slow addition of AcOH. This 
solution was washed with aq. 0.1% K2CO3, dried (MgSO4), and evaporated. Yield: 1.80 g 
(95%); colorless oil. – [α]D20 = -58.0 (c = 0.90, CHCl3) {ref. [37]: [α]D20 = -58.8 (c = 1.04, 
CHCl3)}. 
 
Methyl (2R,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate [(2R,4R)-59] 
[88] 
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As described by ref. [62, 63]: 1.86 g (7.00 mmol) of (2R,4R)-58 in 30 ml of CH2Cl2 was 
esterified at 0 °C by 3.0 g (7.2 mmol) of CH2N2 in 20 ml of Et2O. Yield: 1.97 g (100%); 
colorless crystals. – M.p. 82-84 °C. – [α]D20 = +39.5 (c = 1.00, CHCl3). 
 
Methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-acetate [(2S,4R)-95][74] and 
methyl (2S,4R)-1-benzyloxycarbonyl-4-(benzyloxycarbonyl)oxypyrrolidine-2-acetate 
[(2S,4R)-82] 
COOCH3
N
PhCH2OCOO
COOCH2Ph
  
                                                              (2S,4R)-82 
 
According to ref. [89, 90]: To a solution of 525 mg (2.68 mmol) of (2S,4R)-86 and 1.08 g (8.87 
mmol) of DMAP in 20 ml of CH2Cl2, 688 mg (4.03 mmol) of CbzCl was added at – 23 °C. 
This solution was continued to stir for 48 h, and then washed with H2O, dried (MgSO4) and 
evaporated. The residual oil was purified by CC (φ 25 × 220; n-heptane/acetone, 3:1) to yield 
(2S,4R)-95 and (2S,4R)-82.  
(2S,4R)-95: 462 mg (59%); [α]D20 = -55.3 (c = 1.21, CHCl3); colorless oil. 
(2S,4R)-82: 184 mg (17%); colorless oil. – TLC: Rf = 0.42 (n-heptane/acetone, 3:2). – [α]D20 
= -43.0 (c = 0.90, EtOAc). – 1H NMR (C6D5NO2, 120 °C): δ = 2.25-2.32 (m, 1 H, 
CH2CHCH2COO), 2.49-2.56 (m, 1 H, CH2CHCH2COO), 2.68 (dd, J = 15.4/8.6 Hz, 1 H, 
CH2COO), 3.06 (dd, J = 15.4/3.9 Hz, 1 H, CH2COO), 3.66 (s, 3 H, OCH3), 3.79 (dd, J = 
12.4/5.4 Hz, 1 H, NCH2), 3.98 (dt, J = 12.4/2.0 Hz, 1 H, NCH2), 4.45-4.52 (m, 1 H, NCH), 
5.22 (s, 4 H, CH2Ph), 5.31-5.35 (m, 1 H, NCH2CHO), 7.23-7.40 (m, 10 H, Haromat). – IR: ~ν  = 
3034, 2954, 1738, 1704, 1416, 1265, 1230, 753, 698 cm-1. – MS; m/z (%): 428 (12) [M+1]+, 
384 (14), 186 (15), 181 (13), 158 (10), 140 (39), 91 (100). – C22H25NO7 (427.45): calcd. C 
64.63, H 5.89, N 3.28; found C 65.01, H 5.84, N 3.17. 
 
(2S,4R)-1-Benzyloxycarbonyloxy-4-(bezyloxycarbonyl)oxypyrrolidine-2-carboxylic acid  
[(2S,4R)-81] [91] 
 
To a solution of 1.62 g (6.11 mmol) of (2S,4R)-58 in 40 ml of THF,  490 mg (12.2 mmol) of 
NaH (55~60% in oil) was added at r.t. The resulting mixture was stirred for 1.5 h and then 
 
                                                          6. Experimental Section……………    ………….. - 182 - 
1.15 g (6.73 mmol) of CbzCl was added at 0 °C. The reaction mixture was stirred at r.t. for 20 
h, quenched with ice-water, acidified with aq. 2 N HCl to pH 1~2, and extracted (Et2O). The 
extract was dried (Na2SO4) and concentrated. Yield: 1.45 g (59%); colorless oil. 
 
Methyl (2S,4R)-1-Benzyloxycarbonyl-4-(benzyloxycarbonyl)oxypyrrolidine-2-acetate 
[(2S,4R)-82] 
 
To a solution of 1.05 g (2.63 mmol) of (2S,4R)-81 and 8 µl of DMF in 8 ml of CH2Cl2, 502 
mg (3.95 mmol) of (COCl)2 was added at 0 °C. After 20 min, the solution was stirred at r.t for 
1 h. The solvent was removed in vacuo to give the acid chloride as colorless oil. The above 
acid chloride in 8 ml of Et2O was slowly added to 365 mg (8.30 mmol) of CH2N2 in 35 ml of 
Et2O at 0 °C. After 1 h, the excessive CH2N2 was decomposed with AcOH, and then the 
reaction mixture was evaporated to give yellow oil. Purification by CC (φ 25 × 300; iso-
hexane/acetone, 3:1) yielded 210 mg (19%) of the diazoketone as yellow oil. 
 
To a solution of 200 mg (0.473 mmol) of the above diazoketone in 1.0 ml of MeOH, a 
solution of 10 mg (0.06 mmol) of silver acetate and 37 mg (0.36 mmol) of TEA in 1.0 ml of 
MeOH was added at r.t. The new solution turned to be brown in several minutes, and then 
was warmed to 60 °C in 50 min, finally decolorized with active carbon. The reaction mixture 
was concentrated to yellow oil. Purification by CC (φ 18 × 340; n-heptane/acetone, 3:1). 
Yield: 110 mg (59%); colorless oil. All analytical data were identical with the about product 
prepared from (2S,4R)-86. 
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6.2 Biological experiments: 
 
6.2.1 The Subcellular fractions from frontal cortex and brain stem 
 
Subcellular fractions of frontal cortex and brain stem were obtained from freshly bovine 
brains according to a known procedure that has been slightly modified [92]. 10 g of each region 
(frontal cortex or brain stem) were homogenized in 100 ml of 0.32 M sucrose with a potter 
(PotterS 800 rpm, 12 up-and-down strokes) and then centrifuged at 3000 × g for 10 min in a 
Sorvall SS34 rotor. The supernatant was diluted with 0.32 M sucrose to 140 ml. 6 Aliquots of 
the resulting suspension were layered on 1.2 M sucrose. Centrifugation at 257 000 × g for 16 
min in a Hitachi P70AT rotor gave a pellet, termed P2A. The interphase at the gradient was 
collected and then diluted with 0.32 M sucrose to 140 ml. 6 Aliquots of the resulting 
suspension were layered on 1.2 M sucrose 12 ml of 0.8 M sucrose. Centrifugation as 
described above yielded a pellet, termed P2B. The interphase at the gradient was collected 
and diluted again with 0.32 M sucrose. Centrifugation as above yielded a pellet, termed P2C. 
All the above procedures were carried out at 4 °C. 
 
P2B from bovine frontal cortex (= bfcP2B) and P2C from bovine brain stem (= bbsP2C) were 
suspended in buffer I (119 mM NaCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 4.7 
mM KCl, 11 mM Glucose and 25 mM Tris HCl pH 7.2) or buffer II (2.5 mM CaCl2 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 4.7 mM KCl, 11 mM Glucose and 144 mM Tris HCl pH 7.2). The 
protein concentration was determined with bovine serum albumin as a standard as described 
by Bradford [93]. 
The preparations of P2B from frontal cortex and P2C from brain stem using porcine brains or 
calf brains were completely performed in the same way as above. The final membrane 
fractions for uptake experiments were termed as follows: 
bfcP2B (P2B from bovine frontal cortex), cfcP2B (P2B from frontal cortex), pfcP2B (from 
porcine frontal cortex); 
bbsP2C (P2C from bovine brain stem), cbcP2C (P2C from calf brain stem), pbsP2C (from 
porcine brain stem). 
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6.2.2  Inhibition of GABA-uptake 
 
6.2.2.1  Inhibition of GAT-1 mediated GABA-uptake 
 
Aliquots of about 50-100 µg protein bfcP2B (alternatively cfcP2B or pfcP2B) were 
preincubated with 10 µM aminooxyacetic acid and a test compound in 200 µl of buffer I for 
10 min at 37 °C. After the addition of 25 µl of 12.5 nM [3H] GABA and 25 µl of 250 nM 
GABA, the sample was incubated at 37 °C for 4 min. Then the incubation was terminated by 
the filtration in a Brandel M-24R Harvester through Whatman GF/C filters, which had been 
immersed in 0.9% NaCl for 1 h. The filters were washed with 0.9% NaCl (4 × 2 ml) and then 
measured in 3 ml of Rotiszint Eco Plus by the use of a Packard TriCarb 1600 Counter. 
Specific uptake was defined as difference between entire-uptake and non-specific uptake, 
which was determined with identical samples lacking NaCl (buffer II).  
 
6.2.2.2 Inhibition of GAT-3 mediated GABA-uptake 
 
Aliquots of about 50-100 µg protein bbsP2C (alternatively cbsP2C or pbsP2C) were 
preincubated with 10 µM aminooxyacetic acid, 10 µM NNC-711 and a test compound in 200 
µl of buffer I for 10 min at 37 °C. After the addition of 25 µl of 50 nM [3H] GABA and 25 µl 
of 1 µM GABA, the sample was incubated at 37 °C for 4 min. Then the incubation was 
terminated by the filtration in a Brandel M-24R Harvester through Whatman GF/C filters, 
which had been immersed in 0.9% NaCl for 1 h. The filters were washed with 0.9% NaCl (4 × 
2 ml) and then measured in 3 ml of Rotiszint Eco Plus by the use of a Packard TriCarb 1600 
Counter. Specific uptake was defined as difference between entire-uptake and non-specific 
uptake, which was determined with identical samples lacking NaCl (buffer II). 
 
6.2.3 Evaluation 
 
IC50 values were calculated by nonlinear regression analysis using Prism 2 (GraphPad 
Software TM). All the results were given as means ± SEM from three experiments if not stated 
otherwise. 
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7      SRUCTURE LIST OF NEW COMPOUNDS AND MAIN 
SYNTHETIC ROUTES  
 
7.1 List of new compounds: 
 
All the compounds in my thesis listed below were synthesized at the first time and their page 
numbers where they are mentioned rank below. The suffix of each compound number 
respectively represents the following residues a-d if not illustrated otherwise. 
OMe
OMe
OMe
S
S
Na b c d
N
RO
COOCH2Ph
OMe
       
N
RO
COOCH2Ph
OMe
 
N
COOCH2Ph
COO
R1O
R2
 
N
COOCH2Ph
COO
R1O
R2
 
R  =   H                                         R = H                             R1  =   Cbz,     R2  =   Et          R1   =   Cbz,   R2   =   Me 
(2S,4R)-69 30,33-34,85,87  (2R,4R)-69 30,33-34,85,87  (2R,4R)-80 33-34,59-60, 92     (2S,4R)-82 35 43,59,181  
R  =   Cbz-                                R =   Cbz-                          R1  =  TBDMS-    R2  =  Et      R1 = TBDMS-   R2 = Et 
(2S,4R)-77  33-34, 87-88      (2R,4R)-77  33-34, 87-88   (2S,4R)-71 31-32, 89-92          (2R,4R)-71 31-32, 89-92 
R  =  TBDMS-                         R = TBDMS-                      R1  =  H         R2  =  Et  
(2S,4R)-70  30-31, 86-87       (2R,4R)-70  30-31, 86-87  (2R,4R)-73 32, 43-44, 51-52 
            
                
COOCH3
(CH2)nN
OH
R  
                
                    
(CH2)n
COO
N
OH
R
R1
 
n  =  0                                                                                         n  =  0,          R1  =  Me
(2S,4R)-39a  12, 15, 20, 101-102, 156 
(2S,4R)-39b  12, 15, 20, 102-123, 158 
 (2R,4R)-39a  14, 15, 20, 102, 113, 122, 157 
 (2R,4R)-39b  14, 15, 20, 103, 113, 123, 159
 
n  =  1                                                                                         n  =  1            R1  =  Et
(2S,4R)-86 (R = -H·HCl) 36, 40, 43, 58, 96, 107-109, 181      (2R,4R)-64 (R = -H·HCl) 28,32,37,58, 93, 104-107 
(2S,4R)-91a  40-41, 46, 107, 125, 166                                      (2R,4R)-88a   37-39, 104, 114, 165 
(2S,4R)-91b  40-41, 46, 108, 125, 168                                      (2R,4R)-88b  37, 39, 46, 105, 115, 125, 167 
(2S,4R)-91c   40-41, 46, 108, 127, 171                                     (2R,4R)-88c   37, 39, 46, 106, 115, 127, 169 
(2S,4R)-91d   40-41, 109, 173                                                   (2R,4R)-88d   37, 39, 107, 116, 171 
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(CH2)n
N
O
O
R  
            
(CH2)n
COO
N
CH3COO
R
R1
 
n  = 0                                                                                         n  = 0,              R1  =   Me 
(1S,4S)-41a  13, 15, 112, 158                                                   (2R,4S)-48a  15, 113, 157 
                                                                                                   (2R,4S)-48b  15, 113, 159
 n  =  1                                                                                        n  =  1,              R1  =   Et
(1S,5S)-92a  40-41, 117, 165 
(1S,5S)-92b  40-41, 117, 167 
(1S,5S)-92c  40-41, 118, 170 
(1S,5S)-92d  40-41, 119, 172 
(1S,5S)-98    (R = -Cbz)  44, 119, 148 
 (2R,4S)-90a  37, 39, 114, 166 
(2R,4S)-90b  37, 39, 115, 168 
(2R,4S)-90c  37, 39, 115, 170 
(2R,4S)-90d  37, 39, 116, 172 
(2R,4S)-99 [R = -Cbz , (4S)-HCOO] 44,45,120,149 
             
(CH2)nCOOCH3
N
O
R                 
R1(CH2)nCOON
O
R  
 n  =  0                                                                                       n  =  0,        R1  =   Me
(2S)-50     (R  =  -Tr)  18, 121, 131 
(2S)-52a   20-24, 27, 48, 53, 55, 122, 132-134                       (2R)-52a  20-22, 53, 122-123, 135-136 
(2S)-52b   20-23, 27, 48, 53, 123, 135-136                             (2R)-52b  20-22, 53, 123-124, 136-137 
n  =  1                                                                                        n  =  1,        R1  =   Et 
(2S)-100a  46-47, 50, 125                                                                                    
(2S)-100b  46-48, 125, 139-140                                               (2R)-101b   46-48, 126, 140-142
(2S)-100c   46-48, 127, 142-143                                               (2R)-101c   46-48, 127, 143-145 
(2S)-108     (R  =   -Cbz)  51, 128, 145                                     (2R)-112    (R =  -Cbz)  51-52, 128, 146
                
(CH2)nCOOCH3
N
OH
R
OMe
                 
R1(CH2)nCOON
OH
R
OMe
 
 n  =  0                                                                                            n   =  0,                 R1  =   Me 
(2S,4R)-51    (R  =  -Tr)  19, 131 
(2S,4R)-53a  21-25, 53, 55-57, 104, 132-134, 162 
(2S,4R)-53b  21-25, 53, 135-136, 162 
(2S,4R)-61     (R =  -Cbz)  26-27, 54, 57, 137, 147 
(2S,4R)-114   (R =  -H)  54-55, 104, 152 
 
(2R,4S)-53a   21-22, 53, 134-135, 162 
(2R,4S)-53b   21-22, 53, 136-137, 163 
(2R,4S)-61  (R =  -Cbz)  57, 138, 147 
n  =  1                                                                                        n  =  1,                 R1  =   Et
(2S,4R)-102b  47-49, 139-140, 175                                        (2R,4S)-102b  47-49, 140-142, 175 
(2S,4R)-102c  47-49, 142-143, 177                                         (2R,4S)-102c  47-49, 143-145, 178 
(2S,4R)-109   (R =   -Cbz)  51, 62-64, 145, 149, 155              (2R,4S)-113   (R =  -Cbz)  51-52, 146, 150 
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(2S,4R)-115   (R =  -H)  61, 63, 111, 155
           
(CH2)nCOOCH3N
OH
R
OMe
              
R1(CH2)nCOON
OH
R
OMe
 
n  =  0                                                                                         n  =  0,               R1   =   Me
(2S,4S)-51    (R  =  -Tr) 19, 131  
(2S,4S)-53a  21-25, 53, 56-57, 132-134, 166                          (2R,4R)-53a   21-22, 53, 134-135, 161 
(2S,4S)-53b  21-25, 53, 135-136, 163                                     (2R,4R)-53b  21-22, 53, 136, 137, 164 
 n   =  1                                                                                        n  =  1,               R1  =  Et 
(2S,4S)-102b  47-49, 139-140, 176                                          (2R,4R)-103b  47, 49, 140-142, 176-177 
(2S,4S)-102c  47-49, 142-143, 178                                           (2R,4R)-103c  47, 49, 143-145, 179 
              
(CH2)nCOOHN
OH
R                    
(CH2)nCOOHN
OH
R  
n  =  0                                                                                       n  =  0
(2S,4S)-40a  12-13, 15-17, 158                                              (2R,4R)-40a  14-15, 157 
(2S,4S)-40b  12-13, 15, 17, 160                                             (2R,4R)-40b  14-15, 159
n  = 1                                                                                         n  =  1    
(2S,4S)-89a   40-42, 165                                                         (2R,4R)-89a  37-39, 165 
(2S,4S)-89b  40-41, 167                                                          (2R,4R)-89b  37, 39, 167 
(2S,4S)-89c   40-41, 169-170                                                  (2R,4R)-89c  37, 39, 169 
(2S,4S)-89d   40-41, 172                                                         (2R,4R)-89d  37, 39, 171 
(2S, 4S)-96   (R =  -Cbz)  44, 148, 153-154                            (2R,4R)-96   (R =  -Cbz)  43, 148, 153 
(2S,4S)- 97   (R =  -H)  44-45, 153-154                                  (2R,4R)-97   (R =   -H)  43, 153
          
(CH2)nCOOH
N
OH
R              
(CH2)nCOOHN
OH
R  
n  =  0                                                                                         n  =  0 
(2S,4R)-40a   12-13, 15-17, 112, 156                                       (2R,4S)-40a   14-15, 157 
(2S,4R)- 40b   12-13, 15-17, 158, 160                                      (2R,4S)-40b   14-15, 159          
n  =  1                                                                                         n  =  1 
(2S,4R)-89a  40-42, 117, 166                                                    (2R,4S)-89a  37, 39, 166 
(2S,4R)-89b  40-41, 117-118, 168-169                                     (2R,4S)-89b  37, 39, 168 
(2S,4R)-89c  40-41, 118-119, 171                                             (2R,4S)-89c  37, 39, 170
(2S,4R)-89d   40-41, 119, 173                                                   (2R,4S)-89d  37, 39, 172
                                                                                                   (2R,4S)-96   (R   =  -Cbz)  45, 149 
(2S,4R)-97  (R =  -H)  44-45, 152                                             (2R,4S)-97   (R =  -H)  45, 153
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(CH2)nCOOH
N
OH
R
OMe
                 
(CH2)nCOOHN
OH
R
OMe
 
n  =  0                                                                                         n  =  0
(2S,4R)-57a   25, 53, 161-162                                                 (2R,4S)-57a  25, 53, 162 
(2S,4R)-57b   25, 53, 162-163                                                 (2R,4S)-57b  25, 53, 163
(2S,4R)-62    (R  =  -Cbz)  26-27, 147, 151                             (2R,4S)-62   (R  =  -Cbz)  147-148, 151-152       
(2S,4R)-63    (R =  H)  26-27, 57, 151                                     (2R,4S)-63   (R =  -H)  27, 57, 151-152 
n  =  1                                                                                         n  =  1
 (2S,4R)-104b  49, 175                                                               (2R,4S)-104b  49, 175-176 
(2S,4R)- 104c  49, 177                                                              (2R,4S)-104c 49, 179 
(2S,4R)-110   (R  =  -Cbz)  51, 149-150, 154                           (2R,4S)-110   (R  =  -Cbz)  52, 150 
(2S,4R)-111   (R  =  -H)  51, 61-62, 153                                   (2R,4S)-111  (R  =  -H)  52, 154-155
                
(CH2)nCOOH
N
OH
R
OMe
                  
(CH2)nCOOHN
OH
R
OMe
 
 n  =  0                                                                                        n  =  0
(2S,4S)-57a   25, 53, 160-161                                                  (2R,4R)-57a   25, 53, 161 
(2S,4S)-57b  25, 53, 163-164                                                   (2R,4R)-57b  25, 53, 164
n  =  1                                                                                         n  =  1 
(2S,4S)-104b  49, 176                                                               (2R,4R)-104b  49, 176-177 
(2S,4S)-104c   49, 178-179                                                       (2R,4R)-104c  49, 179 
 
         
R1
N
PhCH2O
R
COO
                    
N
PhCH2O
COCHN2
COOCH2Ph  
R1  =  Me                                                                                 
(2S,4R)-85     (R  =  -Cbz)  36, 96-97                                       (2S,4R)-84       36, 95                                    
(2S,4R)-87     (R   =  -H⋅HCl)  36, 40, 110-111                                      
(2S,4R)-93a   40-41, 110, 173 
(2S,4R)-93c   40-41, 110-111, 174 
R1   =   H 
(2S,4R)-94a  40-41, 173 
(2S,4R)-94c  40-41, 1
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7.2       Main synthetic routes: 
 
7.2.1.  N-Unsubstituted 4-hydroxypyrrolidine derivatives. 
N
OH
COOH
H
SOCl2
MeOH N
OH
COOCH3
H HCl.
1.
                                                  Lit. 
N
OH
H
COOH
1. AcOH/Ac2O
2.  2 N HCl N
OH
H
COOH
SOCl2
MeOH N
OH
COOCH3
H
2.
HCl.
                                             Lit.                                   Lit. 
N
OH
COOCH2Ph
COOH N
OH
COOCH2Ph
OMe
-e
MeOH N
O
COOCH2Ph
OMe
Si
N
OH
COOH
H
3.
                                               Lit. 
N
O
COOCH2Ph
Si
COOC2H5 N
O
COOCH2Ph
Si
COOC2H5+
I II 
N
OH
COOCH2Ph
COOC2H5
TBAF
N
OH
H
COOC2H5
HCl.
I 
N
OH
COOH
COOCH2Ph
N
PhCH2O
COOH
COOCH2Ph
(COCl)2 CH2N2 AgOAc
N
PhCH2O
COOCH2Ph
COOCH3
H2
N
OH
H
COOCH3
. HCl
4.
MeOH
                                               Lit. 
7.2.2.  4-Hydroxy pyrrolidine derivatives. 
N
OH
H
(CH2)nCOOCH3
. HCl
N
OH
R
(CH2)nCOOCH3
RX
N
OH
R
(CH2)nCOOH
N
OH
R
(CH2)nCOOH
1.
N
R
(CH2)n
O
O
 
1). n  =  0,    R  =  24a-b,  X  = Br 
2). n  =  1,    R  =  24a-c,  X  =  Br; R  =  24d,  X  =  I;  R  =  Cbz,  X  =  Cl. 
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N
OH
H
(CH2)nCOO
. HCl
N
OH
R
(CH2)nCOO
RX
N
OH
R
(CH2)nCOOH
N
CH3COO
R
COO
N
OH
R
(CH2)nCOOH
2. R1
R1
R1
 
1). n  =  0,    R1  =  Me,     R  =  24a-b. 
2). n  =  1,    R1  =  Et,       R  =  24a-c,  X  =  Br;  R  =  24d,  X  =  I;  R  =  Cbz, (4S)-HCOO-. 
 
N
OH
COOCH2Ph
COOH
10% Pd-C N
OH
H
COOH
H2,  MeOH
3. 
 
7.2.3.  4-Hydroxy-4-(4-methoxyphenyl)pyrrolidine derivatives. 
N
OH
R
(CH2)nCOOCH3
N
O
R
(CH2)nCOOCH3 N
OH
R
(CH2)nCOOCH3
OMe
N
OH
R
(CH2)nCOOCH3
OMe
+1.
ArMgBr
     
                                                                                                             I                                II   
 
N
OH
R
(CH2)nCOOH
OMe
N
OH
R
(CH2)nCOOH
OMe
II I 
 
1). n  =  0,   R  =  24a-b;        R  =  Cbz  (no compound I). 
2). n  =  1,   R  =  24b-c;        R  =  Cbz  (no compound I).  
R1 N
OH
R
(CH2)nCOOH
OMe
N
OH
R
(CH2)nCOOH
OMe
N
OH
R
(CH2)nCOO
2. +
                                                                                              I                                    II 
 
The same procedure as above gave the corresponding (2R) stereoisomers. 
1). n  =  0,   R1  =  Me,    R  =  24a-b;         R  =  Cbz  (no compound I). 
2). n  =  1,   R1 =  Et,       R  =  24b-c;         R  =  Cbz  (no compound I). 
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N
OH
COOCH2Ph
(CH2)nCOOR
OMe
N
OH
H
(CH2)nCOOR
OMe
N
OH
COOCH2Ph
(CH2)nCOOH
OMe
N
OH
H
(CH2)nCOOH
OMe
3.
 
1). n  =  0,    R  =  H,  Me.                                                                              1). n  =  0.  
2). n  =  1,    R  =  H,  Me.                                                                              2). n  =  1. 
RBr
N
OH
H
(CH2)nCOOCH3
OMe
N
OH
R
(CH2)nCOOCH3
OMe
4.
 
 
1). n  =  0,     R  =   24a. 
2). n  =  1,     R  =   24c. 
 
R    =   24a-d 
 
OMe
OMe
OMe
S
S
Na: b: c: d:
 
 
 
 
 
 
 
 
Lebenlauf 94 
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